C o n s u l t a n t Pat h o l o g y
liver pathology
Consultant Pathology Series David E. Elder, MB, ChB, FRCPA Series Editor Tumorigenic Melanocytic Proliferations David E. Elder Brain Tumors Richard Prayson, Bette Kleinschmidt-DeMasters, and Mark L. Cohen Head and Neck Pathology Leon Barnes, Raja Seethala, and Simion Chiosea Liver Pathology Linda D. Ferrell and Sanjay Kakar
Forthcoming Volumes in the Series Thyroid Papillary Lesions Virginia A. LiVolsi and Jennifer L. Hunt Urinary Bladder Diagnosis Robert O. Petersen
C o n s u l t a n t Pat h o l o g y Volume 4
liver pathology EDITORS Linda D. Ferrell, MD Professor and Vice Chair of Clinical Affairs Director of Surgical Pathology Department of Pathology University of California San Francisco San Francisco, California Sanjay Kakar, MD Associate Professor and Vice Chair of Pathology University of California, San Francisco Chief of Pathology San Francisco VA Medical Center San Francisco, California
New York
Acquisitions Editor: Richard Winters Cover Design: Joe Tenerelli Compositor: S4Carlisle Publishing Services Printer: SCI Visit our website at www.demosmedpub.com © 2011 Demos Medical Publishing, LLC. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher. Medicine is an ever-changing science. Research and clinical experience are continually expanding our knowledge, in particular our understanding of proper treatment and drug therapy. The authors, editors, and publisher have made every effort to ensure that all information in this book is in accordance with the state of knowledge at the time of production of the book. Nevertheless, the authors, editors, and publisher are not responsible for errors or omissions or for any consequences from application of the information in this book and make no warranty, expressed or implied, with respect to the contents of the publication. Every reader should examine carefully the package inserts accompanying each drug and should carefully check whether the dosage schedules mentioned therein or the contraindications stated by the manufacturer differ from the statements made in this book. Such examination is particularly important with drugs that are either rarely used or have been newly released on the market. Library of Congress Cataloging-in-Publication Data Liver pathology / Linda D. Ferrell and Sanjay Kakar, editors. p. ; cm. — (Consultant pathology series ; 4) Includes bibliographical references. ISBN 978-1-933864-93-8 1. Liver — Diseases. I. Ferrell, Linda D. II. Kakar, Sanjay.
III. Series: Consultant pathology series ; 4.
[DNLM: 1. Liver Diseases — pathology. 2. Liver — pathology. WI 700] RC846.9.L582 2011 616.3'623071 — dc22
2011001173
Special discounts on bulk quantities of Demos Medical Publishing books are available to corporations, professional associations, pharmaceutical companies, health care organizations, and other qualifying groups. For details, please contact: Special Sales Department Demos Medical Publishing 11 W. 42nd Street, 15th Floor New York, NY 10036 Phone: 800–532–8663 or 212–683–0072 Fax: 212–941–7842 E-mail:
[email protected] Made in the United States of America 11 12 13 14 15
5 4 3 2 1
My parents, Savita and Ramesh, for guiding me to make erudite choices and inculcating a simple uncomplicated view of life. My late uncle Vinni, for being a treasure trove of inspiration and an unending source of the zeal to excel. My sister, Shalini, for always considering me an unconditional hero capable of achieving anything. My mentors, Larry and Linda, for shepherding me in the world of pathology, and for sharing their penchant of making the correct diagnosis, both in life and in liver biopsies. My patients, whose condition I hope this exercise will help to ameliorate in some small way. My wife Shalini and son Soham for making everything worthwhile. SANJAY KAKAR
My husband, Rick, for his support, even when I was working late and at home on the book. Roddy and Peter, for helping me start along the pathway of liver. All the co-authors, who helped make this book possible. LINDA D. FERRELL
This page intentionally left blank
C on ten ts
Series Foreword Preface Acknowledgments Contributors
xv xvii xix xxi
1. Acute Hepatitis
1
Sanjay Kakar 1.1 Acute Hepatitis With Inflammation-Dominant Pattern 1.2 Acute Hepatitis With Bridging Necrosis 1.3 Resolving Hepatitis 1.4 Nonspecific Reactive Hepatitis
2. Acute Liver Failure
7 9 11 13
15
Rageshree Ramachandran and Sanjay Kakar 2.1
Acute Liver Failure With Necrosis-Dominant Injury Pattern Sanjay Kakar
3. Autoimmune Hepatitis/Overlap Syndromes
18
21
Kay Washington 3.1 3.2 3.3 3.4 3.5
Autoimmune Hepatitis With Bile Duct Injury Versus Primary Biliary Cirrhosis Autoimmune Hepatitis–Primary Biliary Cirrhosis Overlap Syndrome Autoimmune Hepatitis–Primary Sclerosing Cholangitis Overlap Syndrome Chronic Hepatitis C With Autoantibodies Versus Autoimmune Hepatitis Syncytial Giant Cell Hepatitis
4. Fatty Liver Disease
26 30 32 34 36
39
Matthew M. Yeh and Elizabeth M. Brunt 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8
Steatosis With Inflammation Versus Steatohepatitis Steatohepatitis With Minimal Ballooning Steatohepatitis Without Activity Nonalcoholic Steatohepatitis With Moderate/Marked Portal Inflammation Steatohepatitis With Elevated Serum Iron Indices and Siderosis Alcoholic Steatohepatitis Drugs and NAFLD Microvesicular Steatosis
vii
41 43 45 47 52 54 56 57
viii
CONTENTS
4.9 4.10 4.11
Pediatric Fatty Liver Disease Cynthia Behling Chemotherapy-Associated Steatohepatitis Due to Irinotecan Vikram Deshpande and Gregory Y. Lauwers Subacute Steatohepatitis Linda D. Ferrell
5. Hepatic Granulomas and Granulomatous Hepatitis
58 61 64
67
Laura W. Lamps 5.1 5.2 5.3 5.4 5.5 5.6
Necrotizing Epithelioid Granulomas Sarcoidosis Fibrin Ring Granulomas Schistosomiasis Cat Scratch Disease Chronic Granulomatous Disease David E. Kleiner
6. Cholestasis
70 73 77 79 82 85
89
Jay H. Lefkowitch 6.1 6.2 6.3 6.4 6.5 6.6 6.7
Drug-Induced Pure Cholestasis Bile Ductular Cholestasis Associated With Sepsis Crohn Disease With Primary Sclerosing Cholangitis Chronic Large Bile Duct Obstruction of Uncertain Cause Primary Sclerosing Cholangitis, Exclude Cholangiocarcinoma Immunoglobin G4–Associated Cholangitis Versus Primary Sclerosing Cholangitis Vikram Deshpande Hepatolithiasis Polly W. Y. Lam and Wilson M. S. Tsui
7. Bile Duct Damage and Ductopenia
96 99 102 104 107 110 113
117
Kay Washington 7.1 7.2 7.3 7.4
Primary Biliary Cirrhosis With Nonspecific Changes and Positive Antimitochondrial Antibody Antimitochondrial Antibody-Negative Primary Biliary Cirrhosis Primary Biliary Cirrhosis With Ductopenia Primary Biliary Cirrhosis With Cirrhosis
8. Ductal Plate Malformations and Cystic Diseases of the Liver
120 123 125 128
131
Barton Kenney and Dhanpat Jain 8.1 8.2 8.3 8.4 8.5
Congenital Hepatic Fibrosis Versus Cirrhosis Caroli Disease/Syndrome Versus Other Cystic Disease Adult Polycystic Liver Disease Versus Caroli Disease Choledochal Cyst Solitary Hepatic Cyst Versus Hydatid Cyst
143 145 147 149 151
CONTENTS
9. Hereditary Hyperbilirubinemias
ix
153
Sarangarajan Ranganathan 9.1
Dubin-Johnson Syndrome
10. Neonatal Cholestatic Liver Disease
157
159
Grace E. Kim and Linda D. Ferrell 10.1 Biliary Atresia 10.2 Neonatal Hepatitis With Hypopituitarism 10.3 Paucity of Intrahepatic Bile Ducts 10.4 Neonatal Hepatitis Due to Alpha-1-Antitrypsin Deficiency
11. Sinusoidal Dilatation and Congestion
164 167 170 172
175
Sanjay Kakar 11.1 Budd-Chiari Syndrome Versus Biliary Disease 11.2 Sinusoidal Obstruction 11.3 Veno-Occlusive Disease (Sinusoidal Obstruction Syndrome) 11.4 Amyloidosis
12. Peliosis Hepatis
177 180 182 184
187
Sandra Fischer and Maha Guindi 12.1 Alcoholic Lipopeliosis 12.2 Lipopeliosis in Transplanted Donor Livers
13. Portal Hypertension Without Cirrhosis
188 189
191
Sandra Fischer and Maha Guindi 13.1 Hepatoportal Sclerosis 13.2 Portal Vein Thrombosis 13.3 Budd-Chiari Syndrome 13.4 Regressed Cirrhosis Case
14. Clinical and Morphological Spectrum of Liver Diseases in Pregnancy
191 193 195 199
203
Andrew Kenneth Burroughs and Amar Paul Dhillon 14.1 14.2 14.3
Recurrent Cholestasis of Pregnancy Acute Fatty Liver of Pregnancy Toxemia/HELLP Syndrome
15. Drug-Induced Liver Injury
205 207 210
213
David E. Kleiner 15.1 15.2 15.3 15.4 15.5
Acetaminophen-Induced Fulminant Liver Failure Statin-Associated Acute Hepatotoxicity Drug-Induced Autoimmune Hepatitis Drug-Induced Cholestatic Hepatitis Drug-Induced Ductopenia
217 220 223 226 229
x
CONTENTS
15.6 15.7 15.8 15.9
Methotrexate-Induced Chronic Liver Disease Liver Injury Due to Total Parenteral Nutrition Amiodarone-Induced Phospholipidosis Drug-Induced Microvesicular Steatosis
16. Cytoplasmic Globules
232 235 237 240
243
Elaine S. Chan and Matthew M. Yeh 16.1 16.2
Alpha-1-Antitrypsin Deficiency Alpha-1-Antichymotrypsin Deficiency
17. Glycogenic Abnormalities on Liver Biopsy
245 249
251
Michael Torbenson 17.1 17.2 17.3 17.4 17.5 17.6
Glycogenic Hepatopathy Glycogen in the Liver: Abnormal Versus Normal Glycogenic Hepatopathy, Cause Uncertain Glycogenic Hepatopathy, Type II Diabetes Glycogen Pseudo–Ground-Glass Smooth Endoplasmic Reticulum Proliferation
18. Macrophage Infiltrate
255 257 258 260 261 263
265
Ryan M. Gill, Sanjay Kakar, and Linda D. Ferrell 18.1 Gaucher Disease 18.2 Niemann-Pick Disease
19. Approach to Liver Biopsy With Minimal or Nonspecific Histologic Findings
271 273
275
Dhanpat Jain and Sanjay Kakar 19.1
Mild Hepatic Steatosis Versus Ito Cell Lipidosis Katharine van Patten, Sanjay Kakar, and Dhanpat Jain
20. Interpreting Iron in Liver Specimens
278
281
Michael Torbenson 20.1 20.2 20.3 20.4 20.5 20.6
Genetic Hemochromatosis Grading Iron Hepatic Iron Index Marked Hepatic Iron but No Genetic Mutation Iron in the Setting of Chronic Hepatitis C Neonatal Hemochromatosis Linda D. Ferrell
21. Wilson Disease
284 289 291 293 294 296
299
Linda D. Ferrell 21.1 21.2 21.3
Fulminant Form of Wilson Disease Chronic Hepatitis Due to Wilson Disease Cirrhosis With Chronic Hepatitis Consistent With Wilson Disease
301 304 305
CONTENTS
22. Liver Transplant Pathology
xi
307
Oyedele Adeyi 22.1 22.2 22.3 22.4 22.5 22.6 22.7 22.8 22.9 22.10
Acute Cellular Rejection Recurrent Hepatitis C Acute Cellular Rejection Versus Recurrent Hepatitis C Late Cellular Rejection Versus Autoimmune Hepatitis Versus Recurrent Hepatitis C Fibrosing Cholestatic Hepatitis C Versus Biliary Obstruction Versus Adverse Reaction to Medication Mechanical Biliary Obstruction Versus Chronic Rejection Chronic Rejection Versus Recurrent Primary Sclerosing Cholangitis Versus Non-PSC Stricture Zone 3 (Centrilobular) Necrosis Cytomegalovirus Hepatitis Graft Versus Host Disease
23. Benign Hepatocellular Lesions
309 311 313 315 319 323 326 330 337 340
343
Valérie Paradis 23.1 23.2 23.3 23.4 23.5 23.6
Atypical Focal Nodular Hyperplasias on Imaging Focal Nodular Hyperplasia Versus Inflammatory/Telangiectatic Hepatocellular Adenoma Hepatocellular Adenoma Subtyping: Inflammatory/Telangiectatic Versus Steatotic Adenoma Hepatocellular Adenoma Subtyping: Associated Liver Nodules Hepatocellular Adenoma Subtyping: Inflammatory/ Telangiectatic Adenoma Hepatocellular Adenoma Subtyping: Adenoma With Atypical Features
24. Biliary Neoplasms
347 349 351 354 356 359
361
Kisha Mitchell and Dhanpat Jain 24.1 24.2 24.3 24.4 24.5 24.6 24.7
Bile Duct Adenoma Versus Biliary Hamartoma Intrahepatic Cholangiocarcinoma Versus Hepatocellular Carcinoma Cholangiocarcinoma in Association With Von Meyenburg Complexes Diagnosis of Hilar/Extrahepatic Cholangiocarcinoma Bile Duct Cystadenoma/Carcinoma Versus Foregut Cyst Biliary Adenofibroma Vikram Deshpande and Gregory Y. Lauwers Biliary Papillomatosis/Intraductal Cholangiocarcinoma Wilson M. S. Tsui
25. Hepatocellular Carcinoma
365 370 373 375 378 381 383
387
Prodromos Hytiroglou 25.1 25.2 25.3
Well-Differentiated Hepatocellular Carcinoma Poorly Differentiated Hepatocellular Carcinoma Early Hepatocellular Carcinoma
394 398 403
xii
CONTENTS
26. Hepatocellular Carcinoma Variants
407
Shriram Jakate and Deborah Giusto 26.1
Pseudoglandular Hepatocellular Carcinoma Versus Cholangiocarcinoma and Metastatic Adenocarcinoma 26.2 Hepatocellular Versus Neuroendocrine Carcinoma 26.3 Hepatocellular Carcinoma, Clear Cell Variant 26.4 Scirrhous Hepatocellular Carcinoma 26.5 Combined Hepatocellular-Cholangiocarcinoma 26.6 Diffuse Cirrhosis-Like Hepatocellular Carcinoma 26.7 Spectrum of Cytoplasmic Contents in Hepatocellular Carcinoma 26.8 Poor Differentiation and Vascular Invasion in Hepatocellular Carcinoma 26.9 Pedunculated Hepatocellular Carcinoma 26.10 Ablated Hepatocellular Carcinoma
27. Metastatic Tumors: Illustration of Immunohistochemical Workup
409 412 414 417 419 421 423 425 427 428
431
Rageshree Ramachandran and Sanjay Kakar 27.1 27.2
Hepatocellular Carcinoma Versus Metastatic Adenocarcinoma Hepatocellular Carcinoma Versus Metastatic Polygonal Cell Tumor
28. Hepatoblastoma
436 438
441
Sarangarajan Ranganathan 28.1 28.2 28.3 28.4
Biopsy Diagnosis of Hepatoblastoma Macrotrabecular Hepatoblastoma Versus Hepatocellular Carcinoma Small Cell Hepatoblastoma Versus Other Small Round Cell Tumors Teratoid Hepatoblastoma Versus Malignant Teratoma/Yolk Sac Tumor
29. Vascular Tumors 29.1 29.2 29.3 29.4
Cavernous Hemangioma Variants Linda D. Ferrell Epithelioid Hemangioendothelioma Hala R. Makhlouf and Zachary D. Goodman Hepatic Angiosarcoma Hala R. Makhlouf and Zachary D. Goodman Infantile Hemangioma Michael Torbenson
30. Hematopoietic Tumors of the Liver
447 449 452 455
457 457 459 462 465
469
Patrick A. Treseler and John P. Higgins 30.1 30.2 30.3 30.4 30.5 30.6 30.7
Dense Small B-Cell Infiltrate With Reactive Follicles Diffuse Large B-Cell Infiltrate Portal Infiltrate With Reed-Sternberg Cells Polymorphic Lymphoid Infiltrate in a Transplant Patient Sinusoidal T-Cell Infiltrate Portal and Lobular Infiltration by Blasts Portal and Lobular Infiltration by Mature Granulocytes
476 480 482 485 487 490 492
CONTENTS
31. Other Infiltrative Neoplasms of Liver
xiii
495
Lawrence Burgart 31.1
Portal-Based Infiltrative Neoplasm Versus Biliary Disease
32. Mesenchymal Tumors of the Liver 32.1 32.2 32.3 32.4 32.5
Mesenchymal Hamartoma Wendy L. Frankel and Xiaoping Zhou Embryonal Sarcoma Wendy L. Frankel and Xiaoping Zhou Angiomyolipoma Cherise Marie Cortese and Raouf E. Nakhleh Angiomyolipoma, Inflammatory Variant Linda D. Ferrell Malignant Angiomyolipoma—Malignant Perivascular Epithelioid Cell Tumor William A. Ahrens
496
499 499 502 505 508 510
Appendices A. Adequacy of Needle Biopsy B. Grading and Staging C. Special Stains in Liver Biopsy Pathology
515 515 517 521
Index
523
This page intentionally left blank
S e r i e s Forewo rd
D
iagnostic surgical pathology remains the gold standard for diagnosis of most tumors and many inflammatory conditions in most, if not all, organ systems. The power of the morphologic method is such that, in many instances, a glance at a thin section of tissue stained with two vegetable dyes is sufficient to determine with absolute certainty whether a patient should undergo a major procedure or not, or whether a patient is likely to live a healthy life or die of an inoperable tumor. In such cases, the diagnostic process is one of “gestalt,” a form of almost instantaneous pattern recognition that is similar to the recognition of faces, different brands of automobiles, or breeds of dogs. In other “difficult” cases, the diagnosis is not so obvious. In many of these cases, a diagnosis may be possible, but may be outside of the experience of the routine practitioner. In such a circumstance, it may be possible for a practitioner with more experience—a consultant—to make a diagnosis rather readily. In other cases, the problem may really not be suited to the histologic method. In these cases as well, a consultant may be invaluable in determining that it is simply not possible to make a reliable diagnosis with the materials available. In yet other cases, the diagnosis may be ambiguous, and again a consultant’s opinion can be important in establishing a differential diagnosis that may guide clinical investigation. There are many fine consultants available to the practicing surgical pathology community. Many of them have authored textbooks, and many of them give presentations at national meetings. However, these materials can offer only a superficial insight into the vast amount of knowledge that is
embedded in these individuals’ cerebral cortices—and in their filing cabinets. This series represents an effort to enable the dissemination of this hitherto-inaccessible knowledge to the wider community. Our authors are individuals who have accumulated large collections of difficult cases and are willing to share their material and their knowledge. The cases are based on actual consultations, and the indications for the consultation, when available, are presented, because these are the records of the manner in which these cases presented themselves as being problematic. We have asked the consultants, when possible, to present their consultation letters in much the same form (albeit edited to some degree) as that in which they were first presented, because these represent the true records of the clinical encounter. In addition, we asked the authors to amplify upon these descriptions, with brief reference to the literature, and to richly illustrate the case reports with high-quality digital images. Images from books in the series, as well as additional images to amplify the presentation of the cases, will be made available on a website for downloading, study, and use in education. These images, in some cases, have been derived from virtual slides, which also may be made available in the future from a digital repository for their additional educational value. David E. Elder, MB, ChB, FRCPA Professor of Pathology and Laboratory Medicine Hospital of the University of Pennsylvania Philadelphia, Pennsylvania
xv
This page intentionally left blank
Preface
T
he Hippocratic Oath enshrines the idea of medicine as more of art than science. This is particularly true of liver pathology, where the blend of the myriad H&E patterns, the intricate maze of reticulin network, the rich hues of a trichrome, the deep azure of the Prussian blue, and the blithe shades of PASD can inspire even the most insipid of imaginations. This text is an attempt to amalgamate the art and science of liver pathology using histologic patterns as a template to embark upon the diagnostic exercise. This book is part of the Consultant Pathology Series and will focus on diagnostic problems in liver pathology through case examples. The book is divided into two sections: non-neoplastic and neoplastic liver diseases. Liver biopsy interpretation in non-neoplastic liver diseases involves two steps: recognition of the morphological pattern of injury and identification of the disease processes that led to the identified pattern. The first step is essentially a morphological exercise and since the liver has a limited repertoire of response to injury, there is considerable overlap of morphological patterns across diverse disease processes. The second step requires correlation of the morphological pattern with clinical presentation, radiological findings, and laboratory data to establish an etiological diagnosis. It can be valuable to examine the biopsy without knowledge of clinical information for an unbiased appraisal of histologic abnormalities and perhaps as an act of showmanship for an uninitiated trainee or clinical colleague, but any attempt to establish the final liver biopsy diagnosis without the requisite clinical information is an act of brashness that is avoided by the astute pathologist. The non-neoplastic diseases section follows a patternbased approach comprising an introduction that defines the clinical and morphological features of the pattern and the relevant differential diagnoses. The individual disease entities and the exercise of reaching an etiological diagnosis are illustrated through case examples. The examples have been chosen from cases referred to experts in the field and highlight
the wide spectrum of problems in liver biopsy diagnosis. The format includes a case history, relevant laboratory data, imaging information and histologic features, followed by a discussion. The latter focuses on how the diagnosis was established based on the provided clinical and histologic features, and how the relevant differential diagnoses were excluded. The initial chapters cover patterns encountered in the most hepatitic and biliary disorders, followed by developmental, genetic, and pediatric diseases. Adverse drug reaction is one of the most common causes of liver injury and a systematic evidencebased approach is presented in chapter 15, embellished with numerous case examples. Both academic and community pathologists are increasingly presented with allograft-related problems. Chapter 22 outlines a pragmatic approach to determining the etiology of allograft liver dysfunction with emphasis on differential diagnosis. The neoplastic diseases section also follows a case-based approach with emphasis on the morphological and immunohistochemical features that establish the diagnosis and exclude other close mimics. Since limited tissue is available in needle biopsies, judicious use of immunohistochemistry is critical for diagnosis and a practical approach is outlined in chapter 27. In addition to typical hepatocellular and biliary tumors and biliary neoplasms, the approach to challenging situations like histological variants, hematopoietic disorders, and mesenchymal tumors is also illustrated through case examples. We hope that the style of this text and of this series in general will provide the requisite ammunition to the pathologist for assimilation of clinical and histological data to solve diagnostic conundrums, judiciously employ the immunohistochemical armamentarium, and generate pathology reports that provide the missing pieces of the jigsaw puzzle to the hepatologist.
xvii
Linda D. Ferrell, MD Sanjay Kakar, MD
This page intentionally left blank
Ac k n ow ledg m en ts
We would like to acknowledge the help of Caren Hale for organizing the manuscript and images. We appreciate the efforts of our publisher, Demos Medical Publishing, in their meticulous scrutiny of the written material and molding the text into its final shape. Special mention is due to Rich Winters, Executive Editor, for his unstinting effort and support throughout the gestation of this text as it evolved from an idea to its present final form.
xix
This page intentionally left blank
C o ntribu to rs
Oyedele Adeyi, MB, BS, FCAP, FRCP(C) Staff Pathologist Laboratory Medicine Program University Health Network Assistant Professor Laboratory Medicine and Pathobiology University of Toronto Toronto, Ontario, Canada William A. Ahrens, MD Adjunct Assistant Professor Department of Pathology University of North Carolina, Chapel Hill Chapel Hill, North Carolina Director of Gastrointestinal and Hepatobiliary Pathology Department of Pathology Carolinas Medical Center Charlotte, North Carolina Cynthia Behling, MD, PhD Staff Pathologist Department of Pathology Pacific Rim Pathology Group Sharp Memorial Hospital San Diego, California Elizabeth M. Brunt, MD Professor Department of Pathology and Immunology Washington University St. Louis, Missouri Lawrence Burgart, MD Clinical Professor of Pathology Department of Pathology University of Minnesota College of Medicine Minneapolis, Minnesota
Andrew Kenneth Burroughs, MBChB, Hons, FEBG, FRCP, FMedSci Consultant Physician and Hepatologist Royal Free and University College Medical School Professor of Hepatology University College London London, United Kingdom
Sandra Fischer, MD Assistant Professor of Pathology Laboratory Medicine Program Department of Laboratory Medicine and Pathobiology University Health Network University of Toronto Toronto, Ontario, Canada
Elaine S. Chan, MD Resident Department of Pathology University of Washington Seattle, Washington
Wendy L. Frankel, MD Vice Chair and Director of Anatomic Pathology Department of Pathology The Ohio State University Columbus, Ohio
Cherise Marie Cortese, MD Assistant Professor and Consultant Department of Laboratory Medicine and Pathology Mayo Clinic, Florida Jacksonville, Florida Vikram Deshpande, MD Assistant Professor of Pathology Department of Pathology Massachusetts General Hospital Assistant Professor of Pathology Department of Pathology Harvard Medical School Boston, Massachusetts Amar Paul Dhillon, MD, FRCP, FRCPath Professor of Histopathology Department of Cellular Pathology University College of London Medical School London, United Kingdom Linda D. Ferrell, MD Professor and Vice Chair of Clinical Affairs Director of Surgical Pathology Department of Pathology University of California, San Francisco San Francisco, California
xxi
Ryan M. Gill, MD, PhD Clinical Instructor Department of Pathology University of California San Francisco, California Deborah Giusto, MD Associate Pathologist Department of Pathology 4path Pathology Services Justice, Illinois Zachary D. Goodman, MD, PhD Director, Liver Pathology Research Department of Pathology Center for Liver Diseases Inova Fairfax Hospital Falls Church, Virginia Maha Guindi, FRCPC Associate Professor of Pathology Laboratory Medicine Program Department of Laboratory Medicine and Pathobiology University Health Network University of Toronto Toronto, Ontario, Canada
xxii
John P. Higgins, MD Associate Professor of Pathology Department of Pathology Stanford University Stanford, California Prodomos Hytiroglou, MD Professor of Pathology Department of Pathology Aristotle University Medical School Thessaloniki, Greece Dhanpat Jain, MBBS, MD Director of Gastrointestinal Pathology Associate Professor Department of Anatomic Pathology Yale University School of Medicine New Haven, Connecticut Shriram Jakate, MD, FRCPath Professor of Pathology, Gastroenterology, and Hepatology Department of Pathology Rush University Medical Center Chicago, Illinois Sanjay Kakar, MD Associate Professor and Vice Chair of Pathology University of California, San Francisco Chief of Pathology San Francisco VA Medical Center San Francisco, California Barton Kenney, MD Assistant Professor Department of Anatomic Pathology Yale University School of Medicine New Haven, Connecticut Grace E. Kim, MD Professor of Pathology Associate Director of Surgical Pathology Director of Pediatric Pathology Department of Anatomic Pathology University of California, San Francisco San Francisco, California David E. Kleiner, MD, PhD Director, Clinical Operations Laboratory of Pathology National Cancer Institute National Institutes of Health Bethesda, Maryland Polly W. Y. Lam, FRCPA, FHKCPath Senior Medical Officer Department of Pathology Queen Elizabeth Hospital Hong Kong, China
CONTRIBUTORS
Laura W. Lamps, MD Professor and Vice Chair Director, Diagnostic Laboratories Department of Pathology University of Arkansas for Medical Sciences Little Rock, Arkansas Gregory Y. Lauwers, MD Vice Chairman Department of Pathology Massachusetts General Hospital Chief, Gastrointestinal Pathology Service Department of Pathology Massachusetts General Hospital Professor of Pathology Department of Pathology Harvard Medical School Boston, Massachusetts Jay H. Lefkowitch, MD Professor of Clinical Pathology Department of Pathology College of Physicians and Surgeons Columbia University New York, New York Hala R. Makhlouf, MD, PhD Chief, Division of Hepatic Pathology Department of Hepatic and Gastrointestinal Pathology Armed Forces Institute of Pathology Washington, DC Kisha Mitchell, MD Assistant Professor Department of Anatomic Pathology Yale University School of Medicine New Haven, Connecticut Raouf E. Nakhleh, MD Professor Laboratory Medicine and Pathology Mayo Clinic, Florida Jacksonville, Florida Valérie Paradis, PD, PhD Professor Department of Pathology Beaujon Hospital INSERM U773 Beaujon Hospital Clichy, France Rageshree Ramachandran, MD, PhD Department of Pathology University of California San Francisco, California
Sarangarajan Ranganathan, MD Director, Anatomic Pathology Pediatric Pathology Division Associate Professor Department of Pathology Children’s Hospital University of Pittsburgh Medical Center Pittsburgh, Pennysylvania Michael Torbenson, MD Associate Professor Department of Pathology The Johns Hopkins School of Medicine Baltimore, Maryland Patrick A. Treseler, MD, PhD Professor of Pathology Department of Pathology University of California, San Francisco San Francisco, California Wilson M. S. Tsui, FRCPath, FHKCPath Consultant Pathologist Department of Pathology Caritas Medical Centre Hong Kong, China Katharine van Patten, MD Clinical Instructor Department of Anatomic Pathology Yale University School of Medicine New Haven, Connecticut Kay Washington, MD, PhD Professor Department of Pathology Vanderbilt University Medical Center Nashville, Tennessee Matthew M. Yeh, MD, PhD Associate Professor Department of Pathology University of Washington School of Medicine Seattle, Washington Xiaoping Zhou, MD, PhD Fellow, Gastrointestinal and Liver Pathology Department of Pathology The Ohio State University Columbus, Ohio
1 Acute Hepatitis SANJAY KAKAR
D E F I N I T I ON
4. Absence of fibrosis: Fibrosis is the morphological hallmark of chronicity in liver disease. By definition, there is no fibrosis in acute hepatitis. In clinical terms, chronicity is defined by persistence of clinical, biochemical, or serological evidence of liver dysfunction for more than 6 months.
Acute hepatitis is clinically defined by elevation of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) (at least twice normal). Markers of biliary disease like alkaline phosphatase (ALP) are either normal or the ratio of serum activity of ALT to serum activity of ALP is greater than or equal to 5 (1). By definition, there is no prior history of chronic liver disease. Histologically, acute hepatitis is defined by lobular hepatocellular injury. This pattern of injury typically comprises the following four features:
RO LE O F T H E PAT H O LO GIST
The diagnosis of acute hepatitis can be established in most cases from clinical and serological data. When liver biopsy is performed, the role of the pathologist is two-fold: (i) to confirm the diagnosis of acute hepatitis and exclude other etiologies like biliary disease, (ii) to help in establishing the etiology of acute hepatitis based on the morphological features. Several subpatterns can be recognized within the acute hepatitis pattern of injury. These subpatterns can be very helpful in narrowing the differential diagnosis.
1. Hepatocellular injury with or without necrosis: This is the hallmark of acute hepatitis and may be observed in the form of hepatocellular swelling and/or hepatocellular dropout (acidophil bodies/Councilman bodies/apoptosis). In severe cases, there may be necrosis of groups of hepatocytes (confluent necrosis). The necrosis may be random and nonzonal, or it may show predilection for certain zones such as around central veins. Bridging necrosis with centro-portal, centro-central, or less commonly portoportal bridging can be present, and may carry higher risk of progression to chronic hepatitis. When confluent necrosis is widespread (multiacinar confluent necrosis or panacinar necrosis), it constitutes the morphologic counterpart of fulminant hepatitis or acute liver failure (Chapter 2). The terms massive and submassive hepatic necrosis have also been used for these situations.
SUBPAT T ER NS O F ACUT E H EPAT IT IS Inflammation-Dominant Acute Hepatitis Defining features
1. Hepatocellular damage: hepatocellular swelling, acidophil bodies, necrosis (Figures 1.1 and 1.2). 2. Lobular inflammation: lymphocyte-predominant in most cases, variable numbers of other inflammatory cells can be present. 3. Portal inflammation may be present, but is not sufficient or necessary for the diagnosis.
Regenerative features like binucleate hepatocytes, mitoses, and thicker cell plates are common. Prominent Kupffer cells are often present in the sinusoids and can form small aggregates (microgranulomas). If the hepatocellular injury is severe enough to interfere with bile secretion, cholestasis can be present (cholestatic hepatitis). 2. Inflammation: The inflammatory infiltrate typically involves the hepatic parenchyma with variable involvement of portal tracts. Interface inflammation, characteristic of chronic hepatitis, can be present in some cases and is prominent in some etiologies like acute hepatitis A. The infiltrate is predominantly composed of lymphocytes, but depending on the underlying etiology and duration of illness, other types of cells like macrophages, plasma cells, and eosinophils can be present. 3. Absence of bile duct injury: Injury to interlobular bile ducts is absent or minimal. Bile ductular reaction can occur in the areas of hepatocellular necrosis and should not be misinterpreted as biliary injury. Neutrophils are commonly present in association with ductules. This phenomenon has been referred to as pericholangitis, but it should not be mistaken for acute cholangitis.
F I G U R E 1 . 1 Inflammation-dominant pattern of injury highlighting portal and lobular inflammation. The bile duct is intact. Interface activity is present. Hepatocellular swelling are not seen in the lobule.
1
2
CHAPTER
1:
ACUTE
FIGURE 1. 2 Same case as in Figure 1.1 emphasizing the hepato-
cellular swelling, dropout, lobular inflammation, and prominent Kupffer cells.
H E PAT I T I S
F I G U R E 1 . 4 Hepatocellular ballooning with Mallory-Denk bodies helps in the identification of steatohepatitic pattern of injury.
FIGURE 1. 3 Lobular inflammation and hepatocellular swelling in acute alcoholic hepatitis can mimic inflammation-dominant pattern of acute hepatitis when fat is absent or minimal.
F I G U R E 1 . 5 Same case as Figure 1.3. Pericellular fibrosis also points
Differential diagnosis
present clinically as acute hepatitis. The presence of fibrosis is helpful in establishing chronicity in these cases. The leading differential diagnoses of inflammationdominant acute hepatitis pattern are acute viral hepatitis, adverse drug reaction, autoimmune hepatitis, and Wilson disease. The etiology remains undetermined in 10% to 15% of cases.
Distinction from biliary disease is generally not a problem as the predominant pattern of hepatocellular injury is obvious and there is hepatitic pattern of liver enzyme elevations. Acute alcoholic hepatitis can clinically present as acute hepatitis. The histological pattern of injury is steatohepatitis (steatosis, hepatocellular swelling, Mallory-Denk bodies with or without pericellular fibrosis) and is usually different from the inflammation-dominant pattern of acute hepatitis. In some cases, the steatosis is minimal or absent and the hepatocellular swelling may be mistaken for acute hepatitis pattern of injury. The presence of Mallory-Denk bodies and pericellular fibrosis, along with history of alcohol intake help in establishing the correct diagnosis (Figures 1.3–1.5). In some instances, acute exacerbation of previously unknown chronic disease can
toward a steatohepatitic etiology.
1. Acute viral hepatitis: diagnosis rests on serological tests. Since these assays can occasionally yield false-negative results, polymerase chain reaction (PCR) for viral RNA/ DNA can be obtained. 2. Adverse drug reaction: diagnosis rests on history of exposure to drugs known to cause the pattern of injury observed on liver biopsy (see Chapter 15). Herbal supplements and over-the-counter medications should be
CHAPTER
1:
ACUTE
specifically sought. The temporal profile of disease onset and drug exposure is important in establishing causality. The disease usually subsides after cessation of the offending agent, but it can persist for weeks to months in some cases. Prominent eosinophilic infiltrate, granulomas, relatively sparse portal inflammatory component, sharply defined perivenular necrosis with minimal inflammation, and cholestasis out of proportion to hepatocellular injury (with or without bile duct damage) favor adverse drug reaction, but all these features lack specificity and sensitivity (see Chapter 15). 3. Autoimmune hepatitis (AIH) is a form of chronic hepatitis but can present clinically as acute hepatitis. Most cases with acute presentation also have fibrosis on liver biopsy and are classified as chronic hepatitis. However, around 10% of AIH lack fibrosis at initial presentation and need to be distinguished from other causes of acute hepatitis (2,3). High necroinflammatory activity and numerous plasma cells are typical of AIH, but are not specific. These features are seen in the active phase of the disease and are less prominent during the quiescent phase. Plasma cells can be observed in other causes of acute hepatitis and in biliary diseases like primary biliary cirrhosis (PBC). In some cases of AIH, plasma cells may be inconspicuous or absent. Hence, AIH does not have any specific histological features. The diagnosis is dependent on a scoring system based on clinical, laboratory, and histological findings (see Chapter 3). 4. Wilson disease can show steatosis or a steatohepatitis-like picture with glycogenated nuclei, acute hepatitis or fulminant hepatic failure, or chronic hepatitis or cirrhosis (see Chapter 21). Hepatic disease usually manifests earlier than neurological disease (mean age 8–12 years), and onset of liver disease after 50 years is rare. Low ceruloplasmin level and elevated 24-hour urinary copper can be obtained. Ceruloplasmin is an acute phase reactant and can be normal in 10% of cases. Histochemical stains for copper (rubeanic acid, rhodanine) or copper binding protein (orcein) are unreliable (4,5). Quantitative determination of copper by spectrophotometry using the tissue from the paraffin block is a reliable indicator of hepatic copper in Wilson disease. Normal hepatic copper levels are 15 to 55 μg/g of dry liver tissue. Patients with untreated Wilson disease invariably have levels exceeding 250 μg/g, and often exceeding 1000 μg/g. Normal hepatic copper excludes the possibility of untreated Wilson disease. Since copper is excreted in the bile, conditions with chronic cholestasis (like PBC and primary sclerosing cholangitis) also show elevated hepatic copper. However, these conditions rarely enter the clinical or histological differential diagnosis of Wilson disease. 5. Celiac disease is primarily considered a gastrointestinal disease, but can involve other organ systems. The most frequent manifestation of liver involvement by celiac disease is mild elevations of transaminases. This can be observed in 40% to 50% of untreated patients (6,7). Histologically, these patients show nonspecific reactive
H E PAT I T I S
3
hepatitis and revert to normal within 6 to 12 months of gluten-free diet. Other histological manifestations include acute hepatitis, chronic hepatitis, nodular regenerative hyperplasia and, rarely, cirrhosis. In addition, coexisting celiac disease is seen in 3% to 6% of AIH, PBC, and primary sclerosing cholangitis. The relationship of celiac disease and autoimmune liver disease is not clear. Autoimmune liver dysfunction often does not respond to gluten-free diet. Serological tests for celiac disease should be done in all cases of unexplained liver dysfunction. Cholestatic Hepatitis Pathologic features
This pattern shows features of inflammation-dominant acute hepatitis accompanied by cholestasis. This pattern is different from other acute hepatitis patterns both clinically and histologically. Clinically, a mixed hepatitis/cholestatic pattern of liver enzymes is often present with ALT and/or AST elevated (at least twice normal), ALP elevated (typically less than 5 times normal), and ratio of ALT activity to ALP activity is less than 5. Histologically, the picture can be dominated by cholestasis with only mild hepatocellular injury. Differential diagnosis
Most cases are drug related (Case 15.4). Any etiologies listed under inflammation-dominant acute hepatitis pattern can potentially lead to cholestatic hepatitis. Viral hepatitis A is well known to be associated with cholestasis (8,9). Acute Hepatitis, “Toxic” Pattern Pathologic features
The histologic picture is dominated by necrosis, whereas the inflammation is minimal or absent. Differential diagnosis
1. Dose-dependent drug toxicity: Most drugs lead to inflammation-dominant pattern of liver injury as the liver damage is immune mediated (idiosyncratic). In few instances (acetaminophen, halothane), the damage is due to direct dose-dependent toxicity of the drug or its metabolite (Case 15.1). 2. Toxins: organic solvents, mushroom poisoning, herbal medications. 3. Nonhepatotropic viruses: herpes simplex, adenovirus (Chapter 2). 4. Vascular etiologies: ischemia, acute onset of venous outflow obstruction as in Budd-Chiari syndrome. Vascular events superimposed on underlying chronic liver disease or cirrhosis can clinically present as acute hepatitis (Figure 1.6). Clinical or serological data and presence of fibrosis in areas unaffected by ischemic injury help in identifying the underlying chronic liver disease.
4
CHAPTER
1:
ACUTE
H E PAT I T I S
FIGURE 1. 6 Necrosis-dominant pattern of liver injury evidenced
F I G U R E 1 . 7 Acute hepatitis with centrizonal necrosis related
by parenchymal extinction and minimal inflammation. This was the result of an ischemic event in the setting of chronic hepatitis C and cirrhosis. Without this history, this would be interpreted as parenchymal extinction due to acute/subacute event since there is no definite fibrosis.
to Chaparral leaf, a herbal drug.
Acute Hepatitis With Bridging Necrosis Pathologic features
The morphology is similar to inflammation-dominant acute hepatitis pattern with the additional presence of bridging necrosis. Regenerative nodules can also be present. These features can be mistaken for bridging fibrosis and interpreted as chronic hepatitis or even cirrhosis. The distinction between bridging necrosis and fibrosis can be challenging on needle biopsies, but can be accomplished in most cases by trichrome and elastic stains (Case 1.2). Differential diagnosis
Same as inflammation-dominant acute hepatitis pattern.
F I G U R E 1 . 8 Same case as in Figure 1.7. Trichrome stain is helpful in highlighting the centrizonal necrosis. The pale staining cells around the central vein are macrophages. There is no fibrosis.
Acute Hepatitis With Centrizonal Necrosis Pathologic features
Inflammation-dominant acute hepatitis pattern with varying degrees of hepatocellular injury and inflammation accompanied by necrosis around the central vein (Figures 1.7 and 1.8). Differential diagnosis
Most cases are associated with adverse drug reaction, especially if the centrizonal necrosis is sharply circumscribed and is out of proportion to the inflammation. Prominent centrizonal necrosis can also occur in AIH (10).
Resolving Hepatitis Pathologic features
Mild portal and lobular inflammation with scattered pigmentladen macrophages in the sinusoids, often more prominent around the central vein. Hepatocellular damage is typically mild. Periodic acid-Schiff diastase (PASd) stain can highlight the macrophages. The PASd-positive macrophages are the most characteristic feature of this pattern, but their numbers can vary depending on the duration of the disease.
CHAPTER
1:
ACUTE
H E PAT I T I S
5
Differential diagnosis
A vast majority of cases with this pattern represent adverse drug reaction, but the resolving phase of any acute hepatitis can lead to this picture. Mild Hepatitis Pattern Pathologic features
The features are similar to inflammation-dominant acute hepatitis pattern, but are mild. Hepatocellular swelling or dropout can be minimal, and lobular inflammation can be focal. This makes it challenging to recognize this as acute hepatitis pattern and distinguish it from biliary disease. A combination of clinical and biopsy features are necessary for this distinction: 1. Liver enzymes: Elevated ALT and/or AST, with normal or near-normal ALP favors hepatitic disease. If ALP is elevated, the ratio of serum activity of ALT to serum activity of ALP 5 favors a hepatitic process. 2. Autoantibodies: Elevated IgG, smooth muscle antibodies, and liver-kidney microsomal antibodies are typical of AIH, whereas elevated IgM and antimitochondrial antibodies favor PBC. 3. Biopsy: Since only mild hepatocellular injury can be seen in biliary disease, it does not establish hepatitic etiology (Figure 1.9). Both portal and lobular inflammation can also be seen in biliary diseases. On the other hand, nondestructive inflammatory involvement of the bile ducts can be seen as a minor finding in hepatitic disease (Figure 1.10), but destructive bile duct features or ductopenia are not seen. Hence liver enzymes and autoantibodies play an important role in distinguishing mild hepatitic pattern from biliary disease. 4. Copper: Since copper is secreted in the bile, it accumulates in periportal hepatocytes in biliary diseases.
F I G U R E 1 . 1 0 Lymphocytic infiltration of bile duct in chronic hepatitis C. Destructive bile duct lesions or granulomatous cholangitis is not seen.
Demonstration of copper in periportal hepatocytes by histochemical stains (rhodanine, rubeanic acid, or orcein) favors biliary disease (11,12). Negative copper stain is not informative. Differential diagnosis
1. All the 4 etiologies listed above for inflammationdominant acute hepatitis pattern can also lead to mild hepatitis pattern of injury, although AIH is less likely with mild injury. 2. Nonspecific reactive hepatitis is a term used to describe portal and lobular inflammation, with or without mild hepatocellular damage that can occur in systemic inflammatory disorders (like systemic lupus erythematosus [SLE], rheumatoid arthritis, celiac disease) and infections, especially in the abdomen (see Chapter 1.4). 3. Chronic hepatitis. Mild hepatitis pattern without fibrosis can be seen early in the course of chronic hepatitis, especially chronic hepatitis C. Screening for anti-HCV antibodies is carried out by enzyme immunoassays. False-positive and less commonly false-negative results can occur (13). False negativity typically occurs in recent infections, immunocompromised states, dialysis, and cryoglobulinemia (14). Recombinant immunoblot assays or direct testing for viral RNA by PCR are considered confirmatory tests. Giant Cell Hepatitis Pathologic features
FIGURE 1. 9 Prominent lobular inflammation in PBC.
The features are similar to inflammation-dominant acute hepatitis pattern with additional presence of multinucleated hepatocytes. This feature is well described in neonatal hepatitis.
6
CHAPTER
1:
ACUTE
Small multinucleated cells can occur in acute hepatitis due to any cause, but true syncytial giant cells are uncommon in older children and adults. Differential diagnosis
The majority of these cases represent AIH, and autoantibodies are present in a significant number of cases (see Chapter 3.5). The overlap syndrome of AIH and primary sclerosing cholangitis has also been linked to giant cell hepatitis. Viral infections like measles, Epstein-Barr virus, paramyxovirus, HIV, and hepatotropic viruses (A, B, and C) have been associated with giant cell hepatitis. Certain drugs like 6-mercaptopurine and methotrexate have been implicated but the evidence is not strong. PAT H OL OG Y R E P ORT
The diagnosis should encompass the morphologic subpattern of acute hepatitis followed by a discussion of etiological diagnosis in the comment. The term “active hepatitis” can be used in place of “acute hepatitis” in pathology diagnosis. This term connotes active hepatocellular injury without specifying the acute or chronic nature of the process. The 2 scenarios where the term “active hepatitis” can be useful are: 1. If necrosis is present in the liver biopsy, areas of liver parenchymal collapse can be extremely difficult to distinguish from fibrosis. Trichrome and elastic stains can be helpful in this distinction. If this distinction cannot be made based on the histologic features, the use of “active hepatitis” as the diagnostic term avoids definite categorization of the disease process as acute or chronic. 2. By definition, acute hepatitis resolves within 6 months. In the absence of complete clinical information, the term “active hepatitis” can be used.
H E PAT I T I S
References 1. Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology. 2006;43:618–631. 2. Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am J Surg Pathol. 1995;19:699–708. 3. Fujiwara K, Fukuda Y, Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis. J Gastroenterol. 2008;43:951–958. 4. Gollan JL, Gollan TJ. Wilson disease in 1998: genetic, diagnostic and therapeutic aspects. J Hepatol. 1998;28(suppl 1):28–36. 5. Davies SE, Williams R, Portmann B. Hepatic morphology and histochemistry of Wilson’s disease presenting as fulminant hepatic failure: a study of 11 cases. Histopathology. 1989;15:385–394. 6. Duggan JM, Duggan AE. Systematic review: the liver in coeliac disease. Aliment Pharmacol Ther. 2005;21:515–518. 7. Volta U. Pathogenesis and clinical significance of liver injury in celiac disease. Clin Rev Allergy Immunol. 2009;36:62–70. 8. Gordon SC, Reddy KR, Schiff L, Schiff ER. Prolonged intrahepatic cholestasis secondary to acute hepatitis A. Ann Intern Med. 1984;101:635–637. 9. Glikson M, Galun E, Oren R, Tur-Kaspa R, Shouval D. Relapsing hepatitis A. Review of 14 cases and literature survey. Medicine (Baltimore). 1992;71:14–23. 10. Hofer H, Oesterreicher C, Wrba F, Ferenci P, Penner E. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol. 2006;59:246–249. 11. Lefkowitch JH. Special stains in diagnostic liver pathology. Semin Diagn Pathol. 2006;23:190–198. 12. Nemolato S, Serra S, Saccani S, Faa G. Deparaffination time: a crucial point in histochemical detection of tissue copper. Eur J Histochem. 2008;52:175–178. 13. Kesli R, Ozdemir M, Kurtoglu MG, Baykan M, Baysal B. Evaluation and comparison of three different anti-hepatitis C virus antibody tests based on chemiluminescence and enzyme-linked immunosorbent assay methods used in the diagnosis of hepatitis C infections in Turkey. J Int Med Res. 2009;37:1420–1429. 14. Chronic hepatitis C. Current disease management. National Institute of Health. http://digestive.niddk.nih.gov/ddiseases/pubs/chronichepc/ chronichepc.pdf
Case 1.1
Acute Hepatitis With Inflammation-Dominant Pattern SANJAY KAKAR
C L I N IC AL I N F OR M AT I ON
A 38-year-old man presented with a 6-week history of weakness, abdominal pain, jaundice, dark urine, and light colored stools. On examination, there was mild hepatomegaly but no stigmata of chronic liver disease. Liver enzyme results showed ALT 569 U/L, AST 621 U/L, ALP 136 U/L, total bilirubin 12.7 mg/dl, direct bilirubin 7.1 mg/dl. Serological tests for hepatitis A, B, C, D, and E were negative. There were no autoantibodies, and ceruloplasmin levels, and serum IgG were normal. No significant drug history could be elicited. Radiology studies did not reveal any evidence of venous outflow obstruction. R E A SON F OR R E F E R R AL
The clinical and histologic impression was acute hepatitis, but the etiology could not be determined.
F I G U R E 1 . 1 . 2 The hepatic parenchyma shows foci of hepatocyte dropout and prominent Kupffer cells along the sinusoids.
PAT H OL OG I C F E AT U R E S
The liver biopsy showed mild portal inflammation comprising of lymphocytes, few plasma cells, and rare eosinophils (Figure 1.1.1). There was no significant interface inflammation, and the bile ducts were intact. The hepatic parenchyma demonstrated mild hepatocellular swelling as well as several foci of hepatocyte dropout (Figure 1.1.2). Scattered foci of lobular lymphocytic inflammation were present (Figure 1.1.3). Prominent Kupffer cells were seen in the sinusoids, some forming small clusters (Figure 1.1.2). In addition, there was mild steatosis with no evidence of steatohepatitis (Figure 1.1.2).
F I G U R E 1 . 1 . 3 There are foci of lobular inflammation and mild
steatosis.
There was no fibrosis on trichrome stain. PASd stain highlighted macrophages in the sinusoids (Figure 1.1.4). There were no globules to suggest alpha-1-antitrypsin deficiency.
DIAGNO SIS
Acute hepatitis C .
FIGURE 1. 1. 1 Mild predominantly lymphocytic portal inflammation
with minimal interface activity and normal bile duct.
7
8
CHAPTER
1:
ACUTE
FIGURE 1. 1. 4 PASd stain highlights the macrophages in the
sinusoids. D I SC U SSI ON
The histologic picture shows inflammation-dominant acute hepatitis pattern of injury. The typical differential diagnosis in this setting is acute viral hepatitis, adverse drug reaction, AIH, and Wilson disease. In this patient, serological tests for hepatitis A, B, and C were negative arguing against acute viral hepatitis. After thorough review of medication history, no offending drugs or herbal supplements were identified. The lack of prominent plasma cells and absence of high necroinflammatory activity were not characteristic of AIH, although this diagnosis cannot be excluded on histologic grounds. The lack of elevated IgG and autoantibodies did not favor this possibility. Workup for Wilson disease revealed normal serum ceruloplasmin and urinary copper. Celiac disease, a rare cause of acute hepatitis, was considered but serological test for tissue transglutaminase antibodies was negative, making this unlikely.
H E PAT I T I S
The cause of 10% to 15% of acute hepatitis cases cannot be determined after complete workup. On further exploration, it was found that the patient got a tattoo 2 months prior to biopsy. He was tested for hepatitis B virus DNA, hepatitis C virus RNA, and human immunodeficiency virus (HIV) RNA. The PCR results for hepatitis C virus RNA yielded a copy number of 105/ml; tests for hepatitis B and HIV were negative. The clinical presentation, history of exposure, and positive hepatitis C virus (HCV) RNA led to the diagnosis of acute hepatitis C. Most cases of acute hepatitis C are asymptomatic and remain clinically undetected (1–4). Symptomatic disease occurs in around 25% of cases (4). Rare cases of fulminant hepatitis have been reported (1). Symptomatic disease, history of recent exposure, and demonstration of HCV RNA help to establish the diagnosis in the setting of clinical presentation of acute hepatitis. The viral RNA appears in the serum within 1 to 2 weeks of the infection (4). However, seroconversion can take 2 to 6 months and hence serological testing for antiHCV antibodies alone may yield false-negative results (1–4). Majority of the patients (50%–80%) will progress to chronic hepatitis C (1–3), defined by persistence of viral RNA after 6 months. Spontaneous resolution is more likely to occur in patients younger than 40 years, women, and those with symptomatic disease, whereas immunosuppressed individuals are more likely to progress to chronic disease (4). There is no correlation between HCV genotype or viral copy numbers and disease clearance.
References 1. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis. 2005;9:383–398. 2. Heller T, Rehermann B. Acute hepatitis C: a multifaceted disease. Semin Liver Dis. 2005;25:7–17. 3. Chung RT. Acute hepatitis C virus infection. Clin Infect Dis. 2005;41:S14–S17. 4. Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol. 2008;103:1283–1297.
Case 1.2
Acute Hepatitis With Bridging Necrosis SANJAY KAKAR
C L I N IC AL I N F OR M AT I ON
A 42-year-old man presented with abdominal pain, jaundice, and tender hepatomegaly of 4 weeks’ duration. ALT and AST levels were greater than 1000 U/L, and ALP was minimally elevated. Ultrasound showed multiple liver nodules raising the possibility of cirrhosis. There was no history of prior liver disease. Serological tests for hepatitis A, B, and C as well as autoantibodies were negative. Serum ceruloplasmin was normal, and urinary copper was not elevated. There was no significant medication history. R E A SON F OR R E F E R R AL
The biopsy was preliminarily interpreted as chronic hepatitis with marked activity and possible cirrhosis, etiology undetermined. F I G U R E 1 . 2 . 2 Confluent necrosis associated with florid ductular
reaction.
PAT H OL OG I C F E AT U R E S
The liver biopsy showed marked portal and panacinar lymphoplasmacytic infiltrate (Figure 1.2.1). The bile ducts were intact. The hepatic parenchyma showed hepatocellular swelling, dropout, and confluent necrosis associated with ductular reaction (Figure 1.2.2). A nodular architecture was seen in several areas in the biopsy (Figure 1.2.3). It was difficult to determine whether this represents bridging necrosis or bridging fibrosis. The areas of bridging showed pale staining on trichrome in contrast to dense staining of portal tract collagen (Figures 1.2.4 A and B). No elastic fibers were seen in the area of bridging (Figure 1.2.5). These features support an acute process with necrosis and parenchyma collapse.
F I G U R E 1 . 2 . 3 Several areas in the biopsy showed a nodular architecture raising the possibility of cirrhosis.
DIAGNO SIS
Acute hepatitis with bridging necrosis and regenerative nodules, etiology undetermined.
DISCUSSIO N
The histologic picture shows inflammation-dominant pattern of injury with bridging necrosis and regenerative nodules. The distinction between bridging necrosis and bridging fibrosis in this setting can be challenging. The differentiation of acute
1. 2. 1 Dense portal and lobular lymphoplasmacytic infiltrate. The bile duct is intact.
FIGURE
9
10
CHAPTER
1:
ACUTE
H E PAT I T I S
A F I G U R E 1 . 2 . 5 Orcein stain shows absence of elastic fibers in the areas of bridging supporting necrosis with parenchymal collapse rather than fibrosis. Elastic fibers are present in the portal tract (left).
B FIGURE 1. 2. 4 (A) The trichrome stain showed pale staining in the
areas of bridging indicating that this represents necrosis rather than fibrosis. The portal tract shows dense staining of collagen. (B) The trichrome stain showed pale staining in the areas of bridging indicating that this represents necrosis rather than fibrosis. The portal tract shows dense staining of collagen.
hepatitis with confluent necrosis versus acute exacerbation of chronic disease can have important therapeutic implications. Although this can be challenging on hematoxylin and eosin (HE) stain on liver biopsy, histochemical stains for trichrome, elastic fibers, and reticulin can be very helpful. The combination of these 3 stains can distinguish necrosis from fibrosis in nearly all cases (1,2). 1. Trichrome stain: Areas with necrosis with parenchymal collapse are characterized by loose stroma with spaces between collagen fibers. Congestion or hemorrhage is often present in these areas. The trichrome stain shows a characteristic two-toned appearance in acute hepatitis with necrosis. The portal areas and walls of central veins
show dark and dense staining that reflects the presence of normal collagen bundles. The areas of necrosis with parenchymal collapse show lighter staining. Fibrous septa in chronic liver disease also show darkly staining dense collagen. It is important to have a good trichrome stain to appreciate the two-toned appearance. Areas of necrosis can be easily interpreted as fibrosis in overstained trichrome stain. 2. Elastic stain: Elastic fibers are present in normal portal tracts as well as in fibrous septa of chronic liver disease. They get deposited 2 to 3 months after injury. Absence of elastic fibers on elastic stains (Verhoeff elastic or orcein stain) favors necrosis over fibrosis. 3. Reticulin stain: Necrosis is accompanied by collapse of liver architecture. In these areas, reticulin stain outlines the collapsed residual architecture, but shows dense indistinct staining in fibrotic areas. The differential diagnosis in this setting is acute viral hepatitis, adverse drug reaction, AIH, and Wilson disease. Rare cases of celiac disease can also present with acute hepatitis (3,4). The clinical and laboratory workup does not support any of these possibilities in this case. The etiology of acute hepatitis cannot be determined in 10% to 15% of cases.
References 1. Scheuer PJ, Maggi G. Hepatic fibrosis and collapse: histological distinction by orcein staining. Histopathology. 1980;4:487–490. 2. Ferrell LD, Greenberg MS. Special stains can distinguish hepatic necrosis with regenerative nodules from cirrhosis. Liver Int. 2007;27: 681–686. 3. Duggan JM, Duggan AE. Systematic review: the liver in coeliac disease. Aliment Pharmacol Ther. 2005;21:515–518. 4. Volta U. Pathogenesis and clinical significance of liver injury in celiac disease. Clin Rev Allergy Immunol. 2009;36:62–70.
Case 1.3
Resolving Hepatitis SANJAY KAKAR
C L I N IC AL I N F OR M AT I ON
A 54-year-old woman presented with abdominal pain and mild jaundice for 2 weeks. Serological tests for viral hepatitis and autoantibodies were negative. ALT and AST were 400 to 500 U/L, and ALP was normal. The patient had been on lisinopril for hypertension for 2 months. Based on the clinical features, a diagnosis of lisinopril-induced liver injury was made. The drug was discontinued, but the ALT and AST did not return to normal 2 months after withdrawal, and a liver biopsy was performed. R E A SON F OR R E F E R R AL
The biopsy showed mild hepatocellular injury, and was referred for a definite diagnosis. PAT H OL OG I C F E AT U R E S F I G U R E 1 . 3 . 1 (B) The hepatic parenchyma shows mild lobular inflammation and pigment-laden macrophages along the sinusoids, especially around the central veins.
The liver biopsy shows mild portal inflammation composed of lymphocytes. The bile ducts are intact and there is no interface inflammation. Mild hepatocellular swelling is seen. There are small foci of lobular inflammation and scattered pigmentladen macrophages along the sinusoids (Figures 1.3.1A and B). PASd stain highlights these macrophages, especially around the central veins (Figure 1.3.2). D I AG N OS I S
Resolving hepatitis likely related to lisinopril-induced liver injury.
F I G U R E 1 . 3 . 2 The pigmented macrophages are highlighted by the
PASd stain. DISCUSSIO N
The histologic picture shows the resolving hepatitis pattern of injury. Mild hepatocellular damage and PASd-positive macrophages in the sinusoids are the characteristic features of this pattern. Most cases are due to adverse drug reaction. Clinical and biochemical resolution of drug-induced acute hepatitis occurs promptly in most cases following cessation of the offending agent. In a few instances, the resolution can be delayed for several weeks to months and these cases are more likely to be biopsied.
FIGURE 1. 3. 1 (A) The hepatic parenchyma shows mild lobular
inflammation and pigment-laden macrophages along the sinusoids, especially around the central veins.
11
12
CHAPTER
1:
ACUTE
This pattern can be seen in the resolving phase of acute hepatitis of any etiology. Viral hepatitis serologies and workup for AIH and Wilson disease should be considered in these cases, especially if a drug-related etiology is not readily apparent. Since hepatitis C serological tests can be false negative, testing for HCV RNA by PCR should be considered to exclude the diagnosis with certainty. Similar histological findings can be observed in nonspecific reactive hepatitis, a term used to describe mild hepatocellular injury in systemic diseases (1). These diseases include autoimmune diseases like SLE, rheumatoid arthritis, and celiac disease, and systemic infectious or inflammatory disorders.
H E PAT I T I S
Abdominal infections are particularly prone to show nonspecific reactive hepatitis. The patient was on lisinopril, which has been related to acute and fulminant hepatitis, and helped to establish the diagnosis (2).
References 1. Burt AD. Nonspecific reactive hepatitis. In: Burt AD, Portmann BC, Ferrell LD, eds. MacSween’s Pathology of the Liver. 5th ed. Churchill Livingstone, Elsevier, Philadelphia, PA; 2007: 881–883. 2. Larrey D, Babany G, Bernuau J, et al. Fulminant hepatitis after lisinopril administration. Gastroenterology. 1990;99:1832–1833.
Case 1.4
Nonspecific Reactive Hepatitis SANJAY KAKAR
C L I N IC AL I N F OR M AT I ON
A 64-year-old woman presented with acute cholecystitis and underwent cholecystectomy. Mild dilatation of the common bile duct was seen in the intrahepatic cholangiogram. The liver enzymes at the time of surgery showed mild elevation of ALT and AST (150–200 U/L), and ALP was mildly elevated (less than twice normal). Serological tests for viral hepatitis were negative. Antinuclear antibodies (ANAs) were present (1:160); test for smooth muscle antibodies was negative. An intraoperative core-needle liver biopsy was performed. R E A SON F OR R E F E R R AL
The biopsy showed mild hepatocellular inflammation and no definite cholestatic features, but a definite etiological diagnosis was not apparent.
F I G U R E 1 . 4 . 2 Mild lobular inflammation with minimal hepatocel-
lular injury.
PAT H OL OG I C F E AT U R E S
DISCUSSIO N
The liver biopsy shows mild lymphocytic portal inflammation without significant interface inflammation (Figure 1.4.1). The bile ducts are intact and there is no ductular reaction. Small foci of lobular inflammation are present (Figure 1.4.2). There is no fibrosis.
The histologic picture shows a mild hepatitis pattern of injury characterized by mild inflammation and hepatocellular damage. The patient has dilated biliary tree raising the possibility of large duct obstruction. However, the absence of portal expansion, edema, and ductular reaction does not support this possibility. The mild hepatitis pattern seen in this biopsy does not reliably distinguish between a mild acute hepatitis pattern and biliary disease. The following steps are essential to achieve this distinction:
D I AG N OS I S
Nonspecific reactive hepatitis, possibly related to acute cholecystitis.
1. Pattern of liver enzyme elevation: The mild elevation of ALT and AST with normal ALP, in this case, favors hepatitic disease. 2. Autoantibodies: ANA are not useful in distinguishing hepatitic versus biliary disease. Antimitochondrial antibodies were subsequently obtained to exclude PBC. ALP level can be normal in early PBC, and the biopsy may show nonspecific changes resembling the mild hepatitis pattern. 3. Serum immunoglobulins: Elevated serum IgG is characteristic of AIH, whereas increase in IgM level is typical of PBC. Both IgG and IgM were normal in this case. 4. Copper stain: Since copper is secreted in the bile, it tends to accumulate in biliary disease in periportal hepatocytes. Presence of periportal copper favors biliary disease, but a negative result is not helpful in excluding biliary disease. The copper stain was negative in this case. This exercise establishes a hepatitic pattern of biliary disease. The differential diagnosis includes a mild form of the 4 conditions that cause inflammation-dominant acute hepatitis
FIGURE 1. 4. 1 Mild lymphocytic inflammation in the portal tract
without interface activity.
13
14
CHAPTER
1:
ACUTE
pattern of injury: viral hepatitis, adverse drug reaction, AIH, and Wilson disease. The positive ANA had originally raised the clinical question of AIH. However, ANA can be positive in up to 30% of the normal population using 1:40 as the cutoff and in 3% with 1:320 as the cutoff. The modest transaminase elevations, negative SMA, normal IgG, absence of prominent necroinflammatory activity, and paucity of plasma cells do not provide support for AIH (1,2). The clinical and laboratory data do not support the other three possibilities. Rare possibilities like celiac disease should be evaluated with tissue transglutaminase antibodies depending on the clinical situation. In this case, the patient was undergoing surgery for acute cholecystitis. Nonspecific liver involvement is very common
H E PAT I T I S
in abdominal infections and manifests as mild hepatocellular injury and inflammation. The overall clinical and histological information points toward the diagnosis of nonspecific reactive hepatitis (3).
References 1. Czaja AJ, Norman GL. Autoantibodies in the diagnosis and management of liver disease. J Clin Gastroenterol. 2003;37:315–329. 2. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol. 1999;30:394–401. 3. Burt AD. Nonspecific reactive hepatitis. In: Burt AD, Portmann BC, Ferrell LD, eds. MacSween’s Pathology of the Liver. 5th ed. Churchill Livingstone Elsevier, Philadelphia, PA; 2007: 881–883.
2 Acute Liver Failure RAGESHREE RAMACHANDRAN AND SANJAY KAKAR
In Asia, viral hepatitis is the most common cause of ALF. Hepatitis B is common in China, Hong Kong, and Taiwan, whereas hepatitis E accounts for many cases in India (9). Acute flares of chronic HBV may present clinically as ALF in previously asymptomatic chronic HBV carriers. The 2000–2006 data from the Pediatric Acute Liver Failure Study Group shows that the cause cannot be identified in approximately 50% of cases (10). In the population aged 0 to 3 years, acetaminophen accounts for only 3% of cases compared with 12% overall in children. Metabolic disease represents 10% to 15%, and viral causes comprise 6% to 8% of cases. Ischemia and autoimmune disease each account for less than 10% of pediatric cases. The outcome in the pediatric setting is more favorable than that of adults, with high rates of survival for acetaminophen toxicity and hepatitis A–induced ALF. Death is attributed to cerebral edema or sepsis in most cases. Morbidities include respiratory distress with mechanical ventilatory support, acute renal failure, and infection (7). In the United States, approximately 5% to 10% of liver transplantations are performed every year for ALF (11). Outcome is predicted by degree of encephalopathy and patient age. The role of underlying etiology and histopathology (including severity of confluent necrosis) in predicting outcome is unclear (12), though biopsy diagnosis can be useful in assigning etiology, as in the case of AIH (13).
D E FI N I T I ON A N D T E R M I N OL OG Y
Acute liver failure (ALF) is defined as the onset of hepatic encephalopathy and coagulopathy within 8 to 26 weeks of the onset of symptoms in patients without known underlying liver disease (1). It can progress rapidly to multiorgan failure within a matter of days, necessitating emergency liver transplantation. Overall mortality rate is high and can reach up to 85% (2). Other terms that have been used are fulminant hepatitis, massive necrosis, and submassive necrosis. Since necrosis may not be present in every case and some cases may not be due to hepatitic causes, the term ALF is more appropriate. C L IN I C AL F E AT U R E S
In the United States, drugs are the most common cause of ALF in adults (Table 2.1), accounting for 25% to 50% of cases (3–6). Of these, acetaminophen accounts for the majority of drug-related cases. Based on the Acute Liver Failure Study Group data collected from 1998 to 2007, the remaining causes in the adult population include hepatitis B virus (HBV) (7%), hepatitis A virus (3%), autoimmune hepatitis (AIH) (5%), ischemia (4%), and Wilson disease (2%). In 14% of cases, the cause of fulminant hepatitis cannot be identified (7). Rare instances of ALF have been reported with amyloidosis (8).
PAT H O LO GIC FEAT UR ES A ND DIFFER ENT IA L DIAGNO SIS
TA B LE 2. 1 Causes of acute liver failure Disease Category
Specific Etiologies
Infectious (viral)
Hepatotropic viruses Hepatitis A, B, less commonly D, E Nonhepatotropic viruses HSV-1, HSV-2, adenovirus
Drugs/toxins
Dose-dependent toxicity Acetaminophen Ecstasy, cocaine Idiosyncratic reaction Isoniazid, halothane, herbal medications Toxins Amanita phalloides (mushrooms)
Metabolic
Wilson disease, Reye syndrome, nonalcoholic steatohepatitis (rare)
Pregnancy-associated
Acute fatty liver of pregnancy, HELLP syndrome
Vascular
Budd-Chiari syndrome, veno-occlusive disease, shock/sepsis (ischemia)
Other
AIH, metastatic neoplasms, amyloidosis
Liver biopsy is often contraindicated due to the risk of severe bleeding. In cases where biopsy is performed, the histologic features can be a useful guide to the etiology of ALF. Based on the morphological features, ALF can be divided into 3 histological patterns (Table 2.2): TA BL E 2 . 2 Histological patterns of injury in acute liver failure
and their differential diagnosis
Abbreviations: AIH, autoimmune hepatitis; HSV, herpes simplex virus.
Histological Pattern
Common Disease Entities
Necrosis with prominent inflammatory activity
Acute viral hepatitis, idiosyncratic drug reaction, AIH, Wilson disease
Necrosis with little inflammation
Dose-dependent drug toxicity (acetaminophen), toxins, nonhepatotropic viruses (herpes simplex), vascular etiologies
Microvesicular steatosis
Drugs (tetracycline, zidovudine, valproic acid), acute fatty liver of pregnancy, rare metabolic conditions
Abbreviation: AIH, autoimmune hepatitis.
15
16
CHAPTER
2:
ACUTE
LIVER
FAILURE
2. Necrosis with little or no inflammation. The liver shows confluent necrosis, with negligible inflammation. The leading cause in this category is dose-dependent drug injury exemplified by acetaminophen. The anesthetic agent halothane, recreational drugs such as cocaine and 3,4-methylenedioxymethylamphetamine (MDMA, Ecstasy), industrial organic compounds such as carbon tetrachloride, and herbal agents such as pennyroyal, glue thistle, and germander can lead to the same pattern. Some cases of ALF due to Wilson disease can also have this morphology. Infections with nonhepatotropic viruses typically result in necrosis with negligible inflammation. Herpes simplex and adenoviral hepatitis are the most common in this category. Other less common causes of ALF with minimal inflammation include metastatic carcinoma, acute Budd-Chiari syndrome, and ischemic hepatitis. FIGURE 2. 1 Atorvastatin-induced ALF showing confluent necrosis, prominent inflammatory activity, and a small area of residual liver parenchyma (left).
3. Extensive microvesicular steatosis. The liver biopsy shows diffuse microvesicular steatosis with little inflammation. A variable degree of cholestasis and necrosis may be present. These morphological changes are a manifestation of mitochondrial injury and are often accompanied by lactic acidosis (16).
1. Necrosis with prominent inflammatory activity. The liver shows confluent necrosis accompanied by prominent portal and panacinar inflammation (Figure 2.1). The confluent necrosis often involves the majority of the liver parenchyma (massive/submassive hepatic necrosis) and can be associated with prominent ductular reaction. Cholestasis may be present. The inflammation is dominated by lymphocytes and plasma cells; neutrophils can be seen in association with ductular reaction. Necrosis can be distinguished from fibrosis on trichrome and elastic stains (see Case 1.2).
Most cases result from drug toxicity (see Cases 4.8 and 15.9) related to tetracycline (antibiotic), valproic acid (anticonvulsant), zidovudine (nucleoside analog used in human immunodeficiency virus [HIV]), L-asparaginase (chemotherapeutic drug), and amineptine (antidepressant) (17–23). Other settings that can lead to microvesicular steatosis include alcohol foamy degeneration, Reye syndrome, acute fatty liver of pregnancy, Jamaican vomiting sickness, and rare metabolic conditions like congenital deficiency in urea-cycle enzymes and carnitine deficiency.
The differential diagnosis of this pattern of injury includes viral hepatitis, AIH, idiosyncratic drug reaction, and Wilson disease. The distinction may not be possible on histologic grounds alone, and correlation with clinical and laboratory tests is necessary. Serological tests and/or viral titers are necessary for the diagnosis of hepatotropic viral hepatitides. Immunohistochemical stains for hepatitis B core antigen and hepatitis B surface antigen can be useful in cases of acute exacerbation of chronic hepatitis but are negative in acute hepatitis B. Travel history to areas where viral hepatitis E is endemic can be helpful. The presence of numerous plasma cells raises the possibility of AIH, but it is not a specific finding. The diagnosis can be supported by elevated immunoglobulin G (IgG) levels and serum autoantibodies smooth muscle antibody. If liver biopsy is undertaken after preemptive treatment with steroids, inflammation may not be marked and plasma cells may not be prominent. Commonly implicated drugs in ALF include isoniazid, other antimicrobials (sulfonamides, cotrimoxazole, ketoconazole), monoamine oxidase inhibitors, and anticonvulsants (phenytoin, valproate) (14,15). Any drug that causes acute hepatitis can potentially cause ALF. Wilson disease should always be considered in patients younger than 50 years and especially if there is associated hemolysis.
References 1. Schiødt FV, Lee WM. Fulminant liver disease. Clin Liver Dis. 2003;7: 331–349, vi. 2. Ichai P, Samuel D. Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl. 2008;14(suppl 2):S67–S79. 3. Williams R. Classification, etiology, and considerations of outcome in acute liver failure. Semin Liver Dis. 1996;16:343–348. 4. Lee WM. Acute liver failure. Clin Perspect Gastroenterol. 2001;2:101–110. 5. Williams R. Changing clinical patterns in acute liver failure. J Hepatol. 2003;39:660–661. 6. Hanje AJ, Chalasani N. How common is chronic liver disease from acute drug-induced liver injury? Gastroenterology. 2007;132:2067–2068, discussion 2068–2069. 7. Lee WM, Squires RH Jr, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: summary of a workshop. Hepatology. 2008;47:1401–1415. 8. Hung HH, Huang DF, Tzeng CH, et al. Systemic amyloidosis manifesting as a rare cause of hepatic failure. J Chin Med Assoc. 2010;73:161–165. 9. Cheng VC, Lo CM, Lau GK. Current issues and treatment of hepatic failure including transplantation in Hong Kong and the Far East. Semin Liver Dis. 2003;23:239–250. 10. Squires RH Jr, Shneider BL, Bucuvalas J, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr. 2006;148:652–658. 11. Gotthardt D, Riediger C, Weiss KH, et al. Fulminant hepatic failure: etiology and indications for liver transplantation. Nephrol Dial Transplant. 2007;22(suppl 8):viii5–viii8.
CHAPTER
2:
ACUTE
12. Hanau C, Munoz SJ, Rubin R. Histopathological heterogeneity in fulminant hepatic failure. Hepatology. 1995;21:345–351. 13. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938. 14. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug-induced liver injury in the United States. Liver Transpl. 2004;10:1018–1023. 15. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935–952. 16. Pessayre D, Mansouri A, Berson A, Fromenty B. Mitochondrial involvement in drug-induced liver injury. Handb Exp Pharmacol. 2010;196: 311–365. 17. De Bus L, Depuydt P, Libbrecht L, et al. Severe drug-induced liver injury associated with prolonged use of linezolid. J Med Toxicol. 2010;6: 322–326.
LIVER
FAILURE
17
18. Haas S, Rockstroh JK, Spengler U, Fischer HP. Nucleoside induced hepatopathy in HIV patients. Diagnostic value of liver biopsy assessment. Pathologe. 2004;25:406–411. 19. Koch RO, Graziadei IW, Zangerle R, Romani N, Maier H, Vogel W. Acute hepatic failure and lactate acidosis associated with antiretroviral treatment for HIV. Wien Klin Wochenschr. 2003;115:135–140. 20. Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krähenbühl S. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase. Digestion. 2006;74:28–32. 21. Huang YL, Hong HS, Wang ZW, Kuo TT. Fatal sodium valproateinduced hypersensitivity syndrome with lichenoid dermatitis and fulminant hepatitis. J Am Acad Dermatol. 2003;49:316–319. 22. Uchida T, Kao H, Quispe-Sjogren M, Peters RL. Alcoholic foamy degeneration—a pattern of acute alcoholic injury of the liver. Gastroenterology. 1983;84:683–692. 23. Lionte C. Lethal complications after poisoning with chloroform—case report and literature review. Hum Exp Toxicol. 2010;29:615–622.
Case 2.1
Acute Liver Failure With Necrosis-Dominant Injury Pattern SANJAY KAKAR
C L I N I C AL I N F OR M AT I ON
A previously healthy 65-year-old man presented with abrupt onset of fever and abdominal pain. Regular medications included aspirin and acetaminophen. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) was markedly elevated (>1500 U/L). Serological studies for hepatitis A, B, and C as well as autoantibodies were negative. A liver biopsy was obtained. The patient was presumptively treated for acetaminophen toxicity but developed renal failure and hepatic encephalopathy. R E A S ON F OR R E F E R R A L
To establish etiology of liver failure. PAT H OL OG I C F E AT U R E S
F I G U R E 2 . 1 . 2 The nuclei of the hepatocytes at the periphery of the necrotic areas show eosinophilic ground-glass appearance with smudging and margination of nuclear chromatin.
The liver biopsy showed widespread hemorrhage and confluent nonzonal hepatocellular necrosis (Figure 2.1.1). The inflammatory infiltrate was scant. At the periphery of the necrotic areas, the nuclei of viable hepatocytes showed ground-glass or smudged appearance with margination of nuclear chromatin (Figure 2.1.2). Some nuclei showed large eosinophilic inclusions with a surrounding halo (Figure 2.1.3). Occasional multinucleated cells were present. Macrovesicular steatosis was also present, perhaps as an incidental finding. Portal tracts were largely unremarkable with intact bile ducts. Immunohistochemistry for herpes simplex virus (HSV) was positive, confirming the diagnosis (Figure 2.1.4).
F I G U R E 2 . 1 . 3 Some hepatocytes show prominent eosinophilic intranuclear inclusions surrounded by a halo.
DIAGNO SIS
Herpes simplex virus hepatitis leading to acute liver failure.
DISCUSSIO N
The histologic pattern of necrosis with minimal inflammation is typical of HSV hepatitis. The presence of viral inclusions excludes other etiologies that can cause a similar pattern of
FIGURE 2. 1. 1 Widespread hemorrhagic nonzonal necrosis with no
significant inflammation.
18
CASE
2.1:
ACUTE
LIVER
FAILURE
FIGURE 2. 1. 4 Immunohistochemistry shows herpes simplex virus
inclusions in the nuclei of infected cells.
injury, such as dose-dependent adverse drug reaction (acetaminophen), toxin-mediated injury, and vascular etiologies. HSV hepatitis usually occurs in neonates, pregnant women, or immunocompromised patients. However, fulminant HSV infection can affect otherwise healthy people. Hepatic involvement is the result of disseminated infection and can occur with both HSV types 1 and 2. Symptoms are generally nonspecific but may include fever, headache, and abdominal or muscle pain. Marked elevation of transaminases in the absence of jaundice and hepatomegaly is typical. Mucocutaneous manifestations are observed in half of the cases (1,2). Since the disease can follow a rapidly progressive course, early diagnosis and treatment with acyclovir are imperative. The presence of mucocutaneous rash, genital symptoms, and anicteric hepatitis with prominent transaminase elevations helps in raising clinical suspicion for HSV hepatitis. In cases of ALF of unknown etiology, preemptive antiviral therapy (acyclovir) is recommended during evaluation for liver transplantation (3). Survival rate is greater than 40% after transplantation for HSV-induced ALF and patients are advised to stay on lifelong antiviral prophylaxis, usually acyclovir (4). HSV-1 and HSV-2 are synonymous with human herpes viruses 1 and 2 (HHV-1 and HHV-2). Varicella-zoster virus (VZV), Epstein-Barr virus (EBV), and cytomegalovirus (CMV), are also part of the human herpes virus family (HHV-3, -4, and -5, respectively) and have the potential to cause hepatitis. EBV causes an infectious mononucleosis-like syndrome, with frequent but mild liver involvement in most cases. Liver transaminases can be elevated but jaundice is rare. The liver usually shows a diffuse lymphocytic sinusoidal infiltrate. A few atypical lymphocytes and occasional nonnecrotizing granulomas can be present. Focal apoptotic bodies can be seen, but cholestasis or prominent hepatocellular damage is not present. In situ hybridization and/or polymerase chain
WITH
NECROSIS-DOMINANT
INJURY
19
reaction can be used to confirm EBV infection (5). However, these cases are rarely biopsied. Rare cases of ALF have been reported with EBV (6). CMV is a cause of neonatal hepatitis in infancy. In immunocompetent individuals, it causes an infectious mononucleosis-like syndrome similar to EBV. Nonnecrotizing granulomas can be present. Among the immunocompromised hosts, CMV is especially common in renal transplant recipients. In liver transplant recipients, CMV hepatitis has to be distinguished from acute rejection. Characteristic CMV inclusions can be identified in hepatocytes, but significant inflammation or necrosis seen in other forms of acute hepatitis is often not present. Small neutrophilic collections resembling microabscesses can be present around the hepatocytes with viral inclusions (7,8). HHV-6 can cause mild, nonspecific hepatitis. HHV-8 seropositivity is common in patients with cirrhosis (9), but its role in ALF is unclear. Adenoviral hepatitis is histologically similar to HSV hepatitis and usually occurs in immunocompromised hosts but may rarely involve healthy individuals (10). Immunohistochemistry or in situ hybridization is necessary to confirm the diagnosis. Other less-common viral infections that can cause acute hepatitis with widespread necrosis include yellow fever, dengue fever, and Ebola fever. Parvovirus B19 can cause fulminant hepatitis in children. Mild nonspecific liver inflammation can also be seen with Coxsackie virus, rubella, and measles.
References 1. Peters DJ, Greene WH, Ruggiero F, McGarrity TJ. Herpes simplexinduced fulminant hepatitis in adults: a call for empiric therapy. Dig Dis Sci. 2000;45:2399–2404. 2. Sharma S, Mosunjac M. Herpes simplex hepatitis in adults: a search for muco-cutaneous clues. J Clin Gastroenterol. 2004;38:697–704. 3. Norvell JP, Blei AT, Jovanovic BD, Levitsky J. Herpes simplex virus hepatitis: an analysis of the published literature and institutional cases. Liver Transpl. 2007:1428–1434. 4. Riediger C, Sauer P, Matevossian E, Müller MW, Büchler P, Friess H. Herpes simplex virus sepsis and acute liver failure. Clin Transplant. 2009;23(suppl 21):37–41. 5. Suh N, Liapis H, Misdraji J, Brunt EM, Wang HL. Epstein-Barr virus hepatitis: diagnostic value of in situ hybridization, polymerase chain reaction, and immunohistochemistry on liver biopsy from immunocompetent patients. Am J Surg Pathol. 2007;31:1403–1409. 6. Ader F, Chatellier D, Le Berre R, Morand P, Fourrier F. Fulminant Epstein-Barr virus (EBV) hepatitis in a young immunocompetent subject. Med Mal Infect. 2006;36:396–398. 7. Seehofer D, Rayes N, Tullius SG, et al. CMV hepatitis after liver transplantation: incidence, clinical course, and long-term follow-up. Liver Transpl. 2002;8:1138–1146. 8. Razonable RR. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol. 2008;14: 4849–4860. 9. Chou AL, Huang WW, Tsao SM, Li CT, Su CC. Human herpesvirus type 8 in patients with cirrhosis: correlation with sex, alcoholism, hepatitis B virus, disease severity, and thrombocytopenia. Am J Clin Pathol. 2008;130:231–237. 10. Wang WH, Wang HL. Fulminant adenovirus hepatitis following bone marrow transplantation. A case report and brief review of the literature. Arch Pathol Lab Med. 2003;127:e246–e248.
This page intentionally left blank
3 Autoimmune Hepatitis/Overlap Syndromes KAY WASHINGTON
modified in 1999 (2,3) (Table 3.2). This system classifies cases as definite or probable AIH, based on weighted parameters. In multiple reports, this system has a high degree of sensitivity (97%–100%) for diagnosis of AIH. The system also effectively
AU TOI M M U N E H E PAT I T I S Definition
Autoimmune hepatitis (AIH) is characterized as an unresolving hepatitis usually associated with hypergammaglobulinemia and tissue-directed autoantibodies and responding in most cases to immunosuppressive therapy. The pathogenesis appears to be aberrant autoreactivity in genetically susceptible individuals (1), with molecular mimicry between viral and self-antigens the likely basis for the autoimmune response.
TA BL E 3 . 2 The revised international autoimmune hepatitis group
modified scoring system
Diagnosis and Scoring Criteria
AIH is diagnosed by consideration of the combination of clinical and laboratory features with exclusion of other causes of liver disease such as viral hepatitis, Wilson disease, alpha1-antitrypsin deficiency, primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), alcohol abuse, and drug reaction (Table 3.1). Essential features are elevated serum transaminase levels, usually with antinuclear antibody (ANA) and/or smooth muscle antibody (SMA) seropositivity; immunoglobulin G (IgG) levels greater than 1.5 times normal; and compatible liver histology. Serum bilirubin levels are variable, but alkaline phosphatase is usually only mildly elevated. Diagnosis of AIH is straightforward in 50% of cases and is aided by serum studies and the scoring system developed by the International Autoimmune Hepatitis Working Group and TA B LE 3. 1 Histologic differential diagnosis of autoimmune
hepatitis Disease
Distinguishing Features
AIH
Prominent plasma cells Often very active necroinflammatory activity May show centrilobular necrosis and inflammation early in disease course
Chronic viral hepatitis
Portal lymphoid aggregates (HCV); steatosis (HCV); ground glass hepatocytes (HBV)
Drug-induced hepatitis
No helpful distinguishing features; may mimic AIH
Wilson disease
Mallory’s hyaline; copper deposition; prominent glycogenated nuclei
Primary biliary cirrhosis
Florid duct lesions and ductopenia
Primary sclerosing cholangitis
Fibrous obliteration of bile ducts
Category
Score
Female sex
2
ALP:AST (or ALT) ratio 1.5 1.5–3.0 3.0
2 0 2
Serum globulins or IgG above normal 2.0 1.5–2.0 1.0–1.5 1.0
3 2 1 0
Autoantibodies (ANA, SMA, or LKM-1) 1:80 1:80 1:40 1:40
3 2 1 0
Hepatitis viral markers Positive Negative
3 3
Drug history Positive Negative
4 1
Average alcohol consumption Low (25 grams/day) High (60 grams/day)
2 2
Liver histology Interface hepatitis Lymphoplasmacytic infiltrate Hepatocyte rosette pattern of regeneration None of the above Biliary changes Other features Other autoimmune disorders in patients or first-degree relatives
Abbreviations: AIH, autoimmune hepatitis; HBV, hepatitis B virus; HCV, hepatitis C virus.
3 1 1 5 3 3
Comments
Lower titers are considered significant in children and should be scored at least 1.
The patient should be tested for markers of hepatitis A, B, and C infection; tests for other viruses such as EBV and CMV may be considered. Recent use of known or suspected hepatotoxic drugs.
“Biliary changes” refers to bile duct patterns of injury typical of PBC or PSC or with ductopenia in an adequate biopsy. “Other features” are any suggesting an alternative etiology, eg, nonalcoholic fatty liver disease.
2
(continued)
21
22
CHAPTER
3:
AU T O I M M U N E
H E PAT I T I S / O V E R L A P
TA B LE 3. 2 The revised international autoimmune hepatitis group
modified scoring system (continued) Category Optional parameters in patients who are seronegative for ANA, SMA, and LKM-1 Seropositivity for other defined autoantibodies HLA DR3 or DR4
Score
Comments
2
Other defined antibodies are those with published evidence of relevance to AIH and include p-ANCA, anti-LC1, anti-SLA, and anti-ASGPR.
1 2 3
Response to therapy Complete relapse Interpretation of aggregate scores Pretreatment Definite AIH Probable AIH
15 10–15
Post-treatment Definite AIH Probable AIH
17 12–17
SYNDROMES
system that is more widely applicable in routine clinical practice (4). In this simplified system, 3 categories for grading histology are defined: 1. Typical histology for AIH. Each of the following 3 features is required: i. Interface hepatitis, with lymphocytic/lymphoplasmacytic inflammation in portal tracts and extending into the lobule (Figures 3.1 and 3.2) ii. Emperipolesis (engulfment of lymphocytes by hepatocytes) (Figure 3.1) iii. Hepatocyte rosette formation (Figure 3.3) 2. Histology compatible with AIH. Chronic hepatitis pattern of injury with lymphocytic infiltration but lacking some of the features considered “typical.” 3. Atypical histology for AIH. Features suggestive of other diagnoses (eg, steatohepatitis) are present.
Abbreviations: AIH, autoimmune hepatitis; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ANA, antinuclear antibody; ASGPR, asialoglycoprotein receptor; AST, aspartate aminotransferase; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HLA, human leukocyte antigen; IgG, immunoglobulin G; SMA, smooth muscle antibody; LC1, liver cytosol 1 antibody; anti-LKM-1, anti–liver-kidney microsomal antibody; p-ANCA, protoplasmic antineutrophil cytoplasmic antibodies; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; SLA, soluble liver antigen. From Ref. 2.
TA B LE 3. 3 Simplified diagnostic criteria for AIH Feature
Cutoff
Points
ANA or SMA
1:40
1
ANA or SMA
1:80
2*
OR LKM
1:40
OR SLM
Positive
IgG
Liver histology
Absence of viral hepatitis
FIGURE 3.1 Prominent interface hepatitis with emperipolesis (engulfment of lymphocytes by hepatocytes, arrow) in autoimmune hepatitis.
upper limit of normal
1
1.10 times upper limit of normal
2
Compatible with AIH
1
Typical AIH
2
Yes
2 6: probably AIH 7: definite AIH
*Addition of points achieved for all antibodies (maximum, 2 points) Abbreviations: AIH, autoimmune hepatitis; ANA, antinuclear antibody; IgG, immunoglobulin G; LKM, liver-kidney microsomal antibody; SMA, smooth muscle antibody. From Ref. 4.
excludes AIH in patients with PSC and biliary disorders (96%–100% accuracy for exclusion of definite AIH). The overall diagnostic accuracy of the scoring system is roughly 90%. Recently, a simplified scoring system (Table 3.3) has been proposed by the same group, with the goal of producing a
F I G U R E 3 . 2 Lobular necroinflammatory activity with apoptotic hepatocyte (arrow) in autoimmune hepatitis.
CHAPTER
3:
AU T O I M M U N E
H E PAT I T I S / O V E R L A P
SYNDROMES
23
TA BL E 3 . 4 Helpful clinicopathologic features for distinguishing
autoimmune hepatitis, primary biliary cirrhosis, primary biliary cirrhosis, and hepatitis C virus
FIGURE 3. 3 Hepatocellular regeneration resulting in “rosettes” in autoimmune hepatitis.
Clinical and Immunologic Features of AIH Clinical features
AIH, like most autoimmune disorders, is more common in female patients, with a male:female ratio of roughly 1:4. It can present at any age, but younger patients appear to have a more severe form of the disease. Presentation varies widely, ranging from asymptomatic elevations of serum liver enzymes, to massive hepatic necrosis resulting in fulminant hepatic failure, to cirrhosis with portal hypertension. Approximately 30% of patients, usually younger patients, will have an acute presentation mimicking acute viral hepatitis. Roughly 20% of patients will be asymptomatic, with elevated transaminases identified on screening examination or during evaluation for amenorrhea, thyroid disease, arthralgia, or diabetes mellitus. Such patients tend to be older (mean age, 48 years) than patients symptomatic at diagnosis (mean age, 41 years). About 50% of patients with AIH will have concurrent autoimmune disorders, most commonly thyroid disease or rheumatoid arthritis. The presence of ulcerative colitis, however, should raise questions about the diagnosis of AIH; such patients are more likely to have PSC (Table 3.4). Immunologic features
The 3 most commonly reported antibodies in AIH are ANA, SMA, and anti-liver-kidney microsomal (LKM) antibodies (Table 3.5). In general, though useful for diagnosis, the autoantibody titer does not reliably reflect disease severity or outcome. Of the patients with AIH, 70% to 80% have ANA or SMA antibodies or both (1:40). The ANA react mainly with histones and DNA, yielding a homogeneous pattern, but other patterns also occur, with no apparent clinical significance (5–22). The SMA reacts with several cytoskeletal components, including F-actin. Overall, 3% to 4% of the patients (usually children) present with anti-LKM-1 antibodies, without ANA or SMA.
Disease
Most Useful Features
AIH
• “Definite AIH” or “probable AIH” on modified AIH scoring system • Prominent lobular hepatitis • Prominent interface hepatitis with numerous plasma cells • Negative viral studies, including HCV RNA
PBC
• • • •
PSC
• Abnormal cholangiogram • Concentric periductal fibrosis • Ductopenia
HCV
• HCV RNA in serum • Plasma cells usually not prominent • Lobular activity is usually mild; severely active chronic hepatitis favors AIH
Florid duct lesion Ductopenia High titer AMA High alkaline phosphatase with lower transaminase levels
Abbreviations: AIH, autoimmune hepatitis; AMA, antimitochondrial antibodies; HCV, hepatitis C virus; PBC, primary biliary cirrhosis; PBV, primary biliary cirrhosis; PSC, primary sclerosing cholangitis.
TA BL E 3 . 5 Autoantibodies in autoimmune hepatitis Antibody
Test
Comments
ANA
Usual test is indirect IF. Hep-2 cells give higher values than tissue sections; ELISAs not sufficiently standardized.
Specific IF pattern has no clinical significance. Other liver diseases associated with ANA include PBC, PSC, HCV, drug injury, NASH.
SMA
IF and ELISA
Directed against F-actin; found alone or in conjunction with ANA in up to 87% of patients.
SLA/LP
Immunoassay or Western blot; commercial ELISA assay now approved
High specificity for AIH but limited sensitivity.
LKM
Indirect IF
Patients with Type 2 AIH usually have only LKM antibodies. LKM antibodies may be found in other conditions, notably hepatitis C.
Abbreviations: AIH, autoimmune hepatitis; ANA, antinuclear antibody; ELISA, enzyme linked immunosorbent assay; F-actin, filamentous-actin; HCV, hepatitis C virus; IF, immunofluorescence; LKM, liver-kidney microsomal antibody; anti-LKM, anti–liver-kidney microsomal antibody; NASH, nonalcoholic steatohepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; SLA/LP, soluble liver antigen/liver pancreas antigen; SMA, anti–smooth muscle antibody.
This serologic marker is more common in southern Europe, but the true prevalence is not known; less than 4% of patients in the United States have LKM-1 antibodies compared with 20% in Europe. Antibodies against the soluble liver antigen/ liver pancreas antigen (SLA/LP) are found in 10% to 30% with AIH; although testing for this autoantibody is not routine, it appears to have a global distribution. Protoplasmic
24
CHAPTER
3:
AU T O I M M U N E
H E PAT I T I S / O V E R L A P
antineutrophil cytoplasmic antibodies (p-ANCA), though not specific, are present in 60% to 90% of patients (23). AIH may be subclassified based on the autoantibody profile (Table 3.6); Type 1 AIH is defined as ANA and/or SMA positive and has a bimodal age distribution with peaks between 10 and 20 and 45 and 70 years of age. Type 2 AIH is characterized by the presence of anti-LKM-1 antibodies; the majority of these patients are young women with severe disease. However, because Type 1 AIH is much more common than Type 2, most young women with severe disease are Type 1 AIH. Patients with Type 2 AIH present between ages 2 and 4 years and may have ectodermal dysplasia, mucocutaneous candidiasis, and endocrinopathies suggesting autoimmune polyglandular syndrome Type 1 (24). Type 3 AIH, characterized by positivity for SLA/LP antibodies, is clinically indistinguishable from Type 1. Approximately 10% to 20% of AIH patients are initially seronegative for the conventional autoantibodies, which may appear after immunosuppressive therapy is begun. p-ANCA testing may be helpful in this subgroup of patients, and viral hepatitis B and C should be excluded prior to initiation of treatment. Natural History and Treatment of AIH
AIH is characterized by a fluctuating clinical course, with waxing and waning of necroinflammatory activity, but symptomatic AIH is considered a progressive disease that if untreated will usually result in cirrhosis. About one-third of patients are cirrhotic at presentation and have a less favorable outcome (62% vs 94% 10-year survival) (5). Rarely, patients present with acute liver failure (ALF). The mainstay of treatment for AIH is long-term immunosuppression, typically corticosteroid therapy with or without azathioprine. In most cases, the necroinflammatory process responds promptly to immunosuppressive therapy, although relapses with withdrawal of therapy are common and the disease can recur following liver transplantation. After a biochemical response is achieved, many patients can be maintained on azathioprine monotherapy. A second liver biopsy to determine treatment endpoints based on histologic response is not uniform medical practice.
SYNDROMES
F I G U R E 3 . 4 Normal histologic findings after resolution of autoimmune hepatitis with corticosteroid therapy.
It is generally felt that histologic improvement lags behind biochemical improvement by several months, and often biopsies show low-grade necroinflammatory activity as long as 6 months after normalization of transaminase levels. Some hepatologists require normal histology on liver biopsy before withdrawal of treatment (Figure 3.4). However, histologic resolution does not guarantee that the patient will remain in remission. Portal plasma cell infiltrates during immunosuppressant therapy are associated with relapse upon drug cessation (6,7). For patients who present with fulminant hepatic failure secondary to AIH, liver transplantation may be necessary. Recurrence of AIH in the hepatic allograft is relatively common, occurring in approximately one-third of adult patients (8), and is more common in children. Outcome in most cases appears to be favorable, with few patients requiring retransplantation (8–10). Hepatocellular carcinoma, a relatively common complication of chronic viral hepatitis, is rarely seen in AIH, occurring only in the setting of cirrhosis (11).
References TA B LE 3. 6 Serologic classification of autoimmune hepatitis Autoantibodies
Features
Type 1
ANA and/or SMA
Most common type
Type 2
LKM, ANA, and SMA negative
Young children in the United States; initially thought to have worse prognosis but responds well to treatment.
Type 3
SLA/LP
Indistinguishable clinically from Type 1; clinical course is controversial, possibly more likely to relapse after corticosteroids.
Abbreviations: AIH, autoimmune hepatitis; ANA, antinuclear antibody; LKM, liverkidney microsomal antibody; SMA, smooth muscle antibody; SLA/LP, soluble liver antigen/liver pancreas antigen.
1. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006;354:54–66. 2. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31(5):929–938. 3. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993;18:998–1005. 4. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169–176. 5. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005;42(1):53–62. 6. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redecker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol. 2004;99:1510–1516.
CHAPTER
3:
AU T O I M M U N E
H E PAT I T I S / O V E R L A P
7. Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int. 2003;23(2):116–123. 8. Campsen J, Zimmerman MA, Trotter JF, et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl. 2008;14(9):1281–1286. 9. Gonzalez-Koch A, Czaja AJ, Carpenter HA, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl. 2001;7(4):302–310. 10. Vogel A, Heinrich E, Bahr MJ, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant. 2004;18(1):62–69. 11. Yeoman AD, Al-Chalabi T, Karani JB, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology. 2008;48(3): 863–870. 12. Batts KP, Ludwig J. Chronic hepatitis: an update on terminology and reporting. Am J Surg Pathol. 1995;19(12):1409–1417. 13. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13:372–374. 14. Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology. 1993;105:1824–1832. 15. Singh R, Nair S, Farr G, Mason A, Perrillo R. Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol. 2002;97:2670–2673. 16. Pratt DS, Fawaz KA, Rabson A, Dellelis R, Kaplan MM. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology. 1997;113:664–668.
SYNDROMES
25
17. Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental features of bile duct injury. Hepatology. 2001;34:659–665. 18. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology. 1992;15:572–577. 19. Zen Y, Harada K, Sasaki M, et al. Are bile duct lesions of primary biliary cirrhosis distinguishable from those of autoimmune hepatitis? Interobserver histological agreement on trimmed bile ducts. J Gastroenterol. 2005;40:164–170. 20. Daniels JA, Torbenson M, Anders RA, Boitnott JK. Immunostaining of plasma cells in primary biliary cirrhosis. Am J Clin Pathol. 2009;131(2):243–249. 21. Umemura T, Zen Y, Hamano H, Kawa S, Nakanuma Y, Kiyosawa K. Immunoglobin G4-hepatopathy: association of immunoglobin G4bearing plasma cells in liver with autoimmune pancreatitis. Hepatology. 2007;46(2):463–471. 22. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. Dig Dis Sci. 1997;42(8):1688–1696. 23. McFarlane IG. Autoimmune hepatitis: diagnostic criteria, subclassifications, and clinical features. Clin Liver Dis. 2002;6(3): 605–621. 24. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001;33(3):544–553.
Case 3.1
Autoimmune Hepatitis With Bile Duct Injury Versus Primary Biliary Cirrhosis KAY WASHINGTON
C L I N I C AL I N F OR M AT I ON
A 35-year-old woman presented with fatigue. There was no history of medication use other than occasional nonsteroidal anti-inflammatory agents for headache, and the patient did not consume alcohol. Physical examination revealed mild icterus and no hepatomegaly or splenomegaly. There were no stigmata of chronic liver disease. Laboratory testing revealed elevated serum transaminases (10 times normal), mildly elevated alkaline phosphatase (twice normal), elevated total bilirubin (3 times normal), and serum IgG (2 times normal). Serologic studies for hepatitis A and B were negative; polymerase chain reaction testing for hepatitis C RNA was negative. R E A S ON F OR R E F E R R A L
The biopsy shows a hepatitic pattern of injury with lymphocytic infiltration of bile ducts but without bile duct loss. Do the findings represent autoimmune hepatitis (AIH) or PBC?
FIGURE
3.1.2
Prominent lobular hepatitis and sinusoidal
lymphocytosis.
PAT H OL OG I C F E AT U R E S
The liver biopsy shows a hepatitis pattern of injury, with portal and periportal lymphoplasmacytic infiltrates, moderate interface hepatitis (Figure 3.1.1), and spotty hepatocyte necrosis with acidophilic bodies in the lobule (Figure 3.1.2). Plasma cells are prominent in the portal infiltrate and are present in clusters both in the lobule (Figure 3.1.3) and in portal tracts. Although bile ducts are focally infiltrated by
F I G U R E 3 . 1 . 3 Cluster of lobular plasma cells.
lymphocytes and show reactive changes (Figure 3.1.1), there is minimal bile duct loss and no florid duct lesions are seen. No hepatocyte “rosettes” are noted, and there is minimal emperipolesis.
DIAGNO SIS
Autoimmune hepatitis with moderate activity, with minor bile duct injury.
FIGURE 3. 1. 1 Portal lymphoplasmacytic inflammatory infiltrate with interface hepatitis and infiltration of bile duct by lymphocytes.
26
CASE
3.1:
AU T O I M M U N E
H E PAT I T I S
27
D I S C U S S I ON
The pathologic features when considered in concert with the laboratory findings are strongly suggestive of AIH. Further serologic tests were positive for antinuclear and smooth muscle-directed antibodies at less than 1:80 and negative for antimitochondrial antibodies. Application of the modified scoring system for AIH (see Table 3.2 in Chapter 3) based upon the available information provided yields a pretreatment score in the “definite AIH” range. Based on the biopsy and serologic findings, PBC can be excluded, and in the absence of a significant drug history and of evidence of viral hepatitis, the diagnosis of AIH can be made. Grading and Staging
Although not specifically developed for AIH, grading systems developed for chronic hepatitis are often used to grade and stage the necroinflammatory activity and extent of fibrosis. Four-tiered systems such as those described by Batts and Ludwig (1) and Scheuer (2) are perhaps the most widely used in everyday practice. In the Batts and Ludwig system, lobular and interface hepatitis are graded as minimal, mild, moderate, or severe, with the more severe determining the overall grade if a discrepancy exists between portal and lobular necroinflammatory activity. Staging is based on fibrosis, with stage 1 characterized by portal expansion of portal tracts without periportal extension, stage 2 by periportal fibrosis, stage 3 by portal-portal and portal-central bridging fibrosis, and stage 4 by cirrhosis (1).
F I G U R E 3 . 1 . 4 Cirrhosis in autoimmune hepatitis often shows no distinguishing features; degree of activity ranges from minimal in “burned out” cases to severe.
Distinction of Chronic Hepatitis From Chronic Biliary Disease
Distinction of chronic hepatitis from chronic cholestatic disorders such as PBC and PSC is based upon clinical and laboratory findings and histologic features (see Table 3.4 in Chapter 3). AIH is characterized by a hepatitis pattern of injury, usually with prominent interface hepatitis. In the acute phase, lobular inflammation may predominate and fibrosis is minimal. Plasma cells are often prominent and are sometimes seen singly and in clusters in the lobule; however, roughly one-third of biopsies from patients with well-documented AIH will have few or no plasma cells (3). The severity of necroinflammatory activity is quite variable, ranging from mildly active hepatitis to bridging necrosis to massive hepatic necrosis. Hepatocyte regeneration may be prominent, with regenerating rosettelike structures. Ballooning degeneration, spotty hepatocyte necrosis, and apoptotic bodies are common but not specific. As the disease progresses, periportal fibrosis with bile ductular reaction, formation of portal-portal and portal-central bridges, and nodular regeneration result in cirrhosis (Figure 3.1.4) with variable necroinflammatory activity. In PBC, destruction of interlobular bile ducts by a nonsuppurative inflammatory process (Figure 3.1.5) eventually results in chronic cholestasis. In advanced stages of the disease, feathery degeneration of hepatocytes (cholate stasis), due to accumulation of bile salts within the cytoplasm,
F I G U R E 3 . 1 . 5 Bile duct infiltration by lymphocytes in early-stage primary biliary cirrhosis. Note lobular lymphoplasmacytic infiltrate with mild interface inflammation.
imparts a pale appearance to periportal or periseptal hepatocytes (Figure 3.1.6). Canalicular bile plugs are scarce to nonexistent. Although interface inflammation may be identified, it is not as prominent as in AIH, and lobular inflammation is minimal. Bile ductular reaction is common in intermediate stages of PBC but disappears in late-stage disease, leaving empty-appearing fibrous septa. Periportal and periseptal hepatocytes accumulate copper in chronic cholestasis but not in AIH, and this copper storage can be demonstrated with a variety of special stains. Orcein or aldehyde fuchsin stains, which are generally used to demonstrate accumulation of hepatitis B surface antigen, will also highlight increased copper-binding protein, which, like hepatitis B surface antigen, contains a large number of sulfhydryl groups. Positive
28
CHAPTER
3:
AU T O I M M U N E
H E PAT I T I S / O V E R L A P
SYNDROMES
FIGURE 3. 1. 6 Feathery degeneration in late stage primary biliary cirrhosis is a result of chronic cholestasis and imparts a pale appearance to periportal or periseptal hepatocytes.
F I G U R E 3 . 1 . 7 Zone 3 hepatocyte necrosis and lymphoplasmacytic
staining is seen as granular deposition in periportal hepatocytes. Any of the special stains for copper itself, such as rhodanine or rubeanic acid stain, may also be used. This copper accumulation is not specific, but when found in a precirrhotic liver biopsy, it is highly suggestive of chronic cholestasis, if rare entities such as Wilson disease and Indian childhood cirrhosis have been excluded. Mallory’s hyaline may also be found in periportal hepatocytes in chronic cholestasis and is morphologically indistinguishable from that found in alcoholic liver disease but is not a feature of AIH.
whereas the fact that in PBC an appreciable number of the plasma cells express IgM has prompted investigation as to whether this differential expression can be used to distinguish among the autoimmune liver diseases. However, the utility of this approach has not been validated (9). IgG4-bearing plasma cells have been described in liver disease associated with autoimmune pancreatitis, but are not present in significant numbers in typical AIH (10).
Morphologic Overlap Between PBC and AIH
The liver biopsy findings in AIH vary with the stage of the disease but always reflect a hepatitis pattern of injury. Although distinction of AIH with interface and lobular hepatitis from the classic form of PBC with florid duct lesions and ductopenia is not difficult, some cases of PBC contain appreciable numbers of plasma cells in the portal inflammatory infiltrate and exhibit interface inflammation. However, AIH lacks florid duct lesions and extensive bile duct injury and loss. Prominent lobular necroinflammatory activity is not a feature of PBC, and its presence favors AIH. Centrilobular injury with prominent hepatocellular necrosis and mononuclear inflammation in some cases of AIH, probably representing an early stage of the disease (4,5) (Figure 3.1.7), is also not seen in PBC. Bile duct destruction is generally not prominent in AIH, but up to 12% of AIH biopsies may show duct destruction, and an additional 12% show lymphocytic infiltration of bile duct epithelium without ductopenia (6,7). Taken in isolation the bile duct injury may be indistinguishable from early-stage PBC (8), but consideration of the overall histologic pattern of injury and correlation with serologic, laboratory, and clinical findings will help establish the diagnosis of AIH. It has been observed that plasma cells in AIH are predominantly IgG positive, with few IgM-expressing cells,
infiltration is prominent in some cases of autoimmune hepatitis and may represent an early phase of the disease.
CLINIC A L SIGNIFIC A NCE O F DIST INGUISH ING A IH FRO M P BC
Accurate distinction of AIH from PBC is critically important for selection of appropriate medical therapy. The majority of cases of AIH respond to immunosuppressive therapy, which can be lifesaving in severely active cases and can prevent progression to cirrhosis. In contrast, PBC is treated with the choleretic agent UDCA; in patients with a biochemical response, defined as a greater than 40% decrease in alkaline phosphatase levels within 1 year, survival is improved (11) and transplantation may be avoided. Immunosuppression has been shown in randomized clinical trials to be ineffective in PBC. In addition to being ineffective, steroids can exacerbate osteoporosis that commonly affects elderly women with PBC.
References 1. Batts KP, Ludwig J. Chronic hepatitis: an update on terminology and reporting. Am J Surg Pathol. 1995;19(12):1409–1417. 2. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatology. 1991;13:372–374. 3. Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology. 1993;105:1824–1832. 4. Singh R, Nair S, Farr G, Mason A, Perrillo R. Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol. 2002;97:2670–2673.
CASE
3.1:
AU T O I M M U N E
5. Pratt DS, Frwaz KA, Rabson A, Dellelis R, Kaplan MM. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology. 1997;113:664–668. 6. Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental features of bile duct injury. Hepatology. 2001;34:659–665. 7. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology. 1992;15:572–577. 8. Zen Y, Harada K, Sasaki M, et al. Are bile duct lesions of primary biliary cirrhosis distinguishable from those of autoimmune hepatitis? Interobserver histological agreement on trimmed bile ducts. J Gastroenterol. 2005;40:164–170.
H E PAT I T I S
29
9. Daniels JA, Torbenson M, Anders RA, Boitnott JK. Immunostaining of plasma cells in primary biliary cirrhosis. Am J Clin Pathol. 2009;131(2):243–249. 10. Umemura T, Zen Y, Hamano H, Kawa S, Nakanuma Y, Kiyosawa K. Immunoglobin G4-hepatopathy: association of immunoglobin G4bearing plasma cells in liver with autoimmune pancreatitis, Hepatology. 2007;46(2):463–471. 11. Kuiper EM, Hansen BE, De Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136(4):1281–1287.
Case 3.2
Autoimmune Hepatitis–Primary Biliary Cirrhosis Overlap Syndrome KAY WASHINGTON
with numerous collections of mononuclear cells within the lobule and scattered acidophilic bodies (Figure 3.2.3), without bridging necrosis. No hepatocyte rosettes are identified.
C L I N I C AL I N F OR M AT I ON
A 68-year-old woman presented with fatigue. She had elevated liver tests (ALT and AST 4 times normal, alkaline phosphatase 3 times normal, total bilirubin twice normal) and high titer autoantibodies, with ANA, SMA, and AMA positive at 1:1280. Liver biopsy was performed to clarify the nature of the liver disease and to assess for fibrosis.
DIAGNO SIS
Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome .
R E A S ON F OR R E F E R R A L
The liver biopsy shows a combination of bile duct loss and prominent interface and lobular hepatitis with plasma cells. Do the findings represent AIH, PBC, or AIH/PBC overlap syndrome? PAT H OL OG I C F E AT U R E S
The biopsy shows a hepatitis pattern of injury with significant bile duct loss. Most portal tracts contain a moderately dense lymphoplasmacytic infiltrate, with circumferential interface hepatitis and minimal bile ductular reaction (Figure 3.2.1). Focal emperipolesis is seen. The majority of portal tracts in the biopsy lack identifiable bile ducts, although granulomatous florid duct lesions are not seen (Figure 3.2.2). Periportal hepatocytes show mild swelling and cytoplasmic rarefaction, without Mallory’s hyaline accumulation. Plasma cells are present in clusters in the portal inflammatory infiltrate and at the limiting plate. There is moderate to severe lobular hepatitis
F I G U R E 3 . 2 . 2 Portal tract with bile duct loss, without significant
ductular reaction.
FIGURE 3. 2. 1 Portal mononuclear cell infiltrate with plasma cells, interface inflammation, and with no identifiable interlobular bile duct.
F I G U R E 3 . 2 . 3 Prominent lobular necroinflammatory activity similar to autoimmune hepatitis.
30
CASE
3.2:
AU T O I M M U N E
H E PAT I T I S – P R I M A RY
D I S C U S S I ON
The diagnosis of AIH/PBC overlap syndrome in this case is based upon an aggregate score of “probable AIH” using the modified scoring system, the presence of high-titer AMA, and the combination of bile duct loss with a hepatitic pattern of injury. The existence of such overlap cases has been controversial, but there is agreement that the term should not be overused, and cases must demonstrate histologic, clinical, and serologic overlap to be classified as such. Up to 10% to 14% of AIH or PBC patients in some series may belong in the AIH/PBC overlap category (1,2), although criteria have varied among studies. Aggregate scores of definite or probable AIH using the modified scoring system of the International Autoimmune Hepatitis Group (3) and cholestatic biochemical studies combined with seropositivity for AMA are helpful. Alternatively, 2 out of 3 criteria for diagnosis of AIH and PBC have been required (Table 3.2.1) (1,4) for diagnosis. Liver biopsies in AIH/PBC overlap cases show features of both PBC (granulomatous inflammation and bile duct lesions) and autoimmune hepatitis (lobular hepatitis with spotty hepatocyte necrosis and acidophil bodies and moderate to severe interface hepatitis) (5). Granulomatous bile duct destruction and well-developed florid duct lesions are not seen in typical AIH. Because interface hepatitis and portal inflammatory infiltrates are common in typical PBC cases, these features alone cannot be used as discriminating features for AIH/PBC overlap. Lobular hepatitis with acidophilic bodies has been reported to be a more useful feature for discriminating between AIH and a spurious AIH/PBC overlap syndrome and may be more reliable than identification of mild forms of bile duct injury (6). Because some patients with clinical and histologic features of autoimmune hepatitis will have serum antimitochondrial antibodies, the presence of AMA in a patient with otherwise typical AIH is not considered sufficient for diagnosis of overlap syndrome. In some cases this apparent AMA positivity is caused by misreading of IF-type tests (confusing anti-LKM antibodies with AMA). In other patients, however, the AMA is truly positive but usually in low titer. Conversely, patients with PBC may have a positive ANA and are not considered to have AIH/PBC overlap unless there is clear evidence of a hepatitic component of liver injury. TABLE 3.2.1 Diagnostic criteria for AIH/PBC overlap syndrome AIH features (2 out of 3 criteria required) • ALT levels 5 times upper limit of normal • Serum IgG levels 2 times upper limit of normal or positive SMA • Liver biopsy with moderate to severe interface hepatitis or lobular acidophilic bodies PBC features (2 out of 3 criteria required) • Alkaline phosphatase levels 2 or GGT levels 5 times upper limit of normal • Positive AMA • Liver biopsy showing florid duct lesions Abbreviations: AIH, autoimmune hepatitis; ALT, alanine aminotransferase; AMA, antimitochondrial antibodies; GGT, gamma glutamyl transpeptidase; IgG, immunoglobulin G; PBC, primary biliary cirrhosis. From Refs. 1, 4.
BILIARY
CIRRHOSIS
31
The combination of seropositivity for AMA and for antibodies directed against double-stranded DNA has been described in almost 50% of AIH/PBC overlap syndrome patients compared with 2% of AIH or PBC patients and may represent a useful serologic profile for diagnosis of a subset of overlap syndrome cases (7), although validation studies are needed. In addition to the more commonly encountered cases with “overlapping” simultaneous features of both diseases, rare patients who switch from one disease to another over time have been reported (8). Implications for Therapy and Outcome
Combination therapy with ursodeoxycholic acid (UDCA) and immunosuppression has been advocated, largely on an empiric basis, for treatment of AIH/PBC overlap syndrome, although in some retrospective cohorts in which AIH/PBC overlap patients were identified from treatment trials of PBC patients, response to UDCA without immunosuppression was similar for both groups (4). However, some small nonrandomized studies do offer support for combined UDCA and immunosuppression, and some clinicians advocate dual therapy especially in cases that meet classic criteria for diagnosis of AIH (9) or when treatment with UDCA alone does not result in rapid biochemical response. Higher rates of liver transplantation and complications of portal hypertension in AIH/PBC overlap compared with PBC have been reported, suggesting that the higher risk of adverse outcome associated with overlap with AIH may justify the addition of immunosuppression to the therapeutic regimen in selected patients (10).
References 1. Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998;28:296–301. 2. Heurgue A, Vitry F, Diebold MD, et al. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease. Gastroenterol Clin Biol. 2007;31(1):17–25. 3. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31(5):929–938. 4. Joshi S, Cauch-Dudek K, Wanless IR, et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology. 2002;35(2):409–413. 5. Terracciano LM, Patzina RA, Lehmann FS, et al. A spectrum of histopathologic findings in autoimmune liver disease. Am J Clin Pathol. 2000;114(5):705–711. 6. Suzuki S, Arase Y, Ikeda K, et al. Clinical and pathologic characteristics of the autoimmune hepatitis and primary biliary cirrhosis overlap syndrome. J Gastroenterol Hepatol. 2004;19:699–706. 7. Muratori P, Granito A, Pappas G, et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol. 2009;104(6):1420–1425. 8. Angulo P, El-Amin O, Carpenter HA, Lindor KD. Development of autoimmune hepatitis in the setting of long-standing primary biliary cirrhosis. Am J Gastroenterol. 2001;3021–3027. 9. Poupon R. Autoimmune overlapping syndromes. Clin Liver Dis. 2003;7:865–878. 10. Silveira MG, Talwalkar JA, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol. 2007;102(6):1244–1250.
Case 3.3
Autoimmune Hepatitis–Primary Sclerosing Cholangitis Overlap Syndrome KAY WASHINGTON
tract contains an interlobular bile duct, but many ducts are distorted and show reactive epithelial change; concentric periductal fibrosis is not noted. There is a moderate degree of lobular inflammation (Figure 3.3.3). Canalicular bile plugs are not present.
C L I N I C AL I N F OR M AT I ON
A 16-year-old girl presented with chronic diarrhea and elevated liver tests (serum ALT and AST 4 times normal, alkaline phosphatase 2 times normal), with normal total bilirubin. The ceruloplasmin level was slightly higher than normal. ANA and anti-SMA were positive, both at 1:80. Endoscopic retrograde cholangiopancreatography (ERCP) showed minimal narrowing of large bile ducts just proximal to the common bile duct, with normal intrahepatic ducts. R E A S ON F OR R E F E R R A L
The liver biopsy shows features of chronic hepatitis and subtle evidence of bile duct loss and injury. Do the findings represent AIH or PSC? PAT H OL OG I C F E AT U R E S
The biopsy shows a hepatitic pattern of injury with a moderate portal chronic inflammatory infiltrate consisting primarily of lymphocytes and plasma cells, and a moderate degree of interface hepatitis (Figure 3.3.1). Portal tracts are enlarged by periportal fibrosis and bile ductular reaction, with focal bridging fibrosis (Figure 3.3.2). Each portal
F I G U R E 3 . 3 . 2 Prominent portal plasma cells with degenerative
changes in interlobular bile duct. Note lack of concentric periductal fibrosis.
FIGURE 3. 3. 1 Lymphoplasmacytic portal inflammatory infiltrate
and mild interface hepatitis. Note degenerative changes in interlobular bile duct, without bile duct loss.
F I G U R E 3 . 3 . 3 Lobular hepatitis and sinusoidal lymphocytosis.
32
CASE
3.3:
AU T O I M M U N E
H E PAT I T I S – P R I M A RY
D I AG N OS I S
Autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome.
D I S C U S S I ON
AIH/PSC overlap has been reported in up to 50% of pediatric patients initially identified as PSC or AIH (1,2). In adults, this overlap syndrome is rarer and is reported in roughly 6% of patients initially diagnosed with AIH (3) and 8% of PSC patients (4). Many pediatric cases are initially diagnosed as AIH; in one 16-year prospective study in which 55 children with AIH were followed, 27 (49%) developed cholangiographic findings typical of PSC (1). Such overlap cases tend to have a worse outcome, with reduction in survival (5) compared with classic AIH and are more likely to require liver transplantation (1). The term “autoimmune sclerosing cholangitis” has been proposed by Gregorio and colleagues for AIH/PSC overlap syndrome (1) in children. Criteria for Diagnosis
AIH/PSC overlap is defined as definite or probable AIH (see Table 3.3 in Chapter 3) with cholangiographic evidence of PSC (6). Use of magnetic resonance cholangiopancreatography (MRCP) imaging techniques is becoming more common in the diagnostic evaluation of autoimmune liver disease and may facilitate early identification of AIH/PSC overlap cases. The liver biopsy in AIH/PSC overlap syndrome (Figures 3.3.1–3.3.3) shows portal inflammation, interface hepatitis, and lobular necroinflammatory activity typical of AIH combined with varying degrees of bile duct injury. As in typical PSC, the liver biopsy may show subtle bile duct injury or loss, and the presence of biliary lesions must be established by cholangiographic studies. The classic lesion for PSC, well-established periductal fibrosis, is rarely seen in biopsies from children with PSC or with AIH/PSC overlap. The finding of ductopenia in a liver biopsy from a young patient suspected of having AIH should prompt consideration of AIH/PSC overlap syndrome. Simultaneous or Sequential Presentation
Sequential syndromes of AIH evolving into PSC are rare in adults but have also been reported (7); such patients may be identified by biliary imaging techniques when their disease
SCLEROSING
CHOLANGITIS
33
becomes refractory to immunosuppression. Early studies interpreted as evolution of AIH to PSC must be interpreted in light of new information regarding prevalence of bile duct changes at diagnosis of AIH (8). In studies performed without ERCP or MRCP at diagnosis, concurrence of AIH and PSC may not have been adequately excluded. Implications for Therapy and Outcome
In most series, these AIH/PSC overlap patients are treated empirically with a combination of immunosuppression and ursodeoxycholic acid (UDCA) (9,10). Although UDCA may lead to improvement in liver tests in PSC, it has not been shown to improve overall survival. As in classic PSC, there is an increased risk of cholangiocarcinoma.
References 1. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001;33(3):544–553. 2. el-Shabrawi M, Wilkinson ML, Portmann B, et al. Primary sclerosing cholangitis in childhood. Gastroenterology. 1987;92(5 pt 1):1226–1235. 3. Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med. 1996;125:588–598. 4. van Buuren HR, van Hoogstraten HJE, Terkivatan T, Schalm SW, Vleggaar FP. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol. 2000; 33:543–548. 5. Al-Chalabi T, Portmann BC, Bernal W, McFarlane IG, Heneghan MA. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther. 2008;28(2):209–220. 6. Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol. 2000;33(4):537–542. 7. Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatol. 2002;36(6):1393–1399. 8. Abdalian R, Dhar P, Jhaveri K, Haider M, Guindi M, Heathcote EJ. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology. 2008;47(3):949–957. 9. Floreani A, Rizzotto ER, Ferrara F, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005;100:1516–1522. 10. Miloh T, Arnon R, Shneider B, Suchy F, Kerkar N. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol. 2009;7(2):239–245.
Case 3.4
Chronic Hepatitis C With Autoantibodies Versus Autoimmune Hepatitis KAY WASHINGTON
C L I N I C AL I N F OR M AT I ON
A 30-year-old woman with hypothyroidism presented with fatigue and had elevated transaminase levels (AST and ALT 3 times normal, alkaline phosphatase normal, total bilirubin normal). Hepatitis virus serologies were negative for hepatitis A and B; hepatitis C antibody test was positive. Serum ANA was positive at 1:640 and SMA at 1:320. R E A S ON F OR R E F E R R A L
The biopsy shows chronic hepatitis with prominent plasma cells. Do the findings represent AIH or chronic hepatitis C? PAT H OL OG I C F E AT U R E S
The liver biopsy shows a portal lymphoplasmacytic infiltrate (Figure 3.4.1) without nodular lymphoid aggregates and germinal centers. Circumferential interface hepatitis is present, with minimal bile ductular reaction. Interlobular bile ducts are unremarkable, and there is no cholestasis. Numerous aggregates of small lymphocytes associated with hepatocyte loss and scattered acidophilic bodies are noted in the lobule (Figure 3.4.2). Periportal fibrosis is present, without bridging. No steatosis is seen. Further investigation reveals that the patient is negative for hepatitis C RNA by PCR-based testing methods and is positive for p-ANCA.
F I G U R E 3 . 4 . 2 Spotty hepatocyte necrosis and sinusoidal lymphocytosis.
DIAGNO SIS
Chronic hepatitis with moderate activity and periportal fibrosis, favor autoimmune hepatitis.
DISCUSSIO N
This patient was considered to have autoimmune hepatitis with false-positive HCV antibodies based on negative PCR for HCV-RNA and clinical features, such as concurrent thyroid disease and positive p-ANCA, favoring an autoimmune etiology. Such cases can present diagnostic and management challenges, as antiviral therapy with interferon may exacerbate autoimmune conditions, whereas immunosuppression, the mainstay of therapy for AIH, can enhance viral replication. Of the patients with chronic HBV or HCV 20% to 40% are persistently positive for various autoantibodies, usually at low titers (~1:20 or 1:40) (1). The use of the AIH Scoring System can be helpful in excluding AIH in patients known to have HCV (2). Conversely, patients with AIH can have a false-positive test for anti-HCV antibodies but will have undetectable HCV-RNA. Three categories of patients with potential concurrent AIH/hepatitis C may be identified: • Patients with true AIH and false-positive anti-HCV antibodies (undetectable HCV-RNA)
FIGURE 3. 4. 1 Prominent plasma cells in portal tracts, with interface
hepatitis.
34
CASE
3.4:
CHRONIC
H E PAT I T I S
C
35
• Patients with true HCV and autoantibodies at low titers but no other signs of AIH • Patients with true HCV and features of AIH including young age, female gender, high autoantibody titers (1:320), hypergammaglobulinemia, and history of extrahepatic autoimmune disorders There has been considerable controversy about the diagnosis and management of chronic hepatitis patients with autoimmune markers, particularly regarding the presence of anti-LKM antibodies in HCV patients in southern Europe. It has recently been shown that anti-LKM1 antibodies directed against cytochrome P450 2D6 (CYP2D6) can cross-react with HCV proteins, perhaps as a result of molecular mimicry at the B cell level (3). The current general consensus is that interferon therapy is usually safe in HCV patients with anti-LKM1 F I G U R E 3 . 4 . 4 Minimal lobular inflammation in chronic hepatitis C.
autoantibodies. Patients with chronic viral hepatitis should be screened for autoantibodies before starting interferon therapy and monitored carefully. p-ANCA testing may be useful, as this autoantibody is rare in chronic hepatitis C, but relatively common in AIH. Liver biopsy in hepatitis C often shows less interface hepatitis (Figure 3.4.3) and lobular activity (Figure 3.4.4) than in AIH, although the histologic findings can be indistinguishable.
References
FIGURE 3. 4. 3 Portal lymphocytic inflammatory infiltrate in chronic
hepatitis C, with reactive changes in bile ducts. Note minimal interface hepatitis.
1. McFarlane IG. Autoimmune hepatitis: diagnostic criteria, subclassifications, and clinical features. Clin Liver Dis. 2002;6(3):605–621. 2. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31(5):929–938. 3. Marceau G, Lapierre P, Beland K, Soudeyns H, Alvarez F. LKM1 autoantibodies in chronic hepatitis C infection: a case of molecular mimicry? Hepatology. 2005;42:675–682.
Case 3.5
Syncytial Giant Cell Hepatitis KAY WASHINGTON
C L I N I C AL I N F OR M AT I ON
A 20-year-old man developed progressive fatigue over a 2-month span and sought medical attention when he noticed scleral icterus. There was no history of alcohol or drug use, and he was taking no medications. Serum ALT and AST were 10 times normal. Serum total bilirubin was 3 times normal. Serologic studies for hepatitis A and B, as well as molecular studies for hepatitis C were negative. ANA test was positive at 1:160; anti-SMA was negative. R E A S ON F OR R E F E R R A L
The liver biopsy shows active hepatitis with numerous syncytial giant cells. What is the etiology of the giant cell hepatitis in this adult patient? PAT H OL OG I C F E AT U R E S
F I G U R E 3 . 5 . 2 Multinucleated giant cells in zone 3.
The biopsy shows active hepatitis, with numerous apoptotic hepatocytes and spotty hepatocyte necrosis. The portal tracts contain a mononuclear inflammatory infiltrate with scattered plasma cells, and circumferential interface hepatitis is present (Figure 3.5.1). Areas of bridging necrosis are present, and some portal tracts show early fibrosis and bile ductular reaction. The most striking feature is the presence of numerous multinucleated hepatocytes, more prominent in this case in zone 3 of the lobule. The hepatocyte giant cells have a fused or syncytial appearance, and contain from 5 to more than 20 nuclei (Figure 3.5.2). Mild hepatocellular cholestasis is noted.
DIAGNO SIS
Syncytial giant cell hepatitis, probably autoimmune in etiology, with bridging necrosis.
DISCUSSIO N
Giant cell transformation of hepatocytes is a nonspecific tissue reaction in neonates that is rarely seen outside of infancy. In children it is particularly striking in cholestatic disorders and is prominent in neonatal hepatitis, but syncytial hepatocyte giant cells are also seen to a lesser extent in extrahepatic biliary atresia, paucity of intrahepatic bile ducts, alpha-1-antitrypsin deficiency, and many other disorders. In older patients, the presence of numerous hepatocyte giant cells is termed adult or postinfantile giant cell hepatitis or syncytial giant cell hepatitis. This pattern of injury is seen in autoimmune liver disease, drug reactions, and is occasionally reported in human immunodeficiency virus (HIV), hepatitis C (1), and hepatitis B infections. Some cases of adult giant cell hepatitis do not have a clearly established etiology, however, and are regarded as idiopathic. Adult giant cell hepatitis has the same range of histologic features seen in viral or autoimmune hepatitis (AIH), with the additional finding of multinucleated hepatocyte giant cells. The number of multinucleated giant cells, defined as hepatocytes with more than 4 nuclei per cell, is variable, but these cells should be more than a rare isolated occurrence.
FIGURE 3. 5. 1 Interface hepatitis with ballooning degeneration of
hepatocytes.
36
CASE
3.5:
SYNCYTIAL
GIANT
The giant cells may be located anywhere within the lobule and sometimes contain Mallory’s hyaline. A 1991 report of paramyxovirus-like particles in biopsies from 8 of 10 patients with adult syncytial giant cell hepatitis stimulated intense interest in an infectious case among idiopathic cases. However, most investigators have been unable to confirm this finding, and the nature of the ultrastructural findings has been questioned. In one series, 40% of patients (2) had evidence of autoimmune disease such as positive ANA or SMA. About 25% of reported patients with postinfantile giant cell hepatitis remain stable or have gradual resolution of the disease. Corticosteroid treatment results in improvement in some but not all patients, and in the setting of autoimmune hepatitis the clinical course may be severe, with most patients progressing to cirrhosis (3). One-third of patients die of liver
CELL
H E PAT I T I S
37
disease, and the remainder progress to cirrhosis or liver failure. Disease recurrence after liver transplantation has been reported and may require retransplantation (4).
References 1. Moreno A, Moreno A, Perez-Elias MJ, et al. Syncytial giant cell hepatitis in human immunodeficiency virus-infected patients with chronic hepatitis C: 2 cases and review of the literature. Hum Pathol. 2006;37(10):1344–1349. 2. Devaney K, Goodman ZD, Ishak KG. Post-infantile giant-cell transformation in hepatitis. Hepatol. 1992;16:327–333. 3. Estradas J, Pascual-Ramos V, Martinez B, Uribe M, Torre A. Autoimmune hepatitis with giant-cell transformation. Ann Hepatol. 2009;8(1):68–70. 4. Pappo O, Yunis E, Jordan JA, et al. Recurrent and de novo giant cell hepatitis after orthotopic liver transplantation. Am J Surg Pathol. 1994;18(8):804–813.
This page intentionally left blank
4 Fatty Liver Disease MATTHEW M. YEH AND ELIZABETH M. BRUNT
I N T ROD U C T I ON
Nonalcoholic steatohepatitis (NASH) is nearly universally associated with metabolic syndrome, which includes central obesity, hypertension, type 2 diabetes or glucose intolerance (insulin resistance), dyslipidemia (hypertriglyceridemia, low high-density triglycerides, and elevated low-density triglycerides), and systemic hypertension. Metabolic syndrome has become an emerging epidemic in the 21st century, not only in the Western countries, but also across the world. NASH may progress to advanced fibrosis, that is, cirrhosis, and may develop hepatocellular carcinoma; therefore, pathologists often encounter liver biopsies in their daily practice to determine the diagnosis of NASH, its differential diagnosis, and activity (grade) and fibrosis (stage) of the disease (1,2). In adults the injury pattern of NASH is zone 3 based and includes the constellation of macrovesicular steatosis, lobular inflammation, liver cell injury, particularly ballooned hepatocytes (Figure 4.1), with or without centrizonal “chicken-wire” fibrosis (Figure 4.2), as cardinal histologic features (3–6). The injury pattern in children may differ from adults. This is discussed in more detail in Chapter 4.10. Clinical evaluation, serologic and laboratory tests, and current imaging modalities, can strongly suggest the presence of hepatic steatosis, but none can distinguish steatohepatitis from uncomplicated steatosis; likewise, these evaluations can generally detect advanced liver disease (ie, portal hypertension), but none can truly assess the degree of liver necroinflammatory injury, lesser stages of fibrosis,
F I G U R E 4 . 2 Masson’s Trichrome stain demonstrates chicken-
wire fibrosis with collagen fibers within the sinusoidal spaces and surrounding the hepatocytes.
and architectural remodeling. Liver biopsy evaluation, therefore, remains the “gold standard” to unequivocally diagnose steatohepatitis and to document the severity of hepatic injury and fibrosis (3,4,7). Of importance, biopsy assessment has also shown that not all individuals with unexplained liver test elevations have fatty liver (8), not all phenotypic “NASH” patients have steatosis (9), and that the full spectrum of fatty liver disease may be present when laboratory values are normal (10). In addition, examination of liver biopsy is useful for detecting possible concomitant or alternative processes (11–13). In fact, studies have reported the observation of histologic features of NASH in biopsies from patients with other serologically and/or clinically defined chronic liver diseases (14,15). Finally, it needs to be emphasized that pathologists can make the diagnosis of steatohepatitis but cannot make the diagnosis of nonalcoholic steatohepatitis as that diagnosis requires the clinical exclusion of alcohol use.
References 1. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;134–140. 2. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002;35:1485–1493. 3. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–2474.
FIGURE 4. 1 Features of NASH including macrovesicular steatosis,
lobular inflammation, and ballooned hepatocytes.
39
40
CHAPTER
4:
FAT T Y
4. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321. 5. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–438. 6. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–1419. 7. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–S112. 8. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol. 2001;35:195–199. 9. Merriman RB, Ferrell LD, Patti MG, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology. 2006;44:874–880.
LIVER
DISEASE
10. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286–1292. 11. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology. 2000;31:241–246. 12. Brunt EM. Liver biopsy interpretation for the gastroenterologist. Curr Gastroenterol Rep. 2000;2:27–32. 13. Ishak KG. Chronic hepatitis: morphology and nomenclature. Mod Pathol. 1994;7:690–713. 14. Brunt EM, Ramrakhiani S, Cordes BG, et al. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol. 2003;16:49–56. 15. Sanyal AJ, Contos MJ, Sterling RK, et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol. 2003;98:2064–2071.
Case 4.1
Steatosis With Inflammation Versus Steatohepatitis MATTHEW M. YEH AND ELIZABETH M. BRUNT
C L I N IC AL I N F OR M AT I ON
A 40-year-old man underwent gastric bypass because of morbid obesity. He had not had routine checkup for his liver tests. As the liver was mildly enlarged at surgery, a liver biopsy was performed by the surgeon during the gastric bypass surgery. R E A SON F OR R E F E R R AL
There is steatosis and inflammation in the liver biopsy. The referring pathologist’s specific question is whether a diagnosis of steatohepatitis can be established. PAT H OL OG I C F E AT U R E S
The liver biopsy shows a moderate amount of macrovesicular steatosis in zone 3 (Figure 4.1.1). There are also scattered inflammatory foci in the lobules, composed predominantly of lymphocytes and Kupffer cells (Figure 4.1.2). Ballooned hepatocytes are not identified, and a Masson’s Trichrome stain shows no significant fibrosis.
F I G U R E 4 . 1 . 2 The biopsy also shows inflammatory foci in the hepatic lobules, composed predominantly of lymphocytes, Kupffer cells, and pigmented macrophages. Ballooned hepatocytes are not identified.
D I AG N OS I S DISCUSSIO N
Moderate steatosis and lobular inflammation, no evidence of steatohepatitis, history of morbid obesity.
The diagnosis of steatohepatitis may not be as straightforward as the diagnosis of chronic viral hepatitis such as hepatitis B or C, as the latter depends on the combination of clinical, laboratory, and histologic findings. In particular, serology and virology play very critical roles in the clinical evaluation of these diseases; therefore, if virologic and serologic data are compatible, a diagnosis of chronic viral hepatitis is relatively easily reached, and biopsy is largely done for evaluation of activity and fibrosis (1). The diagnosis of steatohepatitis, on the other hand, is not analogous to that of viral hepatitis, as it has been generally conceptualized that steatosis is a necessary but not sufficient component to constitute a diagnosis of steatohepatitis, and inflammation and features of liver cell injury, in particular, a rather specific liver cell injury form, that is, ballooning degeneration (Figure 4.1.3), not typically seen in other liver diseases, are also required features for a confident diagnosis of steatohepatitis to be established. In fact, it has become clearer that steatosis, ballooning, and lobular inflammation are considered the common constellation of minimal criteria for the diagnosis of NASH in adults (2,3). Although it is well known that significant liver disease may exist with liver enzymes in the normal range among nonalcoholic fatty liver disease (NAFLD) patients, it is generally recognized that patients with NASH typically present with mild elevation of serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (4).
FIGURE 4.1.1 Moderate macrovesicular steatosis in zone 3
distribution pattern.
41
42
CHAPTER
4:
FAT T Y
LIVER
DISEASE
References 1. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology. 2000;31:241–246. 2. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis. 2004;24:3–20. 3. Yeh MM, Brunt EM. Pathology of fatty liver: differential diagnosis of nonalcoholic fatty liver disease. Diagn Path. 2008;14:586–597. 4. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37:1202–1219.
FIGURE 4. 1. 3 Several ballooned and swollen hepatocytes with rarefied and clumped cytoplasm.
Case 4.2
Steatohepatitis With Minimal Ballooning MATTHEW M. YEH AND ELIZABETH M. BRUNT
C L I N IC AL I N F OR M AT I ON
DISCUSSIO N
A 55-year-old woman was evaluated for persistent mildly elevated liver tests. She has a medical history of type 2 diabetes. All viral and autoimmune serologic tests were negative. A liver biopsy was performed for further evaluation of her abnormal liver tests.
Hepatocytic ballooning is characterized by cytoplasmic alterations, swelling, and enlargement of hepatocytes, which result in loss of normal hexagonal shape (Figure 4.2.2). The cytoplasm is rarefied or finely reticulated, suggesting accumulation of intracellular fluid; at the ultrastructural level, minute vacuoles of steatosis, and/or other acute or chronic toxic cell injuries have been reported (1,2). Microvesicular steatosis may resemble ballooning degeneration as the hepatocytes may also be enlarged; nonetheless, the nuclei remain centrally located and may appear to be indented by the small fat droplets in microvesicular steatosis (Figure 4.2.3). The presence of larger and hyperchromatic nuclei in the ballooned hepatocytes may also be a subtle difference in distinguishing those with microvesicular steatosis. Predominant microvesicular steatosis is a histologic manifestation of severe liver disease caused by massive mitochondrial dysfunction and should not be seen as the primary type of steatosis in individuals with NAFLD (1,2,3). The enlarged and swollen, glycogen-rich hepatocytes of glycogenosis may occur in glycogen storage diseases or in glycogenic hepatopathy (Figure 4.2.4), which may also mimic ballooned hepatocytes. Glycogenic hepatopathy is a well-characterized entity commonly associated with type 1 diabetics with poor glycemic control (4). Typically, biopsies from patients with glycogenic hepatopathy show diffuse involvement of all hepatocytes, lack zonal and significant steatosis, lobular or portal inflammation, lobular spotty necrosis, and the characteristic perisinusoidal fibrosis of NASH. Megamitochondria can be seen in affected hepatocytes. The clinical setting is also very different (see Chapter 17).
R E A SON F OR R E F E R R AL
There is a moderate amount of macrovesicular steatosis as well as foci of lobular inflammation in the liver biopsy. Only 1 to 2 hepatocytes with possible ballooning are identified. The question from the referring pathologist is whether the findings in the liver biopsy are sufficient for the diagnosis of steatohepatitis. PAT H OL OG I C F E AT U R E S
The liver biopsy shows liver parenchyma with moderate macrovesicular steatosis, in a zone 3 distribution. There are scattered foci of inflammatory infiltrates in the hepatic lobules, composed predominantly of lymphocytes and Kupffer cells. Rare ballooned hepatocytes are identified, located in zone 3 (Figure 4.2.1). Masson’s Trichrome stain shows focal perivenular/pericellular fibrosis.
D I AG N OS I S
Steatohepatitis, with type 2 diabetes.
FIGURE 4. 2. 1 The liver biopsy shows moderate macrovesicular
F I G U R E 4 . 2 . 2 Ballooned hepatocytes are characterized by swelling and enlargement of hepatocytes, loss of the normal hexagonal shape, and rarefied or finely reticulated cytoplasm.
steatosis, foci of mononuclear inflammatory infiltrates in the lobule, and adjacent two ballooned hepatocytes.
43
44
CHAPTER
4:
FAT T Y
FIGURE 4. 2. 3 The hepatocytes in microvesicular steatosis are enlarged, with centrally located nuclei.
LIVER
DISEASE
Hepatocellular cholestasis may result in swollen and enlarged hepatocytes with flocculent cytoplasm, so-called feathery degeneration in the perivenular region in processes that result in acute cholestasis; in many ways, these may also mimic ballooned hepatocytes. However, the clinical setting of biliary obstruction or drug/toxin injury, the absence of the typical perisinusoidal/pericellular fibrosis, and the presence of canalicular cholestasis differentiates this from the ballooning degeneration of NASH. Cholate stasis, the morphologic alteration in periportal hepatocytes in chronic cholestasis, is also manifested by cellular swelling and cytoplasmic material clumped around the nucleus and large lucent peripheral areas of the cell. Sometimes Mallory-Denk bodies (Mallory’s hyaline) may also be present (5). These changes are noted, however, in the periportal or periseptal regions. Although these findings may be discerned from ballooning degeneration in NASH by the clinical setting and zonal location in the noncirrhotic liver, it is difficult to differentiate these, in advanced fibrosis, as the remodeled parenchyma usually no longer has a distinctly zonal architecture. A copper stain may be able to highlight cholate stasis in this setting. A recent study using immunohistochemistry shows that loss of keratin 8/18 immunostaining can serve as an objective marker of ballooning degeneration (6). Although not widely used, it may be useful in equivocal cases.
References
FIGURE 4. 2. 4 Enlarged and swollen, glycogen-rich hepatocytes in glycogenic hepatopathy. Note that there is no significant steatosis or inflammation.
1. Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol. 1998;15:246–258. 2. Fujii H, Ikura Y, Arimoto J, et al. Expression of perilipin and adipophilin in nonalcoholic fatty liver disease; relevance to oxidative injury and hepatocyte ballooning. J Atheroscler Thromb. 2009;16:893–901. 3. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis. 2001;21:57–69. 4. Torbenson M, Chen YY, Brunt E, et al. Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus. Am J Surg Pathol. 2006;30:508–513. 5. Li MK, Crawford JM. The pathology of cholestasis. Semin Liver Dis. 2004;24:21–42. 6. Lackner C, Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM, Denk H. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol. 2008;48:821–828.
Case 4.3
Steatohepatitis Without Activity MATTHEW M. YEH AND ELIZABETH M. BRUNT
C L I N IC AL I N F OR M AT I ON DIAGNO SIS
A 65-year-old diabetic and overweight man had evidence of portal hypertension, but no known underlying etiology on clinical testing. The patient denied past or current alcohol use; medications included antidiabetic, antihyperlipidemic, and antihypertensive agents.
Cirrhosis, etiology not known, clinical history of overweight, and diabetes.
DISCUSSIO N R E A SON F OR R E F E R R AL
Cryptogenic cirrhosis is the clinical term applied to cases such as this. The findings represent “burned-out” liver disease. This process may occur with a variety of liver diseases in which not only the serologic findings, but also the histopathologic features of the active disease are no longer evident. The common diseases that may result in this process include alcoholic and NASH, autoimmune hepatitis (AIH), and, less commonly, drug-induced liver disease and viral hepatitides. The biliary and metabolic diseases (alpha-1-antitrypsin deficiency and hemochromatosis) would not be in the differential, as histopathologic features of these entities can be documented with careful evaluation. Wilson disease is diagnosed or excluded by tissue copper quantitation. There is a large volume of literature that supports a linkage of biopsy-proven NASH with subsequent “cryptogenic” cirrhosis (1–4). A semantic problem arises with the concept of “cryptogenic”: if the underlying cause of burned-out cirrhosis is known, then, by definition, the cirrhosis is no longer “cryptogenic.” If active features remain, the potential etiology of NAFLD/NASH may be suggested (Figures 4.3.2 and 4.3.3). This, however, is not a small concern; many articles refer to “cryptogenic cirrhosis” as an identified outcome of,
The liver biopsy shows cirrhosis; the referring physician wonders whether the cause can be determined. PAT H OL OG I C F E AT U R E S
Low power evaluation shows that the liver is cirrhotic, and mild to moderate septal inflammatory mixed mononuclear infiltrates admixed with ductular reaction are noted. Occasional lipogranulomas are noted in the septa. On higher power evaluation, no steatosis, ballooning, or Mallory-Denk bodies are seen (Figure 4.3.1). Features of acute cholestasis and chronic cholestasis (cholate stasis) are not appreciated. Lobular inflammation is absent or only focal. Trichrome stain highlights the cirrhotic remodeling; focal perisinusoidal fibrosis is present. Periodic acid–Schiff diastase (PASd) is negative for globules, and iron stain shows varying amounts of periseptal hepatocellular granular reactivity among the nodules.
FIGURE 4. 3. 1 There is obvious cirrhosis with almost no inflammation or hepatocellular alterations to suggest an underlying etiology. The differential diagnosis of “cryptogenic cirrhosis” is broad and includes, but is not limited to, alcoholic and nonalcoholic fatty liver diseases as well as “burned-out” autoimmune liver disease.
F I G U R E 4 . 3 . 2 Same patient as in Figure 4.3.1, but 12 years prior. There is active liver disease noted on this low power evaluation.
45
46
CHAPTER
4:
FAT T Y
LIVER
DISEASE
cirrhosis due to ALD. A distinguishing feature of cirrhosis due to ALD is micronodular cirrhosis; however, ALD may also result in mixed micro- and macronodular cirrhosis, and thus, if not present uniformly, micronodularity should not be relied upon for characterization. In summary, cirrhosis secondary to either alcoholic or NAFLD may result in features of inactive liver disease; focal perisinusoidal fibrosis, when present, may strongly support either of these as an underlying etiology. Accurate and astute clinical history may be the only avenue of arriving at the correct diagnosis. Cryptogenic cirrhosis is a term that should only be applied with truly unknown etiology.
References FIGURE 4. 3. 3 On higher power evaluation of the cirrhotic biopsy, there is evidence of hepatocellular ballooning and Mallory-Denk bodies. These features would suggest the possibility of “steatohepatitis” as the initiating cause of cirrhosis. However, they cannot distinguish alcoholic from nonalcoholic fatty liver.
or synonymously with, NASH, which completely ignores the possibility that cirrhosis of “unknown etiology” could be due to the various other processes discussed. In fact, some investigators have utilized the presence of features of NAFLD in an allograft liver as evidence for NASH as the underlying cause of the original disease in the native liver (2,5–8). For pathologists, it is important to keep the differential diagnostic possibilities in mind and to maintain the usage of the term “cryptogenic” for liver disease of truly unknown etiology. Cirrhosis due to burned-out steatohepatitis, whether of alcoholic or nonalcoholic etiology, may, or may not, have residual foci of perisinusoidal fibrosis by histologic evaluation. Steatosis is most commonly absent, as it is recognized that with progression, the active lesions of steatohepatitis may abate (9–12). Hepatocellular ballooning may be present rarely; affected hepatocytes may contain Mallory-Denk bodies. Lipogranulomas in the septa are described as a feature of prior alcoholic steatohepatitis (13), but they may also occur in NAFLD. Either process may result in cholestasis if there is decompensated liver disease and/or sepsis, but features of chronic cholestasis such as copper deposition, have only been described in alcoholic liver disease (ALD) (14). Iron deposition may also occur in cirrhosis and likely is a result of the diminution of hepcidin production due to decreased liver cell mass. Alcohol is also a direct suppressant of hepcidin production by hepatocytes and, thus, iron deposition is common in
1. Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol. 2004;99:292–298. 2. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664–669. 3. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology. 2000;32:689–692. 4. Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med. 2000;108:9–13. 5. Charlton MR, Kondo M, Roberts SK, Steers JL, Krom RA, Wiesner RH. Liver transplantation for cryptogenic cirrhosis. Liver Transpl Surg. 1997;3:359–364. 6. Contos MJ, Cales W, Sterling RK, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl. 2001;7:363–373. 7. Maor-Kendler Y, Batts KP, Burgart LJ, et al. Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases. Transplantation. 2000;70:292–297. 8. Ong J, Younossi ZM, Reddy V, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl. 2001; 7: 797–801. 9. Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol. 1995;20:127–130. 10. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21:3–16. 11. Brunt EM. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Semin Diagn Pathol. 2005;22:330–338. 12. Brunt EM, Tiniakos DG. Alcoholic and nonalcoholic fatty liver disease. In: Odze RD, Goldblum JR, eds. Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas. 2nd ed. Philadelphia, PA: Elsevier; 2009:1007–1014. 13. Yip WW, Burt AD. Alcoholic liver disease. Semin Diagn Pathol. 2007;23:149–160. 14. Hall PDLM. Alcoholic liver disease. In: MacSween RNM, Burt AD, Portmann BC, Ishak KG, Scheuer PJ, Anthony PP, eds. Pathology of the Liver. 4th ed. London, UK: Churchill Livingstone; 2002:273–311.
Case 4.4
Nonalcoholic Steatohepatitis With Moderate/Marked Portal Inflammation MATTHEW M. YEH AND ELIZABETH M. BRUNT
C L I N IC AL I N F OR M AT I ON
A 45-year-old woman with phenotypic metabolic syndrome (increased waist to hip ratio, hypertension, elevated fasting glucose, and high high-density lipoprotein (HDL) levels) and elevated ALT had been biopsied for confirmation of clinical diagnosis of fatty liver and evaluation of severity of injury (grade and stage). The clinical workup was negative for viral hepatitis markers; ceruloplasmin and alpha-1-antitrypsin levels were normal. Antinuclear antibody (ANA) was positive but in low titer. Globulin levels were normal. Platelets were slightly depressed, but other hematologic values were normal. R E A SON F OR R E F E R R AL
The liver biopsy, otherwise suggestive of steatohepatitis, showed bridging fibrosis with prominent portal inflammation. The clinical concern was for AIH or AIH-overlap with steatohepatitis.
F I G U R E 4 . 4 . 2 Higher power evaluation of the same biopsy as in
Figure 4.4.1 shows ballooned hepatocytes, pigmented Kupffer cells, and a suggestion of perisinusoidal fibrosis. Mononuclear lobular inflammation is also present.
PAT H OL OG I C F E AT U R E S
The liver architecture is altered by bridging fibrosis and nodularity (Figure 4.4.1). There is evidence of hepatitis and hepatocellular injury including mixed small- and large droplet macrovesicular steatosis in an azonal distribution, hepatocyte ballooning, scattered inflammatory foci of mononuclear cells, single droplet lipogranulomas surrounded by Kupffer cells and an occasional eosinophil, and microgranulomas (Figure 4.4.2). Masson’s Trichrome stain highlights enlarged
F I G U R E 4 . 4 . 3 Trichrome stain highlights the dense portal chronic inflammation of a residual portal tract and zone 3 perisinusoidal fibrosis.
portal areas, septal fibrosis, and residual foci of perisinusoidal fibrosis (Figures 4.4.3 and 4.4.4). On higher magnification, expansion of septa by chronic inflammation with mixed mononuclear cells and focal “interface hepatitis” are noted (Figure 4.4.5). Plasma cells were not dominant in either portal or lobular infiltrates. Hepatitic rosettes were not present. No evidence of confluent or bridging necroses was seen.
FIGURE 4. 4. 1 On low power evaluation, there is evidence of fatty liver, bridging fibrosis, and nodularity. Portal/septal chronic inflammation is brisk, and interface activity can be seen.
47
48
CHAPTER
4:
FAT T Y
FIGURE 4. 4. 4 On trichrome stain the perisinusoidal fibrosis is evi-
dent and “dense.”
FIGURE 4. 4. 5 Interface hepatitis can be appreciated on this high
power view.
D I AG N OS I S
Nonalcoholic steatohepatitis with moderate activity and bridging fibrosis.
LIVER
DISEASE
with notable polymorphonuclear leukocytes is most likely indicative of alcoholic rather than nonalcoholic origin. The finding is common in association with ductular reaction and may represent cholangiolitis due to pancreatitis. In this setting, the portal areas take on a somewhat “holly-leaf” configuration; the proliferated ductular structures are intimately admixed with the spikes. The most common infiltrates in steatohepatitis, however, are “chronic” mixed mononuclear cells and occasionally, eosinophils. An important consideration in any liver biopsy with steatosis or steatohepatitis with or without notable portal chronic inflammation is Wilson disease (see Chapter 21). This disease has unknown prevalence, but studies have shown that Wilson disease is not restricted to the pediatric age group and may be diagnosed in individuals in middle age or older age groups (1). The key to the diagnosis is a high index of suspicion; this may first come from the pathologist. The primary clinical finding is often otherwise unexplained elevated liver tests. Histopathologic features can be as variable as the clinical features; none are absolutely diagnostic or required, and they may be present in varying combinations (1,2). Macrovesicular steatosis and portal chronic inflammation, swollen hepatocytes with or without Mallory-Denk bodies, “atypical lipofuscin” characterized by either non–zone 3 restriction or by large chunky granules, canalicular bile stasis, and megamitochondria are described. There may be portal expansion and portalbased fibrosis, or cirrhosis may be present. It is not uncommon for clinical evidence of either fulminant or submassive necrosis to show histologic features of cirrhotic remodeling with marked lobular activity. Copper staining itself is not the diagnostic standard for this disease. Although very high hepatic copper is present, histochemical stains for copper or copperbinding protein may not be able to detect it. Thus, the standard for diagnosis is copper quantitation from liver tissue; this can be obtained from the paraffin block (1). Explant livers from treated patients commonly show cirrhosis without activity and copper deposition extensively throughout the nodules. Portal accentuation (inflammation, fibrosis) is a common finding in pediatric NAFLD (3) (Figure 4.4.6). Portal chronic inflammation has also been noted as a feature of resolution of NASH in treatment trials (3,4) (Figure 4.4.7). Portal inflammation may also be a component of the injury in NASH (5) and has recently been shown to correlate with both increased fibrosis as well as more severe clinical features of NASH in adults and children (5,6). Finally, portal inflammation that is “disproportionate” to the lobular injury may be an indication of concurrent liver disease such as chronic viral hepatitis, AIH, and other forms of chronic liver disease (7,8). NASH and Other Concurrent Disease(s)
D I SC U SSI ON Significance of Portal Inflammation in NASH
Portal infiltrates can be characterized as either “chronic inflammation” dominant or polymorphonuclear leukocyte dominant. In the setting of steatohepatitis, portal expansion
The concept that more than one disease process could occur and could be detectable by liver biopsy evaluation was proposed and initially published by 2 groups (9–11) and subsequently confirmed by others. Two strong arguments allowed this concept to be accepted: (1) NAFLD was increasingly recognized as a widespread entity in the United States, and (2)
CASE
4.4:
NONALCOHOLIC
S T E AT O H E PAT I T I S
49
Diagnostic Criteria of Concurrent Disease
FIGUR E 4. 4. 6 Liver biopsy from a pediatric NAFLD patient high-
lights portal accentuation and portal chronic inflammation.
Investigators’ criteria for diagnosing both steatohepatitis and another liver disease differ. The authors’ criteria are more “strict” than for otherwise uncomplicated steatohepatitis so that this condition is not overdiagnosed (15). Thus, in addition to steatosis, ballooning may or may not be seen, Mallory-Denk bodies may or may not be present; but in noncirrhotic livers, zone 3 perisinusoidal fibrosis is required (see Figure 4.4.4). Lobular inflammation is a nondiscriminatory finding of most forms of chronic hepatitis and thus is not a required feature. Zone 3 accentuation of the necroinflammatory lesions may be lost with progression of fibrosis and architectural remodeling. Other groups have utilized less stringent criteria and discuss steatosis, lobular inflammation, and ballooning as features to characterize concurrent steatohepatitis (13,16). Suggesting that another form of chronic liver disease is present in a clinical and histologic setting of steatohepatitis can be characterized by finding the diagnostic lesions of the entity, such as periportal globules to suggest alpha-1antitrypsin deficiency, or markedly increased hepatocellular iron to suggest possible iron overload. Other, more common processes are discussed below. Hepatitis C Virus With Steatosis: Concurrent or Synonymous?
Steatosis alone has been recognized as a cofactor of progression in most liver diseases, including viral hepatitides, AIH, primary biliary cirrhosis, hereditary hemochromatosis (15). Steatosis can be found in the majority of hepatitis C virus (HCV) cases; the incidence of steatohepatitis, however, is significantly less (16) (Figures 4.4.8 and 4.4.9). Steatosis is thought to be related to “host” effects of weight, insulin resistance (IR), and diabetes mellitus (DM) in genotypes non-3 HCV, whereas genotype 3 HCV commonly results in hepatic steatosis due to viral
FIGUR E 4. 4. 7 Relative increase of portal inflammation compared
with the decrease in lobular inflammation and other features of active steatohepatitis has been reported in responders in treatment trials. This was demonstrated in the case of a patient who had clinical and histologic response to rosiglitazone.
chronic hepatitis C patients who lost weight showed improved liver tests and histologic findings in spite of lack of viral load alterations (10). Although exact figures are virtually impossible to discern, published work from referral centers has shown that around 5% of subjects with other diagnosed forms of chronic liver disease also have NAFLD or NASH (11-13). It is now currently accepted that even alcoholic liver disease can be concurrent with NAFLD/NASH, as proposed in the 1990s (14), although distinguishing the 2 typically relies on clinical findings.
F I G U R E 4 . 4 . 8 This biopsy is from a patient with HCV; it was done for grading and staging of HCV. The biopsy clearly shows the lesions of active steatohepatitis: zone 3 steatosis, ballooning, and perisinusoidal fibrosis. This is, therefore, a case of concurrent HCV and steatohepatitis.
50
CHAPTER
4:
FAT T Y
LIVER
DISEASE
F I G U R E 4 . 4 . 1 0 The trichrome stain demonstrates the diagnosis of
steatohepatitis in this case; zone 3 perisinusoidal fibrosis. The patient, however, is ANA positive. FIGURE 4. 4. 9 The trichrome stain of the same case highlights the
zone 3 perisinusoidal fibrosis.
promotion of hyperlipidemia but not the metabolic effects of IR. Whether steatosis promotes fibrosis, lack of response to treatment, and hepatocellular carcinoma in HCV-infected subjects are ongoing discussions recently reviewed (17). In a prospective study of biopsies and demographics in 278 hepatitis C patients (16), steatosis was noted in 34% and concurrent steatohepatitis in 9%. Two retrospective series documented steatohepatitis and HCV in 5% of cases (11,12). Bedossa et al showed that nongenotype 3 biopsies with steatohepatitis had greater fibrosis as well as elevated liver tests and serum triglycerides compared with controls. The study used ballooning and perisinusoidal fibrosis as features of concurrent steatohepatitis. The impact of concurrent underlying IR and/or DM on response to treatment for HCV has been reviewed (18,19). In brief, treatment of either has a potentially positive effect on both; whereas the presence of IR and/or DM negatively impacts response to HCV therapy and is related to progression of fibrosis. ANA/ASMA/AMA Pos NAFLD/NASH: What Does This Mean to the Pathologist?
Up to 5% of biopsies with features of other forms of chronic liver disease may have histopathologic features of concurrent steatohepatitis (11). This number may actually have increased since the original studies were published, as the prevalence of obesity has not abated. However, studies have also shown a range of non–organ-specific autoantibody positive cases of NAFLD. Typically, the autoantibody is ANA and/or anti–smooth muscle antibody (ASMA), but less commonly, antimitochondrial antibodies (AMA) or protoplasmic antineutrophil cytoplasmic antibodies (p-ANCA) have been noted (Figure 4.4.10). The prevalence has varied but may be as high as 30% overall (20,21). For a pathologist, the presence of a positive serologic test should initiate care in evaluation of liver biopsies in order to either document or exclude a concurrent disease. In a case
F I G U R E 4 . 4 . 1 1 This is an example of AMA positive primary biliary
cirrhosis (PBC) and steatohepatitis concurrent disease. The photomicrograph illustrates a florid duct lesion and shows some of the steatosis present elsewhere in the biopsy. The biopsy also had zone 3 perisinusoidal fibrosis.
with positive AMA, florid duct lesion and other features of chronic cholestasis (such as the presence of periportal copper in a noncirrhotic liver) that suggest primary biliary cirrhosis should be noted (Figure 4.4.11). A positive ANA with or without positive ASMA, however, is more common than AMA, and potentially raises considerable difficulties. Just as the presence of ANA cannot be considered diagnostic of AIH, simply the presence of plasma cells in portal inflammation cannot be considered sufficient criteria; in overlap of AIH and NASH, portal inflammation is marked and plasma cells are abundant, are present at the interface, and are present in the lobules. In addition, hepatitic rosettes and/or confluent necroses may be noted. A final finding for consideration of overlap with AIH is the presence of elevated globulins, particularly immunoglobulin G (IgG), in the serum. Without this, the diagnosis may be suggested but not unequivocally made. Alternatively, patients
CASE
4.4:
NONALCOHOLIC
with AIH may be receiving steroid therapy and may have steatosis (but not steatohepatitis with zone 3 perisinusoidal fibrosis) due to the medications. At the current time, the meaning of ANA-positive steatohepatitis is not clear; some authors have found increased severity of steatohepatitis (22–24), but this is not necessarily the case (25).
References 1. Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int. 2003;23:139–142. 2. Ishak KG. Inherited metabolic diseases of the liver. Clin Liver Dis. 2002;6:455–479, viii. 3. Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005;42:641–649. 4. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:195–203. 5. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–2474. 6. Brunt EM, Kleiner DE, Wilson LA, et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology. 2009;49:809–820. 7. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis. 2004;24:3–20. 8. Brunt EM, Clouston AD. Histologic features of fatty liver disease. In: Bataller R, Caballeria J, eds. Nonalcoholic Steatohepatitis (NASH). Barcelona: Permanyer; 2007:95–110. 9. Clouston AD, Powell EE. Interaction of non-alcoholic fatty liver disease with other liver diseases. Best Pract Res Clin Gastroenterol. 2002;16: 767–781. 10. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut. 2002;51:89–94. 11. Brunt EM, Ramrakhiani S, Cordes BG, et al. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol. 2003;16:49–56.
S T E AT O H E PAT I T I S
51
12. Ramesh S, Sanyal AJ. Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis. 2004;24:399–413. 13. Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver. 2001;21:266–271. 14. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997;25: 108–111. 15. Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol. 2007;128:837–847. 16. Bedossa P, Moucari R, Chelbi E, et al. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology. 2007;46:380–387. 17. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology. 2005;42:5–13. 18. Cross TS, Rashid MM, Berry PA, Harrison PM. The importance of steatosis in chronic hepatitis C infection and its management: a review. Hepatology Research. 2010;40:237–247. 19. Blonsky JJ, Harrison SA. Review article: nonalcoholic fatty liver disease and hepatitis C virus—partners in crime. Aliment Pharmacol Ther. 2008;27:855–865. 20. Loria P, Lonardo A, Leonardi F, et al. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci. 2003;48:2173–2181. 21. Loria P, Carulli L, Lonardo A. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2005;100:1200–1201. 22. Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2004;99:1316–1320. 23. Niwa H, Sasaki M, Haratake J, et al. Clinicopathological significance of antinuclear antibodies in non-alcoholic steatohepatitis. Hepatol Res. 2007;37:923–931. 24. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:1103–1109. 25. Brunt EM. Pathology of hepatic iron overload. Semin Liver Dis. 2005;25:392–401.
Case 4.5
Steatohepatitis With Elevated Serum Iron Indices and Siderosis MATTHEW M.YEH AND ELIZABETH M. BRUNT
C L I N I C AL I N F OR M AT I ON DIAGNO SIS
A 48-year-old man presented with abnormal liver tests. He had metabolic syndrome including type 2 diabetes, obesity, and hyperlipidemia. Laboratory data also showed elevated serum iron indices, including increased transferrin saturation and ferritin. There was no family history of liver diseases. Physical examination did not reveal abnormal skin pigmentation and he had no joint pain. A liver biopsy was performed while results for genetic testing were awaited.
Steatohepatitis with mild iron deposition in the hepatocytes and sinusoidal lining cells.
DISCUSSIO N
Similar to alcoholic liver disease, iron deposition in NAFLD is not uncommon, especially in end-stage liver cirrhosis. Previous studies examining liver explants found increased iron in a significant number of nonbiliary cirrhosis cases, including NAFLD, with hepatic iron indices or 1.9 (the value commonly associated with hereditary hemochromatosis), indicating that nonbiliary cirrhosis may result in abnormal iron accumulation (1,2). The current explanation is that endstage liver disease leads to decreased expression of hepcidin, a negative regulator of iron homeostasis. Loss of hepcidin results in promoting excess release of iron from the reticuloendothelial cells, enhancing duodenal iron absorption and increasing iron uptake by the hepatocytes. Therefore overinterpretation of iron overload in biopsies from NAFLD-induced cirrhosis needs to be cautioned against. Iron deposition in NAFLD may be hepatocellular (Figure 4.5.1), reticuloendothelial (Figure 4.5.2), or both.
R E A S ON F OR R E F E R R A L
The liver biopsy shows features of steatohepatitis. In addition, there is significant hepatocyte iron deposition on using Perls’ iron stain. The specific question from the referring pathologist and hepatologist is whether the patient has hemochromatosis. PAT H OL OG I C F E AT U R E S
Besides the features of steatohepatitis, the liver biopsy also shows a mild degree of (grade 2 of 4) iron granules deposition within the hepatocytes and sinusoidal lining cells on using Perls’ iron stain (Figure 4.5.1).
FIGURE 4. 5. 1 Perls’ iron stain shows mild iron deposition in the hepatocytes and Kupffer cells.
F I G U R E 4 . 5 . 2 Perls’ iron stain demonstrates deposition in Kupffer
cells in an NAFLD case.
52
CASE
4.5:
NASH
WITH
E L E VAT E D
The pattern of iron deposition in the hepatocytes may inhomogenously involve zone 1, or may be similar to hereditary hemochromatosis, with a decreasing gradient from zone 1 to zone 3. Iron deposition in the reticuloendothelial cells, is typically punctuate and may be panacinar. NAFLD has been reported to be associated with increased serum iron indices including transferrin saturation and ferritin independent of genetic hemochromatosis. However, other studies showed the C282Y HFE gene mutation was enriched in NAFLD patients (3,4) and there was a significant correlation among the mutation, hepatic iron concentration or tissue iron stain, and degree of fibrosis (3). Thus liver biopsy in NAFLD patients may also provide prognostic implication in assessing hepatic iron stores, in addition to confirming the diagnosis. Although elevated serum ferritin may be a manifestation of aberrant HFE genetics (4), it has to be noted that elevated serum ferritin levels do not necessarily reflect increased hepatic iron stores, as ferritin is a known acute phase reactant protein and may be nonspecifically elevated in NAFLD alone or in insulin resistance (5,6). Whether
SERUM
IRON
INDICES
53
aberrant genetics, iron deposition, and localization of increased iron in NAFLD relate to progression of disease are areas of active investigation.
References 1. Ludwig J, Hashimoto E, Porayko MK, Moyer TP, Baldus WP. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology. 1997;112:882–888. 2. Deugnier Y, Turlin B, le Quilleuc D, et al. A reappraisal of hepatic siderosis in patients with end-stage cirrhosis: practical implications for the diagnosis of hemochromatosis. Am J Surg Pathol. 1997;21:669–675. 3. George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology. 1998;114:311–318. 4. Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in nonalcoholic steatohepatitis. J Hepatol. 1999;31:421–429. 5. Bugianesi E, Manzini P, D’Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 2004;39:179–187. 6. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. J Hepatol. 2007;46:700–707.
Case 4.6
Alcoholic Steatohepatitis MATTHEW M.YEH AND ELIZABETH M. BRUNT
As can be recalled, the term “nonalcoholic steatohepatitis,” credited to Ludwig et al from the 1980 publication (1) derived from the initial consideration of liver biopsy findings identical to ALD in patients who did not consume alcohol. These findings included macrosteatosis, ballooning, the presence of Mallory’s hyaline, now referred to as Mallory-Denk bodies (2), lipogranulomas, and varying degrees of fibrosis, including perisinusoidal, “chicken-wire” fibrosis. The clinical features included female gender, overweight, diabetes, and hyperlipidemia. These same clinical and histologic findings had been previously or concurrently reported in the similar setting of overweight and/or diabetes by others in the United States (3,4), Europe (5), and Japan (6) and were subsequently confirmed from studies around the world. Unfortunately, both the negative nomenclature (“non” alcoholic) and the concept of inseparability from “alcoholic histologic features” are embedded in the literature. Currently, there is discussion in the literature as to the amount of alcohol intake required for consideration of ALD (7). However, as pointed out, more than simply an amount may be causative; in fact, types of alcohol consumed and patterns are also important considerations (8). Most NAFLD literature lists consumption of 20g/d for men and 10g/d for women as the upper limit for “exclusion of ALD” as a contributor to liver disease.
F I G U R E 4 . 6 . 1 Active steatohepatitis with perisinusoidal fibrosis. Whether the lesions are caused by the patient’s diabetes or “mild alcohol” use, or both, cannot be discerned by histology.
DIAGNO SIS
Steatohepatitis, history of obesity, diabetes, and alcohol use.
DISCUSSIO N
The overlapping and often inseparable features of ALD and NAFLD are likely a reflection of the overlapping underlying pathophysiology of these 2 processes. The features in common include steatosis, that is, macrovesicular steatosis with or without lobular inflammation and with or without foci of microvesicular steatosis, with or without megamitochondria; and steatohepatitis, that is, steatosis with hepatocyte ballooning, with or without Mallory-Denk bodies, lobular inflammation, varying degrees of portal inflammation, and with or without varying amounts of perisinusoidal fibrosis. Cirrhosis, with or without the features above, may also occur in both processes. It is for these reasons, as illustrated in the case, pathologists cannot always assign an etiology, and it is recommended that the report simply state what is present, that is, steatohepatitis, and what is known clinically, that is obesity, diabetes, alcohol use. However, there are features of ALD that, to date, have not been reported in NAFLD. First, alcoholic hepatitis or cirrhosis due to alcohol may have a veno-occlusive lesion of subendothelial fibrosis or obliteration (9). Secondly, alcoholic hepatitis may or may not have steatosis but is characterized by numerous hepatocytes with Mallory-Denk bodies and satellitosis (polymorphonuclear leukocytes surrounding the affected cells). The affected hepatocytes may be ballooned or undergoing apoptosis and are eosinophilic and shrunken.
C L I N I C AL I N F OR M AT I ON
The patient is a 58-year-old obese, diabetic man with elevated liver tests: alanine aminotransferase (ALT) 59 IU/L, aspartate transaminase (AST) 76 IU/L, and hemoglobin A1C (HbA1C) 7.7. The patient’s history includes “mild” alcohol use. R E A S ON F OR R E F E R R A L
The question in this liver biopsy is one of attribution of cause of elevated liver tests: specifically, are they due to alcoholic steatohepatitis or nonalcoholic steatohepatitis? PAT H OL OG I C F E AT U R E S
The histologic features of the biopsy are those of markedly active steatohepatitis with grade 1 (5%–33%) macrovesicular steatosis in a nonzonal distribution, marked ballooning and evidence of Mallory-Denk bodies, moderate lobular and portal chronic inflammation. Perisinusoidal and periportal fibrosis can be discerned even on the hematoxylin and eosin (HE)–stained slides (Figure 4.6.1).
54
CASE
4.6:
ALCOHOLIC
Thirdly, canalicular cholestasis has yet to be reported in NAFLD. Finally, alcoholic foamy degeneration has also not been reported in NAFLD. This is an uncommon form of ALD; the hepatocytes appear uniformly foamy and there is little to no portal and/or lobular inflammation (10).
References 1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980 Jul;55(7);434–438. 2. Zatloukal K, French SW, Denk H, et al. From Mallory to MalloryDenk inclusion bodies: what, how and why? Exp Cell Res. 2007;313: 2033–2049. 3. Miller DJ, Ishimaru H, Klatskin GGA. Nonalcoholic liver disease mimicking alcoholic hepatitis and cirrhosis. Gastroenterology. 1979;77:27A.
S T E AT O H E PAT I T I S
55
4. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Progr Liver Dis. 1986;8:283–298. 5. Thaler H. Die fettleber und ihre pathogenetische Beziehung zur Leberzirrhose. Virchows Arch. 1962;335:180–188. 6. Itoh S, Tsukada N, Motomura Y, Ichinoe A. Five patients with nonalcoholic diabetic cirrhosis. Acta Hepato-Gastroenterol. 1979;26:90–97. 7. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis. 2001;21:17–26. 8. Day CP. Who gets alcoholic liver disease: nature or nurture? J R Coll Physicians Lond. 2000;34:557–562. 9. Goodman ZD, Ishak KG. Occlusive venous lesions in alcoholic liver disease. A study of 200 cases. Gastroenterology. 1982;83:786–796. 10. Hall P. Alcoholic liver disease. In: MacSween RNM BA, Burt AD, Portmann BC, et al. eds. Pathology of the Liver. 4th ed. London, UK: Churchill Livingstone; 2002; 273–311.
Case 4.7
Drugs and NAFLD MATTHEW M.YEH AND ELIZABETH M. BRUNT
The associations of medications with NAFLD continues to expand. As noted by authorities in the field, it is important to consider that the patient may have NAFLD and may be on a particular medication, but the disease may be related to the patient’s underlying metabolic condition rather than to the medication (1). Two drugs deserve specific comment: methotrexate and amiodarone. The injury of both may be exacerbated by the presence of underlying steatohepatitis due to insulin resistance; however, there are clues to distinguish the injuries. Methotrexate use may result in hepatocellular anisonucleosis and focal necrosis, nonzonally distributed macrovesicular steatosis that is commonly ”mild” (<33%), mild to moderate portal inflammation, and portal-based fibrosis (2). Zone 3 perisinusoidal fibrosis is not a characteristic of uncomplicated methotrexate, but excess alcohol use is known to result in progression of fibrosis with use of methotrexate (2). Injury to the Canals of Hering is speculated (3). Amiodarone toxicity is somewhat more challenging, as hepatic manifestations of this medication include not only the well-known phospholipidosis, but also Mallory-Denk bodies and steatosis. Amiodarone may also, however, result in cholestasis, “acute hepatitis,” and features of Reyes syndrome (ie, microvesicular steatosis) (4). The most common
feature of amiodarone use and/or toxicity is phospholipidosis, with little or no steatosis. Alternatively, less frequently, biopsies with “alcoholic steatonecrosis”-like features, including Mallory-Denk bodies, occur; it has been noted that these biopsies commonly also show cirrhosis. These 2 injury patterns reflect separate reactivity patterns to metabolic mechanisms of the drug in hepatocytes (5). As with all liver biopsies, careful attention to all clinical details of the patient, as well as all histologic features can be quite useful in biopsy interpretation.
References 1. Farrell GC. Drugs and steatohepatitis. Sem Liv Dis. 2002;22:185–194. 2. Roenigk HH, Auerback R, Maibach H, Weinstein G, Lebwoh M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol. 1998;38:478–485. 3. Hytiroglou P, Tobias H, Saxena R, Abramidou M, Papadimitriou CS, Theise ND. The Canals of Hering might represent a target of methotrexate hepatic toxicity. Am J Clin Pathol. 2004;121:324–329. 4. Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology. 1989;9:679–685. 5. Zimmerman HJ. Drugs used in cardiovascular disease. In: Zimmerman HJ, ed. Hepatoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins;1999:639–672.
56
Case 4.8
Microvesicular Steatosis MATTHEW M.YEH AND ELIZABETH M. BRUNT
C L I N IC AL I N F OR M AT I ON
The patient is a 33-year-old woman who suffers from epilepsy. She has taken valproic acid regularly. She is noted to have abnormal liver tests. A liver biopsy was performed. R E A SON F OR R E F E R R AL
There is no significant steatosis in the liver biopsy; however, many hepatocytes are swollen and enlarged. The referring pathologist’s specific question is whether these cells represent ballooned hepatocytes in steatohepatitis. PAT H OL OG I C F E AT U R E S
The liver biopsy shows hepatic parenchyma with no significant macrovesicular steatosis. However, there are patches of swollen and flocculent hepatocytes (Figure 4.8.1). High power magnification of these hepatocytes reveal centrally located nuclei with microvesicular steatosis showing very fine lipid droplets within the cytoplasm (Figure 4.8.2).
F I G U R E 4 . 8 . 1 Significant macrovesicular steatosis is not present in the liver biopsy; however, there are patches of hepatocytes with microvesicular steatosis showing swollen and flocculent hepatocytes.
D I AG N OS I S
Microvesicular steatosis associated with valproic acid use.
D I S C U S S I ON
It is important to recognize the significance of classifying steatosis into macrovesicular and microvesicular because of the different clinical implications, and therefore pathologists should be familiar with their exact definitions when interpreting liver biopsies. Not only is purely microvesicular steatosis not common, but it also suggests very specific conditions that typically warrant clinically urgent awareness such as Reyes syndrome, alcoholic foamy degeneration, acute fatty liver of pregnancy, and certain drug toxicities, including valproic acid. Severe mitochondrial dysfunction underlies this type of steatosis, which is typically associated with markedly elevated liver tests, with or without hepatic encephalopathy. Nonzonal aggregates of hepatocytes may contain microvesicular steatosis in a minority of cases of NAFLD, and the significance is yet to be elucidated. True microvesicular steatosis is characterized by enlargement of the hepatocytes and flocculent alteration of the cytoplasm with centrally located nuclei (Figures 4.8.1 and 4.8.2). As the morphology may resemble ballooned hepatocytes in which the hepatocytes are swollen in both lesions, the distinction is important and the clinical implications are very different. Clinical presentations likewise differ. In general, the nuclei in
F I G U R E 4 . 8 . 2 Higher magnification of Figure 4.8.1 reveals centrally
located nuclei with very fine lipid droplets within the cytoplasm.
ballooned hepatocytes are hyperchromatic and may be located at the periphery of the cytoplasm, whereas the nuclei in hepatocytes with microvesicular steatosis are located at the center of the cells. There is also a finite difference in the cytoplasmic contents, in which the cytoplasm in ballooned hepatocytes is rarefied or finely reticulated; this suggests accumulation of intracellular fluid within injured cells, whereas the visualization of droplets of steatosis in microvesicular steatosis can be quite variable, and the confirmation often requires the use of Oil red O on a frozen section of a liver biopsy. 57
Case 4.9
Pediatric Fatty Liver Disease CYNTHIA BEHLING
C L I N I C AL I N F OR M AT I ON DIAGNO SIS
A 13-year-old obese boy was noted to have elevated serum transaminases but no stigmata of liver disease. Further clinical testing demonstrated negative viral markers for hepatitis B and C (including viral RNA studies for HCV), normal levels of serum ceruloplasmin, and negative autoimmune markers. The astute pediatrician ordered an ultrasound which demonstrated fatty liver. The patient and his parents agreed to be part of a clinical trial and a liver biopsy was performed.
Severe fatty change with periportal fibrosis consistent with steatohepatitis (Type 2 pattern, stage 1c by Kleiner methodology for staging nonalcoholic steatohepatitis).
DISCUSSIO N
Shortly after the first descriptions of a nonalcoholic fatty liver disease similar to that in adults, Moran et al reported steatohepatitis in a group of obese children (1). Pediatric fatty liver was little studied until more than a decade later when the rapidly increasing incidence of obesity in children drew attention to diseases associated with obesity, including fatty liver. Pediatric fatty liver disease is now considered the most common liver disease in children and adolescents (2). Estimates of the prevalence of fatty liver disease have been made from epidemiologic studies with various direct and surrogate measures of liver steatosis, such as elevated serum ALT and AST or imaging studies, since liver biopsy of otherwise healthy children is considered an unacceptable risk. A population-based autopsy study that reported histologic findings in a series of 742 children showed fatty liver present in 13% of children aged 2 to 19 (3). In addition, the magnitude of the problem in the United States can be estimated in the following manner. In 2006, there were 73.7 million
R E A S ON F OR R E F E R R A L
The patient was referred to a pediatric gastroenterology clinic for evaluation of possible fatty liver disease and treatment. PAT H OL OG I C F E AT U R E S
The liver biopsy demonstrated severe fatty change (grade 3, for . 66% of hepatocytes with fat) and periportal fibrosis (Figure 4.9.1). The fat consisted of both large and small droplet type of macrovesicular steatosis (Figure 4.9.2). In addition, the degree of lobular inflammation was only mild and no ballooned hepatocytes were noted. The portal zone also contained somewhat prominent lymphoid infiltrate in the form of an aggregate of lymphocytes, but no prominent plasma cell infiltrate was present. The trichrome stain confirmed the presence of periportal fibrosis, but no centrizonal fibrosis was noted (Figure 4.9.1).
B
A
FIGURE 4. 9. 1 (A) Low power examination of the trichrome-stained sections of the liver biopsy showed severe steatosis involving 80%–90%
of hepatocytes. A portal tract on the left is expanded by inflammation and periportal as well as septal fibrosis. Two normal central (terminal hepatic) veins are noted, with relative lack of fatty change in hepatocytes in Zone 3 near the central veins. (B) At higher magnification, portal and lobular inflammation are noted, with distortion of the portal architecture and periportal fibrosis.
58
CASE
4.9:
P E D I AT R I C
FAT T Y
LIVER
DISEASE
59
B
A
FIGURE 4. 9. 2 Other examples of the Type 2 pediatric fatty liver pattern demonstrate typical portal inflammation and fibrosis, (A) and
relative sparing of zone 3 by fat and fibrosis, (B) No ballooned hepatocytes are noted in either example.
children, and of these, 17.1% are obese (12.6 million). Of the obese children, 3% to 10% could have fatty liver (378 000–1.26 million), and a small percentage could also have steatohepatitis and possible progression of disease. Further details about calculating the prevalence of fatty liver can be found in the reviews by Patton (2) and Loomba, et al (4). Risk Factors
The risk factors for fatty liver disease in children are primarily associated with obesity and certain ethnicities, including groups such as Hispanic children (5). Genetic factors likely contribute to risk as well, with several family studies suggesting increase in the proportion of family members with fatty liver. Fatty liver has been identified in about two-thirds of the siblings and three-fourths of the parents of children with fatty liver (6). Prognosis
One of the more significant early observations of pediatric fatty liver disease related to prognosis was the presence of fibrosis. Although it is now recognized that fibrosis may be dynamic, its presence implies a degree of liver injury that may be more difficult to repair and that may be more likely to progress. Advanced fibrosis and cirrhosis have been reported in pediatric fatty liver disease (7). Spectrum of Histologic Changes in Pediatric Steatohepatitis
One of the first descriptions of fatty liver in children was a study in 1995 reporting biopsy findings from 14 patients with “idiopathic” steatohepatitis. These biopsies showed a variable amount of hepatic fat, mixed portal inflammation, and portal fibrosis present in all of the biopsy samples. More advanced
fibrosis including bridging (portal-portal and/or centralportal) and zone 3, and perisinusoidal fibrosis was present in all but one of the cases (8). Further systematic investigation of the histologic features of pediatric fatty liver disease has been published in several major studies to date (9–11). In the first, liver biopsies from 100 children with fatty liver were grouped according to clustered histologic features. Three distinct groups were identified. Of the biopsies 17% showed a classic (termed Type 1) pattern of steatohepatitis in which there was zone 3 predominant injury with perisinusoidal fibrosis and ballooned hepatocytes previously described in Chapter 4. Half of the cases were grouped into a portal-based pattern (termed Type 2), with portal inflammation and fibrosis but little or no ballooning degeneration. The remainder showed a hybrid pattern with features of both. Subsequent studies have also noted the portal-based pattern of liver injury that accounts for a varying number of cases of pediatric NASH (10,11). At this time it is unknown whether the portal-based inflammation represents a phase in the evolution of the fatty liver disease or a possible different pathophysiologic mechanism. Of practical importance is the recognition that some cases of pediatric, and rare cases of adult, NASH have a different “look.” Liver injury may occur even in a case with no ballooned hepatocytes or apparent zone 3 injury. Biopsy reports for these patients should mention the possibility of an alternate pattern of injury, which may include cases with less ballooning and a more zone 1 portal-predominant pattern, cases with marked steatosis but relatively little inflammation or fibrosis, and cases which have similar features and distribution of features as NASH in adults. It is not clear why there are different patterns of fatty liver disease. Various factors may influence the accumulation of fat in different zones of the liver, including hormones (as suggested by gender differences in the prevalence of fatty
60
CHAPTER
4:
FAT T Y
liver and adolescent age of onset), differences in insulin resistance, dietary factors and interaction with gut flora, and metabolic correlates of visceral versus subcutaneous fat. Role of Liver Biopsy
Imaging studies can reveal steatosis and advanced fibrosis. However, liver biopsy allows refinement of the degree of steatosis, even if minor, and also allows grading of fat as well as staging of fibrosis and the exclusion of the presence of other liver diseases. The staging system developed by the NAFLD consortium pathology group as described by Kleiner et al (10) includes a Stage 1c for the periportal pattern of injury in early-stage disease when no pericentral fibrosis is present; so this methodology is recommended for usage in cases of pediatric NASH. Differential Diagnosis
The etiology of many of the other diseases that cause fatty liver in childhood can be distinguished on the basis of clinical history and/or age at presentation. Metabolic and mitochondrial diseases typically present in infancy or very early childhood, whereas the incidence of NAFLD is estimated at only 0.7% for children aged 2 to 4 (3). Fatty liver related to intestinal abnormalities (short gut, intestinal bypass, or total parenteral nutrition) is also discernable based on clinical history. The predominant histologic mimic of NAFLD is Wilson disease, which can be more definitively diagnosed by serum and urine testing for copper as well as genetic testing.
LIVER
DISEASE
References 1. Moran JR, Ghishan FK, Halter SA, Greene HL. Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol. 1983;78:374–377. 2. Patton HM, Sirlin C, Behling C, Middleton M, Schwimmer JB, Lavine JE. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr. 2006;43(4):413–427. 3. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006; 118(4):1388–1393. 4. Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology. 2009;50(4):1282–1293. 5. Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr. 2003;143:500–505. 6. Schwimmer JB, Celedon MA, Lavine JE, et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology. 2009;136(5):1585–1592. 7. Molleston JP, White F, Teckman J, Fitzgerald JF. Obese children with steatohepatitis can develop cirrhosis in childhood. Am J Gastroenterol. 2002;97:2460–2462. 8. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE. Idiopathic steatohepatits in childhood: a multicenter retrospective study. J Pediatr. 1995;127(5):700–704. 9. Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005;42(3):641–649. 10. Kleiner DE, Brunt EM, Van Natta M, et al. Nonalcoholic steatohepatitis clinical research network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313–1321. 11. Carter-Kent C, Yerian LM, Brunt EM, et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology. 2009;50(4):1113–1120.
Case 4.10
Chemotherapy-Associated Steatohepatitis Due to Irinotecan VIKRAM DESHPANDE AND GREGORY Y. LAUWERS
C L I N IC AL I N F OR M AT I ON
A 56-year-old male had a prior history of pT3N1 adenocarcinoma of the sigmoid colon. Three years following this resection, an imaging study detected 3 foci of metastasis in the left lobe of the liver. Preoperative chemotherapy with 5-fluorouracil plus irinotecan was instituted and a hemihepatectomy was performed 6 weeks after the end of chemotherapy.
R E A SON F OR R E F E R R AL
Intraoperatively, in addition to the 3 foci of metastatic disease, the liver was noted to be yellow. A frozen section was evaluated to assess the status of the background liver.
PAT H OL OG I C F E AT U R E S
The specimen as well as the frozen and paraffin sections showed striking hepatic steatosis (Figures 4.10.1, 4.10.2). The change was most prominent in zone 3 and zone 2 (Figure 4.10.3). In addition to steatosis (Figure 4.10.4), ballooned hepatocytes, some containing “soft” Mallory’s hyaline, were also noted (Figure 4.10.5). Spotty foci of hepatocellular dropout were present as was a sparse lobular lymphocytic infiltrate. The portal tracts were essentially unremarkable.
F I G U R E 4 . 1 0 . 2 Metastatic colonic adenocarcinoma (arrow) with
steatosis in the adjacent nonneoplastic liver.
F I G U R E 4 . 1 0 . 3 The steatosis predominantly involves zones 2 and 3.
DIAGNO SIS
Chemotherapy-associated steatohepatitis due to irinotecan.
FIGURE 4. 10. 1 Fatty liver associated with irinotecan associated
steatohepatitis.
61
62
CHAPTER
4:
FAT T Y
LIVER
DISEASE
is a higher risk of postoperative morbidity and mortality in patients with marked hepatic steatosis (3). Broadly 2 forms of liver injury are recognized: steatosis/steatohepatitis and hepatic sinusoidal pattern of injury. The former pattern of injury is associated predominantly with 5-FU and irinotecan, whereas sinusoidal injury as evidenced by sinusoidal dilatation has been predominantly seen with oxaliplatin. Chemotherapy and Steatosis
FIGURE 4. 10. 4 Diffuse steatosis associated with irinotecan.
The backbone of first-line chemotherapy regimens is 5-FU, and modern chemotherapy regimens combine 5-FU/leucovorin with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX). An association between steatosis and chemotherapy was first discovered by several pathological and radiological studies. Computed tomography scan screening before and after chemotherapy showed 47% of patients treated with 6 to 12 cycles of 5-FU develop evidence of steatosis (4). Irinotecan and Steatohepatitis
FIGURE 4. 10. 5 Irinotecan associated steatohepatitis. Note the
ballooned hepatocytes (arrow) and Mallory’s hyaline (arrow head).
Steatohepatitis was first noted in a small series that observed an increased rate of steatohepatitis in 14 patients treated with irinotecan or oxaliplatin (5). The association of irinotecan and steatohepatitis was further clearly demonstrated in a larger series treated with FOLFIRI (5-FU/leucovorin with irinotecan) with 20% of these patients developing steatohepatitis (3). The increased rate of steatohepatitis caused by irinotecan has clinically relevant consequences, since these patients have a significantly increased 90-day mortality rate compared with patients without steatohepatitis (14.7% vs 1.6%) (3). However, others did not confirm an increase in morbidity or mortality in patients treated preoperatively with irinotecan-containing regimens (6-8), although this may reflect the variability in diagnosing and grading steatosis and steatohepatitis. Furthermore, in a recent study, steatosis and steatohepatitis correlated with body mass index (BMI) and not chemotherapy (8). However, the delayed surgical resections (12.4 weeks vs 6.4 weeks) in this series may have been a confounding factor (3,8).
D I S C U S S I ON
About one-third of patients with colorectal cancer will present with liver metastasis, either at the time of diagnosis or during the course of the disease. Surgical resection of the metastases is frequently coupled with systemic neoadjuvant chemotherapy. The drugs with efficacy in the neoadjuvant setting include 5-fluorouracil (5-FU), irinotecan, and oxaliplatin; the latter 2 are frequently infused in conjunction with 5-FU. A major goal of this therapy is to decrease the tumor size and burden sufficiently so that unresectable patients can become candidates for surgery, and this is successfully achieved in about 12.5% of patients (1). In addition, there is evidence that this form of therapy may improve overall survival of individuals with metastatic liver disease (2). This neoadjuvant approach damages the adjacent liver parenchyma. This is an important clinical issue, since there
Oxaliplatin
Oxaliplatin has been specifically associated with sinusoidal dilatation and hemorrhage (Figure 4.10.6) (9). Furthermore, centrizonal perisinusoidal and veno-occlusive fibrosis, peliosis, and nodular regenerative hyperplasia have developed following use of this drug (9,10). Other morphological lesions associated with oxaliplatin include small vessel loss, hepatocyte plate disruption, and parenchymal extinction lesions (8). Preoperative Assessment of Risk for Hepatic Toxicity
Novel methods are needed to identify patients at high risk for postoperative complications. Abdominal ultrasound, CT
CASE
4.10:
C H E M O T H E R A P Y- A S S O C I AT E D
S T E AT O H E PAT I T I S
63
References
FIGURE 4. 10. 6 Oxaliplatin associated sinusoidal congestion.
scans, and magnetic resonance imaging (MRI) have limited utility since they can detect steatosis but not steatohepatitis. Chemical-shift imaging MRI may be more efficacious in predicting chemotherapy-induced liver injury (11). Preoperative liver biopsies are also proposed for patient selection, but opinions are mixed about whether these biopsies can be helpful. Others have advocated performing laparoscopy prior to doing the hepatectomy (3).
C ON C L U S I ON S
Irinotecan may result in steatohepatitis and significant liver injury. New strategies to minimize the postoperative morbidity caused by irinotecan such as the use of atorvastatin (lipitor) may decrease the severity of steatohepatitis (12). Great caution should be used in considering hepatectomy in obese, diabetic, and alcoholic patients who have received neoadjuvant chemotherapy.
1. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644-657, discussion 57–58. 2. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677–3683. 3. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–2072. 4. Peppercorn PD, Reznek RH, Wilson P, Slevin ML, Gupta RK. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer. 1998;77:2008–2011. 5. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005;200:845–853. 6. Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg. 2007;11:860–868. 7. Sahajpal A, Vollmer CM Jr, Dixon E, et al. Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes. J Surg Oncol. 2007;95:22–27. 8. Ryan P, Nanji S, Pollett A, et al. Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy. Am J Surg Pathol. 2010;34:784–791. 9. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–466. 10. Rubbia-Brandt L, Lauwers GY, Wang H, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatinassociated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 2010;56:430–439. 11. O’Rourke TR, Welsh FK, Tekkis PP, et al. Accuracy of liver-specific magnetic resonance imaging as a predictor of chemotherapy-associated hepatic cellular injury prior to liver resection. Eur J Surg Oncol. 2009;35:1085–1091. 12. Hyogo H, Tazuma S, Arihiro K, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism. 2008;57:1711–1718.
Case 4.11
Subacute Steatohepatitis LINDA D. FERRELL
5 months from an early stage 1 fibrosis with focal pericentral fibrosis to extensive centrizonal sinusoidal fibrosis, as well as periportal and bridging fibrosis, indicative of a stage 3 fibrosis by both Brunt (1) and Kleiner methodologies (2). There was marked fatty change and large numbers of ballooned hepatocytes, many with well-formed Mallory-Denk bodies, were present in centrizonal areas (Figure 4.11.1–4.11.3). The
C L I N I C AL I N F OR M AT I ON
A 33-year-old, morbidly obese woman was admitted for abdominal pain of 2-weeks’ duration. Past history was significant for “long-limb” Roux-en-Y gastric bypass surgery 5 months prior to this admission, a procedure that resulted in an anastomosis of jejunum to the distal ileum. She had a BMI of 45.3 at that time, and had lost 40 pounds after her surgery. She had complications from the surgery that resulted in a return to the operating room at that institution for anastomotic leak and stricture. A liver biopsy done at the referring institution at the time of the bypass showed severe fatty change with minimal lobular inflammation associated with focal sinusoidal fibrosis on trichrome stain consistent with stage 1 fibrosis by the Brunt methodology (1), or stage 1a by the Kleiner methodology (2). No ballooned hepatocytes were present. Past medical history was unremarkable, with no evidence for diabetes, hyperlipidemia, alcohol, or other substance abuse. At the time or referral for abdominal pain, the patient had stable vital signs, and was noted to have a height of 5 ft 1 in, and weight of 211 pounds, with BMI 39.9. Abnormal laboratory tests included AST of 80 and ALT of 143. Ultrasound showed hepatic steatosis. The patient was immediately taken to the operating room due to concerns for small bowel obstruction or perforation, but these complications were not found. The long-limb Roux-en-Y was revised to the conventional Roux-en-Y. However, the surgeon was unable to close the abdomen due to marked swelling of the liver, which appeared to be grossly fatty. Liver biopsy at this time (5 months after the first biopsy, see above) demonstrated extensive fibrosis with many ballooned hepatocytes and abundant Mallory-Denk bodies, consistent with a rapidly progressive steatohepatitis. Postoperatively, the patient required blood transfusions, and she became septic due to fungemia, developed respiratory distress syndrome, and renal failure, and died 20 days post-op. An autopsy was performed that demonstrated similar changes of advanced damage to the liver as was seen in the biopsy, with the addition of ischemic necrosis as an additional finding.
F I G U R E 4 . 1 1 . 1 Centrizonal region demonstrates extensive pericellular fibrosis. Hepatocytes contain mostly large droplets of fat, but some small droplets is also present. There are several ballooned hepatocytes containing prominent Mallory-Denk bodies but inflammation is sparse.
R E A S ON F OR R E F E R R A L
The patient was referred to UCSF with the clinical diagnosis of possible small bowel ischemia or perforation and a diagnosis of fatty liver disease with no evidence of active steatohepatitis on the previous liver biopsy. PAT H OL OG I C F E AT U R E S
4 . 1 1 . 2 Centrizonal region demonstrates severe fatty change, congestion, ductular reaction, and extensive pericellular fibrosis. Numerous swollen hepatocytes are present.
FIGURE
Both the biopsy at the time of the second surgery and the autopsy showed a marked progression of fibrosis within only 64
CASE
4.11:
SUBACUTE
FIGURE 4.11.3 Centrizonal region (higher magnification of previous
figure) highlights the Mallory-Denk bodies in swollen hepatocytes. Inflammatory infiltrate is scant.
scarring was most prevalent in the centrizonal areas, and centrizonal veins were difficult to identify. Bile stasis was seen in canaliculi. In addition, in the autopsy sample, zones of ischemic necrosis of hepatic parenchyma were also present.
D I AG N OS I S
Steatohepatitis, active and chronic, with extensive fibrosis.
D I S C U S S I ON
This case demonstrates an unusual variant of nonalcoholic steatohepatitis with an aggressive subacute course, leading
S T E AT O H E PAT I T I S
65
to extensive fibrosis within 5 to 6 months after an unusual, long-limb Roux-en-Y procedure. This procedure likely resulted in abnormal hepatic-enteric interactions mimicking those seen in the jejunal-ileal bypass procedure (3), which in turn was discovered to cause severe liver damage as well. This pattern of rapidly progressive fibrosis is rare in the setting of NASH but can be seen associated with alcoholic liver injury. In fact, many of the features are more typical of alcoholic steatohepatitis, including the abundant ballooned hepatocytes with Mallory-Denk bodies, cholestasis, and sclerosis of hepatic veins. Another unusual feature is the extensive sinusoidal and pericellular fibrosis without as much evidence of nodularity, a finding that can also be seen in chronic alcoholic liver disease where regeneration is limited. Caldwell and Hespenheide (4) has described subacute liver failure in obese women as a rare clinical entity but did not describe the pathologic features in his series. Other rare settings with histologic findings showing similar extensive pericellular fibrosis have been noted and include rapid weight loss due to conventional gastric bypass as well as weight loss while on the high protein Atkin’s diet (5).
References 1. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroentroenterol. 1999;94: 2467–2474. 2. Kleiner D, Brunt E, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321. 3. Shibata H, Mackenzie J, Huang S. Morphologic changes of the liver following small intestinal bypass for obesity. Arch Surg. 1971;103:229–237. 4. Caldwell SH, Hespenheide EE. Subacute liver failure in obese women. Am J Gastroenterol. 2002;97(8):2058–2062. 5. Tan V, Jimenez C, Merriman R, Ferrell L. Variants of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) with rapidly progressive course. Mod Path. 2008;21(suppl 1):317A.
This page intentionally left blank
5 Hepatic Granulomas and Granulomatous Hepatitis LAURA W. LAMPS
granulomas/granulomatous inflammation may be divided into the following morphologic categories.
I N T ROD U C T I ON
Granulomas are aggregates of macrophages, often admixed with other inflammatory cells, which usually result from chronic antigen presentation. The liver is involved in many granulomatous diseases, some of which are intrinsic hepatic diseases, whereas others are disseminated systemic diseases that involve the liver in addition to other organs. Hepatic granulomas are reportedly present in 2% to 10% of all liver biopsy specimens examined in general pathology practice, and of those supposedly 13% to 36% have no discoverable etiology even after extensive evaluation (1–4). There are several classification schemes that address types of granulomas/granulomatous inflammation. Regardless of the classification used, the morphology of the granulomas may provide clues to the diagnosis (2–4) (Table 5.1). Hepatic
Epithelioid Granulomas With or Without Necrosis
Epithelioid granulomas are discrete lesions with distinct edges. Necrotizing epithelioid granulomas frequently have an infectious etiology, although no specific organism is detected in some circumstances. Necrotizing granulomas in infectious disease processes often do not respect the architecture of the liver and destroy adjacent structures. Infections that cause epithelioid granulomas include, but are not limited to, Mycobacterium tuberculosis (see Chapter 5.1), tuberculoid leprosy, schistosomiasis (see Chapter 5.4), and brucellosis. Liver involvement is seen in
TA B LE 5. 1 Classification of granulomatous inflammation in the liver by histologic pattern
Fibrin Ring Granuloma
Microgranulomas
Lipogranulomas
Stellate Abscess With Granulomatous Inflammation
Infectious Q-fever
Infectious
Mineral oil
Bartonella
Rhodococcus equi
Tularemia
M. tuberculosis
Drug reaction
Toxoplasmosis
Listeria (rare)
Tularemia
Whipple disease
Listeriosis
Brucellosis
Foreign body reaction
Salmonella
Other Nonspecific reaction to liver injury
Fungi, esp. Candida
MAI (immunocompromised patients)
Melioidosis
MAI (immunocompetent patients)
Sarcoidosis
CMV
Actinomycosis
Lepromatous leprosy
Tuberculoid leprosy
Autoimmune diseases
EBV
Nocardia
Histoplasmosis
Tertiary syphilis
Primary biliary cirrhosis
Leishmaniasis
Other Chronic granulomatous disease
Leishmaniasis
Chlamydia
CVID
Whipple disease (rare)
Hodgkin disease
Schistosomiasis
Other paraneoplastic conditions
Fungal infections
Chronic granulomatous disease of childhood
Foamy Macrophage Aggregates
Other Drug reaction
Predominantly Suppurative, ±Granulomatous Inflammation
Epithelioid Granuloma, Infectious Causes
Epithelioid Granulomas, Other Causes
Viral infections (rare) Abbreviations: CMV, cytomegalovirus; CVID, common variable immunodeficiency; EBV, Epstein-Barr virus; MAI, Mycobacterium avium-intracellulare.
67
68
CHAPTER
5:
H E PAT I C
GRANULOMAS
almost all cases of miliary tuberculosis, and is common in both localized extrapulmonary and pulmonary tuberculosis (2,5–6). The hallmark of hepatic tuberculosis is necrotizing granuloma, and confluent granulomas can lead to masses (tuberculomas). Periportal lymphadenopathy is common (6). There is often an accompanying reactive hepatitis. It may be difficult to detect mycobacteria on special stains; thus, culture and polymerase chain reaction (PCR) assays may be of value. The lesion typical of tuberculoid leprosy is a discrete, tuberculoid granuloma with associated giant cells. Bacilli are often rare and difficult to detect in this variant (7–9). Other atypical mycobacteria that occasionally cause liver disease include M. kansasii and BCG (Bacillus Calmette-Guerin). Brucellosis occurs primarily in domestic and barnyard animals, and humans contract infection through occupational exposure and by ingesting contaminated food. Hepatic involvement is seen in approximately half of the cases (10–12). Liver biopsies often (although not always) show noncaseating granulomatous inflammation, sometimes with giant cells. Granulomas may be discrete and epithelioid or small and poorly formed. Organisms are difficult to culture and are rarely seen on special stains; thus, serologic studies and exposure history are helpful in making the diagnosis (13–15). Sarcoidosis involves the liver in 50% to 100% of cases. Autopsy studies have shown that the liver is secondary only to the lungs and lymph nodes in frequency of involvement by granulomas (2). Sarcoid granulomas are noncaseating, epithelioid with variable giant cells, and severe lesions may be confluent. Sarcoid granulomas are often accompanied by fibrosis, which may lead to cirrhosis (2,13–15). Noncaseating granulomas are also reported in 18% to 64% of cases of primary biliary cirrhosis (see Chapter 5.2). They may be portal or lobular but are often associated with bile duct lesions. Granulomas are seen in a minority of cases of primary sclerosing cholangitis, in which they are usually well-formed, nonnecrotizing, and epithelioid (2–4). Lipogranulomas
These contain lipid and are associated with mineral oils in foods and medications (16–17). Whether or not they are directly associated with fatty liver disease remains controversial. Microgranulomas
Microgranulomas have been defined as 3 to 7 macrophages in cross-section, often admixed with other inflammatory cells and/or apoptotic hepatocytes. This pattern is very nonspecific and does not carry any special diagnostic significance; it has been associated with a number of infections and drugs (3). Fibrin Ring Granulomas
This distinctive form of hepatic granuloma consists of an epithelioid granuloma with a central lipid vacuole surrounded by a fibrin ring. Although classically described in association with
AND
G R A N U L O M AT O U S
H E PAT I T I S
Q fever, these lesions are nonspecific and have been observed in the context of numerous diseases including leishmaniasis, Boutonneuse fever, Hodgkin disease, allopurinol reaction, toxoplasmosis, cytomegalovirus (CMV) infection, mononucleosis, Mycobacterium avium-intracellulare (MAI) infection, and typhoid fever (2–4,18) (see Chapter 5.3). Foamy Macrophage Aggregates
This pattern of granulomatous inflammation is usually due to infection and is frequently seen in immunocompromised patients. There may be very little associated additional inflammatory response. MAI is most commonly associated with this pattern; usually, but not always, in the setting of AIDS. The liver is involved in over 50% of disseminated cases (19–20). Organisms are usually abundant on acid-fast staining in immunocompromised patients. Other causes of foamy macrophage aggregates include Rhodococcus equi, lepromatous leprosy, visceral leishmaniasis (kala-azar), and Whipple disease. In addition, hepatic histoplasmosis frequently features portal lymphohistiocytic inflammation and sinusoidal Kupffer cell hyperplasia rather than discrete granulomas, and organisms are present in portal macrophages and Kupffer cells (21). Granulomatous Inflammation With or Without Admixed Suppurative Inflammation
Although the term “granulomatous inflammation” is often used to describe any type of granuloma in a biopsy, strictly speaking this term implies poorly formed granulomas with indistinct edges, often with admixed inflammatory cells of other types. Granulomatous inflammation with associated hepatocellular and/or duct damage is often associated with drug-induced liver injury. When suppurative inflammation predominates, certain infectious etiologies should be suspected (Table 5.1). Francisella tularensis, which causes tularemia, is a Gramnegative coccobacillus endemic in many areas of North America. It is transmitted to humans from rodents and rabbits. Hepatic involvement is often a component of disseminated infection (22,23). Histologically, there are suppurative microabscesses with occasional surrounding macrophages; as the lesions evolve they may become more granulomatous (23). Periportal lymph nodes may show discrete, well-delineated areas of cortical necrosis (23). Organisms are rarely seen on special stains; thus cultures, serologic tests, and molecular testing are useful diagnostic modalities. Hepatic listeriosis is also usually seen in the context of disseminated infection in immunocompromised patients and diabetics. Histologically, scattered microabscesses are seen, often with small granulomas (24). Sometimes an exclusively microgranulomatous pattern, and rarely true epithelioid granulomas, may be present. Occasionally short pleomorphic Gram-positive rods may be identified, but blood culture is the most important diagnostic test. Many fungal infections also cause a mixed suppurative and granulomatous pattern, including aspergillus, mucormycosis and related zygomycetes, and Cryptococcus (25–28).
CHAPTER
5:
H E PAT I C
GRANULOMAS
Stellate Abscesses With Associated Granulomatous Inflammation
This pattern is also usually associated with infectious etiologies and is most commonly associated with cat scratch disease (CSD). Bartonella henselae is the most common cause of cat scratch disease. A small percentage of patients (1%–2%) develop disseminated CSD, and these patients usually lack the characteristic skin papule and superficial adenopathy (29,30) (see Chapter 5.5). Liver lesions are often multiple and have associated abdominal lymphadenopathy. Hepatic CSD patients are usually not immunocompromised (30). The characteristic histologic lesion of hepatic CSD consists of irregular, stellate microabscesses surrounded by an inner layer of palisading histiocytes, a surrounding rim of lymphocytes, and an outermost thick layer of fibrous tissue. This outer fibrous zone is very pronounced in the liver. Diagnostic aids include patient history with specific questions pertaining to cat exposure, silver impregnation stains (Warthin-Starry or Steiner), molecular assays, and enzymelinked immunosorbent assay (ELISA). Other entities that can produce similar lesions include tularemia, tuberculosis, and hepatic candidiasis (31). In addition to the morphology of the granulomas, the pathologist should evaluate the location, presence or absence of necrosis, nature of accompanying inflammatory infiltrate, organisms or foreign material, and other morphologic changes in the liver biopsy. Special stains for microorganisms are invaluable in evaluating granulomatous processes in the liver. It is also important to decide whether or not the granuloma is incidental to some other chronic disease process (such as hepatitis C infection) or represents a second true pathologic process; in some cases, it is impossible to make this distinction on morphologic grounds alone.
References 1. Harrington PT, Gutierrez JJ, Ramirez-Ronda CH, Quiñones-Soto R, Bermúdez RH, Chaffey J. Granulomatous hepatitis. Rev Infect Dis. 1982;4:638–655. 2. Ishak KG. Granulomas of the liver. In: Ioachim HL, ed. Pathology of Granulomas. New York, NY: Raven Press; 1983. 3. Kleiner DE. Granulomas in the liver. Sem Diagn Pathol. 2006;23: 161–169. 4. Gaya DR, Thorburn D, Oien KA, Morris AJ, Stanley AJ. Hepatic granulomas: a 10 year single centre experience. J Clin Pathol. 2003;56: 850–853. 5. Essop AR, Posen JA, Hodkinson JH, Segal I. Tuberculosis hepatitis: a clinical review of 96 cases. Q J Med. 1984;53:465–477. 6. Oliva A, Duarte B, Jonasson O, Nadimpalli V. The nodular form of local hepatic tuberculosis: a review. J Clin Gastroenterol. 1990;12:166–173. 7. Karat AB, Job CK, Rao PS. Liver in leprosy: histological and biochemical findings. Br Med J. 1971;1:307–310.
AND
G R A N U L O M AT O U S
H E PAT I T I S
69
8. Chen TS, Drutz DJ, Whelan GE. Hepatic granulomas in leprosy: their relation to bacteremia. Arch Pathol Lab Med. 1976;100:182–185. 9. Sehgal VN, Tyagi SP, Kumar S, Gupta MC, Hameed S. Microscopic pathology of the liver in leprosy patients. Int J Dermatol. 1972;11:168–172. 10. Williams RK, Crossley K. Acute and chronic hepatic involvement of brucellosis. Gastroenterology. 1982;83:455–458. 11. Ablin J, Mevorach D, Eliakim R. Brucellosis and the gastrointestinal tract: the odd couple. J Clin Gastroenterol. 1997;24:25–29. 12. Cervantes F, Bruguera M, Carbonell J, Force L, Webb S. Liver disease in brucellosis: a clinical and pathological study of 40 cases. Postgrad Med J. 1982;58(680):346–350. 13. Valla DC, Benhamou JP. Hepatic granulomas and hepatic sarcoidosis. Clin Liver Dis. 2000;4:269–285. 14. Ishak KG. Sarcoidosis of the liver and bile ducts. Mayo Clin Proc. 1998;73:467–472. 15. Devaney K, Goodman ZD, Epstein MS, Zimmerman HJ, Ishak KG. Hepatic sarcoidosis. Clinicopathologic features in 100 patients. Am J Surg Pathol. 1993;17:1272–1280. 16. Delladetsima JK, Horn T, Poulsen H. Portal tract lipogranulomas in liver biopsies. Liver. 1987;7(1):9–17. 17. Petersen P, Christoffersen P. Ultrastructure of lipogranulomas in human fatty liver. Acta Pathol Microbiol Scand A. 1979;87(1):45–49. 18. Marazuela M, Moreno A, Yebra M, Cerezo E, Gómez-Gesto C, Vargas JA. Hepatic fibrin-ring granulomas: a clinicopathologic study of 23 patients. Hum Pathol. 1991;22:607–613. 19. Farhi DC, Mason UG III, Horsburgh CR Jr. Pathologic findings in disseminated mycobacterium avium-intracellulare infection. A report of 11 cases. Am J Clin Pathol. 1986;85:67–72. 20. Klatt EC, Jensen DF, Meyer PR. Pathology of mycobacterium aviumintracellulare infection in acquired immunodeficiency syndrome. Hum Pathol. 1987;18:709–714. 21. Lamps LW, Molina CP, West AB, Haggitt RC, Scott MA. The pathologic spectrum of gastrointestinal and hepatic histoplasmosis. Am J Clin Pathol. 2000;113(1):64–72. 22. Ortega TJ, Hutchins LF, Rice J, Davis GR. Tularemic hepatitis presenting as obstructive jaundice. Gastroenterology. 1986;91:461–463. 23. Lamps LW, Havens JM, Sjostedt A, Page DL, Scott MA. Histologic and molecular diagnosis of tularemia: a potential bioterrorism threat endemic to North America. Mod Pathol. 2004;17:489–495. 24. Gebauer K, Hall JC, Donlon JB, Herrmann R, Rofe S, Platell C. Hepatic involvement in listeriosis. Aust N Z J Med. 1989;19:486–487. 25. Chandler FW, Watts JC. Pathologic Diagnosis of Fungal Infections. Chicago, IL: ASCP Press; 1987. 26. Bonacini M, Nussbaum J, Ahluwalia C. Gastrointestinal, hepatic, and pancreatic involvement with Cryptococcus neoformans in AIDS. J Clin Gastroenterol. 1990;12:295–297. 27. Wilkins MJ, Lindley R, Dourakis SP, Goldin RD. Surgical pathology of the liver in HIV infection. Histopathology. 1991;18:459–464. 28. Washington K, Gottfried MR, Wilson ML. Gastrointestinal cryptococcosis. Mod Pathol. 1991;4;707–711. 29. Scott MA, McCurley TL, Vnencak-Jones CL, et al. Cat scratch disease: detection of Bartonella henselae DNA in archival biopsies from patients with clinically, serologically, and histologically defined disease. Am J Pathol. 1996;149:2161–2167. 30. Lamps LW, Gray GF, Scott MA. The histologic spectrum of hepatic cat scratch disease. A series of six cases with confirmed Bartonella henselae infection. Am J Surg Pathol. 1996;20:1253–1259. 31. Johnson TL, Barnett JL, Appelman HD, Nostrant T. Candida hepatitis: histopathologic diagnosis. Am J Surg Pathol. 1988;12:716–720.
Case 5.1
Necrotizing Epithelioid Granulomas LAURA W. LAMPS
C L I N I C AL I N F OR M AT I ON
A 50-year-old woman presented with fever and right upper quadrant pain. Physical examination revealed mild hepatosplenomegaly, and computed tomography (CT) scan of the abdomen revealed multiple liver lesions as well as portal adenopathy. Transaminases and alkaline phosphatase were mildly elevated. Hepatitis viral panel and autoimmune serologies were negative. R E A S ON F OR R E F E R R A L
Necrotizing epithelioid granulomas of uncertain etiology. PAT H OL OG I C F E AT U R E S
The liver biopsy shows numerous caseating epithelioid granulomas with admixed lymphocytes and scattered giant cells (Figure 5.1.1). The granulomas are both portal and lobular and have destroyed the normal architecture of the liver. Some of the granulomas are confluent and associated with fibrosis (Figure 5.1.2). There is a background of reactive hepatocellular changes and a nonspecific lobular hepatitis. A portal lymph node was also biopsied, which showed similar granulomatous inflammation with abundant necrosis (Figure 5.1.3). Multiple sets of special stains revealed rare foci with organisms (Figure 5.1.4). PCR testing was positive for M. tuberculosis.
A
D I AG N OS I S
M. tuberculosis infection involving the liver. B D I S C U S S I ON
F I G U R E 5 . 1 . 1 Hepatic tuberculosis featuring confluent epithelioid
Signs and symptoms of liver disease may be the dominant or presenting features of tuberculosis. Liver involvement is seen in almost all cases of miliary tuberculosis and is common in both localized extrapulmonary tuberculosis and in association with pulmonary tuberculosis (1–4). Patients may present with fever, hepatomegaly, and right upper quadrant pain or they may be asymptomatic. Bilirubin and transaminases may be elevated, along with a disproportionately high alkaline phosphatase (1–4). The histologic hallmark of hepatic tuberculosis is the epithelioid granuloma, often with associated caseous necrosis and giant cells. There may be a surrounding ring of lymphocytes and histiocytes. Granulomas are usually small but may
granulomas with admixed lymphocytes and numerous giant cells, (A). Other granulomas show caseating necrosis, (B).
coalesce to form nodules with central liquefactive necrosis. Older lesions may show fibrosis and calcification (1). Confluent granulomas can lead to masses (tuberculomas) (4). Similar lesions are often found in periportal lymph nodes. There is often an accompanying reactive hepatitis. It may be difficult to detect mycobacteria on special stains; thus, culture and PCR assays may be of value. The differential diagnosis focuses on other causes of necrotizing epithelioid granulomas, which are most often 70
CASE
5.1:
NECROTIZING
EPITHELIOID
GRANULOMAS
71
FIGURE 5. 1. 2 Confluent granulomas with fibrosis and residual giant
cells. Note that the lesion effaces the normal liver architecture.
F I G U R E 5 . 1 . 4 Ziehl-Neelsen stain shows clusters of acid-fast organisms consistent with M. tuberculosis.
infectious (see Table 5.1, Introduction). Schistosomiasis commonly produces epithelioid granulomas, but they are usually associated with eggs or parts of eggs (see Chapter 5.4). Many fungal infections can produce granulomatous inflammation, but it is often mixed with neutrophils. In addition, Gömöri methenamine silver (GMS) stains should highlight fungi, whereas acid-fast bacilli (AFB) stains should be negative. Tuberculoid leprosy may involve the liver and closely mimic M. tuberculosis infection (Figure 5.1.5), and molecular studies A
B FIGURE 5.1.3 A periportal lymph node with confluent granulomas and prominent giant cells, (A). Higher power view shows central caseation, (B).
F I G U R E 5 . 1 . 5 Scattered discrete, epithelioid granulomas in the liver
in a case of tuberculoid leprosy.
72
CHAPTER
5:
H E PAT I C
GRANULOMAS
AND
G R A N U L O M AT O U S
H E PAT I T I S
(see Chapter 5.2). Prominent among them are sarcoidosis, primary biliary cirrhosis, and adverse drug reaction. Unfortunately, special stains for AFB, as well as molecular assays, may be negative even in patients who have an infection. Sampling bias in small biopsy specimens, technical limitations of stains and molecular assays, and the fact that organisms are often rare in immunocompetent patients all affect our ability to demonstrate organisms in tissue. Therefore, our clinical colleagues should be advised that the pattern of necrotizing granulomas is most seen in infections even if stains are negative, and that infectious entities should be rigorously excluded clinically even when special studies are negative.
References
FIGURE 5. 1. 6 A minority of patients with hepatitis C show portal
epithelioid granulomas that are not attributable to other causes.
and/or microbiological cultures may be required to distinguish between the two. More rare infectious causes of epithelioid granulomas include brucellosis, which may cause either discrete, epithelioid noncaseating granulomatous or small, poorly formed granulomas (3,4); MAI, which may rarely cause epithelioid granulomas in immunocompetent persons; tertiary syphilis (1,2); Chlamydia (1,2,5); Whipple disease (1,2,6); Rickettsia conorii (the causative agent of Boutonneuse fever and South African tick bite fever) (7); and viral infections, including EBV and CMV (1,2,8). Furthermore, granulomas that are not attributable to any other underlying etiology have been reported in a minority of hepatitis C biopsies (Figure 5.1.6) (9) and rarely in cases of hepatitis B (10). Noninfectious causes of epithelioid granulomas, which are rarely necrotizing, are discussed in more detail below
1. Ishak KG. Granulomas of the liver. In: Ioachim HL, ed. Pathology of Granulomas. New York, NY: Raven Press; 1983. 2. Kleiner DE. Granulomas in the liver. Semin Diagn Pathol. 2006;23: 161–169. 3. Essop AR, Posen JA, Hodkinson JH, Segal I. Tuberculosis hepatitis: a clinical review of 96 cases. Q J Med. 1984;53:465–477. 4. Oliva A, Duarte B, Jonasson O, Nadimpalli V. The nodular form of local hepatic tuberculosis: a review. J Clin Gastroenterol. 1990;12:166–173. 5. Ragnaud JM, Dupon M, Echinard E, Lacut JY, Aubertin J. Hepatic manifestations of psittacosis. Gastroenterol Clin Biol. 1986;10(3):234–237. 6. Cho C, Linscheer WG, Hirschkorn, MA, Ashutosh K. Sarcoidlike granulomas as an early manifestation of Whipple’s disease. Gastroenterology. 1984;87:941–947. 7. Walker DH, Gear JH. Correlation of the distribution of Rickettsia conorii, microscopic lesions, and clinical features in South African tick bite fever. Am J Trop Med Hyg. 1985;34:361–371. 8. Clarke J, Craig RM, Saffro R, Murphy P, Yokoo H. Cytomegalovirus granulomatous hepatitis. Am J Med. 1979;66:264–269. 9. Harada K, Minato H, Hiramatsu K, Nakanuma Y. Epithelioid cell granulomas in chronic hepatitis C: immunohistochemical character and histological marker of favourable response to interferon-alpha therapy. Histopathology. 1998;33:216–221. 10. Tahan V, Ozaras R, Lacevic N, et al. Prevalence of hepatic granulomas in chronic hepatitis B. Dig Dis Sci. 2004;49:1575–1577.
Case 5.2
Sarcoidosis LAURA W. LAMPS
C L I N IC AL I N F OR M AT I ON
PAT H O LO GIC FEAT UR ES
A 45-year-old African American woman went for a preoperative screening prior to hysterectomy for uterine leiomyomas. She was found to have elevated transaminases as well as an abnormal chest x-ray. Subsequent CT scan revealed hilar lymphadenopathy. Other pertinent medical history included obesity and hypertension.
Sections of a wedge liver biopsy showed numerous well-developed epithelioid granulomas with associated lymphocytes and scattered giant cells (Figure 5.2.1). The granulomas were often confluent, and there was associated fibrosis. The granulomas were predominantly based in portal tracts, but bile ducts were intact and free of inflammation. The background liver showed steatosis. Special stains for AFB and fungi were negative, and no polarizable material was detected.
R E A SON F OR R E F E R R AL
Granulomas of unknown etiology; clinician expected nonalchoholic steatohepatitis (NASH) based on the history.
A
B
C
D
FIGURE 5. 2. 1 Confluent, noncaseating epithelioid granulomas with associated fibrosis and admixed lymphocytes in sarcoidosis, (A,B).
Trichrome stain highlights the associated fibrosis, (C; courtesy of Dr. Joseph Misdraji). Asteroid bodies are seen within giant cells, (D).
73
74
CHAPTER
5:
H E PAT I C
GRANULOMAS
D I AG N OS I S
Sarcoidosis. D I SC U SSI ON
The incidence of hepatic granulomas in sarcoidosis varies from 50% to 100%, but autopsy studies have shown that the liver is secondary only to the lungs and lymph nodes in frequency of involvement by granulomas (1). In many patients, involvement is subclinical. Sarcoid granulomas are compact and epithelioid with variably present giant cells (Figure 5.2.2) (2–5). A surrounding rim of lymphocytes is common, and eosinophils may be present. Severe lesions may be confluent. Caseation is usually absent, but there may be central fibrinoid necrosis (Figure 5.2.3). They are often located in portal tracts, and there
AND
G R A N U L O M AT O U S
H E PAT I T I S
may be associated spotty lobular inflammation and portal lymphocytic inflammation. Many types of inclusions have been described, most commonly the asteroid body (Figure 5.2.1). Sarcoid granulomas are often accompanied by fibrosis (2,3–5). Some patients with hepatic sarcoidosis develop progressive liver disease with portal hypertension and ascites (1,5,6). Although some patients develop cirrhosis, portal hypertension in the absence of cirrhosis has been well documented in sarcoidosis. This appears to be a result of a pressure effect due to portal granulomas and fibrosis rather than fully developed cirrhosis. A subset of sarcoid patients develops a chronic cholestatic process that resembles primary biliary cirrhosis (PBC), with progressive destruction of bile ducts (Figure 5.2.4) (2,5,7,8). This has been referred to as chronic cholestasis of sarcoidosis and may progress to biliary cirrhosis. Histologically, there is progressive bile duct loss and often lymphocytic cholangitis. Rare cases of cholestasis in sarcoidosis are a result of a “mass effect” due to granulomas at the hilum of the liver that compress large bile ducts (4,9).
A FIGURE 5. 2. 2 The classic sarcoid granuloma is epithelioid, noncaseating, and has admixed lymphocytes.
B F I G U R E 5 . 2 . 4 A subset of sarcoidosis patients have a chronic choles-
FIGURE 5. 2. 3 Sarcoid granulomas occasionally contain fibrinoid
necrosis but should not contain caseous necrosis.
tatic disorder that can mimic primary biliary cirrhosis. Note the granulomatous and lymphocytic inflammation in this portal tract, with an atrophic bile duct to the left, (A). A high power view highlights the bile duct damage and infiltration by lymphocytes, (B).
CASE
5.2:
SARCOIDOSIS
75
A C FIGURE 5. 2. 4 The duct has almost disappeared in this portal
tract, (C).
The differential diagnosis includes other causes of noncaseating epithelioid granulomas, both infectious (see above, Chapter 5.1) and noninfectious. A list of noninfectious causes is summarized in Table 5.2.1. Sarcoidosis and PBC (Figure 5.2.5) may have significant overlap in a minority of patients. Antimitochondrial antibodies (AMA) should be negative in sarcoidosis patients, and they should have other signs of their disease, particularly pulmonary, that should help distinguish between sarcoidosis and PBC. Granulomas may be rare and poorly formed in PBC and are occasionally absent altogether. Although some patients with sarcoidosis have been reported to have hepatic vein phlebitis (10), patients with granulomas secondary to vasculitis should have detectable vasculitic lesions, usually with fibrinoid necrosis that are
B F I G U R E 5 . 2 . 5 The classic “florid duct lesion” in primary biliary cir-
rhosis features an epithelioid granuloma with associated lymphocytes and plasma cells adjacent to a damaged bile duct, (A). Adjacent portal tract shows well-developed lymphocytic cholangitis, (B).
TA B LE 5. 2. 1 Selected noninfectious causes of hepatic granulomas Cause
Examples
Primary cholestatic disorders
Primary biliary cirrhosis, primary sclerosing cholangitis (rare)
Vasculitides
Polyarteritis nodosa, lupus
Drug-induced injury
Isoniazid, quinidine, allopurinol
Metal toxicity
Beryllium, copper toxicity
Foreign material
Talc, starch
Inherited diseases
Chronic granulomatous disease
Neoplasms
Hodgkin’s lymphoma, primary hepatic tumors, metastases
Idiopathic
Sarcoidosis
absent in sarcoidosis. Drug-induced granulomatous inflammation usually features a background of hepatitis and hepatocellular injury. A search for polarizable material helps to rule out granulomas secondary to foreign material, although the granulomas of sarcoidosis may contain polarizable calcium oxalate crystals. A complete discussion of granulomatous lesions caused by drugs and toxins is beyond the scope of this chapter. The morphologic features of the granulomas associated with adverse drug reactions are very variable, and the granulomas may be well or poorly formed. Associated necrosis is very rare. Giant cells may be present, and there is a variable associated inflammatory infiltrate that may include lymphocytes, plasma cells, and eosinophils (Figure 5.2.6). There may be associated bile duct and/or vascular injury. The combination of
76
CHAPTER
5:
H E PAT I C
GRANULOMAS
AND
G R A N U L O M AT O U S
H E PAT I T I S
References
FIGURE 5. 2. 6 Epithelioid granuloma with numerous admixed eosi-
nophils and a giant cell in a case of granulomatous hepatitis after ingestion of Echinacea tea.
granulomatous inflammation with significant hepatocellular injury should strongly suggest drug associated liver injury. A few notable drug culprits include allopurinol, nitrofurantoin, isoniazid, phenytoin, quinidine, and hydralazine (1–5,11).
1. Harrington PT, Gutierrez JJ, Ramirez-Ronda CH, Quiñones-Soto R, Bermúdez RH, Chaffey J. Granulomatous hepatitis. Rev Infect Dis. 1982;4:638–655. 2. Ishak KG. Granulomas of the liver. In: Ioachim HL, ed. Pathology of Granulomas. New York, NY: Raven Press; 1983. 3. Valla DC, Benhamou JP. Hepatic granulomas and hepatic sarcoidosis. Clin Liver Dis. 2000;4:269–285. 4. Ishak KG. Sarcoidosis of the liver and bile ducts. Mayo Clin Proc. 1998;73:467–472. 5. Devaney K, Goodman ZD, Epstein MS, Zimmerman HJ, Ishak KG. Hepatic sarcoidosis. Clinicopathologic features in 100 patients. Am J Surg Pathol. 1993;17:1272–1280. 6. Maddrey WC, Johns CJ, Boitnott JK, Iber FL. Sarcoidosis and chronic hepatic disease: a clinical and pathologic study of 20 patients. Medicine. 1970;49:375–395. 7. Valla D, Pessegueiro-Miranda H, Degot C, Lebrec D, Rueff B, Benhamou JP. Hepatic sarcoidosis with portal hypertension. A report of seven cases with a review of the literature. Q J Med. 1987;63:531–544. 8. Kim WR, Ludwig J, Lindor KD. Variant forms of cholestatic diseases involving small bile ducts in adults. Am J Gastroenterol. 2000;95: 1130–1138. 9. Bass NM, Burroughs AK, Scheuer PJ, et al. Chronic intrahepatic cholestasis due to sarcoidosis. Gut. 1982;23:417–421. 10. Reteigm MA, Fashir BM. Biliary tract obstruction due to sarcoidosis: a case report. Am J Gastroenterol. 1997;92:527–528. 11. Russi EW, Bansky G, Pfaltz M, Spinas G, Hammer B, Senning A. BuddChiari syndrome in sarcoidosis. Am J Gastroenterol. 1986;81:71–75.
Case 5.3
Fibrin Ring Granulomas LAURA W. LAMPS
were numerous small granulomas throughout the biopsy, as well as fibrin ring granulomas (Figure 5.3.1). AFB stain revealed scattered acid-fast bacteria, and subsequent PCR confirmed MAI.
C L I N IC AL I N F OR M AT I ON
The patient was a 30-year-old African American woman with human immunodeficiency virus (HIV) and AIDS who presented with a fever of unknown origin, malaise, and weight loss. She was found to have elevated transaminases.
DIAGNO SIS
R E A SON F OR R E F E R R AL
Mycobacterium avium-intracellulare infection.
To determine the etiology of granulomas in the HIV-positive patient. PAT H OL OG I C F E AT U R E S
DISCUSSIO N
The needle biopsy showed a lobular hepatitis with lobular disarray and a predominantly lymphocytic infiltrate. There
Fibrin ring granulomas are a distinctive form of granuloma consisting of an epithelioid granuloma with a central lipid vacuole surrounded by a fibrin ring (Figure 5.3.2) (1,2). The fibrin ring stains with fibrin stains and may not form a distinctive ring (2). These lesions were classically described in association with Coxiella burnetii, the causative agent of Q-fever (2–3). However, these lesions are now known to be quite nonspecific and have been observed in the context of numerous diseases including leishmaniasis (4), Boutonneuse fever (5), toxoplasmosis (5), CMV (6,7), EBV (6,5), MAI (8), typhoid (5), Hodgkin disease (5), and adverse drug reaction (allopurinol) (6,9). When fibrin ring granulomas are seen on liver biopsy, infection should be suspected, although they are also associated with drugs and rarely Hodgkin’s lymphoma. A combination of special stains, serologic studies, and molecular studies may be required to detect the infectious agent.
A
C F I G U R E 5 . 3 . 1 Lobular hepatitis with hepatocyte disarray and reactive
hepatocellular changes in a case of MAI infection, (A). Higher power view shows both small epithelioid and fibrin ring granulomas, (B,C).
B
77
78
CHAPTER
5:
H E PAT I C
GRANULOMAS
AND
G R A N U L O M AT O U S
H E PAT I T I S
References 1. Ishak KG. Granulomas of the liver. In: Ioachim HL, ed. Pathology of Granulomas. New York: NY: Raven Press; 1983. 2. Pellegrin M, Delsol G, Auvergnat JC, et al. Granulomatous hepatitis in Q fever. Hum Pathol. 1980;11:51–57. 3. Srigley JR, Vellend H, Palmer N, et al. Q-fever: the liver and bone marrow pathology. Am J Surg Path. 1985;9:752–758. 4. Moreno A, Marazuela M, Yebra M, et al. Hepatic fibrin-ring granulomas in visceral leishmaniasis. Gastroenterol. 1988;95:1123–1126. 5. Marazuela M, Moreno A, Yebra M, Cerezo E, Gómez-Gesto C, Vargas JA. Hepatic fibrin-ring granulomas: a clinicopathologic study of 23 patients. Hum Pathol. 1991;22:607–613. 6. Kleiner DE. Granulomas in the liver. Semin Diagn Pathol. 2006;23: 161–169. 7. Lobdell DH. “Ring” granulomas in cytomegalovirus hepatitis. Arch Pathol Lab Med. 1987;111:881–882. 8. Lamps LW. Hepatic granulomas, with an emphasis on infectious causes. Adv Anat Pathol. 2008;15:309–318. 9. Stricker BH, Blok AP, Babany G, Benhamou JP. Fibrin ring granulomas and allopurinol. Gastroenterology. 1989;96:1199–1203.
FIGURE 5. 3. 2 The classic fibrin ring granuloma contains a lipid
vacuole surrounded by histiocytes and a fibrin ring.
Case 5.4
Schistosomiasis LAURA W. LAMPS
C L I N IC AL I N F OR M AT I ON
A 67-year-old Filipino man presented with vague abdominal pain. Transaminases were found to be minimally elevated. Hepatitis and autoimmune serologies were negative. R E A SON F OR R E F E R R AL
To determine the nature of calcified structures in liver biopsy. PAT H OL OG I C F E AT U R E S
The liver biopsy shows numerous ovoid calcified structures consistent with the calcified eggs of schistosomiasis (Figure 5.4.1). The eggs are present within remote hyalinized granulomas, with virtually no remaining active inflammatory response. The background liver shows steatosis.
A
D I AG N OS I S
Remote hepatic schistosomiasis.
D I S C U S S I ON
Schistosomiasis is one of the most common diseases in the world and is the most common worldwide cause of portal hypertension (1–3). It is also known as bilharziasis, after its discovery by Sir Theodore Bilharz in Egypt in 1851. These trematodes are endemic in Africa, Asia, and parts of the Americas. In the United States, infected patients are often immigrants, travelers, or persons who have worked abroad. Humans become infected by exposure to contaminated water. Most hepatobiliary disease is caused by S. mansoni, S. japonicum, or S. mekongi, as these prefer mesenteric and portal veins. Once settled in their vein of choice, adult worms copulate and produce thousands of eggs in their lifetimes; approximately 50% of the eggs remain within the body. The severity of the disease and the likelihood of significant sequelae are related to the intensity and duration of the infection. In addition, egg deposition is seemingly random and nonuniform. Acute symptomatic infection most often occurs in immunologically naïve adults infected for the first time; this is rarely seen in inhabitants of endemic areas. Most patients in endemic areas have chronic schistosomiasis and are asymptomatic or have only mild chronic complaints. Hypersensitivity to the eggs themselves is the underlying cause of disease, and the resultant inflammation leads to fibrosis and obstructive hepatobiliary disease. Symptomatic patients present with splenomegaly and signs of portal hypertension, particularly bleeding; hepatic function is usually preserved (1–8).
B
C F I G U R E 5 . 4 . 1 Scattered calcified ovoid structures consistent with
ova in a patient with remote schistosomiasis, (A). A higher power view shows eggs within a hyalinized granuloma. There is no residual active inflammation, (B). At high power, the calcified eggs are blueblack and refractile, (C).
79
80
CHAPTER
5:
H E PAT I C
GRANULOMAS
AND
G R A N U L O M AT O U S
H E PAT I T I S
A
F I G U R E 5 . 4 . 3 Hematoidin pigment is a common feature in hepatic
schistosomiasis.
B FIGURE 5. 4. 2 Granulomatous inflammation in schistosomiasis,
with several epithelioid granulomas surrounding ova, and associated fibrosis, (A). An egg with an embryo is seen within a granuloma, (B; courtesy of Dr. Joseph Misdraji).
Grossly, livers are enlarged and nodular. On cut surface, the typical portal fibrosis known as pipestem or Symmers’ fibrosis may be seen (1). The histologic features of schistosomiasis vary with duration of disease and result from inflammation and fibrosis in reaction to the eggs deposited in tissue; the worms themselves cause little damage. In general, there is an active phase of infection, characterized by more intense inflammation and an inactive phase, characterized by decreasing inflammation and increasing fibrosis and calcification of ova. In chronic schistosomiasis there is typically a granulomatous reaction to the eggs, which are present in varying numbers both within granulomas and fibrotic areas (Figure 5.4.2). The granulomas may be rich in eosinophils, and eggs or egg parts may be detectable within granulomas (1,3,5). As lesions progress, there is increased fibrosis, as well as an increase
in macrophages and giant cells. Remote lesions may show only fibrosis and calcified eggs, with virtually no inflammatory reaction (as in the case presented here). Ultimately, portal tracts become large and densely sclerotic, and fibrous septa link portal tracts together. Sinusoidal fibrosis may also develop. As the fibrosis progresses, eggs may be increasingly difficult to find. Granulomas and fibrosis also affect portal vein branches, leading to phlebitis, sclerosis, and thrombosis. Eventually portal veins are obstructed and destroyed, with subsequent proliferation of hepatic arterial branches (3–7). Schistosomal pigment accumulation in macrophages (Figure 5.4.3) is also a helpful finding. It is finely granular, dark brown, and birefringent; it is considered to be a hemoglobin derivative, presumably released by worms after ingestion of host red blood cells (1). Schistosome eggs are variably acid fast; morphologic and staining characteristics of the eggs of the various species are given in Table 5.4.1. In hematoxylin and eosin (HE) sections, the calcified eggs are generally dark blue or black and somewhat amorphous (1,3–7). Decalcification may reveal partially preserved embryos (8). The worms themselves are slender and elongated, measuring 0.5 to 2.5 cm in length. The inflammatory reaction to the organism may mimic other infectious and noninfectious causes of hepatic granulomas. Schistosome eggs in tissue sections may be distinguished from the eggs of Enterobius, Capillaria, and trematodes by their spines and the acid-fast properties of the eggs (see Table 5.4.1). Microscopic detection of eggs in stool or urine is the most reliable, cost-effective method of diagnosis, although multiple specimens may be required. Worms are occasionally retrieved from biliary lavage. Serologic studies are also useful.
CASE
5.4:
81
SCHISTOSOMIASIS
TA B LE 5. 4. 1 Schistosome target organs, geographical distribution, and staining characteristics of eggs Species
Egg Shape
Staining Properties
Target Organs
Endemic Areas
S. haematobium
Terminal spine
Acid-fast spine
Bladder, ureter, pelvis
Africa Southern Europe Western Asia
S. mansoni
Lateral spine
Acid-fast shell and spine
Gut, liver, lung
Africa Brazil West Indies Puerto Rico
S. japonicum
Small lateral spine
Acid-fast shell and spine
Gut, liver, lung
China Japan Philippines
S. intercalatum
Terminal spine
Acid-fast spine
Gut, liver
West Africa
S. mekongii
Small lateral spine
Acid-fast shell and spine
Gut, liver, lung
Laos Cambodia Thailand
S. malayi
Small lateral spine
Acid-fast shell and spine
Liver
Penang peninsula (Malaysia)
References 1. Ishak KG. Granulomas of the liver. In: Ioachim HL, ed. Pathology of Granulomas. New York, NY: Raven Press; 1983. 2. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet. 2006;368(9541):1106–1118. 3. von Lichtenberg F. Schistosomiasis. In: Connor DH, Chandler FW, et al eds. Pathology of Infectious Diseases. Stamford, CT: Appleton and Lange; 1997:1537–1551. 4. Warren KS. The pathology, pathobiology, and pathogenesis of schistosomiasis. Nature. 1978;273:609–612.
5. Grimaud JA, Borojevic R. Chronic human schistosomiasis mansoni. Pathology of the Disse’s space. Lab Invest. 1977;36:268–273. 6. Davis A. Recent advances in schistosomiasis. Q J Med. 1986; 58:95–110. 7. Elliott DE. Schistosomiasis: Pathophysiology, diagnosis, and treatment. Gastroenterol Clin North Am. 1996;25(3):599–625. 8. Cheever AW. Decalcification of schistosome eggs during staining of tissue sections: a potential source of diagnostic error. Am J Trop Med Hyg. 1986;35:959–961.
Case 5.5
Cat Scratch Disease LAURA W. LAMPS
negative, and there were no fecal leukocytes. Histoplasma urinary antigen test was negative. Purified protein derivative (PPD) skin test was nonreactive.
C L I N I C AL I N F OR M AT I ON
A previously healthy 18-year-old male presented with an 8-month history of fever and abdominal pain. His home contained several dogs and cats. CT scan showed multiple low attenuation hepatic masses in both lobes of the liver. An extensive serological workup was negative. Stool cultures were
R EA SO N FO R R EFER R A L
Stellate microabscesses and granulomatous inflammation of unknown etiology. PAT H O LO GIC FEAT UR ES
A wedge biopsy shows necrotizing granulomatous inflammation with central stellate abscess formation (Figure 5.5.1). Special stains for fungi and AFB are negative. Warthin-Starry stain shows a few pleomorphic coccobacilli in areas of necrosis (Figure 5.5.2). The paraffin block sent for PCR for Bartonella DNA, confirmed the diagnosis of hepatic cat scratch disease (CSD).
DIAGNO SIS
Hepatic cat scratch disease.
A
B FIGURE 5.5.1 A low power view of hepatic cat scratch disease shows
irregular, stellate microabscesses surrounded by granulomatous inflammation and fibrosis, (A). This high power view of the “layered” appearance of the lesions shows central necrosis, palisading histiocytes, mononuclear cells, and an outer rim of fibrosis, (B).
F I G U R E 5 . 5 . 2 Warthin-Starry silver impregnation stain shows small,
pleomorphic bacilli in areas of necrosis.
82
CASE
5.5:
C AT
S C R AT C H
DISEASE
83
D I S C U S S I ON
Bartonella henselae (formerly Rochalimaea henselae (1)) is the major etiologic agent of CSD. There are 4 species of Bartonella, and B. henselae and B. quintana are most frequently associated with human disease (2). Bartonella henselae is the species most commonly associated with the necrotizing granulomatous lesions of “classical” CSD, which typically occurs in immunocompetent patients. The overall incidence in the United States is estimated at 6.6/100 000 persons, but this is considered a low estimate because many patients do not seek medical attention. More than 80% of the patients are children and adolescents under the age of 21. Over 90% of patients with CSD have cat exposure, and in the majority of these cases the exposure consists of a scratch or bite, most characteristically from a young cat or kitten (3,4). Cat scratch disease most often presents as tender, regional lymphadenopathy arising approximately 2 weeks after the development of a distal inoculation site, most often on the hands, arms, or chest. A minority of patients (approximately 5%–20%) have atypical presentations that often lack superficial regional adenopathy and an obvious inoculation site. These atypical forms of CSD can present with severe constitutional symptoms that may mimic neoplasia, collagen vascular diseases, or other systemic infections. Hepatic CSD is rarely associated with either superficial adenitis or an identifiable inoculation site (5,6,7). There are typically multiple low-density lesions on CT scan that mimic metastatic tumor, and there are often accompanying constitutional symptoms including fever, weight loss, and malaise that often support the suspicion of malignancy (6,7). Both the liver and the spleen may be enlarged, and there is often associated intra-abdominal lymphadenopathy (5). Transaminases are usually normal, and an elevated serum alkaline phosphatase is often the only abnormal laboratory value (8). Despite the ominous clinical and radiographic appearances, these lesions often resolve without treatment, and, generally, there are no significant sequelae (5,6). Antibiotic use is controversial, but successful results have been obtained with numerous antibiotics (3,7). The hallmark lesion of hepatic CSD is a granuloma with a central stellate microabscess (Figure 5.5.3) surrounded by 3 distinct zones: an inner zone of palisading histiocytes, an intermediate zone of lymphocytes, and an outer rim of dense fibrosis (5). Morphologic characteristics of the lesions vary widely within the same biopsy, corresponding to the age of the lesions; granulomas with definitive zonation, resolving necrosis, and prominent fibrosis and granulation tissue suggest chronicity. The dense fibrous rind surrounding the lesions may present a problem on needle biopsy (Figure 5.5.4), particularly at frozen section, for the central, diagnostic portion of the biopsy may not be sampled. For that reason, wedge liver biopsy is often required for diagnosis. The first step in the diagnosis of hepatic CSD is a careful history with attention to patient contact with cats. Culture is generally not relied upon for the diagnosis of CSD, as the organism is very fastidious and slow-growing. Several serologic studies are now commercially available, but it has been
A
B F I G U R E 5 . 5 . 3 Hepatic cat scratch disease with characteristic zonated appearance, (A). The outer rim of fibrosis may be particularly prominent in the liver, (B).
shown that some patients never mount a detectable antibody response, and conversely patients may remain serologically positive long after exposure and recovery from their illness. In addition, there is extensive serological cross-reactivity between B. henselae and B. quintana, as well as with other intracellular bacteria such as Coxiella burnetii (4,9,10). Tissue biopsy is one of the most useful ways to diagnose CSD, as well as to exclude other etiologies. Silver impregnation stains (such as Warthin-Starry or Steiner) are the preferred histochemical stain for detection of Bartonella; however, organisms are only variably detectable, and these stains are technically challenging due to the high background of silver precipitate. Immunohistochemical antibodies to Bartonella are available (11). PCR assays are also available for both fresh
84
CHAPTER
5:
H E PAT I C
GRANULOMAS
AND
G R A N U L O M AT O U S
H E PAT I T I S
reveal fungi, and fungal culture may also be useful in separating fungal infection from hepatic CSD. Other entities in the differential diagnosis of hepatic CSD include bacterial abscesses, which have a prominent fibrous “rind” and central suppuration but lack granulomatous features; actinomycosis, which shows filamentous Gram-positive bacteria on tissue Gram stain; and lymphogranuloma venereum (LGV), which may mimic CSD in inguinal lymph nodes but almost never involves the liver.
References
FIGURE 5. 5. 4 The diagnosis of cat scratch disease may be difficult
to make on a needle biopsy, especially if only the outer fibrous areas are sampled.
and formalin-fixed, paraffin-embedded material (9,11). PCR is both sensitive and specific, particularly when combined with Southern blotting and lacks many of the problems inherent in other diagnostic methodologies (9,12). The differential diagnosis primarily includes other infectious processes. The granulomas in M. tuberculosis infection are usually epithelioid, often with caseation, giant cells, and a surrounding ring of lymphocytes and histiocytes but lack the characteristic zonation of the CSD lesions. In addition, mycobacteria can generally be detected with special stains, microbiological techniques, and/or PCR assays. Brucellosis may cause a variety of granulomatous lesions but again lacks the characteristic zonation of CSD. Francisella tularensis typically causes suppurative microabscesses with occasional surrounding macrophages; as the lesions evolve they may become more granulomatous but also lack the zonation typically seen in hepatic CSD. Fungal infections, particularly candidiasis, may closely mimic CSD; but GMS stain should
1. Brenner DJ, O’Connor SP, Winkler HH, Steigerwalt AG. Proposals to unify the genera Bartonella and Rochalimaea, with descriptions of B. quintana comb. nov., B. vinsonii comb. nov., and B. elizabethae comb. nov., and to remove the family Bartonellaceae from the order Rickettsiales. Int J Syst Bacteriol. 1993;43:777–786. 2. Adal KA, Cockerell CJ, Petri WA Jr. Cat scratch disease, bacillary angiomatosis, and other infections due to Rochalimaea. N Engl J Med. 1994;330:1509–1515. 3. Klein JD. Cat scratch disease. Pediatr Rev. 1994;15:348–353. 4. Smith DL. Cat-scratch disease and related clinical syndromes. Am Fam Physician. 1997;55:1783–1789. 5. Lamps LW, Gray GF, Scott MA. The histologic spectrum of hepatic cat scratch disease. A series of six cases with confirmed Bartonella henselae infection. Am J Surg Pathol. 1996;20:1253–1259. 6. Port J, Leonidas JC. Granulomatous hepatitis in cat-scratch disease. Ultrasound and CT observations. Pediatr Radiol. 1991;21:598–599. 7. Larsen CE, Patrick LE. Abdominal (liver,spleen) and bone manifestations of cat scratch disease. Pediatr Radiol. 1992;22:353–355. 8. Rocco VK, Roman RJ, Eigenbrodt EH. Cat scratch disease. Report of a case with hepatic lesions and a brief review of the literature. Gastroenterology. 1985;89:1400–1406. 9. Agan BK, Dolan MJ. Laboratory diagnosis of Bartonella infections. Clin Lab Med. 2002;22:937–962. 10. Barka NE, Hadfield T, Patnaik M, et al. EIA for detection of R. henselaereactive IgG, IgM, and IgA antibodies in patients with suspected catscratch disease. J Inf Dis. 1993;167:1503–1504. 11. Caponetti GC, Pantanowitz L, Lamps LW, Marconi S, Havens JM, Otis CN. Utility of immunohistochemistry to diagnose cat scratch disease. Am J Clin Pathol. 2009;31:250–256. 12. Anderson B, Sims K, Regnery R, et al. Detection of Rochalimaea henselae DNA in specimens from cat scratch disease patients by PCR. J Clin Microbiol. 1994;32:942–948. 13. Shinall EA. Cat-scratch disease: a review of the literature. Pediatr Dermatol. 1990;7:11–18.
Case 5.6
Chronic Granulomatous Disease DAVID E. KLEINER
tissue around these abscesses is not inflamed (Figure 5.6.2). Special stains for fungi show fragments of hyphal forms within the necrotic areas. One of the wedge resections is much larger and mainly consists of hepatic parenchyma. The largest wedge shows diffusely inflamed liver parenchyma, with multiple small nonnecrotizing granulomas in a background of lobular lymphocytic inflammation (Figure 5.6.3). There is portal inflammation associated with disruption of the limiting plate and pseudoxanthomatous changes in periportal hepatocytes. Some of the larger ducts are missing and replaced by inflamed
C L I N IC AL I N F OR M AT I ON
A 23-year-old man presented with sinusitis. He had a history of recurrent pulmonary, hepatic, and bone infections since young childhood. These infections required repeated hospitalizations and chronic administration of antibacterial and antifungal medications. During the workup, he was noted to have elevated liver enzymes: alkaline phosphatase 866 IU/L, alanine aminotransferase (ALT) 52 IU/L, aspartate aminotransferase (AST) 37 IU/L, and a total bilirubin of 0.6 mg/dL. Imaging using ultrasound, CT, and magnetic resonance imaging (MRI) showed multiple hepatic lesions consistent with abscesses. A CT-guided aspirate grew Staphylococcus aureus and Streptococcus mitis. He was started on ceftriaxone, vancomycin, and rifampin and discharged but returned 1 week later with right upper quadrant pain, fatigue, and chills. He was taken to surgery where wedge resections of liver were performed. R E A SON F OR R E F E R R AL
Evaluation of abscesses and granulomatous changes in the surrounding hepatic parenchyma. PAT H OL OG I C F E AT U R E S
Eight separate wedge excisions of hepatic abscesses are available for review. All of them show liver parenchyma replaced with dense fibrous connective tissue. Multiple small wellcircumscribed necrotic abscesses bounded by a palisaded histiocytic infiltrate are present (Figure 5.6.1). The connective
F I G U R E 5 . 6 . 2 Palisaded histiocytes at the edge of the granulomatous abscess.
F I G U R E 5 . 6 . 3 Liver parenchyma distant from the abscesses showing a nonnecrotizing granuloma and numerous foci of lobular inflammation.
Well-circumscribed granulomatous abscesses embedded in dense fibrous connective tissue.
FIGURE 5. 6. 1
85
86
CHAPTER
5:
H E PAT I C
GRANULOMAS
FIGURE 5. 6. 4 Large portal area with periductal inflammation and
narrowing of large duct.
connective tissue, whereas others show constriction with periductal fibrosis and inflammation (Figure 5.6.4). Some of the periportal hepatocytes are positive for copper on rhodanine stain. There is portal fibrosis, but no bridging fibrosis. Collections of pigmented macrophages from individual cells to larger aggregates are present.
D I AG N OS I S
Chronic granulomatous disease with necrotizing granulomatous hepatic abscesses, positive for fungal hyphae. Nonnecrotizing granulomatous hepatitis with secondary sclerosing cholangitis-like changes.
D I SC U SSI ON
Chronic granulomatous disease (CGD) is an inherited immunodeficiency due to a defect in intracellular killing of pathogens by neutrophils (1–3). The incidence has been estimated to be about 1 in 200 000 in the United States. It is inherited through both X-linked and autosomal recessive mechanisms. The specific functional defect is in NADPH oxidase, a membranebound enzyme that catalyzes the oxidation of O2 to superoxide anion, O2. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase has 4 subunits, gp91phox, which is on the X chromosome and p22phox, p47phox and p67phox, which are on chromosomes 16, 7, and 1, respectively. About 70% of patients have the X-linked form of the disease. Because patients with CGD cannot generate superoxide, they are particularly susceptible to infections from certain catalase-positive organisms such as Staphylococcus aureus, Burkholderia sp., Serratia marcescens, Nocardia sp., and Aspergillus sp. Patients usually present with infection and granulomatous disease, with the lungs, skin, lymph nodes, and liver being the most common sites of infection. The diagnosis is established by measurement
AND
G R A N U L O M AT O U S
H E PAT I T I S
of the defect by measurement of superoxide product, dihydrorhodamine oxidation, or other tests (4). Molecular determination of the specific genetic defects is also available and is the only type of testing useful in the prenatal setting (1). This case illustrates several aspects of the hepatic pathology of CGD. Hepatic abscess formation is the main manifestation of clinically significant liver disease and it can be life threatening. The risk of developing hepatic abscesses rises with increasing age and the total number of infections the patient has experienced. About a third of patients with CGD will develop hepatic abscesses, which are typically multiloculated and embedded in a thick cuff of fibrous tissue. The fibrous tissue may be bland and scar-like, as in this case, or it may be inflamed and highly vascular, like inflamed granulation tissue. Staphylococcus aureus is commonly cultured from these abscesses, but fungal organisms may also be found, particularly Aspergillus. Although the appearance of the abscesses is similar to granulomatous abscesses in other diseases, the presence of abundant connective tissue around the abscesses, as well as multiloculation is characteristic of CGD. This architectural peculiarity makes CGD abscesses very difficult to drain percutaneously, and surgical intervention is required when medical management cannot control the infection (5,6). Specimens of abscesses should always be sent for culture, and special stains for microorganisms should be done routinely. Aside from the dramatic development of abscesses, patients with CGD may have more subtle forms of liver disease (7,8). Biopsies of nonabscessed liver can show a wide variety of findings. At one end of the spectrum, biopsies may show only collections of pigmented macrophages. These cells accumulate at sites of inflammation and cell turnover, and they may be the only pathologic manifestation of CGD. In the liver, the larger aggregates tend to accumulate near portal or central veins. In addition, there can be varying degrees of lobular and portal lymphocyte inflammation as well as wellformed, nonnecrotizing epithelioid granulomas. About 90% of specimens will show spotty lobular inflammation and 75% will have nonnecrotizing granulomas (8). On histologic grounds, the differential diagnosis could include both chronic hepatitis and other granulomatous diseases, such as sarcoidosis or primary biliary cirrhosis. Rarely there can be granulomatous destruction of ducts or periductal sclerosis with duct obliteration as seen in this case. Correct diagnosis requires correlation with the clinical history. The chronic cholestatic disease in this patient responded to steroid therapy, which would be unlikely if primary sclerosing cholangitis was present. A recently recognized hepatic complication of CGD is the development of noncirrhotic portal hypertension (7). Patients develop splenomegaly and show a gradual decline in platelet levels over a period of several years. A drop in platelets of more than 9000/μL/year was associated with a 4.7-fold increased risk of mortality as compared with those whose platelet levels were stable. Histologically, there were a variety of findings that might have explained the noncirrhotic portal hypertension. Portal and central veins were narrowed or obliterated by the accumulation of pigmented macrophages or perivascular inflammation in 65% to 90% of cases, depending
CASE
5.6:
CHRONIC
G R A N U L O M AT O U S
on the group examined. These changes are particularly pronounced near abscesses but may be seen elsewhere in the liver. This same study noted that nodular regenerative hyperplasia (NRH) was observed in 40% of patients who died as opposed to only 11% of those who were alive at the end of the follow-up period. NRH may have developed from the venopathy or from drug injury. The mechanism by which portal hypertension contributes to death in CGD is not entirely clear, as patients typically die from infection and sepsis. Portal hypertension may increase the risk of infection by increased bacterial translocation from the gut and may also be worsened by sepsis. Patients with CGD may develop other liver diseases as well, and it has been noted that drug-induced liver injury is a relatively common cause of liver enzyme elevations (8). Patients with CGD have also been reported to have concurrent viral hepatitis infection, and with the advent of bone marrow transplantation as a potentially curative therapy, hepatic graft-versus-host disease has been found. Our understanding of CGD has led to improvements in the management of these patients, enabling many patients to survive into middle age. Although hepatic abscesses remain important, it has become clear that the liver pathology of CGD is more complex than simple localized infections, and attention should be paid to the nonabscessed liver parenchyma. Granulomas in CGD vary from nondescript collections of pigmented macrophages to well-formed nonnecrotizing
DISEASE
87
granulomas to necrotizing granulomatous abscesses. If liver disease is the first manifestation of the disease, the pathologist may be able to suggest the diagnosis by noting the more specific features of CGD, particularly the multiloculated nature of the abscesses and the numerous pigmented macrophages.
References 1. Holland SM. Chronic granulomatous disease. Clin Rev Allergy Immunol. 2010;38:3–10. 2. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore). 2000;79:170–200. 3. Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore). 2000;79:155–169. 4. Elloumi HZ, Holland SM. Diagnostic assays for chronic granulomatous disease and other neutrophil disorders. Methods Mol Biol. 2007;412: 505–523. 5. Chen LE, Minkes RK, Shackelford PG, Strasberg SM, Kuo EY, Langer JC. Cut it out: Managing hepatic abscesses in patients with chronic granulomatous disease. J Pediatr Surg. 2003;38:709–713. 6. Lublin M, Bartlett DL, Danforth DN, et al. Hepatic abscess in patients with chronic granulomatous disease. Ann Surg. 2002;235:383–391. 7. Feld JJ, Hussain N, Wright EC, et al. Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease. Gastroenterology. 2008;134:1917–1926. 8. Hussain N, Feld JJ, Kleiner DE, et al. Hepatic abnormalities in patients with chronic granulomatous disease. Hepatology. 2007;45:675–683.
This page intentionally left blank
6 Cholestasis JAY H. LEFKOWITCH
Histologic cholestasis is a considerable diagnostic challenge for the pathologist because of its diverse causes and the many potential anatomic sites where bile flow may be interrupted. Establishing the etiology of cholestasis requires histologic assessment of the site(s) of cholestasis, the status of the liver parenchyma, and, importantly, the appearances of the portal tracts and constituent intrahepatic bile ducts (1,2). It should also be borne in mind that disorders referable to the biliary tract may not invariably be associated with visible bile in tissue sections. Examples include liver involvement in small duct primary sclerosing cholangitis (PSC), early stages of primary biliary cirrhosis, individuals with intermittent episodes of large bile duct obstruction (eg, alcoholic pancreatitis), stricturing lesions involving specific segments of bile ducts, or large bile duct obstructive diseases which have been treated by placing biliary stents. Despite the absence of histologic bile in such instances, the diagnosis of biliary tract disease rests on recognizing the portal tract and parenchymal changes reflecting involvement of the biliary tree. Cholestasis (Figure 6.1) is most often apparent in centrilobular regions (acinar zones 3) where the products of drug metabolism and the effects of ischemia and/or hypoxia have their greatest physiologic impact. Retained bile within hepatocytes on H&E stain appears as granular yellow-brown pigment and is often present in conjunction with brown bile plugs (bile thrombi) molded within rounded intercellular bile canaliculi (or within longitudinally cut canalicular lumens). Detergent action of retained bile acids in hepatocytes may result in livercell swelling and cytoplasmic rarefaction referred to as “feathery degeneration” (Figure 6.2). Examination of a Prussian blue iron stain may be helpful in the identification of subtle cholestasis that might be hidden by overly saturated eosin on a standard H&E-stained slide, by virtue of the pale nuclear red counterstain used in the iron stain. The chief pigment with which intrahepatocellular bile is likely to be confused is lipofuscin, which shows similar color and texture to bile (Figure 6.3A). DubinJohnson pigment is coarser and more often darker brown in color and extends more deeply into the lobules to involve both centrilobular and midzonal regions or acinar zones 3 and 2 (Figure 6.3B). Both lipofuscin and Dubin-Johnson pigments stain positively on using the long Ziehl-Neelsen stain, whereas bile is negatively stained. Hall’s bile stain may be used to specifically stain bile. Identification of canalicular bile plugs is the most practical means on H&E stain of distinguishing hepatocellular cholestasis from lipofuscin. Hemosiderin pigment (granular, brown, refractile, and glassy) preferentially accumulates in periportal hepatocytes and is, therefore, an unlikely consideration in the differential of perivenular (centrilobular) hepatocellular pigment (except in the later progressive iron-loading stages of
F I G U R E 6 . 1 Cholestasis. The centrilobular region seen here shows
prominent bile within canaliculi and within hepatocytes.
F I G U R E 6 . 2 Feathery degeneration of hepatocytes in cholestasis. Bile and bile salt retention within hepatocytes has caused bile salt–related detergent damage with resultant “feathery degeneration,” including swelling, cytoplasmic rarefaction, and vacuolar degeneration.
classical hereditary HFE hemochromatosis when all 3 acinar zones of the liver show iron overload). Hepatocellular and canalicular cholestasis may also be associated with bile within sinusoidal Kupffer cells. The affected Kupffer cells show diffuse cytoplasmic tan-brown staining on H&E, are positive with diastase-digested periodic acid Schiff (DPAS) stain, and in cases of recent (but resolved) cholestasis may be the only residual evidence of a recent cholestatic
89
90
CHAPTER
6:
C H O L E S TA S I S
FIGURE 6. 3 Centrilobular hepatocyte pigments. (A) Lipofuscin is finely granular, yellow-brown, and localized toward the hepatocyte membrane
in a pericanalicular distribution. (B) Dubin-Johnson pigment seen in these centrilobular hepatocytes is coarse and brown and distributed randomly throughout the liver-cell cytoplasm. The pigment often extends from centrilobular regions more deeply into the lobular periphery.
episode. Uncommonly bile is seen within periportal bile ductular structures (so-called “bile ductular cholestasis”). In pediatric liver specimens, this is one of several features seen in extrahepatic biliary atresia, whereas in adults this distribution is highly suggestive of sepsis (3). Rarely, bile is present in septal or larger caliber bile ducts. This “ductal cholestasis,” in chiefly a postmortem finding, is likely to be related to marked slowing of bile flow during the preterminal period. Cholestasis may be classified according to etiopathogenesis as primary (genetic), secondary (acquired), or due to mechanical obstruction of bile ducts. Some of the hepatobiliary disorders in these 3 categories are shown in Table 6.1. TA B LE 6. 1 Etiopathogenesis of cholestasis
Primary (Genetic) • Bile salt transporter mutations (eg, PFIC-1, BRIC) • Bile salt synthesis defects
Secondary (Acquired) • • • •
Sepsis (endotoxin-cytokine–related) Hepatitis (viral/drug-related) Paraneoplastic (eg, lymphoma cytokine secretion) Preservation injury after liver transplantation (ischemia/ reperfusion injury)
Mechanical (Bile duct disease) • • • • •
PSC Choledocholithiasis Biliary stricture Carcinoma (pancreas/bile duct/ampulla) Late primary biliary cirrhosis
Abbreviations: BRIC, benign recurrent intrahepatic cholestasis; PFIC-1, progressive familial intrahepatic cholestasis 1;PSC, primary sclerosing cholangitis.
Cholestasis may also be classified morphologically according to the histologic patterns identified in acute and chronic cholestasis as described below. H ISTO LO GIC PAT T ER NS IN ACUT E CH O LESTAS IS Cholestasis in Acute Large Bile Duct Obstruction (Pattern 1: Classical Ductular Reaction Type [ Figures 6.4 and 6.5 ])
Acute obstruction of large bile ducts (days to weeks) results in cholestasis accompanied by a triad of classical changes affecting portal tracts, including portal connective tissue edema, mild neutrophil infiltrates, and proliferation of bile ductular structures (4) (Figure 6.6). The ductular structures are characteristically arranged along the margins of the portal tract in portal/periportal regions (“marginal” bile ductular proliferation). The combination of ductular structures and stromal changes is now referred to as the ductular reaction (5,6). The ductular structures evolve from periportal Canals of Hering and/or progenitor/stem cells and are well demonstrated with cytokeratin (CK) 7 and 19 immunostains (Figures 6.7–6.9). Intraluminal and periductular neutrophils are virtually universal in the ductular reaction. Neutrophil chemotaxis into the ductular reaction is mediated by cytokine secretion by the ductular epithelium and by the rich inflammatory cytokine milieu associated with biliary obstruction (7–9). When examining H&E and CK7/CK19 immunostains, care should be given to assessing the quality and nature of the ductular reaction that may be present. This can differ considerably among the different etiologies of cholestatic liver disease. For example, an exaggerated version of the typical ductular reaction seen in acute and chronic large bile duct
CHAPTER
6:
FIGURE 6. 4 Histologic pattern set of acute cholestasis. Four histologic
response patterns include, pattern 1: cholestasis with triad of portal changes including edema, ductular reaction, and neutrophils (classical ductular reaction [DR] type); pattern 2: pure (bland) cholestasis; pattern 3: intrahepatic bile duct disease (b.d.) with bile duct damage and/or loss and cholestasis; and pattern 4: cholestasis associated with hepatitis. See Figure 6.5 for key to diagrams.
FIGURE 6. 5 Key to histologic patterns of acute cholestasis.
obstruction (Figure 6.7) also characterizes fibrosing cholestatic hepatitis due to hepatitis B or C virus reinfection after liver transplantation (10,11) (Figure 6.8) (a progenitor/stem cell activation response due to the severity of the hepatocellular injury and inadequate hepatocyte regeneration). In contrast, the ductular reaction is absent, extremely limited, or consists of only linear arrays of periportal intermediate hepatobiliary cells (“biliary hepatocytes”) in certain cholestatic disorders such as chronic ductopenic rejection and neonatal cholestasis with bile duct paucity (Figure 6.9). Loss of CD10 immunoreactivity on bile canaliculi may be a helpful diagnostic feature in such cases (12) (Figure 6.9C). With complete large bile duct obstruction, parenchymal bile is seen within hepatocytes, bile canaliculi, and sometimes in Kupffer cells. Hepatocellular cholestasis occasionally
C H O L E S TA S I S
91
F I G U R E 6 . 6 Portal tract in acute large bile duct obstruction. The triad of edema, inflammation, and ductular reaction is present. Note the normal-appearing native bile duct at upper left. Although the portal tract features are indicative of acute large duct obstruction in general, the specific anatomic site of obstruction is histologically uncertain and requires further clinical evaluation.
F I G U R E 6 . 7 The ductular reaction in large bile duct obstruction. In this case of primary sclerosing cholangitis, the proliferation of bile ductular structures are highlighted on CK7 immunostain (CK7 immunoperoxidase).
induces a ground-glass–like cytoplasmic appearance due to induction of smooth endoplasmic reticulum (13). Reorganization of hepatic plates into cholestatic liver-cell rosettes may be prominent. Bile infarcts, bile extravasates, and bile lakes accompanying type 1 “ductular reaction” pattern portal lesions are virtually pathognomonic of large duct obstruction. Examples of the type 1 pattern of acute cholestasis include gallstone impaction within the common bile duct (choledocholithiasis), common bile duct obstruction within the swollen and inflamed pancreas in acute pancreatitis, and biliary anastomotic obstruction after liver transplantation due to stricture, kinking, or bile extravasation (biloma).
92
CHAPTER
6:
C H O L E S TA S I S
TA BL E 6 . 2 Causes of intrahepatic “pure” cholestasis Sepsis Drug hepatotoxicity Early large bile duct obstruction Extrahepatic lymphoma Bile salt transporter protein mutations Mitochondriopathies Ischemia/reperfusion injury after transplantation (“functional bile flow impairment”)
FIGURE 6. 8 Marked ductular reaction in fibrosing cholestatic hepatitis C following liver transplantation (CK 7 immunostain). The extensive periportal ductular reaction resembles that seen in large bile duct obstruction, often necessitating radiologic studies to exclude large bile duct disease (CK7 immunoperoxidase).
(acinar zones 3) are primarily affected owing to a number of features specific to this region, including the constitutive localization of drug metabolizing enzymes to perivenular hepatocytes, susceptibility of bile canalicular bile transport systems in zone 3 to ischemia, hypoxia and the effects of circulating cytokines and endotoxins, and slower functional rates of bile flow when compared with periportal regions. The examples shown in Table 6.2 range from mutations of bile salt transport proteins (14–16) (eg, progressive familial intrahepatic cholestasis type 1 or PFIC-1, benign recurrent intrahepatic cholestasis) to endotoxin-related inhibition of BSEP (bile salt export pump) in sepsis.
Cholestasis Associated With Intrahepatic Bile Duct Disease (Pattern 3)
FIGURE 6. 9 Neonatal giant cell hepatitis with cholestasis and bile duct paucity. (A) Liver biopsy from this neonate with jaundice shows centrilobular cholestasis and multinucleated giant hepatocytes (top). The portal tract below shows an unpaired artery (a) without an accompanying interlobular bile duct; there is no apparent periportal ductular reaction. (B) Cytokeratin 7 immunostain shows an array of periportal intermediate hepatobiliary cells, but no well-formed ductular structures. (C) CD10 immunostain shows loss of bile canalicular endopeptidase staining except for focal periportal positivity below and upper left.
Pure (Bland) Cholestasis (Pattern 2)
The presence of cholestasis alone, without accompanying portal tract or parenchymal changes, may result from a variety of intrahepatic disorders or may be the earliest manifestation of large bile duct obstruction (Table 6.2). Centrilobular regions
The importance of the structural and functional integrity of intrahepatic bile ducts to bile secretion is emphasized by cholestatic disorders associated with damage to the smaller caliber bile ducts (usually interlobular bile ducts) within the liver. For histologic cholestasis to be present there must be substantial diffuse damage to intrahepatic bile ducts, potentially including bile duct loss (ductopenia). Idiosyncratic drug hepatotoxicity (Figure 6.10), later stages of primary biliary cirrhosis, and severe liver transplant rejection are examples. The affected duct epithelium may be infiltrated by immune cells (lymphocytes, eosinophils, neutrophils) and may show a variety of reactive features including nuclear pleomorphism and dyspolarity, occasional mitotic figures, cytoplasmic attenuation or vacuolization and disruption of the surrounding basement membrane by inflammatory cells.
Cholestasis Associated With Hepatitis (Pattern 4)
Viral, drug, and autoimmune hepatitis (AIH) are sometimes accompanied by cholestasis. Certain cases of acute hepatitis A may be particularly cholestatic (17). In the author’s experience, of the several causes of chronic hepatitis (eg, hepatitis B virus [HBV] or hepatitis C virus [HCV] infection), it is usually autoimmune hepatitis (in either its acute presentation or in its acute exacerbations) in which cholestasis is identifiable within swollen hepatocytes and/or in bile canaliculi (Figure 6.11). Unusually severe hepatitis with confluent necrosis may
CHAPTER
6:
FIGURE 6. 10 Drug-induced bile duct damage and cholestasis (methimazole
hepatitis). There is centrilobular cholestasis with bile pigment visible within hepatocytes. Sparse lymphocytes are present within the lobule. Hepatocyte nuclei appear atypical, with prominent chromatin and nucleoli, features related to cholestasis rather than true dysplasia. Inset: The bile duct (arrow) is surrounded by lymphocytes and scattered eosinophils and shows pleomorphic and dysmorphic epithelium. The presence of cholestasis and bile duct damage with scattered eosinophils suggested drug hepatotoxicity (in this case related to methimazole).
C H O L E S TA S I S
93
FIGURE 6.12 Marked hepatitis with severe cholestasis. The extensive hepatocellular necrosis, lobular and portal inflammation, and cholestasis in this case were ascribed to drug toxicity. Severe panlobular cholestasis is evident on low magnification. Inset: Striking bile canalicular and Kupffer cell (KC) cholestasis are present.
F I G U R E 6 . 1 3 Chronic large bile duct obstruction. (A) Portal tracts are expanded by fibrous tissue with bile ductular structures (ductular reaction) arranged marginally along the edges of the portal tracts. (B) Periportal hepatocytes are swollen and pale (pseudoxanthomatous change or cholate stasis). (C) Rhodanine stain for copper shows orange granules in periportal hepatocytes. (D) Extensive periportal copper-binding protein is evident on Victoria blue stain. FIGURE 6. 11 Autoimmune hepatitis with cholestasis. There are portal
and lobular infiltrates of plasma cells and lymphocytes. Mild cholestasis is evident within hepatocytes (long arrow) and bile canaliculi (short arrow). Inset: Intracellular bile (long arrow) and canalicular bile (short arrow) are present.
also be the background for substantial histologic cholestasis (Figure 6.12). The parenchymal changes of hepatitis (disarray of liver-cell plates, hepatocyte ballooning and apoptosis, portal and lobular inflammation) should make clear the cause of the cholestasis in such cases.
HISTOLOGIC CHANGES IN CHRONIC CHOLESTASIS
Prolonged cholestasis of many weeks, months, or longer period leads to common histologic endpoints, including the development of portal and periportal fibrosis (usually, although not invariably, associated with a ductular reaction), ongoing parenchymal cholestasis, which may now extend to the lobular periphery (periportal regions) where periportal fibrosis further blocks bile egress, and changes in periportal hepatocytes due to chronic retention of bile salts (“pseudoxanthomatous change”) (1,2) (Figure 6.13). Retained copper
94
CHAPTER
6:
C H O L E S TA S I S
FIGURE 6. 14 Architectural variations in chronic biliary obstruction. (A) The 2 cores in this needle biopsy sample show differences in architecture, with more extensive portal-to-portal bridging fibrosis and developing nodularity (arrow) in the core at left compared with the core at right which shows only mild periportal fibrosis. Such regional variations in close proximity of one another are a recognized feature of the progression of chronic biliary tract disease. This patient had a chronic biliary stricture that was treated with intermittent endoscopic dilatation. (B) The features of chronic biliary tract obstruction consist of a prominent ductular reaction (arrows) and periportal fibrosis. Note preservation of the native bile duct (white arrow). (A&B, hematoxylin, phloxine saffron stain).
and copper-binding protein within periportal hepatocytes is demonstrable on rhodanine and Victoria blue stains, respectively (Figure 6.13). Periportal Mallory-Denk bodies are also a sequelae of intracellular copper retention and hepatocellular oxidative stress (18). The progression toward a “biliary” type of cirrhosis often shows considerable architectural variations across the entire liver such that areas of mild periportal fibrosis may coexist with adjacent regions of more advanced portal-to-portal bridging fibrosis or even fully formed cirrhotic nodules (Figure 6.14). Regenerative hyperplasia of periportal hepatocytes is often evident near fibrotic portal tracts as twinned (or thicker) liver-cell plates. Bridging fibrous septa progressively link portal tracts but may spare terminal venules which can be seen preserved in their normal centrilobular positions well into the developed stage of biliary cirrhosis. The fibrous septa of biliary cirrhosis are characteristically uniform and thick; ductular reaction is often evident. The thick fibrous septa surrounding islands of regenerative liver tissue in the form of nodules renders a low-power “geographic” appearance (Figure 6.15). The “halo effect” that is often visible at the nodule periphery in biliary cirrhosis (Figure 6.15) is due to the combination of periportal edema and pseudoxanthomatous change of periseptal hepatocytes. Depending on the etiology of the biliary cirrhosis, bile ducts may be surrounded by concentric periductal fibrosis and thickened basement
FIGURE 6.15 Biliary cirrhosis. The cirrhotic nodules are intensely cholestatic and are surrounded by regular, thick fibrous septa. A peripheral “halo effect” is present.
membranes, may appear simplified (dystrophic) and lined by only a few epithelial cells, or may be replaced by fibroobliterative scars, collections of chronic inflammatory cells (Figures 6.16 and 6.17), or by lymphoid aggregates and follicles with germinal centers.
CHAPTER
6:
FIGURE 6.16 Chronic large bile duct obstruction (primary sclerosing cholangitis). (A) Periductal, concentric “onion-skin” fibrosis is present. (B) Periductal fibrosis surrounds several interlobular bile duct branches. (C) Basement membrane thickening of small intrahepatic bile ducts may be present in chronic biliary obstruction (Diastase-resistant periodic acid Schiff [DPAS] stain).
References 1. Li MK, Crawford JM. The pathology of cholestasis. Semin Liver Dis 2004;24:21–42. 2. Lefkowitch JH. Scheuer’s Liver Biopsy Interpretation. 8th ed. Edinburgh: Elsevier, 2010:47–74. 3. Lefkowitch JH. Bile ductular cholestasis: an ominous histopathologic sign related to sepsis and “cholangitis lenta.” Hum Pathol. 1982;13:19–24. 4. Christoffersen P, Poulsen H. Histological changes in human liver biopsies following extrahepatic biliary obstruction. Acta Pathol Microbiol Scand. 1970;212:150–157. 5. Roskams T, Desmet V. Ductular reaction and its diagnostic significance. Semin Diagnos Pathol 1998;15:259–269. 6. Roskams TA, Theise ND, Balabaud C, et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology. 2004;39:1739–1745. 7. Crawford JM, Boyer JL. Clinicopathology conferences: inflammationinduced cholestasis. Hepatology. 1998;28:253–260. 8. Kosters A, Karpen SJ. The role of inflammation in cholestasis: clinical and basic aspects. Semin Liver Dis. 2010;30:186–194. 9. Copple BL, Jaeschke H, Klaassen CD. Oxidative stress and the pathogenesis of cholestasis. Semin Liver Dis. 2010;30:195–204. 10. Delladetsima JK, Boletis JN, Makris F, et al. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection. Liver Transplant Surg. 1999;5:294–300.
C H O L E S TA S I S
95
FIGURE 6.17 Intrahepatic bile duct disease. Interlobular bile ducts in biliary tract disease may show dystrophy and simplification, (A) as well as basement membrane thickening in (B) and (C). (C, trichrome stain).
11. Davies SE, Portmann BC, O’Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology. 1991;13:150–157. 12. Byrne JA, Meara NJ, Rayner AC, Thompson RJ, Knisely AS. Lack of hepatocellular CD10 along bile canaliculi is physiologic in early childhood and persistent in Alagille syndrome. Lab Invest. 2007;87: 1138–1148. 13. Popper H, Schaffner F. Pathophysiology of cholestasis. Hum Pathol. 1970;1:1–24. 14. Paulusma CC, Elferink RPJO, Jansen PLM. Progressive familial intrahepatic cholestasis type 1. Semin Liver Dis. 2010;30:117–124. 15. Stapelbroek JM, van Erpecum KJ, Klomp LW, Houwen RH, et al. Liver disease associated with canalicular transport defects: current and future therapies. J Hepatol. 2010;52:258–271. 16. Wagner M, Zollner G, Trauner M. New molecular insights into the mechanisms of cholestasis. J Hepatol. 2009;51:565–580. 17. Teixeira MR Jr, Weller IVD, Murray AM, et al. The pathology of hepatitis A in man. Liver 1982;2:53–60. 18. Müller T, Langner C, Fuchsbichler A, et al. Immunohistochemical analysis of Mallory bodies in Wilsonian and non-Wilsonian hepatic copper toxicosis. Hepatology. 2004;39:963–969.
Case 6.1
Drug-Induced Pure Cholestasis JAY H. LEFKOWITCH
organized into rosette-like structures rather than the usual radiating liver-cell plate pattern (Figure 6.1.2). Some of the cholestatic rosettes do not contain bile, but the alteration in plate architecture in midzonal and centrilobular regions (in contrast to periportal regions, the common site for regenerative liver-cell rosettes in chronic hepatitis) should prompt consideration of cholestatic disease. Bile thrombi are present within centrilobular bile canaliculi and within hepatocytes (Figure 6.1.1).
C L I N I C AL I N F OR M AT I ON
A 55-year-old woman was admitted to an outside hospital for painless jaundice. She was known to have systemic hypertension and had been taking lisinopril for an unspecified length of time. On admission she was jaundiced but had no significant findings on abdominal exam. Her white blood cell count was normal and showed no increase in eosinophils. Serum liver tests showed aspartate aminotransferase (AST) 5 57 (normal Ó40 U/L), alanine aminotransferase (ALT) 5 26 (normal 40 U/L), alkaline phosphatase (ALP) 5 857 (normal 110 U/L), total bilirubin 5 35.1 (normal 1.0 mg/dL), conjugated bilirubin 5 23.5, and normal total protein and albumin. A liver biopsy was obtained and was reported as showing “cholestasis,” without further comment. Because of concern for malignancy (cholangiocarcinoma), she was transferred to our center for further evaluation. During the workup at our institution, MRCP (magnetic resonance cholangiopancreatography) was performed and showed no bile duct dilatation, mass, or defect.
DIAGNO SIS
Marked cholestasis hepatotoxicity.
compatible
with
lisinopril
DISCUSSIO N
The chief biopsy change is cholestasis predominating in centrilobular regions, without portal tract inflammation, bile duct damage or loss, or fibrosis. The liver test results further point to a primary cholestatic injury, with major elevations of bilirubin and ALP. The virtually normal aminotransferases indicate little hepatocellular component to the liver injury (a consideration in certain forms of drug-induced liver injury where the agent causes both hepatocellular injury and canalicular injury—so-called hepatocanalicular drug toxicity). The majority of conditions in the differential diagnosis of pure
R E A S ON F OR R E F E R R A L
Review the liver biopsy to determine the cause of the patient’s persistent jaundice. PAT H OL OG I C F E AT U R E S
There is striking cholestasis in centrilobular regions (Figure 6.1.1). Portal tracts do not show inflammation, bile duct changes, or fibrosis. The lobular parenchyma appears
FIGURE 6. 1. 1 Drug-induced pure cholestasis. (A) The centrilobular region shows striking cholestasis. (B) Bile thrombi are prominent within
bile canaliculi and there is also intrahepatocellular bile (small arrows).
96
CASE
6.1:
DRUG-INDUCED
FIGURE 6. 1. 2 Cholestatic rosettes in drug-induced cholestasis. Cholestasis is prominent (bottom right) and has resulted in the transformation of liver-cell plates into cholestatic rosettes (between arrows). Many rosettes show no obvious bile.
(bland) cholestasis (see Table 6.2, page 92) were clinically excluded or not relevant in this 55-year-old woman. Although pure cholestasis without significant portal tract pathology may be seen in the early days of large bile duct obstruction, MRCP excluded biliary obstruction. Drug hepatotoxicity must always be considered in evaluating this type of cholestasis. Even if there is no previously published report on a specific agent being administered, there is always the potential for a “first time” idiosyncratic liver injury. In this case, lisinopril is thought to be the cause of the cholestasis and clinical jaundice. Lisinopril, along with captopril, enalapril, ramipril, and fosinopril, belongs to the class of angiotension converting enzyme (ACE) inhibitors for which there is a substantial literature regarding cholestatic liver injury (1). In 20 published reports of ACE inhibitor– related liver injury discussed by Yeung et al (1), cholestasis was prominent in 14, hepatocellular injury was dominant in 4, and mixed hepatocellular-cholestatic features were seen in 2 cases. In the present case, the duration of lisinopril administration was not specified, but ACE inhibitor hepatotoxicity shows a wide range of onset, from as early as 5 days to as late as 3 years (1). In 1 report of lisinopril-induced chronic liver disease, initial cholestasis was accompanied on biopsy by prominent portal inflammation (plasma cells, neutrophils) and ductular reaction, and progressed 9 months later to portal fibrosis and developing cirrhosis, without cholestasis (2). Fulminant hepatitis after lisinopril use is also described (3). Lisinopril-induced cholestasis in our case is likely an idiosyncratic drug hepatotoxic injury. There were no indications of a typical hypersensitivity reaction (eg, fever, peripheral or tissue eosinophilia). Other mechanisms of ACE inhibitor liver injury have been postulated to be related to metabolic idiosyncracy (ie, the terminal proline ring present in common among captopril, lisinopril, and enalapril) and to prostaglandin-induced decreased bile flow (ACE inhibitors
PURE
C H O L E S TA S I S
97
F I G U R E 6 . 1 . 3 Cholestasis due to bile salt transporter mutation
(ATP8B1). Pure canalicular cholestasis is evident in this needle biopsy from an infant with progressive familial intrahepatic cholestasis type 1. Two cholestatic rosettes have formed around bile thrombi (arrows). Similarly, bland cholestasis is also evident in benign recurrent intrahepatic cholestasis (BRIC).
favor conversion of arachidonic acid to prostaglandins) (2). In our case lisinopril was discontinued, but follow-up information was not available. Brief mention should be made of BRIC which is among the causes of pure cholestasis (see Table 6.2, page 92), although the patient had suffered no prior sporadic episodes of jaundice, pruritus, or cholestatic liver tests punctuated by long periods (months to years) of normalcy characteristic of BRIC (4–6). The liver in BRIC shows bland canalicular and hepatocellular cholestasis, sometimes with accompanying Kupffer cell bile (5,6) (Figure 6.1.3). A few patients with BRIC show mild portal lymphocytic infiltrates or lobular necroinflammation along with cholestasis; rarely there are portal eosinophils or a ductular reaction (5). The parenchymal cholestasis of BRIC resembles that seen in PFIC-1 (see Chapter 10), and both conditions result from mutations in ATP8B1 which encodes the phosphatidylserine flippase FIC-1 protein. The spectrum of severity of cholestasis in PFIC-1 and BRIC is related to the existence of many heterogeneous ATP8B1 mutations. Folmer et al recently demonstrated complete absence of canalicular ATP8B1 mutant expression in PFIC-1 subjects due to reduced protein stability and its failure to interact with CDC50A (which is required for appropriate endoplasmic reticulumto-canaliculus translocation) (7). In BRIC, ATP8B1 mutant protein stability was not altered and residual expression on canaliculi was present. Folmer et al postulate that stressors such as fever, inflammation, and cytokine release, in tandem with effects on other bile salt transporters, mediate the episodic cholestasis of BRIC (7). Immunohistochemical staining for bile salt transport protein expression on bile canaliculi including bile salt export pump (BSEP), multidrug resistance protein 3 (MDR3), and others, therefore now provides important diagnostic information when applied to cases of unexplained pure intrahepatic cholestasis (6).
98
CHAPTER
6:
References 1. Yeung E, Wong FS, Wanless IR, et al. Ramipril-associated hepatotoxicity. Arch Pathol Lab Med. 2003;127:1493–1497. 2. Droste HT, de Vries RA. Chronic hepatitis caused by lisinopril. Netherlands J Med. 1995;46:95–98. 3. Larrey D, Babany G, Bernuau J, et al. Fulminant hepatitis after lisinopril administration. Gastroenterology. 1990;99:1832–1833. 4. Beaudoin M, Feldmann G, Erlinger S, et al. Benign recurrent cholestasis. Digestion. 1973;9:49–65.
C H O L E S TA S I S
5. Brenard R, Geubel AP, Benhamou JP. Benign recurrent cholestasis. A report of 26 cases. J Clin Gastroenterol. 1989;11:546–551. 6. Liu LU, Qin L, Knisely AS. A patient with persistent pruritus. Semin Liver Dis. 2010;30:205–209. 7. Folmer DE, van der Mark VA, Ho-Mok KS, et al. Differential effects of progressive familial intrahepatic cholestasis type 1 and benign recurrent intrahepatic cholestasis type 1 mutations on canalicular localization of ATP8B1. Hepatology. 2009;50:1597–1605.
Case 6.2
Bile Ductular Cholestasis Associated With Sepsis JAY H. LEFKOWITCH
C L I N IC AL I N F OR M AT I ON
A 70-year-old man with hypertension, type 2 diabetes, coronary artery disease with prior myocardial infarction, and status/ post 2 prior-deceased donor renal transplants with current graft rejection (on hemodialysis) was admitted to the medical intensive care unit because of a major drop in hematocrit following a retroperitoneal hemorrhage. Shortly after admission, he underwent interventional radiologic embolization of L3/L4 arteries with cessation of bleeding. One month prior to this admission, he was diagnosed with tuberculous spinal L5-S1 osteomyelitis (Pott disease) for which he was undergoing multidrug therapy including pyrazinamide and rifampin, and culture of a later spinal biopsy disclosed moraxella osteomyelitis. The latter was treated with a course of levofloxacin. Other medications at the time of admission included cyclosporin and vancomycin. During the first week of admission he had altered mental status and poor respiratory effort and was placed on a ventilator. He was persistently febrile and had bilateral infiltrates on chest X-ray, an elevated white blood cell count of 29 700/mm3, and a tracheal culture was positive for vancomycin-resistant enterococci. Blood cultures were negative. He was jaundiced, but an abdominal ultrasound showed only tiny shadowing gallstones without evidence of bile duct dilatation or acute cholecystitis. Serum liver tests included normal ALT and mildly elevated AST, total bilirubin 5 25.6 with direct bilirubin 5 11.3, and alkaline phosphatase approximately twice normal (254 U/L). Rifampin was discontinued because of jaundice, and a liver biopsy was obtained.
F I G U R E 6 . 2 . 1 Bile ductular cholestasis associated with sepsis. Periportal regions diffusely show dilated bile ductular structures with inspissated bile concretions (“bile ductular cholestasis”). Inset: Centrilobular cholestasis is present within hepatocytes and bile canaliculi.
R E A SON F OR R E F E R R AL
To determine whether jaundice is due to drug toxicity or retroperitoneal hemorrhage. PAT H OL OG I C F E AT U R E S
The liver biopsy shows a striking pattern of cholestasis consisting of markedly dilated periportal bile ductular structures containing inspissated bile concretions affecting all portal and periportal regions (Figures 6.2.1 and 6.2.2). This is accompanied by diffuse centrilobular cholestasis, with bile evident within hepatocyte cytoplasm and in bile canaliculi (Figure 6.2.1, Inset). The portal tracts show mild edema and mixed neutrophil-lymphocyte infiltrates. The native bile ducts appear normal, without intraluminal bile (Figure 6.2.2), whereas the periportal ductular structures are surrounded by neutrophils and are lined by attenuated and flattened low cuboidal epithelium (Figure 6.2.2, Inset). The lobular parenchyma shows no inflammation or significant hepatocellular damage. No eosinophils are evident within the portal tracts or lobules.
F I G U R E 6 . 2 . 2 Bile ductular cholestasis associated with sepsis. The
dilated periportal bile ductular structures contain bile concretions and are surrounded by inflammatory cells. Note the preserved native bile duct (without intraluminal cholestasis) paired with an arteriole at bottom center. Inset: The epithelium of the bile ductular structures ranges from low cuboidal to tapering and attenuated. The surrounding mixed inflammatory cell infiltrate includes numerous neutrophils and scattered lymphocytes.
99
100
CHAPTER
6:
C H O L E S TA S I S
DISCUSSIO N D I AG N OS I S
Bile ductular and parenchymal cholestasis consistent with sepsis.
FIGURE 6. 2. 3 Pure centrilobular cholestasis associated with sepsis.
This is the most common cholestatic response to sepsis, featuring centrilobular bile canalicular and hepatocellular cholestasis without significant changes in portal tracts. (A) Low power demonstrates cholestasis and no significant changes in the portal tract at left. (B) Prominent centrilobular cholestasis.
The liver biopsy in this case was especially helpful in pointing to sepsis as the likely cause of his liver dysfunction, rather than the clinical diagnoses of drug toxicity or recent retroperitoneal hemorrhage. Although blood cultures were negative, the patient had pulmonary infiltrates consistent with pneumonia and an elevated peripheral white blood cell count. D-dimer and lactic dehydrogenase elevations suggested low-grade disseminated intravascular coagulation. The unusual distribution of cholestasis in this case (“bile ductular cholestasis”) is virtually pathognomonic of sepsis (1), although this pattern is uncommon among individuals with sepsis who undergo liver biopsy. Identification of this pattern of cholestasis always warrants immediate discussion with the clinical team, since exclusion and treatment of sepsis have urgency. Elevated serum total bilirubin disproportionate to aminotransferases and alkaline phosphatase is an important clinical feature associated with this picture (2). The liver in sepsis more typically shows pure (bland) cholestasis within bile canaliculi and hepatocytes with a perivenular predilection, without significant portal tract changes (Figure 6.2.3). Gram-negative endotoxin (lipopolysaccharide or LPS) and inflammatory cytokines are the circulating factors that cause this type of cholestasis which appears to be mediated in part through inhibition of canalicular BSEP (3–6). In addition to pure cholestasis and bile ductular cholestasis, a third distinctive histologic picture is seen in postmortem liver tissue from individuals with preterminal sepsis (Figure 6.2.4). The tissue sections appear to have accelerated autolysis with poor staining of all cell nuclei throughout
FIGURE 6. 2. 4 Postmortem hepatic changes in sepsis-related cholestasis. (A) Preterminal fever and accelerated lysosome release result in excessive
autolysis and lysosomal enzyme release with breakdown of endothelial/sinusoidal borders. Hepatocytes show unusually wide separation. (B) Cholestasis is apparent with bile canaliculi and hepatocytes show marked separation with a “jigsaw puzzle”–like appearance.
CASE
6.2:
BILE
DUCTULAR
C H O L E S TA S I S
A S S O C I AT E D
WITH
SEPSIS
101
ghosts of endothelial cells with elongated lining are evident (Figure 6.2.5). Bile thrombi in cross-sectional or longitudinal casts between hepatocytes are seen. In such cases, usually with temperatures exceeding 101°F prior to death, it is likely that as death ensues there is accelerated lysosomal rupture and release from hepatocytes, endothelial cells, and Kupffer cells, which results in degeneration and necrosis of sinusoidal endothelial barriers, with widening of intercellular spaces. Such changes are likely to proceed relatively unabated until postmortem examination and tissue procurement and fixation occur.
References
FIGURE 6. 2. 5 Chronic large bile duct obstruction. The portal tract is expanded by fibrosis, ductular reaction, and chronic inflammation. A septal bile duct (arrow) shows periductal inflammation and fibrosis. Inset: Trichrome stain shows 1 duct with periductal fibrosis compatible with primary sclerosing cholangitis.
the section and a mosaic- or jigsaw puzzle–like separation of hepatocytes and widening of intercellular spaces (Figure 6.2.5). The remnants of sinusoidal architecture are visible, but only
1. Lefkowitch JH. Bile ductular cholestasis: an ominous histopathologic sign related to sepsis and “cholangitis lenta.” Hum Pathol 1982;13:19–24. 2. Riely CA, Dean PJ, Park AL, et al. A distinct syndrome of liver disease with multisystem organ failure associated with bile ductular cholestasis. Hepatology. 1989;10:739A. 3. Crawford JM, Boyer JL. Clinicopathology conferences: inflammationinduced cholestasis. Hepatology. 1998;28:253–260. 4. Kosters A, Karpen SJ. The role of inflammation in cholestasis: clinical and basic aspects. Semin Liver Dis. 2010;30:186–194. 5. Stapelbroek JM, van Erpecum KJ, Klomp LW, Houwen RH. Liver disease associated with canalicular transport defects: current and future therapies. J Hepatol. 2010;52:258–271. 6. Wagner M, Zollner G, Trauner M. New molecular insights into the mechanisms of cholestasis. J Hepatol. 2009;51:565–580.
Case 6.3
Crohn Disease With Primary Sclerosing Cholangitis JAY H. LEFKOWITCH
C L I N I C AL I N F OR M AT I ON
A 37-year-old man with a history of Crohn disease since age 14 and resection of the small- and large-bowel because of obstruction, abscess, and fistula formation 18 years earlier (with a primary anastomosis) was referred to our institution for further clinical management. Two years earlier he had developed a bowel perforation and underwent further bowel resection resulting in the need for total parenteral nutrition (TPN). He had received TPN for the past 2 years but suddenly became jaundiced due to a liver biopsy performed elsewhere 3 months before being seen at our center. The outside endoscopic retrograde cholangiopancreatography (ERCP) report was unavailable to our clinical team. On physical exam the liver was enlarged and palpable, firm but not nodular, without ascites. Serum liver tests showed AST 5 138, ALT 5 99, alkaline phosphatase 5 274, total bilirubin 5 23.2 (conjugated 5 10.2), with normal total protein and albumin. His current medications in addition to TPN therapy included asacol, hydromorphone, trazadone, and fentanyl patch. R E A S ON F OR R E F E R R A L
F I G U R E 6 . 3 . 1 Periportal cholestasis and cholate stasis (pseudoxanthomatous change). The portal tract shown in Figure 6.2.5, Chapter 6.2 is shown at higher magnification. Periportal hepatocytes are swollen and contain bile (arrow). Ductular reaction and chronic inflammatory cells are also apparent.
To determine whether there is fibrosis on the liver biopsy, and if present, is it due to TPN and is it reversible, to be factored into consideration of the patient as a candidate for isolated intestinal transplantation. PAT H OL OG I C F E AT U R E S
Chronic liver disease is evident, with irregular expansion of all portal tracts by lymphocytes, a prominent ductular reaction and mild early periportal fibrosis on trichrome and reticulin stains (see Figure 6.2.5). Marked hepatocellular and bile canalicular cholestasis is present with focal bile in Kupffer cells. Periportal hepatocytes contain bile and appear pale and swollen, demonstrating pseudoxanthomatous change (cholate stasis) (Figure 6.3.1). Approximately two-thirds of the portal tracts show no identifiable native bile duct (Figure 6.3.2). One portal tract showed periductal fibrosis with an “onion-skin” appearance on hematoxylin and eosin (H&E) and trichrome stains (see Figure 6.2.5).
F I G U R E 6 . 3 . 2 Ductopenia. Cholestasis is seen within the lobular pa-
renchyma. The majority of portal tracts in this needle biopsy specimen showed only hepatic artery branches (arrow) without bile ducts of similar caliber. DISCUSSIO N
D I AG N OS I S
Chronic ductopenic liver disease with marked cholestasis, focal periductal and early-mild periportal fibrosis compatible with primary sclerosing cholangitis ([PSC] Crohn disease, clinical).
This biopsy presents the not uncommon diagnostic dilemma of deciphering several confounding possible causes of jaundice and chronic cholestatic liver disease, in this case the history of prolonged administration of parenteral nutrition, several concomitant medications, and underlying Crohn disease (with unavailable ERCP data). Review of published data concerning 102
CASE
6.3:
CROHN
DISEASE
WITH
PRIMARY
FIGURE 6. 3. 3 Cholestasis with bile duct obstructive features in parenteral
nutrition. Liver biopsy from a 10-week-old infant receiving parenteral nutrition since birth due to duodenal atresia. Marked cholestasis with prominent proliferation of bile ductular structures (arrows) and mild periportal fibrosis have developed: a recognized complication of prolonged administration of parenteral nutrition.
the medications administered shows no reports of cholestatic or bile duct injury. Liver injury following parenteral nutrition shows age-related differences, with cholestasis and portal tract features closely resembling those of bile duct obstruction predominating in infants and children (Figure 6.3.3) and fatty liver disease seen in adults (1–4). Loss of bile ducts and ductopenia are not reported for TPN but are a significant late feature in PSC (5–8). The biopsy further demonstrates the problem of focality in obtaining diagnostic lesions in liver biopsies PSC; in this case a single portal tract in the liver biopsy shows periductal “onion-skin” fibrosis (Figure 6.3.1). Liver biopsies in PSC can show diverse features, often indicative of biliary tract obstruction in general but sometimes also mimicking chronic hepatitis (5,6). The biopsy changes and clinical history of Crohn disease are most consistent with PSC. The typical male:female ratio in PSC is 2:1 with a mean age at diagnosis of approximately 40, so this patient’s demographics are consistent with the diagnosis, as are the cholestatic liver test results (9,10). Information regarding a pANCA (perinuclear antineutrophil cytoplasmic antibody) test was not known in this case, but it is positive in 26% to 94% of cases (9). Antinuclear and anti–smooth muscle antibodies (ANA and anti-SMA) may also be positive (11) but are thought to be nonspecific. The importance of such autoantibodies, if positive, is in excluding a possible autoimmune hepatitis (AIH)-PSC “overlap
SCLEROSING
CHOLANGITIS
103
syndrome” (covered in Chapter 3). The present case shows no interface hepatitis or parenchymal hepatitic changes, thereby not providing support for overlap with AIH. The results of the ERCP are critical to review in this case. In PSC, both intraand extrahepatic bile ducts are usually involved (9,10), showing multifocal strictures and segmental dilatations. Single nucleotide polymorphism (SNP) markers were examined in a genome-wide association analysis in PSC and show significant associations with human leukocyte antigen (HLA) and non-HLA genes, the latter including genes involved in bile homeostasis and inflammation (12). Other causes of ductopenic disease including the recently described mutations in the bile canalicular phospholipid transporter gene ABCB4 (MDR3) (13) should be considered if cholangiogram is negative. Bile duct loss without cause in adults is termed idiopathic adulthood ductopenia (14,15).
References 1. Mullick FG, Moran CA, Ishak KG. Total parenteral nutrition: a histopathologic analysis of the liver changes in 20 children. Mod Pathol. 1994;7: 190–194. 2. Body JJ, Bleiberg H, Bron D, Maurage H, Bigirimana V, Heimann R. Total parenteral nutrition-induced cholestasis mimicking large bile duct obstruction. Histopathology. 1982;6:787–792. 3. Baker AL, Rosenberg IH. Hepatic complications of total parenteral nutrition. Am J Med. 1987;82:489–497. 4. Klein S, Nealon WH. Hepatobiliary abnormalities associated with total parenteral nutrition. Semin Liver Dis. 1988;8:237–246. 5. Lefkowitch JH. Primary sclerosing cholangitis. Arch Int Med. 1982;142:1157–1160. 6. Scheuer PJ. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis. Mayo Clin Proc. 1998;73:179–183. 7. LaRusso NF, Shneider BL, Black D, et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology. 2006;44:746–764. 8. Lefkowitch JH, Martin EC. Primary sclerosing cholangitis. Prog Liver Dis. 1986;8:557–580. 9. European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237–267. 10. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660–678. 11. Hov JR, Boberg KM, Karlsen TH. Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol. 2008;14:3781–3791. 12. Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology. 2010;138:1102–1111. 13. Gotthardt D, Runz H, Keitel V, et al. A mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults. Hepatology 2008; 48:1157–1166. 14. Ludwig J, Wiesner RH, La Russo NF. Idiopathic adulthood ductopenia: a cause of chronic cholestatic liver disease and biliary cirrhosis. J Hepatol 1988;7:193–199. 15. Moreno A, Carreño CA, González C. Idiopathic biliary ductopenia in adults without symptoms of liver disease. N Engl J Med. 1997;336: 835–838.
Case 6.4
Chronic Large Bile Duct Obstruction of Uncertain Cause JAY H. LEFKOWITCH
C L I N I C AL I N F OR M AT I ON
A 74-year-old woman underwent liver biopsy because she appeared to have cirrhosis at the time of cholecystectomy for cholelithiasis. R E A S ON F OR R E F E R R A L
In addition to increased fibrous tissue within the portal tracts, 1 septal bile duct is surrounded by edema and shows infiltrating neutrophils lifting off its epithelium from the underlying basement membrane. Centrilobular regions show enlarged and hyperchromatic hepatocyte nuclei with focal trinucleation (Figure 6.4.6). The affected cells show intracellular brown pigment compatible with bile.
The referring pathologist wished to have an explanation for the dysplasia present and the marked ductular reaction of unknown origin. PAT H OL OG I C F E AT U R E S
The liver biopsy shows moderate parenchymal cholestasis with bile in canaliculi, hepatocytes, and Kupffer cells with a centrilobular and midzonal predilection (Figure 6.4.1). Focal periportal bile is also seen. The portal tracts are expanded by fibrosis and show focal portal-to-portal bridging fibrosis, but neither parenchymal nodularity nor an established cirrhosis is present. The portal tracts are infiltrated by mixed acute and chronic inflammatory cells and there is a dramatic periportal ductular reaction broadening the periportal regions (Figures 6.4.2–6.4.5). Neutrophils are readily seen adjacent to the proliferated ductular structures, and collections of rounded, “oval cells” (progenitor cells) are particularly conspicuous in many periportal areas (Figures 6.4.4 and 6.4.5).
F I G U R E 6 . 4 . 2 Ductular reaction in chronic biliary obstruction. The duc-
tular reaction (DR) appears prominently at the edge of this fibrotic portal tract.
FIGURE 6. 4. 1 Features of chronic biliary tract obstruction with bridging
fibrosis and early nodularity. Portal tracts are broadened by fibrosis and a conspicuous ductular reaction. Bridging fibrosis links portal tracts in this field. Inset: The portal tract changes are associated with prominent hepatocellular cholestasis (arrows).
F I G U R E 6 . 4 . 3 Diffuse periportal ductular reaction in chronic biliary ob-
struction. The ductular reaction is striking throughout all periportal regions.
104
CASE
6.4:
CHRONIC
LARGE
6. 4. 4 Periportal ductular reaction. Ductular structures lie parallel to the portal tract (PT) and are associated with mild surrounding neutrophil infiltrates. Collections of rounded putative “progenitor/stem cells” are seen near the ductular structures (arrows).
FIGURE
BILE
DUCT
OBSTRUCTION
105
F I G U R E 6 . 4 . 5 “Oval-like” periportal progenitor/stem cells and the ductular reaction. The bile ductular structure at the top shows small numbers of neutrophils within the epithelium and in the surrounding connective tissue. The collections of rounded cells with little cytoplasm (between arrows) are most likely progenitor/stem cells in nature. Compare their size and cytoplasm with that of periportal hepatocytes at the bottom.
FIGURE 6. 4. 6 Hepatocellular atypia of cholestasis. (A) Centrilobular hepatocytes show tri-nucleation, coarse nuclear chromatin, and hyperchromatism. The affected cells contain bile. This atypia is reactive and should therefore not be regarded as evidence of true liver-cell dysplasia. (B) Hepatocellular nuclear atypia is related to the presence of considerable intracellular and bile canalicular cholestasis (arrows).
DISCUSSIO N D I AG N OS I S
Features of acute and chronic large bile duct obstruction with periportal and focal portal-to-portal bridging fibrosis, unknown etiology.
The liver biopsy shows features of acute and chronic large bile duct obstruction but does not demonstrate cirrhosis (the clinical impression of cirrhosis at cholecystectomy was most likely based on the abnormal capsular surface due to regions of underlying periportal and bridging fibrosis). The ductular
106
CHAPTER
6:
reaction in this case is particularly striking, reflecting diffuse activation of periportal progenitor/stem cells (1–4). Although this reaction is a normal constituent of the changes following biliary obstruction, the reason for its unusually robust nature in this case is not entirely certain. However, it likely is related both to the chronicity of the process and to the evolution of fibrosis demonstrated in the biopsy sample; the cytokine and signaling factors involved are likely to be analogous to the close relationship observed between ductular reaction and the genesis of fibrosis in the evolution of nonalcoholic steatohepatitis (5). The groups of primitive-appearing cells near the ductular reaction (Figures 6.4.4 and 6.4.5 ) are vivid examples of the progenitor/stem cell compartment in the periportal regions of human livers resembling the “oval cells” of rodents (6). The atypical-appearing centrilobular hepatocytes in this case (Figure 6.4.6) need to be distinguished from large-cell dysplasia (7), since, instead, they represent the combination of aging polyploidy (ie, anisonucleosis) with superimposed effects of intracellular bile retention on hepatocyte nuclear morphology. Hepatocytes in cholestasis sometimes demonstrate coarsened nuclear chromatin and peripheral accentuation with resulting atypia; affected cells are not always limited to perivenular areas. Although there is little data in this area, retained intracellular bile salts may potentially alter cellular pH levels with resultant effects on nuclear chromatin. This case further demonstrates the relative anatomic nonspecificity of the features of chronic large bile duct obstruction. Comments at the conclusion of our consultation biopsy report therefore suggested that the patency of the biliary tree
C H O L E S TA S I S
required clinical evaluation in order to exclude several possible causes of chronic large duct obstruction. This differential diagnosis is that of “secondary sclerosing cholangitis” (8), which includes chronically impacted gallstones with choledocholithiasis, chronic pancreatitis or occult pancreatic carcinoma, benign biliary stricture, and cholangiocarcinoma. In this patient’s age group, primary sclerosing cholangitis is a less likely diagnosis. We have not received further clinical follow-up on this patient.
References 1. Roskams T, Desmet V. Ductular reaction and its diagnostic significance. Semin Diagnos Pathol. 1998;15:259–269. 2. Roskams TA, Theise ND, Balabaud C, et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology. 2004;39:1739–1745. 3. Roskams T. Progenitor cell involvement in cirrhotic human liver diseases: from controversy to consensus. J Hepatol. 2003;39:431–434. 4. Zhang L, Theise N, Chua M, Reid LM. The stem cell niche of human livers: symmetry between development and regeneration. Hepatology. 2008;48:1598–1607. 5. Richardson MM, Jonsson JR, Powell EE, et al. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology. 2007;133:80–90. 6. Roskams T, De Vos R, Van Eyken P, Myazaki H, Van Damme B, Desmet V. Hepatic OV-6 expression in human liver disease and rat experiments: evidence for hepatic progenitor cells in man. J Hepatol. 1998;29:455–463. 7. Natarajan S, Theise ND, Thung SN, et al. Large-cell change of hepatocytes in cirrhosis may represent a reaction to prolonged cholestasis. Am J Surg Pathol. 1997;21:312–318. 8. Ruemmele P, Hofstaedter F, Gelbmann CM. Secondary sclerosing cholangitis. Nat Rev Gastroenterol Hepatol. 2009;6:287–295.
Case 6.5
Primary Sclerosing Cholangitis, Exclude Cholangiocarcinoma JAY H. LEFKOWITCH
C L I N IC AL I N F OR M AT I ON
A 43-year-old man with liver disease for approximately 16 years presented for liver transplantation evaluation. At age 27 he had liver function test abnormalities that were initially attributed to alcohol use, but an ERCP done 10 years ago showed some bile duct narrowing that was thought to be congenital. There was no history of inflammatory bowel disease. A year before coming for transplant evaluation he suffered a massive gastrointestinal hemorrhage and was found to have varices which were banded. ERCP was repeated elsewhere with a diagnosis of PSC, with brushings reported as negative. He had ascites, intermittent jaundice, and pruritus. Over the 3 months prior to the current evaluation he had a weight loss of 16 kg. At our center, he underwent a computed tomography (CT) scan without contrast, which showed focal intrahepatic bile duct dilatation without involvement of large ducts. On physical examination the patient was thin with moderate muscle wasting and trace icteric sclerae. Cardiac and pulmonary examinations were normal. On abdominal examination the liver was markedly enlarged, hard, and had a palpable nodular edge 3 fingerbreadths below the right costal margin. Marked splenomegaly was present, but there was no clinical ascites or caput medusae. Peripheral edema and asterixis were absent. Serum liver tests showed mild total bilirubin elevation of 3.7 mg/dL (direct bilirubin 1.7), AST 5 74, ALT 5 63, alkaline phosphatase (ALP) 5 181, total protein 5 6.8, and albumin 5 3.4. Several weeks after evaluation he underwent liver transplantation.
6 . 5 . 1 Developing biliary cirrhosis in small-duct PSC. (A) This field shows a cirrhotic nodule surrounded by thick fibrous septa containing chronic inflammation and ductular reaction. Native bile ducts appear to be missing (arrow). (B) The fibrous septa are chronically inflamed and show a prominent ductular reaction with mild periportal edema. Unpaired hepatic arterioles are seen (arrows).
FIGURE
R E A SON F OR R E F E R R AL
Exclude malignancy in the explant liver and establish a diagnosis of primary sclerosing cholangitis. PAT H OL OG I C F E AT U R E S
The explant liver was green, micronodular, and showed no evidence of tumor in the slices that were cut at 0.5 cm intervals. Histologic sections showed varying architecture in most sections, with regions of mild periportal fibrosis or portal-to-portal bridging fibrosis with developing parenchymal nodularity directly adjacent to areas of already developed cirrhotic nodules (Figure 6.5.1). Most portal tracts showed ductular reaction and chronic inflammation, but few native bile ducts could be identified (Figure 6.5.1B). Periportal hepatocytes were often markedly swollen and pale due to pseudoxanthomatous change and contained large Mallory-Denk bodies (Figure 6.5.2). Copper-binding protein in periportal hepatocytes was present on Victoria
F I G U R E 6 . 5 . 2 Periseptal pseudoxanthomatous change and MalloryDenk bodies. Two adjacent cirrhotic nodules are separated by a thick fibrous septum with chronic inflammation. Periportal hepatocytes are swollen and pale and contain aggregates of Mallory bodies. Inset: Pseudoxanthomatous change and intracellular Mallory-Denk bodies at higher magnification.
107
108
CHAPTER
6:
blue and diastase-resistant periodic acid Schiff (DPAS) stains. Numerous portal tracts showed fibro-obliterative scars replacing bile ducts (Figure 6.5.3). Neither bile duct dysplasia nor cholangiocarcinoma (CCA) was identified histologically in the multiple sections examined. Sections from the liver hilum showed dense periductal lymphoplasmacytic infiltrates and lymphoid structures, the latter including lymphoid aggregates and follicles with germinal centers (Figure 6.5.4). Immunoglobulin G4 (IgG4) immunostain was performed and showed no significant positivity.
FIGURE 6. 5. 3 Fibro-obliterative sclerosing cholangitis. Many portal
tracts in this explant liver showed round-to-ovoid fibro-obliterative scars (arrow). Inset: The native bile duct has been replaced by a discrete scar. The surrounding portal tract connective tissue shows irregular fibrosis, chronic inflammation, and a mild ductular reaction.
FIGURE 6. 5. 4 Primary sclerosing cholangitis involvement of hilar bile
ducts. Larger ducts of the hilum demonstrate an onion-skin pattern of periductal edema, fibrosis, and inflammation. There are dense lymphoplasmacytic infiltrates within the surrounding hilar connective tissue, and a periductal lymphoid follicle with germinal center has formed.
C H O L E S TA S I S
DIAGNO SIS
Fibro-obliterative primary sclerosing cholangitis with developing biliary cirrhosis.
DISCUSSIO N
This case raised several important diagnostic issues in PSC including the risk of development of CCA and histologic surveillance for precursor lesions (ie, dysplasia), histologic features suggesting primary involvement of small ducts (“small duct PSC”), and changes suggesting the possibility of IgG4-associated cholangitis (IAC). Since CCA was not identified, the patient’s weight loss was attributed to his underlying liver disease and liver failure. Lewis et al recently addressed the proposed hyperplasiadysplasia-carcinoma sequence in the context of PSC and CCA (1). Approximately 7% to 30% of PSC patients develop CCA (1–3). In the study by Lewis et al (1), submission of 10 additional tissue cassettes randomly sampled from hilar and large septal ducts in PSC explants, the authors found dysplasia in 83% of PSC explants with CCA and in 36% of PSC explants without CCA (1). Their study highlights the importance of adequate tissue sampling in the identification of bile duct dysplasia. In liver biopsy specimens from individuals with PSC and concomitant or subsequent CCA, Fleming et al found dysplasia in only 19% (4). In our case, cholangiographic evidence of only intrahepatic bile duct disease and the presence of generalized small bile duct loss and/or fibro-obliterative lesions suggest that the patient’s liver disease was primarily small duct PSC, in which there appears to be no risk of developing CCA until there is transition to involvement of large bile ducts (5). Björnsson et al found that 22.9% of their 83 small duct PSC patients progressed to large duct PSC in a median of 7.4 years (5). The inflammatory changes involving hilar ducts in our explant (Figure 6.5.4) suggest that a transition to large bile duct involvement had already occurred, the recent CT results notwithstanding. Among the epithelial changes which can be recognized with adequate sampling of large bile ducts in PSC are mucinous, pyloric, and intestinal metaplasia, and both low- and high-grade dysplasia in the form of flat and/or micropapillary lesions (1) (Figures 6.5.5 and 6.5.6). Intestinal metaplasia appears to be the most significant predictor of bile duct dysplasia in PSC (1). Histologic surveillance for dysplasia in liver biopsy and explant specimens should encompass the spectrum of bile duct epithelial changes described in the conditions “biliary intraepithelial neoplasia” (BilIN) (6) and intraductal papillary mucinous tumors of pancreas and bile ducts (7). The chronic periductal inflammation with lymphoid follicle formation also raised the diagnostic question of IAC (8–10). IgG4-positive plasma cells were found in nearly 25% of explants with PSC in a recent study (11). The PSC patients with tissue IgG4 positivity had a more clinically aggressive course leading to liver transplantation and greater risk of recurrence, compared with IgG4-negative PSC cases. However,
CASE
6.5:
PRIMARY
SCLEROSING
F I G U R E 6 . 5 . 5 Biliary intraepithelial neoplasia (BilIN) involving large
intrahepatic bile duct. A micropapillary lesion has replaced the normal simple cuboidal duct epithelium. This individual underwent partial hepatectomy and large bile duct resection because of previously diagnosed intraepithelial neoplasia. Similar changes constitute part of the spectrum of epithelial dysplastic changes that may be identified in large septal and hilar bile ducts in primary sclerosing cholangitis. The 3 bile ducts at the bottom and the duct at far right center show normal epithelium.
despite the presence of IgG4-positive plasma cells amid the lymphoplasmacytic infiltrates in their explants, the histologic features of IAC were absent. IAC is covered further in the following chapter.
References 1. Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol. 2010;34:27–34. 2. Tischendorf JJ, Hecker H, Krüger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol. 2007;102:107–114. 3. Maggs JRL, Chapman RW. An update on primary sclerosing cholangitis. Curr Op Gastroenterol. 2008;24:377–393. 4. Fleming KA, Boberg KM, Glaumann H, Bergquist A, Smith D, Clausen OP. Biliary dysplasia as a marker of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2001;34:360–365.
CHOLANGITIS
109
F I G U R E 6 . 5 . 6 Comparison of normal bile duct epithelium to intestinal metaplasia and dysplasia. (A) This large conducting bile duct shows normal low-cuboidal epithelium. (B) and (C) Micropapillary lesion showing intestinal metaplasia (many goblet cells are evident) and low-grade dysplasia (BilIN2) reflected in the mild nuclear dyspolarity and atypia.
5. Björnsson E, Olsson R, Bergquist A, et al. The natural history of smallduct primary sclerosing cholangitis. Gastroenterology. 2008;134:975–980. 6. Zen Y, Adsay NV, Bardadin K, et al. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol. 2007;20:701–709. 7. Zen Y, Fujii T, Itatsu K, et al. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology. 2006;44:1333–1343. 8. Björnsson E, Chari ST, Smyrk TC, Lindor K. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology. 2007;45:1547–1554. 9. Webster GJM, Pereira SP, Chapman RW. Autoimmune pancreatitis/ IgG4-associated cholangitis and primary sclerosing cholangitis— overlapping or separate diseases? J Hepatol. 2009;51:398–402. 10. Chung H, Watanabe T, Kudo M, et al. Identification and characterization of IgG4-associated autoimmune hepatitis. Liver Int. 2010;30:222–231. 11. Zhang L, Lewis JT, Abraham SC, et al. IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Am J Surg Pathol. 2010;34:88–94.
Case 6.6
Immunoglobin G4–Associated Cholangitis Versus Primary Sclerosing Cholangitis VIKRAM DESHPANDE
C L I N I C AL I N F OR M AT I ON
A 58-year-old male presented with obstructive jaundice and a 4-cm unresectable pancreatic tumor on CT scan. A palliative gastric/biliary bypass was planned. Intraoperatively, a firm liver was identified, and a wedge biopsy was performed. The alkaline phosphatase was 4 times normal. A subsequent ERCP showed multiple strictures in the intrahepatic bile ducts and pancreatic duct (Figure 6.6.1).
and 6.6.4). On immunohistochemistry 115 IgG4-positive plasma cells were identified per high power field (HPF) (Figure 6.6.5). The IgG4 to IgG ratio was 50% (Table 6.6.1).
DIAGNO SIS
IgG4-associated cholangitis in the setting of autoimmune pancreatitis.
PAT H OL OG I C F E AT U R E S
The liver biopsy shows a dense but patchy portal-based lymphoplasmacytic infiltrate. An acellular zone was noted around the bile ducts (Figure 6.6.2). Occasional bile ducts showed periductal onion-skin–type fibrosis. There was no evidence of bile duct loss. The inflammation was accentuated around the portal venules. Mild lobular inflammation composed of scattered lymphocytes and plasma cells was present as well. In addition, a large portal tract showed an expansive nodule composed of lymphocytes, plasma cells, and eosinophils (Figures 6.6.3
F I G U R E 6 . 6 . 2 Smaller portal tracts may show sparse inflammation.
Note the inflammation is centered around the portal venule.
FIGURE 6. 6. 1 IgG4-associated cholangitis. There is narrowing and irregularity of the distal left and right main hepatic ducts at the confluence with the common hepatic duct. In addition, there is irregularity of the intrahepatic bile ducts.
F I G U R E 6 . 6 . 3 High power view of the inflammatory nodule with
lymphocytes, plasma cells, and numerous eosinophils. Fibroblasts are present in the background.
110
CASE
6.6:
IMMUNOGLOBIN
G 4 – A S S O C I AT E D
CHOLANGITIS
111
TA BL E 6 . 6 . 1 Clinical, imaging, and pathologic features of primary
sclerosing cholangitis and IgG4-associated cholangitis IgG4-Associated Cholangitis
Primary Sclerosing Cholangitis
Age
Older (mean age, 63)
Young (mean age, 39)
Sex
Male predominance
Male predominance
ERCP
Intrahepatic and extrahepatic biliary strictures; irregularly narrow pancreatic duct with strictures
Intrahepatic and extrahepatic biliary strictures
Histology and immunohistochemistry
Inflammatory portalbased nodules and IgG4+ plasma cells
Variable portal-based inflammation, periductal fibrosis. IgG4+ plasma cells typically rare to absent in biopsy
Therapy
Steroids, rituximab
Ursodeoxycholic acid
FIGURE 6. 6. 4 Portal-based inflammatory nodule with inflammatory cells embedded in a myxoid stroma.
Abbreviation: ERCP, endoscopic retrograde cholangiopancreatography.
FIGURE 6. 6. 5 Immunohistochemistry for immunoglobin G4 show-
ing numerous IgG4-positive plasma cells. D I S C U S S I ON
The clinical and radiologic appearance suggests a diagnosis of pancreatic cancer. However, this tumorous pancreatic mass responded to steroids. Steroid response, in conjunction with strictures of the pancreatic duct is characteristic of autoimmune pancreatitis (AIP) (1). Autoimmune pancreatitis is associated with an elevated number of IgG4-positive plasma cells in tissue as well as elevated levels of serum IgG4 (2,3). It is a systemic disease that can involve virtually every organ including the hepatobiliary system (4–7); this disease is now categorized as IgG4-associated systemic disease and hepatic involvement is 1 facet of this systemic disease. Two patterns of hepatic involvement are seen in Ig4-associated systemic disease. The first is a mass-forming lesion involving the hilar region of the liver, mimicking cholangiocarcinoma (5–7). The second form of this disease,
termed IgG4-associated cholangitis (IAC), mimics primary sclerosing cholangitis (PSC). In most instances the disease is identified following a diagnosis of AIP and rarely may precede clinically inapparent pancreatic involvement. Hepatic disease without pancreatic involvement has been reported, albeit rarely (6). Most patients present with obstructive jaundice. On cholangiogram both intra- and extrahepatic strictures are present. This appearance mimics PSC. It is important, therefore, to distinguish this disease from PSC. Unlike PSC, IAC is a steroid responsive disease (6). Furthermore, though PSC is associated with an increased risk of malignancy, there have been no documented cases of IAC-associated malignancy. The presence of pancreatic disease that is compatible with AIP strongly supports IAC. A liver biopsy may assist in making this distinction, although the characteristic features may not always be apparent on a biopsy. The presence of portal-based inflammatory nodules is highly characteristic of IAC (5). The inflammatory nodules are composed of lymphocytes, plasma cells, eosinophils, and are admixed with fibroblasts. Although obliterative phlebitis, an obligate feature of AIP, is not seen in peripheral liver biopsies, a perivascular accentuation in portal tracts is present. The bile ducts may show histological evidence of injury, but accentuation of the inflammation around the duct is rarely seen. However, sections from the hilar region of the liver show both obliterative phlebitis and inflammatory destruction of large-caliber bile ducts (Figure 6.6.6). The key to arriving at a correct diagnosis is a tissue stain for IgG4 (5). Liver biopsy in IAC shows elevated numbers of IgG4-positive plasma cells. In 1 series, 70% of biopsies from IAC cases showed less than 5 IgG4-positive plasma cells per HPF, whereas IgG4-positive plasma cells were either
112
CHAPTER
6:
C H O L E S TA S I S
patients cannot be weaned off steroids. More recently, excellent response to Rituximab has been documented (11,12). In contrast, the vast majority of cases of PSC do not respond to steroids.
References
FIGURE 6. 6. 6 Large-caliber portal vein with lymphoplasmacytic
phlebitis.
absent or fewer than 5 per HPF in PSC. However, in another series, 23% of explants from individuals with PSC showed IgG4-positive plasma cells (8). Compared with cases without IgG4-positive plasma cells, these cases had a more aggressive clinical course and a higher likelihood of recurrence (8). Thus, without the appropriate morphological features (ie, inflammatory nodules), the significance of occasional IgG4positive cells remains uncertain. IgG4 to IgG ratio may help improve the specificity of these markers; however, a cut-off for this variable has not been established. IgG4-positive plasma cells have also been identified in a subset of cases of AIH (9). Although only a relatively small number of cases have been evaluated, IgG4-positive plasma cells have not been observed in liver biopsies from patients with chronic viral hepatitis and primary biliary cirrhosis (10). The mainstay of treatment remains steroids (6). A dramatic normalization of the cholangiogram is typically seen within weeks of starting steroid therapy. However, many
1. Finkelberg DL, Sahani D, Deshpande V, Brugge WR. Autoimmune pancreatitis. N Engl J Med. 2006;355:2670–2676. 2. Deshpande V, Chicano S, Finkelberg D, et al. Autoimmune pancreatitis: a systemic immune complex mediated disease. Am J Surg Pathol. 2006;30:1537–1545. 3. Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344: 732–738. 4. Bjornsson E, Chari ST, Smyrk TC, Lindor K. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology. 2007;45:1547–1554. 5. Deshpande V, Sainani NI, Chung RT, et al. IgG4-associated cholangitis: a comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material. Mod Pathol. 2009; 22:1287–1295. 6. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134:706–715. 7. Zen Y, Harada K, Sasaki M, et al. IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis: do they belong to a spectrum of sclerosing pancreatitis? Am J Surg Pathol. 2004;28:1193–1203. 8. Zhang L, Lewis JT, Abraham SC, et al. IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Am J Surg Pathol. 2010;34:88–94. 9. Chung H, Watanabe T, Kudo M, Maenishi O, Wakatsuki Y, Chiba T. Identification and characterization of IgG4-associated autoimmune hepatitis. Liver Int. 2009;30:221–231. 10. Umemura T, Zen Y, Hamano H, et al. Immunoglobin G4-hepatopathy: association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis. Hepatology. 2007;46:463–471. 11. Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum. 2010;62:1755–1762. 12. Khosroshahi A, Stone JR, Pratt DS, Deshpande V, Stone JH. Painless jaundice with serial multi-organ dysfunction. Lancet. 2009;373:1494.
Case 6.7
Hepatolithiasis POLLY W. Y. LAM AND WILSON M. S. TSUI
C L I N IC AL I N F OR M AT I ON
A 52-year-old Chinese female, who claimed previous good health, presented with epigastric pain, tea-colored urine, and vomiting. She had clinical jaundice. Laboratory tests revealed raised white cell count. Serum bilirubin was 3 times normal, ALP level 4 times normal, and ALT 14 times normal. Her condition improved soon after biliary stent insertion through ERCP, with normalization of serum bilirubin level and white cell count. Her ALT level also gradually returned to normal, whereas the ALP level remained slightly raised. The endoscopic cholangiogram revealed a hilar stricture. CT of the abdomen revealed markedly dilated left intrahepatic duct with multiple intraductal stones. The left lobe of the liver was atrophic, whereas the right lobe appeared normal. There was no mass lesion. Microscopic examination of her bile revealed clonorchis ova. Bile culture also yielded Klebsiella species and Escherichia coli. In view of the presence of left lobar atrophy, left hepatectomy was performed.
are filled with yellowish brown to black stones ranging from 0.5 to 1 cm in size. There is no annular stricture or web. The background liver tissue is atrophic, with more pronounced atrophy of the lateral segment than the quadrate lobe. Microscopic examination revealed bilirubinate stones in the ectatic bile ducts, lymphoplasmacytic infiltration of the duct mucosa, mural fibrosis, and hyperplasia of the peribiliary glands (Figures 6.7.2 and 6.7.3). Occasional portal veins show fibrous obliteration. Occasional ducts show suppurative
R E A SON F OR R E F E R R AL
The case was referred in order to establish the etiology of cholestasis in this patient. PAT H OL OG I C F E AT U R E S
The specimen consists of the left lobe of the liver, measuring 11 6 4 cm (Figure 6.7.1). The left hepatic duct and major branches are markedly dilated and have thickened walls. They
FIGURE 6. 7. 1 Gross specimen showing dilated bile ducts with pig-
mented stones. Noted atrophic fibrotic background liver parenchyma and less severe atrophy in the adjacent segment.
F I G U R E 6 . 7 . 2 Stone-bearing large duct with hyperplasia of peribil-
iary glands.
F I G U R E 6 . 7 . 3 Large bile duct showing lymphoplasmacytic infiltration and fibrosis of wall. Note the superficial location of the inflammatory infiltrate.
113
114
CHAPTER
6:
C H O L E S TA S I S
FIGURE 6. 7. 4 Medium-sized bile duct showing concentric fibrous
F I G U R E 6 . 7 . 6 Orcein stain of a small portal area showing accumu-
thickening.
lation of copper-associated protein in periportal hepatocytes. DISCUSSIO N
FIGURE 6. 7. 5 A portal area with fibrous replacement of interlobular
bile ducts.
inflammation. Some of the medium-sized and small portal areas show marked concentric fibrous thickening of the interlobular bile ducts, with narrowed lumens (Figure 6.7.4). Some portal areas show replacement of the interlobular bile ducts by a dense fibrous scar (Figure 6.7.5). Orcein stain reveals copper-associated protein, indicating chronic cholestasis (Figure 6.7.6). The associated liver parenchyma shows nodularity and fibrosis.
The epigastric pain, clinical jaundice, and laboratory findings indicate an attack of cholangitis. The positive bile culture is in keeping with such a diagnosis (1–16). The most obvious causative factor in this case is the presence of multiplepigmented calcium bilirubinate stones in her intrahepatic bile ducts, but biliary calculi can also arise in bile stasis, so conditions associated with secondary HL should therefore be considered as well (Table 6.7.1). In this case, the previous good health and lack of other diagnostic radiologic abnormality rule out underlying developmental or iatrogenic bile duct abnormalities. Among the various conditions in Table 6.7.1, PSC is a major differential in this case, especially as cholangiectasis and secondary stone formation have been observed in PSC. Although PSC typically has a more insidious onset, cholangitis can be a presenting sign. Many of the microscopic features found in PSC are also found in our case. In fact, changes of sclerosing cholangitis affect the interlobular bile ducts in all cases of primary HL; this is particularly prominent in the chronic and advanced stages. As many as 85% of the medium-sized septal TA BL E 6 . 7 . 1 Conditions resulting in the formation of stones
in intrahepatic bile ducts (secondary HL) Congenital bile duct malformation such as extrahepatic biliary atresia, Caroli disease Bile duct ischemia Previous bile duct surgery
D I AG N OS I S
Primary hepatolithiasis (HL).
Inflammatory condition such as primary sclerosing cholangitis Biliary abscess From Refs. 7.11.
CASE
6.7:
H E PAT O L I T H I A S I S
bile ducts exhibit periductal fibrosis, whereas duct loss (20%), ductal atrophy (10%), and fibro-obliterative scars (7%) are observed in the small interlobular bile ducts (1). The degree of ductopenia is never as significant as PSC and ductular proliferation is only rarely observed. The portal tracts show variable fibrous expansion and only patchy chronic inflammatory infiltrate. The inflammation is not as diffuse and chronic hepatitis-like with interface hepatitis as in PSC. There is no chronic cholestasis nor progression to biliary cirrhosis as long as biliary obstruction can be relieved. There are other aspects in our case which favor primary HL over PSC (Table 6.7.2), including the ethnic group, selective left lobar atrophy, presence of clonorchis in bile, lack of inflammatory bowel disease, and presence of peribiliary gland hyperplasia. The radiologic finding of disproportionate dilatation of an intrahepatic duct, instead of a beaded appearance, also speaks for HL over PSC. Caroli disease should be distinguished because of presence of cholangiectasis and similar clinical presentation in both diseases. In HL, there is predominant involvement of the left lobe and no evidence of ductal plate malformation.
115
Bilirubinate stones and chronic proliferative cholangitis are not observed in uncomplicated Caroli disease. The histologic picture of lymphoplasmacytic infiltration in thickened bile duct walls may raise some suspicion for IAC. Distinction from this condition is important since it is steroid responsive. IAC frequently involves the extrahepatic ducts and presents in the middle to elderly age group with obstructive jaundice. Histologic features include lymphoplasmacytic infiltration, fibrosis (often with a storiform arrangement), and obliterative phlebitis. The inflammatory process is often more dense at the periphery of the duct and extends into periductal soft tissue. The inflammatory cell infiltrate in this case is superficial and the fibrosis does not show a storiform pattern. Even though venous thrombosis is present in this case, the characteristic obliterative phlebitis found in IAC is not seen. Immunohistochemical staining also helps in diagnosis, since IAC is characterized by the presence of large numbers of IgG4-positive plasma cells in the inflammatory cell infiltrate. Another condition to consider is cholangiocarcinoma, since the initial ERCP revealed hilar stricture. Indeed,
TA B LE 6. 7. 2 Comparison between primary sclerosing cholangitis and hepatolithiasis
Primary Sclerosing Cholangitis
Hepatolithiasis
Ethnic group
Much more common in Europe and the United States
Common in East Asia, rare in Western countries except among immigrants of East Asian origin (9)
Age
Wide range but most present between 25 and 40 years (12)
Peaks between 50 and 60 years, range from 20 to beyond 80 years (7)
Gender
Male preponderance of 2–3 to 1
Slight male predominance
Presenting symptoms and signs
Fatigue, vague upper abdominal pain, intermittent jaundice. Cholangitis is less common
Epigastric pain, backache, fever, jaundice. A significant proportion is asymptomatic (4,7)
Laboratory investigations
Raised serum ALP, GGT levels. Bilirubin is raised as disease progresses
During attacks, raised ALP, bilirubin, and ALT levels. WBCs may also be raised
Radiologic findings
Typically “beaded” appearance involving both intra- and extrahepatic bile ducts, strictures, diverticula (13)
Dilatation of first and second divisions of intrahepatic ducts, abrupt nonvisualization of peripheral divisions, calculi, pneumobilia (8,14) Lobar atrophy
Associated disease
Idiopathic inflammatory bowel disease, including ulcerative colitis and Crohn disease
Parasitic infestation, including clonorchiasis and ascariasis
Typical clinical course
Progressive, overall 12–18 years from diagnosis to death or transplantation May be complicated by cholangiocarcinoma
Recurrent attacks of cholangitis may cause death due to sepsis (5) May be complicated by cholangiocarcinoma.
Microscopic findings
Lymphoplasmacytic infiltrates around large intrahepatic ducts, ± acute inflammatory infiltrates Onion-skin type of periductal fibrosis around medium-sized large bile ducts Obliteration of bile ducts which are replaced by fibrous whorls; extensive duct loss May have portal tract inflammation and ductular reaction (11,12)
Bilirubinate stones, fibrous thickening of large ducts, with lymphoplasmacytic infiltration, 6 suppurative cholangitis Periductal lamellar fibrosis of septal and small interlobular ducts Small bile ducts may show duct atrophy, fibrous obliteration, and duct loss Hyperplasia of peribiliary glands (7)
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; GGT, gamma glutamyl transpeptidase; WBC, white blood cell.
116
CHAPTER
6:
cholangitis can be the presenting symptoms in cholangiocarcinoma. Even if we have a firm diagnosis of HL, cholangiocarcinoma should still be excluded, since it is also a known complication of HL (2–4). The hyperplastic peribiliary glands may look alarming to those less familiar with the full spectrum of pathologic changes of HL. Features indicating a benign nature include a lobular arrangement, lack of infiltrating cords, and lack of nuclear pleomorphism. Western pathologists often have the misconception that HL results from parasitic infestation and consider peribiliary glandular proliferation as a feature indicating clonorchiasis, another oriental liver disease. Intrahepatic stones are not regular features in pure clonorchis infestation. The intrahepatic bile ducts are slightly enlarged with thickened wall and do not show marked dilatations and stenoses. The wall thickening is due to florid intramural mucinous glandular hyperplasia (so-called adenomatous hyperplasia) and tissue eosinophilia, quite different from the chronic proliferative cholangitis in HL. Indeed in the olden days, evidence of Clonorchis sinensis infestation could be detected in 30% to 40% of the HL livers (5). Nowadays, the clonorchis worms are seldom found in HL cases. Nonetheless the present case has concomitant clonorchiasis, which may be responsible for the severe recurrent bouts of cholangitis. The term recurrent pyogenic cholangitis (RPC), which is frequently used by Chinese clinicians, also describes a condition characterized by intrahepatic, pigmented stones, although the name emphasizes the clinical presentation of recurrent bouts of cholangitis rather than the stones. This condition, also known as oriental cholangiohepatitis and intrahepatic, pigmented stone disease, shares many clinical and pathologic features with primary pigmented HL (5–9). The 2 terms just describe different aspects of the same disease with HL emphasizing the pathological changes and RPC emphasizing the clinical presentation of the disease (10,15,16). Other than the much more commonly encountered calcium bilirubinate stones, pure cholesterol stones are also recognized in primary HL.
C H O L E S TA S I S
References 1. Tsui WMS, Lam PWY, Mak CK, Ng CS, Tse CCH. Features of sclerosing cholangitis in recurrent pyogenic cholangitis [Abstract]. Int J Surg Pathol. 1995;2S:323. 2. Al-sukhni W, Gallinger S, Pratzer A, et al. Recurrent pyogenic cholangitis with hepatolithiasis—the role of surgical therapy in North America. J Gastrointest Surg. 2008;12:496–503. 3. Zhou YM, Yin ZF, Yang JM, et al. Risk factor for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol. 2008;28:632–635. 4. Kusano T, Isa T, Ohtsubo M, Yasaka T, Furukawa M. Natural progression of untreated hepatolithiasis that shows no clinical signs at its initial presentation. J Clin Gastroenterol. 2001;33:114–117. 5. Chou ST, Chan CW. Recurrent pyogenic cholangitis: a necropsy study. Pathology. 1980;12;415–428. 6. Carmona RH, Crass RA, Lim RC Jr, Trunkey DD. Oriental cholangitis. Am J Surg. 1984;148:117–124. 7. Nakanuma Y, Yamaguchi K, Ohta G, Terada T. Pathologic features of hepatolithiasis in Japan. Hum Pathol. 1988;19:1181–1186. 8. Lim JH. Oriental cholangiohepatitis: pathologic, clinical, and radiologic features. AJR Am J Roentgenol. 1991;157:1–8. 9. Harris HW, Kumwenda ZL, Sheen-Chen SM, Shah A, Schecter WP. Recurrent pyogenic cholangitis. Am J Surg. 1998;176:34–37. 10. Chan FL, Chan JK, Leong LL. Modern imaging in the evaluation of hepatolithiasis. Hepatogastroenterology. 1997;44:358–369. 11. Portmann BC, Nakanuma. Y. Disease of the Bile Ducts in Macsween’s Pathology of the Liver. 5th ed. Chapter 11, Churchill Livingstone Elsevier; 2007. 12. Chapman RW, Arborgh BA, Rhodes JM, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut. 1980;21:870–877. 13. MacCarty RL, LaRusso NF, Wiener RH, Ludwig J. Primary sclerosing cholangitis: findings on cholangiography & pancreatography. Radiology. 1983;149:39–44. 14. Chan FL, Man SW, Leong LLY, Fan ST. Evaluation of recurrent pyogenic cholangitis with CT: analysis of 50 patients. Radiology. 1989;170: 165–169. 15. Tsui WM, Chan YK, Wong CT, Lo YF, Yeung YW. Hepatolithiasis and the syndrome of recurrent pyogenic cholangitis-clinical, radiologic and pathologic features. Semin Liver Dis. 2011 (in press). 16. Tsui WM, Lam PW, Lee WK, Chan YK. Primary hepatolithiasis, recurrent pyogenic cholangitis, and oriental cholangiohepatitis—a tale of three countries. Adv Anat Pathol. 2011 (in press).
7 Bile Duct Damage and Ductopenia KAY WASHINGTON
I N T ROD U C T I ON Bile Duct Damage and Ductopenia
Injury to and loss of interlobular bile ducts occur in a number of inflammatory disorders in adults (Table 7.1); in children, congenital disorders, such as Alagille syndrome, must also be considered. Infiltration of bile duct epithelium by mononuclear inflammatory cells is common in conditions in which there is a dense portal inflammatory infiltrate, such as hepatitis B, hepatitis C (1), and autoimmune hepatitis, but the bile duct is not the primary target of the immune response and biliary injury. In such conditions, bile duct involvement is usually modest and infrequently results in bile duct loss. In other immune-mediated diseases, such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), graft-versushost disease, hepatic allograft rejection, and some cholestatic drug reactions, the bile duct is a primary target of the immune attack and may be destroyed consequently. Duct loss is generally patchy at first, but if progressive, changes of chronic cholestasis ensue when a critical number of ducts have been destroyed. The portal tracts should be systematically evaluated in liver biopsies from adults to assess for bile duct loss to avoid underdiagnosis of liver diseases leading to ductopenia, most commonly PBC and PSC. The threshold for ductopenia has been set at absence of bile ducts in 50% of portal tracts in an adequate sample and was largely based on work on Alagille syndrome (2) and primary biliary cirrhosis (3). Early work recommended evaluation of up to 20 portal tracts for an accurate assessment of ductopenia (4). More lenient recommendations include at least 10 portal tracts (5,6) or at least 5 complete portal tracts (7). As needle biopsies have become smaller in recent years, the difficulties in assessing ductopenia have become more problematic, because many of
TA B LE 7. 1 Differential diagnosis of ductopenia in adults Primary biliary cirrhosis Primary sclerosing cholangitis Chronic hepatic allograft rejection
the portal tracts represented in the biopsy are incomplete or tangentially sectioned. To overcome these limitations, it has been proposed that ductopenia be defined based on the percentage or number of portal tracts containing hepatic arteries without paired bile ducts (8). This method, in which ductopenia is defined as unpaired hepatic artery branches in 10% of portal tracts, or in at least 2 portal tracts regardless of the number of portal tracts present, appears to be more sensitive than bile duct loss in 50% of portal tracts, but further validation studies are needed. P R IMA RY BILIA RY CIR R H O SIS Definition of Primary Biliary Cirrhosis
Primary biliary cirrhosis is a chronic cholestatic liver disease of unknown etiology in which the intrahepatic bile ducts are progressively destroyed by a nonsuppurative inflammatory process. Large intra- and extrahepatic bile ducts are not affected. The serologic hallmark of the disease is the presence of antimitochondrial antibodies (AMA), which are highly specific for the disorder. PBC affects primarily middle aged women and is probably autoimmune in etiology, judging by its association with other autoimmune disorders such as Sjögren syndrome and keratoconjuctivitis sicca, and may in some patients represent a generalized disorder of lacrimal, salivary, and pancreaticobiliary small duct epithelia. Diagnostic criteria for primary biliary cirrhosis
Diagnosis of PBC rests upon a combination of clinical, serologic, and histologic features, including cholestatic serum enzyme pattern, serum AMA, and compatible histology. A probable diagnosis of PBC requires 2 of the following 3 criteria, and a definite diagnosis requires 3: • 1AMA • elevated liver enzymes, usually alkaline phosphatase, for over 6 months • Compatible liver biopsy A more detailed scoring system similar to that used for AIH has been proposed, but not well validated (9); a number of weighted parameters are assessed, including: 1. Cholestatic serum enzyme pattern, as evidenced by alkaline phosphatase/alanine aminotransferase (ALT) ratio 2. Elevated serum IgM 3. AMA titer greater than 1:40, detected by immunofluorescence or PBC-specific AMA-M2 detected by ELISA or immunoblot 4. Florid bile duct lesion
Hepatic graft-versus-host disease Drug reaction Ischemic cholangiopathy Sarcoidosis Idiopathic adulthood ductopenia
117
118
CHAPTER
7:
BILE
DUCT
DAMAGE
AND
DUCTOPENIA
Histologic features
The characteristic lesion of primary biliary cirrhosis is the so-called florid duct lesion, sometimes also called chronic nonsuppurative destructive cholangitis (10). Interlobular bile ducts 40 to 80 microns in diameter are typically involved (Figure 7.1). In early-stage PBC, the diagnostic lesions may be focal and may not be sampled on needle biopsy. The 3 components of the florid duct lesion are inflammation, injury to bile duct epithelial cells, and disruption of the bile duct basement membrane. The inflammatory infiltrate is composed of lymphocytes, scattered eosinophils, macrophages, and a variable number of plasma cells, and is intimately associated with the bile duct. The macrophages may be dispersed throughout the portal inflammatory infiltrate or may be aggregated into loose clusters or occasionally into well-formed granulomas. Granulomas and Kupffer cell aggregates may be present in the lobule. In early stages, the inflammatory infiltrate is largely confined to the portal tract. The biliary epithelial cells of injured bile ducts are swollen, focally stratified, and may be vacuolated. Lymphocytes commonly infiltrate bile duct epithelium. The basement membrane becomes disrupted and fragmented, best visualized on PAS stain. In small portal tracts, bile ducts are often absent and seem to have vanished without a trace (Figure 7.2), although aggregates of lymphocytes or PAS-positive basement membrane material may mark their former location. Canalicular cholestasis is not a feature of early-stage PBC.
F I G U R E 7 . 1 Florid duct lesion in primary biliary cirrhosis, with
granulomatous injury to small interlobular bile duct.
Treatment and Natural History of Primary Biliary Cirrhosis
Most patients with PBC are asymptomatic at diagnosis (11) and identified after screening tests show elevation of serum alkaline phosphatase. Overt symptoms develop in most within 2 to 4 years, although some are asymptomatic for years. The most common presenting symptoms are fatigue (21%) and pruritis (19%), the latter due to the accumulation of bile salts. The mainstay of treatment of early PBC is ursodeoxycholic acid (UDCA), which appears to alter the natural history of the disease by delaying clinical and histologic progression. At least 25% of patients with early PBC (stage I or II) treated with UDCA will have no histologic progression over 4 years, and 25% to 30% will have a complete response (12) characterized by normalization of liver enzyme tests and improvement or stabilization of liver biopsy. With treatment, the survival rate for patients with stage 1 or 2 disease appears to be similar to a healthy control population (13). Without treatment, the mean time to progression from stage 1 or 2 disease to cirrhosis is 4 to 6 years. In contrast to autoimmune hepatitis, corticosteroids are not effective in PBC. Survival is variable in untreated or advanced stage patients, but is generally from 6 to 12 years after presentation for symptomatic patients who do not undergo liver transplantation. Factors decreasing survival are jaundice, loss of bile ducts, cirrhosis, and the presence of other autoimmune disorders. Liver transplantation is the only effective therapy
F I G U R E 7 . 2 Portal tract without bile duct; inflammation and
ductular reaction are minimal, PBC.
for late-stage disease; although histologic disease recurrence is reported in up to 30% of patients, clinically significant and progressive recurrent disease is uncommon (14).
References 1. Souza P, Prihoda TJ, Hoyumpa AM, Sharkey FE. Morphologic features resembling transplant rejection in core biopsies of native livers from patients with hepatitis C. Hum Pathol. 2009;40(1):92–97. 2. Alagille D, Odievre M, Gautier M, Dommergues JP. Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental, and sexual development, and cardiac murmur. J Pediatr. 1975;86(1):63–71. 3. Nakanuma Y, Ohta G. Histometric and serial section observations of the intrahepatic bile ducts in primary biliary cirrhosis. Gastroenterology. 1979;76(6):1326–1332. 4. Witzleben CL. Bile duct paucity (“intrahepatic atresia”). Perspect Pediatr Pathol. 1982;7:185–201.
CHAPTER
7:
BILE
DUCT
DAMAGE
5. Ludwig J, Wiesner RH, LaRusso NF. Idiopathic adulthood ductopenia: a cause of chronic cholestatic liver disease and biliary cirrhosis. J Hepatol. 1988;7(2):193–199. 6. Nakanuma Y, Tsuneyama K, Harada K. Pathology and pathogenesis of intrahepatic bile duct loss. J Hepatobiliary Pancreat Surg. 2003;8(4): 303–315. 7. Sinha J, Magid MS, VanHuse C, Thung SN, Suchy F, Kerkar N. Bile duct paucity in infancy. Semin Liver Dis. 2007;27(3):319–323. 8. Moreira RK, Chopp W, Washington MK. The concept of hepatic artery-bile duct parallelism in the diagnosis of ductopenia in liver biopsy samples. Modern Pathol. 2010;23S1:366A. 9. Yamamoto K, Terada R, Okamoto R, et al. A scoring system for primary biliary cirrhosis and its application for variant forms of autoimmune liver disease. J Gastroenterol. 2003;38(1):52–59. 10. Weisner RH, LaRusso NF, Ludwig J, Dickson ER. Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis. Gastroenterology. 1985;88:108–114.
AND
DUCTOPENIA
119
11. Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology. 2002;123:1044–1051. 12. Leuschner M, Dietrich CF, You T, et al. Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. Gut. 2000;46(1):121–126. 13. Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon R-E, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology. 2005;128:297–303. 14. Khettry U, Anand N, Faul PN, et al. Liver transplantation for primary biliary cirrhosis: a long-term pathologic study. Liver Transpl. 2003;9(1):87–96.
Case 7.1
Primary Biliary Cirrhosis With Nonspecific Changes and Positive Antimitochondrial Antibody KAY WASHINGTON
C L I N I C A L I N F OR M AT I ON
A 52-year-old asymptomatic woman was discovered to have elevated serum alkaline phosphatase (3 times normal), with normal serum total bilirubin and normal transaminase levels. There was no history of drug or alcohol use. Serologic testing was positive for antimitochondrial antibodies (1:640) and negative for antinuclear antibodies and anti–smooth muscle antibodies. Serum IgM was slightly elevated (1.5 times normal).
R E A S ON F OR R E F E R R A L
The liver biopsy shows minimal bile duct injury; are the findings indicative of primary biliary cirrhosis? FIGURE 7.1.2 Portal tract with mild nonspecific chronic inflammatory
infiltrate, minimal interface inflammation, and intact bile duct.
PAT H OL OG I C F E AT U R E S
The overall hepatic architecture is preserved. Most portal tracts are normal (Figure 7.1.1) or contain only a modest lymphocytic infiltrate, with minimal interface inflammation (Figure 7.1.2). A few interlobular bile ducts show mild reactive change and focal infiltration by lymphocytes, and 1 bile duct is surrounded by a cuff of plasma cells (Figure 7.1.3). No granulomas are seen. There is no steatosis.
F I G U R E 7 . 1 . 3 Bile duct surrounded by plasma cells and showing
focal epithelial disruption and infiltration by lymphocytes.
DIAGNO SIS
FIGURE 7. 1. 1 Portal tract with minimal inflammation, normal bile
duct, and no ductular reaction.
120
Nonspecific portal chronic inflammation with minimal bile duct injury and no fibrosis, compatible with primary biliary cirrhosis (PBC), stage 1, in the setting of AMA positivity.
CASE
7.1:
PRIMARY
BILIARY
CIRRHOSIS
D I S C U S S I ON
WITH
Histopathology of Early-Stage PBC
Although interlobular bile duct injury and destruction are the central histologic features of PBC, changes may be patchy and not evident on needle biopsy early in the course of disease. Bile duct destruction is segmental in distribution and may sometimes be revealed through deeper sectioning of the biopsy block. In some cases, the only histologic evidence of the disease is a mononuclear inflammatory infiltrate in portal tracts, with or without interface inflammation, and the differential diagnosis is very broad. Such cases with a nonspecific inflammation warrant careful assessment of the portal tracts for bile duct damage or loss. Bile ducts may show infiltration by lymphocytes and degenerative changes such as vacuolization of epithelial cells, but such changes may also be seen in autoimmune hepatitis (4) and chronic viral hepatitis (Table 7.1.1). If other causes of a mild hepatitis pattern of injury are excluded, a diagnosis of probable PBC may be rendered in the setting of AMA seropositivity. Other nonspecific histologic features seen in some cases of early-stage PBC include small nonnecrotizing granulomas in portal tracts and lobules and aggregates of Kupffer cells in hepatic sinusoids. Hepatocyte injury and apoptosis are usually
CHANGES
121
TA BL E 7 . 1 . 1 Comparison of histologic features of PBC, AIH,
and chronic viral hepatitis
Clinical and Immunologic Features
PBC has a distinctive clinical profile, occurring primarily in women (90% of patients), mostly in the fifth to eighth decades. The disease almost never occurs in children. Other coexisting autoimmune disorders are common and include hypothyroidism, Sjögren syndrome, scleroderma, interstitial lung disease, celiac disease, hemolytic anemia, and autoimmune thrombocytopenia. Most patients are asymptomatic at diagnosis. Portal hypertension, osteopenia, hyperlipidemia, and other complications related to chronic cholestasis, such as malabsorption, deficiencies of fat-soluble vitamins, and steatorrhea, may be seen in advanced disease. The risk of hepatocellular carcinoma, although lower than that in many causes of cirrhosis, is increased in cirrhotic patients with PBC (1). The most specific feature of PBC is the presence of antimitochondrial antibodies in the serum of 90% of patients affected. These antibodies directed to the PDC-E2 antigen, a component of the pyruvate dehydrogenase enzyme complex present on the inner mitochondrial membrane, are highly specific (96%) for PBC. The presence of serum AMA indicates a specific B-cell response to this mitochondrial antigen, but specific T cell responses are seen as well (2). Other circulating autoantibodies such as anti–smooth muscle and antinuclear antibodies and rheumatoid factor are often present, and hypergammaglobulinemia with a selective elevation of IgM is common. Other disease-specific antibodies that may be detected in PBC include the nuclear core protein gp210, which appears to be highly specific (99%) for PBC and may portend a more severe course. This autoantibody is found in 10% to 40% of AMA-positive patients and up to 50% of AMA-negative patients (3).
NONSPECIFIC
Chronic Viral Hepatitis
Feature
PBC
AIH
Chronic cholestasis
Prominent, late
Mild, late stages only
Trace, late stages only
Copper storage
Variable
Minimal
Minimal
Duct loss
Extensive
Rare
Rare
Granulomas
Variable
Absent
Rare
Interface hepatitis
Variable
Key feature; variable
Key feature
Lobular hepatitis
Mild
Variable
Variable
Perivenular necroinflammatory activity
Not seen
Variable, often in early disease
Minimal
Abbreviations: AIH, autoimmune hepatitis; PBC, primary biliary cirrhosis.
TA BL E 7 . 1 . 2 Useful stains in evaluation of bile duct lesions Stain
Shows
Disease
PAS with diastase
Basement membrane
Bile duct injury; PBC
Trichrome
Type I collagen
Useful for identification of bile ducts
Shikata stain (orcein, aldehyde fuchsin)
Increased copper-binding protein in chronic cholestasis
PBC, PSC
Rubeanic acid or rhodanine
Copper deposition in periportal hepatocytes in chronic cholestasis
PBC, PSC
Cytokeratin (AE1/ AE3, CK7, CK19)
Biliary epithelium (bile ducts express CK 7, 8, 18, 19)
Ductopenia
EMA
Biliary epithelium
Ductopenia
Abbreviations: EMA, epithelial membrane antigen PAS, periodic acid–Schiff; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis.
minimal, and active cholestasis and bile plugs are only seen in advanced stage disease. Accumulation of copper within periportal hepatocytes is a feature of chronic cholestasis that may be helpful in diagnosis of PBC. This copper storage can be demonstrated with rhodanine or rubeanic acid stains. Orcein or aldehyde fuchsin stains will highlight increased copper-binding protein (Table 7.1.2). Positive staining for copper or copper-binding protein is seen as granular deposition in periportal hepatocytes. This copper accumulation is not specific, but when found in a precirrhotic liver biopsy is highly suggestive of chronic cholestasis, if rare entities
122
CHAPTER
7:
BILE
DUCT
DAMAGE
such as Wilson disease have been excluded. Mallory’s hyaline may also be found in periportal hepatocytes in chronic cholestasis in advanced disease but is not seen in early-stage PBC.
References 1. Cavazza A, Caballeria L, Floreani A, et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology. 2009;50(4):1162–1168.
AND
DUCTOPENIA
2. Kita H, Naidenko OV, Kronenberg M, et al. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology. 2002;123(4):1031–1043. 3. Itoh S, Ichida T, Yoshida T, et al. Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastroenterol Hepatol. 1998;13(3): 257–265. 4. Zen Y, Harada K, Sasaki M, et al. Are bile duct lesions of primary biliary cirrhosis distinguishable from those of autoimmune hepatitis? Interobserver histological agreement on trimmed bile ducts. J Gastroenterol. 2005;40:164–170.
Case 7.2
Antimitochondrial Antibody-Negative Primary Biliary Cirrhosis KAY WASHINGTON
C L I N I C A L I N F OR M AT I ON
A 36-year-old woman was referred for evaluation of cholestatic liver disease. She had been followed for 5 years with progressive elevation of alkaline phosphatase to 5 times normal, despite treatment with ursodeoxycholic acid (UDCA). Serum transaminase levels were 2 to 3 times normal, and total bilirubin was 1.5 times the upper limit of normal. Further laboratory testing revealed high titer antinuclear antibodies and negative AMA and SMA. A family history of primary biliary cirrhosis was noted. R E A SON F OR R E F E R R AL
The liver biopsy shows destruction of interlobular bile ducts in the setting of negative antimitochondrial antibodies. Do the findings represent primary biliary cirrhosis? F I G U R E 7 . 2 . 2 Non-necrotizing granuloma in portal tract.
PAT H OL OG I C F E AT U R E S
Portal tracts are expanded by a lymphoplasmacytic infiltrate with interface hepatitis and numerous plasma cells. Interlobular bile ducts are focally disrupted by lymphocytes (Figure 7.2.1), and nonnecrotizing granulomas are present in some portal tracts (Figure 7.2.2). Other portal tracts lack bile ducts (Figure 7.2.3). There is mild macrovesicular steatosis and scattered foci of spotty hepatocyte necrosis (Figure 7.2.4), without centrilobular pericellular fibrosis.
F I G U R E 7 . 2 . 3 No interlobular bile duct is identified in this portal tract, which is expanded by a mononuclear inflammatory infiltrate.
DIAGNO SIS
FIGURE 7. 2. 1 Portal tract with lymphoplasmacytic infiltrate; note
focally disrupted bile duct (arrow).
123
Antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis).
124
CHAPTER
7:
BILE
DUCT
DAMAGE
FIGURE 7. 2. 4 Mild macrovesicular steatosis and spotty hepatocyte
necrosis.
AND
DUCTOPENIA
F I G U R E 7 . 2 . 5 Cirrhosis in PBC, with chronic cholestasis and neartotal destruction of interlobular bile ducts. Note lack of ductular reaction.
D I SC U SSI ON
The term “AMA-negative PBC” or “autoimmune cholangitis” has been applied to cases that are clinically, histologically, and biochemically compatible with PBC except for the lack of identifiable antimitochondrial antibodies; serum ANA and anti–smooth muscle antibodies may be present in high titers but are not required for the diagnosis. More sensitive testing using cloned mitochondrial antigens such as a triple hybrid recombinant molecule may identify AMA in some patients previously thought to be seronegative. In retrospective studies, no significant differences between patients with PBC and these AMA-negative patients have been described (1–4), although a prospective study describing 20 patients with autoimmune cholangitis reports that these patients have higher serum levels of aspartate aminotransferase (AST) and bilirubin and lower serum IgM than patients with classic PBC (5). Of the 15 patients with autoimmune cholangitis with biopsies reported in 1 study, 6 had a PBC-like and 7 had a PSC-like pattern of injury, suggesting that “autoimmune cholangitis” may represent a mixed group of autoimmune disorders at varying stages or possibly a transition state (5). AMA-negative patients were slightly younger in 1 study (50 vs. 55 years) but were otherwise indistinguishable (1). Although data are largely lacking, it is thought that the response to UDCA therapy in these patients is the same as for those who are AMA-positive, and there are accordingly no differences in the treatments prescribed for these 2 groups at the present time.
In this case, the mild large droplet steatosis and spotty hepatocyte necrosis are nonspecific findings and are not considered to represent nonalcoholic steatohepatitis. Treatment with UDCA was ineffective, and the patient developed progressive liver disease with cirrhosis and portal hypertension. Liver transplantation was performed 5 years after the biopsy was obtained; the explanted liver showed established biliary cirrhosis with loss of interlobular bile ducts typical of stage 4 PBC (Figure 7.2.5).
References 1. Goodman ZD, McNally PR, Davis DR, Ishak KG. Autoimmune cholangitis: a variant of primary biliary cirrhosis. Clinicopathologic and serologic correlations in 200 cases. Dig Dis Sci. 1995;40(6): 1232–1242. 2. Lacerda MA, Ludwig J, Dickson ER, Jorgensen RA, Lindor KD. Antimitochondrial antibody-negative primary biliary cirrhosis. Am J Gastroenterol. 1995;90(2):247–249. 3. Michieletti P, Wanless IR, Katz A, et al. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut. 1994;35(2):260–265. 4. Taylor SL, Dean PJ, Riely CA. Primary autoimmune cholangitis: an alternative to antimitochondrial antibody-negative primary biliary cirrhosis. Am J Surg Pathol. 1994;18:91–99. 5. Invernizzi P, Crosignani A, Battezzati PM, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology. 1997;25(5): 1090–1095.
Case 7.3
Primary Biliary Cirrhosis With Ductopenia KAY WASHINGTON
C L I N IC AL I N F OR M AT I ON
A 48-year-old woman presented with pruritis, worse at night. She had been treated recently with a course of amoxicillin clavulanate (Augmentin) for acute sinusitis, but otherwise, her past medical history was unremarkable. Review of systems was notable for dry mouth and eyes. Laboratory testing revealed elevated alkaline phosphatase (3.5 times normal), elevated IgM (1.5 times normal), normal serum transaminase levels, positive antimitochondrial antibodies, negative antinuclear antibodies, smooth muscle antibodies, and slightly elevated serum total bilirubin. R E A SON F OR R E F E R R AL
The liver biopsy shows ductopenia with relatively mild portal inflammation and no florid duct lesions. Given the history of treatment with amoxicillin clavulanate, do the findings represent drug reaction or PBC?
F I G U R E 7 . 3 . 2 Minimal lobular inflammation and no cholestasis.
Note area of regenerating hepatocytes (arrow) bounded by atrophic hepatocytes, suggestive of nodular regenerative hyperplasia.
PAT H OL OG I C F E AT U R E S
Interlobular bile ducts are absent from most portal tracts. There is a modest portal chronic inflammatory infiltrate with minimal bile ductular reaction and no significant interface hepatitis (Figure 7.3.1). Focally, portal-portal bridging fibrosis is noted. Centrilobular areas show no canalicular cholestasis (Figure 7.3.2). Alternating areas of hepatocyte regeneration and atrophy are present, suggestive of an element of nodular regenerative hyperplasia.
FIGURE 7. 3. 1 Portal tract with modest chronic inflammatory infil-
trate and no identifiable interlobular bile duct.
DIAGNO SIS
Primary biliary cirrhosis with ductopenia.
DISCUSSIO N
Whereas this case exhibits classic clinical and serologic features of primary biliary cirrhosis, including the not-uncommon finding of nodular regenerative hyperplasia, the histologic finding of ductopenia should prompt consideration of other possible causes of bile duct loss in adults (see Table 7.3.1, Chapter 7). PBC and PSC are usually distinguished easily by their characteristic clinical and pathologic profiles. PBC is overwhelmingly a disorder of middle aged women and affects only small- and medium-sized intrahepatic ducts, whereas PSC is seen in all age groups, is associated with inflammatory bowel disease, and affects large intrahepatic and extrahepatic bile ducts with variable involvement of the smaller biliary radicles. The diagnosis of small duct PSC can be difficult to establish with certainty and is made most confidently in the patient with inflammatory bowel disease. Diagnosis of graftversus-host disease and chronic ductopenic hepatic allograft rejection may be challenging, but these disorders enter the differential diagnosis only in the appropriate clinical setting. Similarly, ischemic cholangiopathy is rarely encountered and is seen primarily in the setting of hepatic artery infusion of 5-FU–based chemotherapy.
125
126
CHAPTER
7:
BILE
DUCT
DAMAGE
Drug reaction should be considered in the differential diagnosis of any pattern of liver injury, and many different drugs, most commonly neuroleptics, anticonvulsants, and antibiotics; specific examples which include ibuprofen, carbamazepine, chlorpromazine, trimethoprim-sulfamethoxazole, and tetracycline have been associated with a cholestatic hepatitis pattern of injury with injury to interlobular bile ducts. Correlation with clinical findings is essential, and a high index of suspicion must often be maintained to arrive at a correct diagnosis. Drug-induced prolonged cholestasis is diagnosed when jaundice persists for more than 6 months or liver tests indicate continued cholestasis for more than 1 year after withdrawal of the offending agent. Acute onset of disease, appropriate drug history, and a period of jaundice suggest a drug-induced lesion. The bile duct injury in drug-induced prolonged cholestasis (Figure 7.3.3) may be relatively subtle, consisting of reactive changes, focal degenerative changes in bile duct epithelium, or overt loss of bile ducts resulting in ductopenia. Infiltration of bile ducts by inflammatory cells, generally lymphocytes, is variable but may be prominent. In early stages of drug-induced bile duct injury, bile duct epithelial cells are swollen and vacuolated. Pyknotic nuclei and mitotic figures may be seen; some bile ducts may appear atrophic, and ductopenia has been reported as early as 10 days following onset of jaundice. Marked canalicular cholestasis is generally present in zone 3 (Figure 7.3.4), and a mild lobular inflammation with occasional eosinophils may be seen. The portal inflammatory infiltrate is variable in density but often contains eosinophils. In the chronic phase, some degree of portal inflammation and bile ductular reaction is found, although canalicular bile plugs, lobular inflammation, and hepatocyte necrosis have generally resolved in biopsies taken late (24 months) after the inciting agent has been discontinued (1). In some patients, liver biopsies show changes similar to primary biliary cirrhosis. In time, most patients recover,
AND
DUCTOPENIA
although it may take several years for liver tests to return to normal, and in some patients, the disease is irreversible and results in biliary cirrhosis (Figure 7.3.5). Fibrosis in the liver biopsy and failure to withdraw the offending drug are factors associated with persistent liver damage (2). The pathogenesis of drug-induced bile duct injury is unclear. Most of the drugs associated with drug-related bile duct paucity undergo biotransformation to toxic intermediates, which may result in direct cellular injury. More likely, immune response targeting bile duct epithelial cells may be responsible, as prolonged cholestasis has been most often seen with drugs considered to induce acute hepatitis or cholestatic hepatitis through a hypersensitivity mechanism. Genetic predisposition probably also plays a role in pathogenesis. In rare instances, careful clinicopathologic correlation may fail to reveal an etiology for ductopenia in the adult
F I G U R E 7 . 3 . 4 Zone 3 cholestasis and canalicular bile plugs
(arrow) in cholestatic hepatitis due to drug reaction to amoxicillin clavulanate.
FIGURE 7. 3. 3 Bile duct.injury due to drug reaction to amoxicillin
clavulanate. The bile duct (arrow) is distorted with loss of individual epithelial cells. Portal inflammation is modest.
F I G U R E 7 . 3 . 5 Ductopenia with canalicular bile plugs in prolonged cholestasis due to drug reaction.
CASE
7.3:
PRIMARY
BILIARY
patient. The term idiopathic adulthood ductopenia has been applied to such cases of chronic cholestasis of unknown etiology associated with loss of intrahepatic bile ducts. This disorder usually affects young to middle-aged adults and is more common in males (3); familial cases are described (4). Reported cases probably represent a heterogeneous group of related disorders, with some representing late onset of paucity of intrahepatic bile ducts, primary sclerosing cholangitis involving small ducts without large duct involvement, and autoimmune-mediated cholangitis. The criteria generally used for idiopathic adulthood ductopenia are onset of cholestasis in late adolescence or adulthood, ductopenia defined as lack of bile ducts in more than 50% of portal tracts, normal cholangiogram, and no known etiology. The liver often shows empty portal tracts with no inflammation. The patient with ulcerative colitis, ductopenia, or other biopsy features consistent
CIRRHOSIS
WITH
DUCTOPENIA
127
with PSC, but a normal cholangiogram, is considered to have isolated small duct PSC. This disorder probably represents less than 5% of cases of chronic cholestasis in adulthood.
References 1. Degott C, Feldmann G, Larrey D, et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology. 1992;15:244–251. 2. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut. 1999;44:731–735. 3. Kim WR, Ludwig J, Lindor KD. Variant forms of cholestatic diseases involving small bile ducts in adults. Am J Gastroenterol. 2000;95(5): 1130–1138. 4. Burak KW, Pearson DC, Swain MG, Kelly J, Urbanski SJ, Bridges RJ. Familial idiopathic adulthood ductopenia: a report of five cases in three generations. J Hepatobiliary Pancreat Surg. 2000;32:159–163.
Case 7.4
Primary Biliary Cirrhosis With Cirrhosis KAY WASHINGTON
C L I N I C AL I N F OR M AT I ON
A 61-year-old woman with known long-standing primary biliary cirrhosis unresponsive biochemically to ursodeoxycholic acid therapy is referred for evaluation for possible liver transplantation. She complains of debilitating fatigue. Review of laboratory tests reveals high titer positive antimitochondrial antibodies. The most recent liver tests reveal total bilirubin twice normal, AST and ALT 1.5 times normal, and alkaline phosphatase twice normal. A liver biopsy is performed for staging purposes. R E A S ON F OR R E F E R R A L
The liver biopsy shows cirrhosis with loss of interlobular bile ducts. Are the findings consistent with primary biliary cirrhosis? F I G U R E 7 . 4 . 2 Ductopenia with minimal bile ductular reaction.
PAT H OL OG I C F E AT U R E S
The biopsy shows irregular regenerating nodules of hepatocytes separated by fibrous bands (Figure 7.4.1). The fibrous septa contain no recognizable interlobular bile ducts, and there is minimal bile ductular reaction (Figure 7.4.2). Only mild necroinflammatory activity is seen. No canalicular cholestasis is identified.
D I AG N OS I S
Cirrhosis secondary to primary biliary cirrhosis (stage 4).
FIGURE 7. 4. 1 Biliary-type cirrhosis with irregular elongated nodules.
DISCUSSIO N
In advanced primary biliary cirrhosis (PBC), changes of chronic cholestasis begin to appear, with swollen and rarefied periportal hepatocytes and accumulation of copper. As periportal fibrosis progresses, portal-portal fibrous bridges are formed. Bile ductular proliferation often subsides in late-stage PBC, and in the cirrhotic stage little ductular or ductal epithelium can be identified. The cirrhosis has a typical biliary pattern, in which the nodules have an irregularly shaped “jigsaw puzzle piece” profile. The value of histologic staging in assessing prognosis in PBC is somewhat controversial, given the lack of uniformity of duct loss and fibrosis in the liver in this disease. However, the presence of portal-portal bridging fibrosis on biopsy has been shown to be a poor prognostic sign. Several staging schemes have been described, and there is little practical difference between the 2 that are most commonly employed, those described by Scheuer (1) and Ludwig (2) (Table 7.4.1). In stage 1 disease, damage to interlobular bile ducts is seen in the form of the florid duct lesion. In stage 2, the effects of duct injury result in extension of the process to involve the periportal areas, and ductular reaction, probably representing a compensatory reaction to bile duct loss, is prominent (Figure 7.4.3). Stage 3 is characterized as a scarring or precirrhotic stage, with bridging fibrosis (Figure 7.4.4). Stage 4 is cirrhosis (see Figure 7.4.5).
128
CASE
7.4:
PRIMARY
BILIARY
CIRRHOSIS
WITH
CIRRHOSIS
129
TA B LE 7. 4. 1 Histologic staging of primary biliary cirrhosis Scheuer (1)
Ludwig (2)
Stage 1
Florid duct lesion (bile duct damage and portal inflammation)
Portal stage (portal inflammation)
Stage 2
Ductular proliferation (portal tracts expanded by fibrosis, with bile ductular reaction; interface hepatitis)
Periportal stage (periportal inflammation and interface hepatitis)
Stage 3
Scarring (fibrosis and loss of bile ducts)
Septal stage (fibrous septa link portal tracts)
Stage 4
Nodular cirrhosis
Cirrhosis
F I G U R E 7 . 4 . 4 Stage 3 primary biliary cirrhosis with bridging fibrosis.
References 1. Scheuer P. Primary biliary cirrhosis. Proc R Soc Med. 1967;60: 1257–1260. 2. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol. 1978;379:103–112.
FIGURE 7. 4. 3 Stage 2 primary biliary cirrhosis, with periportal bile ductular reaction and loss of interlobular bile duct.
This page intentionally left blank
8 Ductal Plate Malformations and Cystic Diseases of the Liver BARTON KENNEY AND DHANPAT JAIN
I N T ROD U C T I ON The Ductal Plate
The development of the embryologic and fetal liver occurs in an organized sequence, beginning with the formation of hepatic anlagen and accrual of liver mass, with subsequent formation and remodeling of the biliary tree (1,2). There is no intrahepatic bile duct (IHBD) system until the first 7 weeks of embryonic development (3). At this time, the portal vein enters the liver at the hepatic hilum and begins branching. As the vein grows inward with its accompanying mesenchyme, a layer of epithelial cells surrounds the portal branches like a cylindrical sleeve (3). This layer of cells is known as the “ductal plate” and eventually forms the intrahepatic biliary tree. The ductal plate can be thought of as a temporary scaffolding constructed by the embryologic liver for building of the mature intrahepatic biliary system (1). The ductal plate cells originate from multipotent progenitor cells that are capable of differentiating into either hepatocytes or cholangiocytes (2). These cells develop CK19 positivity by the 9th to 10th embryonic week (Figure 8.1). The cells that form the liver parenchyma go on to express CK8 and CK18, while losing expression of CK19 (2,3). This binary cell
differentiation is induced by the presence of a periportal gradient of activin/TGF- signaling, the extent of which is modulated by inhibitory influences of hepatocyte nuclear factor 6 (HNF6) and one-cut factor (OC-2). The NOTCH signaling pathway is also believed to play a role in repression of hepatocyte differentiation in future IHBD cells (2,3). The ductal plate develops 2 layers of epithelium, and after 12 weeks undergoes progressive remodeling, starting at the hepatic hilum. Subsequently, this double-layered plate forms slit-like lumina, undergoing the so-called “tubulardilatation” (3). The portal tracts continue to develop with the appearance of hepatic artery branches in the periportal mesenchyme (1). The tubular components of the ductal plate then get incorporated into the mesenchyme by the in-growth of mesenchyme between the plate and the surrounding hepatic progenitor cells. This process forms primitive portal tracts containing the early interlobular bile ducts. The excess epithelium of the plate gradually regresses by apoptosis, leaving only the bile ducts behind, which begin to express CK7 by 20 weeks (Figures 8.2 and 8.3) (1,3). At birth, most peripheral branches of the IHBD system are still immature, and portal vein radicals at this level are still surrounded by ductal plates. Not until 4 weeks postpartum do these structures mature into well-developed portal tracts.
FIGURE 8. 1 (A) Ductal plate in fetal liver showing irregularly shaped and spaced bile ducts embedded in fibrous stoma surrounding a central portal venule. At this stage, the mesenchyme of the portal tract has grown in between the limiting plate of hepatocytes and the ductal plate, and the developing bile ducts can be easily distinguished. (B) CK19 immunostain highlighting the ductal plate epithelium at an earlier stage. The separation of the ductal plate from the hepatocytes has just begun, and a few lumina of developing bile ducts are barely evident. Note that the hepatocytes are also staining for CK19, although less strongly than the ductal plate epithelium.
131
132
CHAPTER
8:
CYSTIC
DISEASE
OF
THE
LIVER
FIGURE 8. 2 Evolution of the ductal plate. Initially a double layer of
epithelium forms, surrounding a portal vein branch. The cell plates fuse to form small ductules. Intervening cell plates involute, leaving separate interlobular bile ducts (bottom left). In DPM, the process goes awry, leading to fibrosis and formation of ectatic bile ducts. Ductal Plate Malformation
The development and remodeling of the ductal plate requires precisely coordinated biologic function and highly regulated epithelial-mesenchymal interaction (3). Aberrant remodeling or a lack of remodeling altogether can lead to persistence of the embryonic bile duct structures, which may retain their primitive ductal plate–like configuration (1,3), an event that is generically referred to as “ductal plate malformation (DPM)” (Figure 8.2). This defect represents the basic underpinning of most variants of fibrocystic liver disease (1). The etiology and pathophysiology of DPM are not well understood but likely represent a defect in the complex epithelial-mesenchymal interaction necessary for proper development of the IHBD system. Abnormalities in cell-cell signaling or adhesion and intracellular cation handling have been implicated, but the precise mechanisms have not been elucidated (2). Some specific signaling defects have been shown to result in biliary abnormalities in animal models, namely deletion of various HNFs. Tissue-specific selection of HNF1 leads to gallbladder abnormalities and inadequate IHBD formation, and whole-body knockout of HNF6 leads to agenesis of the gallbladder, replacement of the cystic duct with a choledochocele, and abnormalities in IHBD formation (2,4–6). Histologically, DPM is represented by the persistence of the ductal plate beyond fetal life. This is represented by
FIGURE 8.3 Histologic evolution of the ductal plate in fetal liver. The ductal plate epithelium stains more intensely with CK19 compared to hepatocytes and can be easily distinguished. (A) Early stage with a single layer of epithelium. (B) Later stage with 2-layered epithelium of the ductal plate. (C) Early formation of ductules (red arrow) with separation of the ducts from the limiting plate of hepatocytes by in-growth of mesenchyme.
CHAPTER
8:
CYSTIC
DISEASE
circumferentially oriented bile ducts at the margin of portal tracts, which are not separated from the hepatocytes by connective tissue. This is frequently accompanied by increased numbers of ectatic bile ducts with irregular contours and a lack of mature bile ducts or portal venules within the portal tracts (2,7) (Figure 8.4). The IHBD system shows increased numbers of immature ducts with irregular geometric shapes, but with well-differentiated ductal epithelium. The presence of increased bile ductular structures can be highlighted by staining for CK19. There may be canalicular and ductal cholestasis. Staining for CD34 reveals increased capillary density within portal tracts, and staining for smooth muscle actin may show a zone of condensed myofibroblasts around biliary structures (8). The hepatic arterioles often show hypertrophy and/or hyperplasia, with increased hepatic artery branches around biliary structures. The portal connective tissue may show moderate to severe fibrosis with variable inflammation. The hepatic lobule is typically normal, unless damaged secondarily by chronic infection or other injury (7).
OF
THE
133
LIVER
CYST IC DISEA SES O F T H E LIV ER
Cystic liver disease can be divided into 3 broad categories: hereditary (DPM-related and non-DPM related), infectious, and neoplastic. The majority of cystic liver disease in the developed world is hereditary and is most commonly associated with polycystic kidney disease (Table 8.1). Other rare conditions are also responsible for a minority of cystic liver disease cases (Table 8.2). Infectious cystic disease is more common in the developing world. Cystic neoplasms are represented by lesions that are either primarily cystic in nature or result from cystic degeneration/necrosis in otherwise solid tumors. Overall, cystic neoplasms are relatively uncommon in clinical practice. Hereditary DPM-Related Cystic Diseases of the Liver
Autosomal recessive polycystic kidney disease (ARPKD) affects between 1:6000 and 1:40 000 live births (9) and is generally a severe and lifelong disease (9,10). ARPKD may present,
FIGURE 8. 4 Comparison of a normal portal tract with persistence of ductal plate–like abnormality. (A) Normal portal tract with a well-
defined interlobular bile duct, portal venule, and hepatic arteriole. (B) DPM in a patient with CHF with ectatic and irregular bile ducts, prominent at the periphery of the portal tract, embedded in fibrous stroma similar to the developing ductal plate in Figure 8.1A. TA B LE 8. 1 Most common fibrocystic liver diseases May Be Associated With Other Condition
Specific Genetic Test Commercially Available
Gene
Protein
Age of Onset
ARPKD
PKHD1 (6p21.1-p12)
Fibrocystin
Young
Yes (CHF)
Yes
ADPKD
PKD1 (16p13.3-p13.12) PKD2 (4q21-q23)
Polycystin 1 and 2
Adult
Yes (CHF)
Yes
PLD
PRKSCH 19p13.2-p13.1 and SEC63 6p21-p23
Hepatocystin
Adult
No
No (research setting)
Caroli disease
None (but syndrome yes. . .PKHD1)
—
Young
Yes (PKD)
No
CHF
PKHD1
—
Young
Yes (PKD)
No
Abbreviations: CHF-congenital hepatic fibrosis, PKD-polycystic kidney disease, ARPKD-autosomal recessive polycystic kidney disease, ADPKD-autosomal dominant polycystic kidney disease, PLD-polycystic liver disease.
134
CHAPTER
8:
CYSTIC
TA B LE 8. 2 Less common syndromes associated with cystic
liver disease Syndrome
Gene
Medullary cystic kidney disease 1
MCKD1 (1q21)
Medullary cystic kidney disease 2
UMOD (16p12)
Nephronophthisis
NPHP1 (multiple)
Meckel syndrome
MKS1, 2, 3 (multiple)
Asplenia with cystic liver, kidney and pancreas
Unknown
Ellis–van Creveld syndrome or chondroectodermal dysplasia
EVC2 (4p16)
Asphyxiating thoracic dystrophy (Jeune syndrome)
Unknown
Congenital disorder or glycosylation, type Ib (phosphomannose isomerase deficiency)
MPI (15q22-qter)
Joubert syndrome
JBTS1 (9q34.3)
Vaginal atresia syndrome
Unknown
Ivermark syndrome
CX43 (possible)
Tuberous sclerosis
TSC1 (9q34), TSC2 (16p13)
Acrocephalopolydactylous dysplasia
Unknown
Bardet-Beidl syndrome
BBS1-5 (many)
COACH syndrome
Unknown
Short rib-polydactyly syndrome, type 1
Unknown
Short rib-polydactyly syndrome, type II
Unknown
Short rib-polydactyly syndrome, type III
Unknown
Short rib-polydactyly syndrome, type IV
Unknown
in its perinatal form, with bilaterally enlarged kidneys and severe renal failure (10). Individuals who survive the initial neonatal complications develop progressive renal, and often hepatic, cyst formation with variable progression to chronic renal failure and portal hypertension with increasing age (11). Approximately 199 different mutations have been recognized in patients with ARPKD. Fundamentally, these mutations affect the PKHD1 gene locus on chromosome 6p21.1 (9). This gene codes for fibrocystin, a 450-kDa hepatocyte growth factor receptor–like protein, which functions on the primary cilia of renal and biliary epithelial cells (11,12). Dysfunction of fibrocystin results in abnormal ciliary signaling, which is fundamental to proliferation and differentiation of renal and biliary epithelium. The fibrocystic disorders associated with ARPKD vary and represent a range of conditions. One end of the spectrum is exemplified by the formation of extensive fibrous septae and nodularity, generally termed as “congenital hepatic fibrosis (CHF).” The other end of the spectrum is represented by the formation of multiple bilary cysts, referred to as “Caroli disease.” There is significant overlap in presentation of these forms, and their separation into distinct entities is not always possible.
DISEASE
OF
THE
LIVER
Hepatic cysts in ARPKD result from dilation of the bile ducts and are in continuity with the remainder of the biliary system (9), although true biliary cysts that are completely isolated may also be present. As DPM underlies this condition, histologic changes include an increase in biliary channels with irregular extension into the parenchyma and extensive branching or anastomosis. There may be an absence of normal interlobular bile ducts (10). Depending on the degree of hepatic and renal involvement, liver and/or kidney transplant may be necessary. Occasionally, cyst fenestration or partial hepatectomy may be indicated if there is mass effect on surrounding structures due to cyst enlargement. In less severe cases, medical management of hypertension with ACE inhibitor or angiotensin-receptor blocker therapy may suffice. CHF is typically associated with ARPKD, with less severe renal involvement and a generally more favorable survival profile (1). The mode of inheritance is autosomal recessive (1). Several clinical forms are recognized: portal hypertensive, cholangitic, mixed portal hypertensive-cholangitic, and latent (13). Most cases are present in childhood, whether in the neonatal, infantile, or juvenile period. In general, baseline liver function tests are within the normal range, although alkaline phosphatase may be slightly elevated. Patients may come to clinical attention as a result of cholangitis, or variceal bleed and/or hepatosplenomegaly due to portal hypertension. The pathology of CHF is best described as DPM of the interlobular bile ducts with superimposed destructive and sclerosing cholangitis (1). The histologic hallmark of CHF is broad and dense fibrous septa with numerous embedded irregularly shaped bile duct structures (13). In the so-called focal form, fibrous enlargement is predominantly relegated to the portal tracts, whereas in the so-called diffuse form, adjacent portal tracts are linked by broad fibrous septa (13). The fibrosis may result in cirrhosis-like nodularity of the liver, although the septa tend to take on a “jigsaw puzzle”–like appearance, cutting out hepatocyte nodules that have geographic shapes rather than the rounded profiles that are more often seen in hepatitic cirrhosis (Figure 8.5). Fibrosis, rather than cyst formation, is the hallmark of this DPM; hence, the nomenclature. Although bridging fibrosis may be present, the hepatocyte lobules are generally normal in architecture and function. The central venules are still identifiable, although they may not remain centrally located in the nodules, and the hepatic cords remain mostly single cell thick; these features can be helpful in differentiation from typical cirrhosis. It should be remembered that hepatic architecture may resemble cirrhosis in the presence of another concomitant liver disorder, for example, alcoholic liver disease or chronic viral hepatitis. When superimposed abnormal bile ducts with cystic changes are present, the disease process is referred to as Caroli syndrome (see below). Caroli disease also occurs as a component of ARPKD; however, it may also occur without associated renal abnormalities. Patients present with recurrent abdominal pain and fever or occasionally with jaundice if the common bile duct becomes obstructed. Liver function tests are typically normal, outside of episodes of biliary obstruction. Complications
CHAPTER
8:
CYSTIC
DISEASE
OF
THE
LIVER
135
FIGURE 8. 5 ARPKD and Caroli disease. (A) Typical appearance of the kidney in a newborn with ARPKD; numerous small cysts distributed
evenly throughout the parenchyma. (B) Segment of liver with Caroli disease with numerous heterogeneous cysts involving the biliary tree. Note that there is no bridging fibrosis or nodularity of the liver.
include recurrent cholangitis, intrahepatic and subphrenic abscesses, sepsis, and lithiasis (10). There is an increased risk of developing adenocarcinoma, with the incidence estimated to be about 7%. Caroli disease generally involves the entire liver, although it may be segmental. The condition is defined by saccular or fusiform dilation of the large IHBDs, generally the right and left hepatic ducts and their corresponding segmental larger ducts (1,14) (Figure 8.6). Intraluminal protrusion of duct wall and the presence of intraductal vascular tracts are common findings (14). Dilated ducts may be associated with marked chronic inflammation, acute inflammatory infiltrates, and a variable degree of fibrosis. Inspissated bile and purulent material may be present within duct lumens. As in ARPKD, the cysts are in continuity with the remainder of the biliary system, rather than being isolated. The cysts correspond to incompletely remodeled DP remnants with a variable degree of dilation (1). Caroli syndrome is defined by the presence of Caroli disease–type changes superimposed with CHF (11,14,15). It is more common than pure Caroli disease without other hepatic abnormalities (1,16). Caroli syndrome involves the entire intrahepatic biliary tree. Histologic findings are defined by overlapping features of CHF and Caroli disease. Overlap of diseases: As discussed above, there is considerable (and often confusing) overlap between many forms of liver involvement with ARPKD. Although significant advances have been made with regard to defining the underlying molecular abnormalities in these disorders, molecular tests for clinical application are currently available for only a few conditions, and even then only at a few centers (Table 8.1). Thus, in practice, clinicopathologic correlation is necessary to make the correct diagnosis. Some key points to remember are as follows: 1. Essentially all ARPKD cases have some degree of associated CHF (9,11). 2. Many ARPKD cases have associated Caroli disease.
3. CHF is often accompanied by cystic biliary changes (Caroli disease), which then warrants classification as Caroli syndrome. 4. Caroli disease can occur independently of ARPKD. The presence of a significant CHF component may necessitate clinical attention due to the potential for development of portal hypertension. A significant Caroli disease component puts the patient at risk for recurrent cholangitis and cholangiocarcinoma. Autosomal dominant polycystic kidney disease (ADPKD) affects between 1:400 and 1:1000 live births and accounts for approximately 5% of cases of end-stage renal disease in the United States and Europe (17). Associated hepatic cysts are a near-universal occurrence. Additional associated conditions include intracranial aneurysm formation (6%–21%) and mitral valve prolapse (26%) (9). Two genes have been implicated in the development of ADPKD. PKD1, located on chromosome 16p13, is the more common culprit and is responsible for a more severe disease phenotype (9,12). PKD1 encodes an integral membrane protein known as polycystin1, which is implicated in cell-cell and cell-matrix interactions (12). A less common mutation event occurs in PKD2, located on chromosome 4q21-q23, which codes for the protein product polycystin2. It appears that polycystin1 and 2 join to form a heterodimeric plasma membrane ion channel involved in the regulation of tubular morphology and function (12). Hepatic cysts in ADPKD arise from dilatation of von Meyenberg complexes (VMCs) (1). Generally, a large number of VMCs are present in the liver, and many show varying degrees of dilation and cystic change. In contrast to the cysts of ARPKD, which maintain their connection to the biliary tree, the cysts of ADPKD may lose connection, grow in size and impinge on the hepatic parenchyma (9) (Figure 8.7). Although Caroli disease is mainly associated with ARPKD, several case reports have described its occurrence with ADPKD as well (15,18).
136
CHAPTER
8:
CYSTIC
DISEASE
OF
THE
LIVER
FIGURE 8. 6 The liver in an autopsy case of CHF. (A) Irregular bridging fibrosis and nodularity mimicking cirrhosis. The fibrous septa are very dense, bland, and lack inflammation. Prominent ductular reaction is seen. (B, C) “Jigsaw”-type irregular bridging fibrosis. (D) The nodules lack the rounded profile of cirrhotic nodules, and the hepatic cords are largely single cell thick. Preservation of central veins can be seen in many of the nodules (arrow). (E) Marked bile ductular reaction in a ductal plate–type configuration (H&E, 10 ). (F) Gross specimen of the liver from the same patient showing features indistinguishable from cirrhosis on cut surface and capsular surface (inset).
CHAPTER
8:
CYSTIC
DISEASE
OF
THE
LIVER
137
FIGURE 8. 7 (A) Coronal MRI image showing massive bilateral kidney enlargement by innumerable cysts typical of ADPKD. (B) Nephrectomy
specimen showing obliteration of the renal parenchyma by cysts of varying sizes with marked enlargement and distortion of the kidney. (C) Axial MRI image showing multiple cysts scattered throughout the hepatic parenchyma. (D) Hepatectomy specimen from the same patient with multiple smooth-walled cysts. (E) Liver cyst lined by simple cuboidal epithelium, which is partly denuded. (F) Low power view of multiple variable-sized cysts surrounded by fibrosis.
138
CHAPTER
8:
CYSTIC
Many patients are managed medically with ACE inhibitor or angiotensin-receptor blocker therapy and dialysis for renal dysfunction. Cyst fenestration or partial hepatectomy may be indicated if there is mass effect on surrounding structures due to cyst enlargement. Bilateral nephrectomy and transplant may be performed due to massive kidney enlargement. Polycystic liver disease (PLD) was initially considered a component of ADPKD, as described above; however, it has now been shown that PLD may occur in a pure form without renal involvement (9,18). PLD is an autosomal dominant condition resulting from mutations in the gene coding for the protein hepatocystin. Two loci have been identified, specifically PRKSCH on chromosome 19p13.2-p13.1 and SEC63 on chromosome 6p21-p23 (1,9,18). PLD is a relatively rare condition, with an incidence below 0.01% based on autopsy data (18,19). The liver disease is less severe than ADPKD, and there is, by definition, no associated renal cystic disease. Most often, patients are asymptomatic with normal liver function tests, and the disease is often discovered incidentally (18). When present, symptoms are caused by cyst enlargement, usually manifesting as right upper quadrant discomfort/pain with associated nausea or early satiety (9,18). Cyst rupture and/or hemorrhage may occur, and infection poses a serious complication. Clinical diagnostic criteria are not well defined, but, in general, the finding of 5 or more cysts in the liver should prompt further investigation for PLD (18). The cysts of PLD generally involve the liver diffusely, and the histologic changes are identical to those seen in ADPKD (Figure 8.8). The cysts appear to arise from VMCs, and they may become completely separated from the biliary system. Fibrosis is not a common finding, and the hepatic lobular architecture is generally intact (18). Most cases of PLD are asymptomatic and do not require any treatment. However, if cyst enlargement causes significant symptoms, cyst aspiration with sclerotherapy or laproscopic fenestration can be useful. In general, a conservative clinical approach is appropriate (18).
DISEASE
OF
THE
LIVER
VMCs, or biliary microhamartomas, are typically small, often multiple, and are almost invariably asymptomatic (1,20). They may be seen in otherwise normal liver, or in association with many of the conditions described above, including ADPKD, CHF, and Caroli syndrome (1). VMCs can be interpreted as DPM of the most peripheral IHBDs (1). The incidence of VMCs increases with age, reaching a peak around the 6th to 7th decade, irrespective of gender (20). VMCs consist of dilated, irregular small ducts lined by biliary epithelium, which are embedded in a fibrous and often hyalinized stroma (1) (Figure 8.8). The lining epithelium can be columnar, but tends to become cuboidal or flat as the ducts become more dilated. VMCs may be present throughout the liver; however, they are most easily recognized on the capsular surface as 1- to 5-mm whitish nodules. Inspissated bile within dilated lumina is common. VMCs are most commonly encountered during laparotomy and are frequently sent for frozen section to rule out metastasis. They are also discovered incidentally in liver biopsies, resections, or at autopsy. No therapy is required; however, the presence of multiple VMCs may prompt one to look for cystic renal disease. It has been suggested recently that VMCs may be precursors for bile duct adenomas and sporadic cholangiocarcinomas (see Chapter 25). Non–DPM-Related Cystic Diseases of the Liver
Simple hepatic cyst: Imaging studies have shown that roughly 18% of individuals in the general population have simple hepatic cysts, often referred to as solitary nonparasitic cysts (21). The prevalence of cysts increases with advancing age; in 1 study reaching 52.3% of patients more than 60 years of age, whereas seen in only 0.16% of those under 20 years of age (9,21). Simple cysts are more common in the right liver lobe and have a female predominance. Most simple hepatic cysts are asymptomatic and detected incidentally (21). However, large cysts may present with abdominal pain or as a mass lesion. The pathogenesis of
FIGURE 8. 8 (A) Liver cut surface with minute punctate whitish lesions representing numerous von Meyenberg complexes (VMCs). (B) VMCs are more readily identified on the capsular surface of the liver. (C) VMCs showing irregular dilated bile ducts, inspissated bile, and surrounding fibrosis.
CHAPTER
8:
CYSTIC
simple cysts is not entirely clear, and could be developmental or degenerative. These cysts are not connected to the biliary tree (in contrast with biliary cysts—see below). Histologically, simple hepatic cysts demonstrate an inner epithelial lining consisting of a simple cuboidal layer surrounded by a rim of fibrous tissue. The lining is frequently denuded and may not be demonstrable on microscopic sections. There is no documented risk of malignancy. Most simple cysts do not require any treatment and can be radiologically monitored to ensure stability. Symptomatic simple cysts can be treated with needle aspiration and sclerotherapy, internal drainage with cystojejunostomy, cyst unroofing, or partial hepatectomy. Recurrence rates are high with aspiration, and laparoscopic unroofing is often preferable. Biliary cysts, in contrast to simple hepatic cysts, are by definition in continuity with the biliary tree. These appear to be congenital in nature and, as such, often present in early life. They likely represent aberrant bile ducts, which become dilated with age due to bile stasis, forming isolated cysts (21). The nomenclature of these lesions is somewhat obtuse, and these cysts were originally grouped under the heading of “choledochal cysts.” However, the classification has been expanded to include intrahepatic biliary cysts as well (Table 8.3). Biliary cysts frequently present with conjugated hyperbilirubinemia in infancy. Older patients tend to present with abdominal pain, with or without a detectable mass. These are usually unilocular cysts, but some are multiloculated. Grossly, the wall is typically thin, and the lining is smooth and free of papillary projections or solid nodules. Histologically, the cyst cavity is often filled with clear serous fluid, and the lining is composed of a single layer of cuboidal biliary-type epithelium, which maintains positivity for CK7 and CK19. The cyst lining is often denuded, leaving a layer of fibrous tissue abutting the surrounding liver parenchyma. Besides choledochal cysts (see later), risk of malignancy, if any, in the other types of biliary cysts remains unknown. In practice, the distinction between simple hepatic cyst and a solitary biliary cyst is often difficult, but is of no clinical significance. Biliary cysts may be surgically resected if they result in cholestasis or repeated episodes of ascending cholangitis. Cilliated foregut cyst is a rare entity, which presents as a solitary cyst within the hepatic parenchyma. It occurs more TA B LE 8. 3 Classification of choledochal cysts Appearance
IHBD
Type I
Saccular/fusiform dilation of segment of entire CBD
No
Type II
Isolated diverticulum of CBD wall, often pedunculated
No
Type III
Dilation of intraduodenal portion of CBD (choledochocele)
No
Type IV
Multiple dilations of intra- and extrahepatic bile ducts
Yes
Type V
Multiple dilations of IHBDs (Caroli disease)
Yes
Abbreviations: IHBD-intrahepatic bile duct, CBD-common bile duct.
DISEASE
OF
THE
LIVER
139
often in men and in the left liver lobe. Foregut cysts are lined by a layer of pseudostratified ciliated columnar epithelium. There is often a surrounding smooth muscle layer and an outer fibrous capsule. No risk of malignancy has been recognized so far. Treatment guidelines are not clear, but the logical approach is to manage these cysts in a similar fashion to simple hepatic cysts. Infectious Hepatic Cysts
Hydatid cyst is caused by the parasite Echinococcus granulosus. The infection is caused by ingestion of Echinococcal eggs, which hatch in the duodenum and invade through the bowel wall to infect mainly the liver and lung. Humans are an accidental intermediate host, a role usually played by sheep. Dogs represent the definitive host. Echinococcal cysts are initially microscopic, but progressively enlarge in size over a number of years. Cysts larger than 10 cm have been described. Histologically, the cyst wall is characterized by an inner, nucleated germinative layer surrounded by an outer anucleated layer with a multilaminated appearance (Figure 8.9). Nonruptured cysts typically lack any fibro-inflammatory response and can be easily shelled out of the liver. With time, many cysts show an inflammatory reaction and fibrosis around the cyst wall that may be rich in eosinophils. The lumen is filled with gelatinous fluid, in which daughter cysts develop over time. As worms develop, the scolices detach and form sand-like sediment within the cyst fluid. Echinococcal cysts must be dealt with carefully due to the risk of anaphylaxis if cyst contents are released into the peritoneal space. Surgical excision is often performed, although sclerotherapy has been utilized in some centers. Concurrent antimicrobial therapy is often used. The cysts are delicate and tend to rupture due to handling during gross examination. One way to avoid this is to aspirate the fluid, which can then be centrifuged to prepare smears from the sediments that show scolices. The cyst membranes can then be submitted as a “swiss-roll” for histologic examination. Other infectious cysts: Pyogenic and amebic liver abscesses are the other common causes of infectious hepatic cysts. Many types of bacteria, including common pyogenic bacteria, have been implicated in the formation of hepatic abscesses. The protozoan parasite Entamoeba histolytica primarily infects the colon, leading to intestinal amebiasis. In up to 40% of these patients, the protozoa gain access to the splanchnic circulation to reach the liver, forming abscesses. These are often solitary, but occasionally can be multiple (Figure 8.10). Amoebic liver abscesses are characteristically hemorrhagic, containing a thick paste-like material referred to as “anchovy-sauce pus.” This is due to liquefactive necrosis of liver tissue admixed with blood secondary to the proteolytic enzyme released by the protozoa. These cysts tend to display an eroded lining with adherent fibrinous material. The protozoa are often located at the edges of the abscess and are very difficult to demonstrate on histologic sections. The diagnosis often rests on a typical histologic appearance combined with serologic evidence of amebiasis. Characteristically, there is minimal
140
CHAPTER
8:
CYSTIC
DISEASE
OF
THE
LIVER
FIGURE 8. 9 (A) Bisected hydatid cyst showing a thick wall with multiple daughter cysts. (B) Multiple daughter cysts extruding from a large hydatid cyst showing a thick, white translucent membrane. (C) Hydatid cyst that was easily shelled out of the liver due to the lack of any inflammatory response. (D) Typical lamellated membrane that appears very pale on H&E stain. The surrounding liver shows fibrosis and dense inflammation. (E) Lamellae of cyst wall are highlighted with a silver stain. (F) Smear made from the centrifuged cyst contents showing numerous worm scolices (hydatid sand).
CHAPTER
8:
CYSTIC
DISEASE
OF
THE
LIVER
141
FIGURE 8. 10 (A) Multiple amebic liver abscesses showing irregular outlines and necrotic debris. The “anchovy-sauce” content is best seen
in fresh specimens and usually drains upon slicing the liver. (B) The abscess is composed mainly of necrotic debris and inflammatory cells. (C) Higher magnification from the abscess to show many macrophage-like structures that represent amebic trophozoites. It is difficult to demonstrate the protozoa in these lesions. (D) Higher magnification from the edge of abscess with PAS stain highlighting amebic trophozoites. The organisms can also be highlighted with trichrome and iron-hematoxylin stain.
host fibro-inflammatory response at the periphery, unless the lesions become secondarily infected with pyogenic bacteria. Pyogenic abscesses in the liver are generally similar in appearance to those seen in other anatomic locations and consist of a purulent exudate composed of neutrophils and fibrin. This gets “walled-off” by a host fibrotic response with time. Pyogenic and amoebic abscesses are managed with specific antimicrobial therapy, percutaneous drainage, or rarely by surgical resection. Cystic Neoplasms of the Liver
Several hepatobiliary neoplasms may present with a cystic appearance. Lesions that are typically cystic include hepatobiliary cystadenoma and cystadenocarcinoma. Lesions like
hemangioma, although multicystic, rarely enter this differential diagnosis due to their characteristic gross and imaging features. Malignant lesions that can become cystic include cholangiocarcinoma and metastatic carcinoma that may be mucinous or undergo extensive necrosis/cystic degeneration (see Chapter 24). Rarely intrabiliary cholangiocarcinomas may present as a multicystic lesion. Among metastatic tumors, well-differentiated neuroendocrine carcinoma (carcinoid) can present as a cystic lesion.
References 1. Desmet V. Pathogenesis of ductal plate malformation. J Gastroenterol Hepatol. 2004;19:S356–S360. 2. Knisely AS. Biliary tract malformations. Am J Med Genet A. 2003; 122A(4):343–350.
142
CHAPTER
8:
CYSTIC
3. Roskams T, Desmet V. Embryology of extra- and intrahepatic bile ducts, the ductal plate. Anat Rec (Hoboken). 2008;291(6):628–635. 4. Clotman F, Lannoy VJ, Reber M, et al. The onecut transcription factor HNF6 is required for normal development of the biliary tract. Development. 2002;129(8):1819–1828. 5. Clotman F, Jacquemin P, Plumb-Rudewiez N, Pierreux CE, Van der Smissen P, Dietz HC, et al. Control of liver cell fate decision by a gradient of TGF beta signaling modulated by onecut transcription factors. Genes Dev. 2005;19(16):1849–1854. 6. Coffinier C, Gresh L, Fiette L, et al. Bile system morphogenesis defects and liver dysfunction upon targeted deletion of HNF1beta. Development. 2002;129(8):1829–1838. 7. Awasthi A, Das A, Srinivasan R, Joshi K. Morphological and immunohistochemical analysis of ductal plate malformation: correlation with fetal liver. Histopathology. 2004;45(3):260–267. 8. Villeneuve J, Pelluard-Nehme F, Combe C, et al. Immunohistochemical study of the phenotypic change of the mesenchymal cells during portal tract maturation in normal and fibrous (ductal plate malformation) fetal liver. Comp Hepatol. 2009;8:5. 9. Tahvanainen E, Tahvanainen P, Kaariainen H, Hockerstedt K. Polycystic liver and kidney diseases. Ann Med. 2005;37(8):546–555. 10. Madjov R, Chervenkov P, Madjova V, Balev B. Caroli’s disease. Report of 5 cases and review of literature. Hepatogastroenterology. 2005;52(62): 606–609. 11. Turkbey B, Ocak I, Daryanani K, Font-Montgomery E, Lukose L, Bryant J, et al. Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis (ARPKD/CHF). Pediatr Radiol. 2009;39(2):100–111.
DISEASE
OF
THE
LIVER
12. Johnson CA, Gissen P, Sergi C. Molecular pathology and genetics of congenital hepatorenal fibrocystic syndromes. J Med Genet. 2003;40(5): 311–319. 13. Desmet VJ. What is congenital hepatic fibrosis? Histopathology. 1992;20(6):465–477. 14. Yonem O, Bayraktar Y. Clinical characteristics of Caroli’s disease. World J Gastroenterol. 2007;13(13):1930–1933. 15. Shedda S, Robertson A. Caroli’s syndrome and adult polycystic kidney disease. ANZ J Surg. 2007;77(4):292–294. 16. Gupta AK, Gupta A, Bhardwaj VK, Chansoria M. Caroli’s disease. Indian J Pediatr. 2006;73(3):233–235. 17. Davies F, Coles GA, Harper PS, Williams AJ, Evans C, Cochlin D. Polycystic kidney disease re-evaluated: a population-based study. Q J Med. 1991;79(290):477–485. 18. Arnold HL, Harrison SA. New advances in evaluation and management of patients with polycystic liver disease. Am J Gastroenterol. 2005;100(11):2569–2582. 19. Kwok MK, Lewin KJ. Massive hepatomegaly in adult polycystic liver disease. Am J Surg Pathol. 1988;12(4):321–324. 20. Redston MS, Wanless IR. The hepatic von Meyenburg complex: prevalence and association with hepatic and renal cysts among 2843 autopsies [corrected]. Mod Pathol. 1996;9(3):233–237. 21. Carrim ZI, Murchison JT. The prevalence of simple renal and hepatic cysts detected by spiral computed tomography. Clin Radiol. 2003;58(8): 626–629.
Case 8.1
Congenital Hepatic Fibrosis Versus Cirrhosis BARTON KENNEY AND DHANPAT JAIN
C L I N IC AL I N F OR M AT I ON
A 26-year-old male presented with severe upper gastrointestinal hemorrhage and was found to have grade 3 esophageal varices, requiring banding. The patient’s grandfather had a renal transplant at the age of 45. Physical examination revealed mild jaundice, caput medusa, and spider telangiectasias on the abdomen. Laboratory studies showed minimal elevation of alkaline phosphatase and normal alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Serologic tests for hepatitis B and C were negative.
best demonstrated on a reticulin stain. There is patchy mild neutrophilic cholangitis and pericholangitis, but the chronic inflammatory infiltrate and interface/lobular activity typical of chronic viral/autoimmune hepatitis is lacking. Features typical of steatohepatitis are not evident.
DIAGNO SIS
Congenital hepatic fibrosis.
R E A SON F OR R E F E R R AL
DISCUSSIO N
Clinical diagnosis is cirrhosis. Do the biopsy findings confirm this impression and point toward an etiology?
The histologic features suggest congenital hepatic fibrosis (CHF), even though the jigsaw-like pattern fibrosis and geographic shape of the nodules cannot be appreciated in a biopsy. Further investigation revealed that several family members had renal disease. Review of abdominal CT scan revealed multiple minute renal cysts. Genetic testing showed a mutation in the PKHD1 gene confirming autosomal recessive polycystic kidney disease (ARPKD). CHF can present at an early age with cholangitis, which may lead to clinical work-up and diagnosis. However, some patients with minimal symptoms progress quietly to severe fibrosis and portal hypertension. At this stage, distinction from other causes of cirrhosis is clinically and histologically difficult, especially on needle biopsy. Family history of renal
PAT H OL OG I C F E AT U R E S
The liver biopsy shows diffuse fibrous expansion of the portal tracts with porto-portal bridging (Figure 8.1.1). Many irregularly shaped bile duct structures are embedded in very bland-appearing broad fibrous septa. The hepatocytic nodules resemble cirrhotic nodules on cursory examination, although many unusual features are evident on a closer look. The nodules have preserved central veins, albeit located at the periphery. The hepatic plates are mostly single cell thick and lack the regenerative activity of cirrhotic nodules, which is
FIGURE 8. 1. 1 (A) Biopsy showing bridging fibrosis, bile ductular reaction, and nodule formation indistinguishable from cirrhosis. Closer examination shows that the fibrous septa are very dense and bland, with many ectatic ducts reminiscent of ductal plate malformation. The central venules can be seen in some of the nodules. The hepatic cords are comprised of 1-cell thick plates. (B) Klatskin trichrome stain highlighting fibrosis.
143
144
CHAPTER
8:
CYSTIC
disease or presence of renal cysts in the patient is helpful in supporting the diagnosis, although the renal cysts may not be typical of ARPKD as seen in this patient. Liver synthetic function and transaminases are generally within normal limits in CHF despite severe portal hypertension. The histologic findings of CHF may overlap with cirrhosis on biopsies, but some features are helpful to distinguish the two. At low power, the fibrous septa in CHF often appear very bland and dense, with numerous irregularly shaped bile ducts suggestive of ductal plate malformation. The irregular shape of the nodules and jigsaw puzzle–like fibrosis may be difficult to appreciate on needle biopsies. CHF may resemble sclerosing cholangitis, which can be excluded clinically by correlation with lack of associated inflammatory bowel disease and endoscopic retrograde cholangio-pancreatography/magnetic resonance cholangiopancreatography findings.
DISEASE
OF
THE
LIVER
The situation can be more complicated in some patients with CHF who also have clinical evidence of concomitant liver disease, most commonly chronic hepatitis C or alcohol use. This situation can be further complicated if the patient has a milder variant of CHF, lacks significant renal disease, and presents at an older age (5–6th decade) (1,2). Even in these situations, the bile ductular reaction maintains a ductal plate-type pattern and remains the most important clue to the diagnosis. Most of these cases have been recognized either at resection or autopsy, and recognition on biopsies can be challenging.
References 1. Averback P. Congenital hepatic fibrosis: asymptomatic adults without renal anomaly. Arch Pathol Lab Med. 1977;101(5):260–261. 2. Zeitoun D, Brancatelli G, Colombat M, et al. Congenital hepatic fibrosis: CT findings in 18 adults. Radiology. 2004;231(1):109–116.
Case 8.2
Caroli Disease/Syndrome Versus Other Cystic Disease BARTON KENNEY AND DHANPAT JAIN
C L I N IC AL I N F OR M AT I ON
A 12-year-old female presented to the emergency department with high fever and abdominal pain. Physical examination revealed mild jaundice, a tender right upper quadrant, and mildly increased liver span. Laboratory findings included leukocytosis with 88% neutrophils, AST 400 U/L, ALT 450 U/L, and alkaline phosphatase 1900 U/L. Urinalysis was normal, and a chest x-ray showed no infiltrates. A liver ultrasound demonstrated multiple cysts.
periductal lymphocytic inflammatory infiltrate and inspissated bile. The hepatic lobules were relatively unremarkable, with no significant inflammation or fibrosis.
DIAGNO SIS
Caroli disease presenting with acute cholangitis.
R E A SON F OR R E F E R R AL
DISCUSSIO N
Intrahepatic biliary dilation and cystic disease in a young patient with systemic symptoms, raising concern for multiple hepatic abscesses. The patient responded to aggressive antibiotic therapy, but the lesions persisted on imaging studies, leading to partial hepatectomy.
The histologic findings prompted a more detailed work-up for cystic liver and kidney disease. Abdominal MRI showed several cystic structures associated with the large intrahepatic bile ducts in the remaining liver, as well as fusiform dilatation of the right and left hepatic ducts. There was no evidence of renal cystic disease. Caroli disease often comes to clinical attention due to recurrent episodes of cholangitis, frequently after a clinical diagnosis of hepatic abscesses. A biopsy is seldom performed, but persistent liver disease or imaging abnormalities may lead to work-up of underlying liver disease and warrant a tissue diagnosis. Caroli disease affects the larger intrahepatic bile ducts, typically the immediate branches of the right and left hepatic ducts. Although Caroli disease may be associated with autosomal recessive polycystic kidney disease (ARPKD),
PAT H OL OG I C F E AT U R E S
The liver grossly showed multiple cystic spaces with denuded lining containing neutrophilic exudate suggestive of abscess formation (Figure 8.2.1). However, a partially preserved biliary-type lining was evident in some cystic spaces, and many dilated bile ducts without any inflammation were present in the background liver. Several of these dilated bile ducts had a fusiform cystic appearance and some showed a moderate
FIGURE 8. 2. 1 (A) Gross liver resection in a case of Caroli disease showing varying sized cysts affecting the large intrahepatic ducts. One of large cysts has yellowish pus sticking to the wall. (B) Whereas many of the cysts looked like abscesses full of neutrophils, others as shown here appear to be markedly dilated bile ducts with irregular outlines and lined by benign cuboidal to columnar cells. There is periductal fibrosis limited to the portal areas; bridging fibrosis and nodularity suggestive of congenital hepatic fibrosis are not seen.
145
146
CHAPTER
8:
CYSTIC
it often presents as an isolated disease process without renal manifestations. Biopsy is of limited use in establishing a diagnosis of Caroli disease, but may help in excluding other liver disorders. Thus, correlation with imaging findings and exclusion of other cystic liver diseases is important. Histology reveals saccular or fusiform dilation of larger ducts, with an associated chronic inflammatory infiltrate and variable fibrosis. A characteristic finding, though not always seen, is protrusion of the duct wall
DISEASE
OF
THE
LIVER
into the lumen, sometimes containing vascular structures. Similar to ARPKD, and in contrast to autosomal dominant polycystic kidney disease and polycystic liver disease, the cysts are dilations of the ducts themselves, rather than isolated structures. A key factor is showing that the cystic change is most prominent in the proximal ductal system. These findings are often difficult to appreciate in limited tissue samples and are best seen in resections or explants.
Case 8.3
Adult Polycystic Liver Disease Versus Caroli Disease BARTON KENNEY AND DHANPAT JAIN
C L I N IC AL I N F OR M AT I ON
R EA SO N FO R R EFER R A L
A 45-year-old male underwent MRI for chronic lower back pain. Multiple liver cysts (>30) were noted as an incidental finding. Repeat imaging confirmed multiple 1- to 4-cm liver cysts with no solid component or contrast enhancement. The cysts were not connected to the biliary system. The kidneys were normal. Laboratory findings included normal creatinine and liver function tests. Persistent abdominal pain and an increase in the size of one cyst led to partial hepatectomy.
Multiple liver cysts of unclear nature. PAT H O LO GIC FEAT UR ES
The gross examination revealed multiple cysts with scant normal hepatic parenchyma. The cysts showed a denuded or partly preserved lining consisting of low columnar to cuboidal bland-appearing epithelium (Figure 8.3.1). Several small von
FIGURE 8. 3. 1 (A) Partial hepatectomy from a patient with adult polycystic liver disease showing numerous cysts. (B) Cut surface shows
multiple smooth-walled cysts. (C) Noncystic areas of the liver show von Meyenburg complexes. (D) Liver cysts are similar to the cysts in autosomal dominant polycystic kidney disease.
147
148
CHAPTER
8:
CYSTIC
Meyenburg complexes were present in the adjacent liver. The cysts were not associated with bile ducts, but one appeared to arise from a dilated ductule at the edge of a von Meyenburg complex. The hepatic parenchyma at the periphery of the cyst showed nonspecific fibrosis without typical features of congenital hepatic fibrosis.
D I AG N OS I S
Autosomal dominant polycystic liver disease.
D I SC U SSI ON
The differential diagnosis in this case included autosomal recessive polycystic kidney disease (ARPKD), autosomal dominant polycystic kidney disease (ADPKD), autosomal dominant polycystic liver disease (ADPLD), and Caroli syndrome, all of which can present with liver cysts that can be indistinguishable on imaging studies and histology. Detailed family history revealed cystic liver disease without renal impairment in two family members. Presence of isolated cystic liver disease without any renal involvement after careful imaging analysis makes ADPLD the most likely diagnosis. Recent confirmation of unique mutations in the PRKSCH and SEC63 genes has confirmed that ADPLD is distinct from its kidney-related counterparts. Genetic sequencing in a research lab within the institution was undertaken, and the patient was found to have
DISEASE
OF
THE
LIVER
a germline mutation in the SEC63 gene on chromosome 6p, consistent with ADPLD. Many ADPLD patients are asymptomatic. In some cases, abdominal pain or fullness prompts clinical work-up. The finding of at least 5 liver cysts on imaging is enough to warrant further investigation for ADPLD. Due to autosomal dominant inheritance, other family members may have cystic liver disease as well, but may be asymptomatic. Of crucial importance is the lack of renal cystic disease, both in the patient and in family members. Typically, liver synthetic function is well preserved, and liver function tests do not show significant abnormalities. Biopsy of the cysts is generally not indicated, and the pathologist is involved either when cysts are resected/unroofed, or if the patient undergoes transplantation. Following partial excision of the cysts or unroofing procedure, often only a very limited amount of adjacent liver parenchyma is present, precluding proper assessment. The histology of the cysts is similar to those seen in ADPKD. In particular, von-Meyenburg complexes may be prominent, and cysts may be seen to emanate from them. Cysts are completely separate from bile ducts, as opposed to ARPKD, although this may be difficult to assess on histology. A combination of family history, detailed imaging findings, exclusion of associated renal disease, and genetic tests help in establishing a final diagnosis in such cases. Often a diagnosis is established without tissue confirmation in the appropriate clinical setting. Genetic testing for ADPLD remains in its infancy but may become commercially available in the near future.
Case 8.4
Choledochal Cyst BARTON KENNEY AND DHANPAT JAIN
C L I N IC AL I N F OR M AT I ON
R EA SO N FO R R EFER R A L
A 12-week-old female infant presented with jaundice. The child was not breast-fed and had no history of neonatal jaundice. Physical examination revealed fullness in the right upper quadrant. Laboratory findings included elevated total (2.4 mg/dL) and direct (1.8 mg/dL) bilirubin. Alkaline phosphatase was markedly elevated (2418 U/L); AST and ALT were normal. Ultrasound revealed a 4.5-cm extrahepatic cyst involving the common bile duct (CBD). The gallbladder and liver appeared normal, and no stones were visualized. The patient underwent resection of the cyst and hepaticojejunostomy.
Classification of extrahepatic cyst involving the CBD. The differential diagnosis included foregut cyst, abscess, and choledochal cyst. PAT H O LO GIC FEAT UR ES
The resection specimen revealed a fusiform cystic dilation involving most of the CBD (Figure 8.4.1). On sectioning, the lumen contained thick dark-green biliary sludge. The wall was smooth and without masses or excrescences. On histologic examination, the wall was thickened and fibrotic, with an
FIGURE 8. 4. 1 (A) Choledochocystectomy specimen with saccular dilation of the common bile duct suggestive of a choledochal cyst. (B) Cholangiogram showing the same finding. (C) Cyst wall consisting of fibrosis and a single layer of biliary type lining epithelium. (D) Higher magnification showing benign columnar biliary epithelium overlying fibrous tissue.
149
150
CHAPTER
8:
CYSTIC
associated lymphocytic infiltrate. The lining epithelium was mostly denuded, but what remained was cuboidal to columnar biliary epithelium with reactive atypia. There was no evidence of malignancy.
D I AG N OS I S
Choledochal cyst.
D I SC U SSI ON
The differential diagnosis of solitary cysts near the hepatic hilum in children includes enterogenous type foregut cysts/duplication cysts, choledochal cysts, and abscess. The gross pathology of choledochal cysts is characteristic, and microscopic examination typically reveals a fibrotic wall lined in places by biliary epithelium. Enterogenous foregut or duplication cysts are lined by squamous, ciliated columnar or gastric type mucosa and may be separate from the biliary tree. The diagnosis of choledocal cyst is often easily established clinically due to the location of the cyst and its biliary connection. These cysts should be resected followed by subsequent hepaticojejunostomy or biliary reconstruction, both due to obstructive symptoms and to a potential risk of malignancy. The incidence of choledochal cysts (biliary cysts) in the West varies from 1:100 000 to 150 000 live births. The frequency is much higher in Asia, where some locations show incidence rates as high as 1:1000 live births (1). There is a female predominance. Most cases present in infancy or childhood, and the majority of the cases are diagnosed in the first
DISEASE
OF
THE
LIVER
decade of life (2). Young children may present with the classic triad of abdominal pain, jaundice, and a palpable mass in approximately 20% of cases, but at least 2 of these 3 findings are present in the majority of patients (2). Older children, and rarely adults, may present with recurrent pancreatitis, fever, abdominal pain, and jaundice. Once suspected, the cysts are usually readily characterized on abdominal imaging as saccular or fusiform dilations of the extrahepatic bile duct(s). Several types of choledochal cysts are recognized (see Table 8.1.3, Case 8.1) (1,3). Type I cysts are by far the most common, representing 80% to 90% of all choledochal cysts. These involve dilation of a segment of the CBD or of the entire CBD. Types IV and V include intrahepatic duct dilation and overlap with, and can be indistinguishable from Caroli disease. In addition to cholangitis and pancreatitis, these cysts are associated with a significant risk of cholangiocarcinoma ranging from 9% to 28% (4,5).
References 1. Singham J, Yoshida EM, Scudamore CH. Choledochal cysts: part 1 of 3: classification and pathogenesis. Can J Surg. 2009;52(5):434–440. 2. Singham J, Yoshida EM, Scudamore CH. Choledochal cysts: part 2 of 3: Diagnosis. Can J Surg. 2009;52(6):506–511. 3. Todani T, Watanabe Y, Narusue M, Tabuchi K, Okajima K. Congenital bile duct cysts: classification, operative procedures, and review of thirtyseven cases including cancer arising from choledochal cyst. Am J Surg. 1977;134(2):263–269. 4. Chaturvedi A, Singh J, Rastogi V. Case report: cholangiocarcinoma in a choledochal cyst. Indian J Radiol Imaging. 2008;18(3):236–238. 5. Franko J, Nussbaum ML, Morris JB. Choledochal cyst cholangiocarcinoma arising from adenoma: case report and a review of the literature. Curr Surg. 2006;63(4):281–284.
Case 8.5
Solitary Hepatic Cyst Versus Hydatid Cyst BARTON KENNEY AND DHANPAT JAIN
C L I N IC AL I N F OR M AT I ON
A 32-year-old male presented with abdominal fullness. Physical examination showed mild right upper quadrant tenderness. Laboratory findings showed leukocytosis with 15% eosinophils. Liver transaminases were normal, whereas total bilirubin and alkaline phosphatase were mildly elevated. CT scan showed an 8-cm irregular cyst with water attenuation. There was focal pericystic calcification, with focal cystwithin-cyst pattern.
R E A SON F OR R E F E R R AL
Hepatic cyst of presumed infectious etiology. The differential diagnosis includes simple hepatic cyst, pyogenic abscess, amoebic abscess, or hydatid cyst. After consultation with the infectious disease team, the patient’s serum was sent for Echinococcus serological testing, which was negative.
PAT H OL OG I C F E AT U R E S
At resection, the right hepatic lobe was sectioned to reveal a single large cyst containing serous fluid and a thick fibrous wall, but without an identifiable lining (Figure 8.5.1). A scant amount of adjacent preserved liver parenchyma was present that appeared unremarkable.
DIAGNO SIS
Simple hepatic cyst.
DISCUSSIO N
The lack of any specific histologic features and the presence of normal adjacent liver parenchyma suggests the diagnosis of simple hepatic cyst. The characteristic laminated wall of hydatid cyst is not seen. Typical features of hepatobiliary cystadenoma/carcinoma such as columnar or mucinous lining epithelium and ovarian-type stroma are not present. Simple cysts are typically solitary, and there is usually no familial history of liver cysts. The cysts tend to grow at a slow rate and can remain asymptomatic for many years. Larger cysts come to clinical attention due to mass effect or incidental detection on imaging studies. The cyst fluid may re-accumulate soon after needle aspiration, which is best avoided as a definitive therapeutic intervention. Due to the risk of anaphylaxis, needle aspiration is contraindicated if hydatid cyst is a consideration. Imaging studies are often nonspecific. Simple hepatic cysts are uniloculated, and the remaining liver generally appears normal. Pathologic examination is important for excluding an infectious cyst or cystic neoplasm. Classification into a hepatic or biliary-type cyst is often not possible and is not clinically relevant.
FIGURE 8. 5. 1 (A) Simple hepatic cyst opened to reveal luminal hemorrhage. (B) Simple hepatic cyst with a thin fibrous cyst wall and smooth inner surface. (C) Histology of the cyst wall showing denuded epithelium, fibrous wall, and mural hemorrhage.
151
This page intentionally left blank
9 Hereditary Hyperbilirubinemias SARANGARAJAN RANGANATHAN
I N T ROD U C T I ON
Elevation of bilirubin is a physiological phenomenon in the first week of life. This is controlled by the complex system of bilirubin conjugation and excretion and is the result of interplay of several enzymes and factors responsible for the uptake of bilirubin by the hepatocyte, its conjugation, release into bile, reabsorption in the enterohepatic circulation, and its ultimate excretion into placenta or urine. Neonatal hyperbilirubinemias are a group of genetic disorders that are characterized by disorder and defects at various steps in this process resulting in pathological elevations of unconjugated or conjugated bilirubins in the neonatal period (1). They need to be differentiated as a group from physiologic hyperbilirubinemia of the newborn that is the result of increased bilirubin production and delayed maturation resulting in decreased excretion by the neonatal liver.
due to a defect in the 39 end of the gene results in the severe form (Type I CJS), and a defect in the variable region results in partial defect in the isoforms causing the less severe Type II CJS (3,4). CJS Type I
This is the more severe form of the disease manifesting in infancy with serum bilirubin levels ranging from 20 to 25 mg dL and may exceed 50 mg/dL. Almost all the bilirubin
U N C O N J U G AT E D H Y P E R B I L I RU B I N E M I A Gilbert Syndrome
Gilbert syndrome (GS) is a familial, autosomal-dominant or recessive disease that is characterized by a mild, chronic unconjugated hyperbilirubinemia. There is a strong male predominance and most patients are diagnosed as young adults. The serum bilirubin level is usually less than 3 mg/dL but can fluctuate and rise during intercurrent illnesses. The remaining liver function tests and liver biopsy are normal with only some lipofuscin accumulation. Association with other genetic defects such as glucose-6-phosphate dehydrogenase (G6PD) deficiency, b-thalassemia, or hereditary spherocytosis can result in neonatal hyperbilirubinemia. It is now known to be caused by mutations or polymorphisms in the bilirubin UDPglucuronosyltransferase (UGT1A1) gene (2,3). Insertion of TA dinucleotide in the TATA box of the UGT1A1 promoter is the underlying abnormality in most Caucasians, with most affected individuals being homozygous. Heterozygosity can also result in higher bilirubin levels compared with normal. GS is not associated with any significant morbidity or mortality.
A
C R I G L E R -N AJ J A R S Y N D ROM E
The Crigler-Najjar syndrome (CJS) was first described by Crigler and Najjar in 1952 as a form of severe congenital unconjugated hyperbilirubinemia that presents in the first few days of life and is fatal due to kernicterus developing as a complication. There are 2 types: CJS Type I and CJS Type II. Both types are associated with the same UGT1A1 gene wherein a complete mutation of all isoforms of bilirubin-UGT cDNA
B F I G U R E 9 . 1 (A) Explanted liver in CJS type I showing a glistening smooth surface with minimal discoloration and no evidence of cirrhosis. (B) Canalicular bile plugs with preserved liver parenchyma and no hepatocellular pigment (H&E 400).
153
154
CHAPTER
9:
H E R E D I TA RY
is unconjugated due to the inability to conjugate bilirubin with uridine diphosphoglucuronic acid. Unlike GS, there is no response of bilirubin to phenobarbital administration. Phototherapy is the treatment of choice together with plasmapheresis and liver transplantation in older children (5). Liver biopsy is normal except for bile plugs in canaliculi. The explanted liver is normal in color and architecture with
HYPERBILIRUBINEMIAS
no evidence of cirrhosis (Figure 9.1). There is canalicular cholestasis with normal hepatocytes and no significant fibrosis (Figure 9.2). CJS Type II
Also known as Arias syndrome, it commonly affects patients in later life. It is associated with marked unconjugated hyperbilirubinemia with a dominance of bilirubin monoglucuronide in the bile, as opposed to CJS Type I that has diglucoronide as the dominant component. Although it is less severe than Type I disease, it can cause kernicterus and lead to death. CO NJUGAT ED H Y P ER BILIRUBINEMIA S Rotor Syndrome
FIGURE 9. 2 DJS with the characteristic pigment accumulation in the
cytoplasm of hepatocytes in the centrilobular region (H&E 400).
This is a rare, familial hyperbilirubinemia that is characterized by a chronic conjugated hyperbilirubinemia without hemolysis. It was originally thought to be related to Dubin-Johnson syndrome (DJS), but its genetic defect is unknown (6). Laboratory tests show a delay in excretion of all forms of organic anions including bromosulphthalein (BSP) and indocyanine green (ICG). The increase in BSP excretion is usually at 45 minutes, but the secondary increase at 90 minutes noted in DJS is not seen in Rotor syndrome due to the absence of reflux of conjugated BSP. Urinary coproporphyrin levels are also markedly increased in Rotor syndrome as compared with other hereditary hyperbilirubinemias and may be 25% to 50% higher
TA B LE 9. 1 Salient laboratory and genetic features of hereditary hyperbilirubinemias Gilbert Syndrome (GS)
Crigler-Najjar Syndrome (CJS)
Rotor Syndrome (RS)
Dubin-Johnson Syndrome (DJS)
Inheritance
Autosomal dominant
Autosomal recessive or dominant
Autosomal recessive
Autosomal recessive
Prevalence
3%
Rare
Rare
1:1300 Iranian Jews
Serum bilirubin
3–10 Unconjugated
20–50 unconjugated
Up to 20 conjugated
Up to 20 conjugated
Serum bilirubin decrease with phenobarbitol
70%
0%—CJS I 77%—CJS II
Not seen
Not seen
BUGT activity
5–53% controls
Severe ↓—CJS I 2–23%—CJS II
Normal
Normal
BSP clearance
Normal
Normal